albuterol profile

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	2083
CHEMBL ID	714
CHEBI ID	2549
SCHEMBL ID	4913
SCHEMBL ID	10025126
MeSH ID	M0000631

Synonym
AB00052154-09
BRD-A88254928-001-04-6
gtpl558
DIVK1C_000943
KBIO1_000943
volmax
sultanol
salbutamol sulfate
ventolin
ventoline
ah-3365
4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
dl-albuterol
salbutol
sultanol n
asmatol
asmol
grafalin
ah 3365
salbetol
1,3-benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-
salomol
asmasal
salbuven
2-(tert-butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol
salbulin
ventilan
cobutolin
bumol
ventolin inhaler
salbuhexal
albuterol [usan]
m-xylene-alpha,alpha'-diol, alpha'-((tert-butylamino)methyl)-4-hydroxy-
dilatamol
hsdb 7206
aerolin
broncovaleas
ventiloboi
farcolin
salamol
tobybron
libretin
salbu-fatol
mozal
asmol uni-dose
asmaven
asmidon
buto-asma
saventol
pneumolat
parasma
alti-salbutamol
sallbupp
buventol
einecs 242-424-0
medolin
salbusian
salmaplon
salbutan
spreor
proventil hfa
asmanil
salbron
4-hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol
sabutal
salbupur
brn 2213614
dl-salbutamol
almotex
novosalmol
theosal
alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol
salbutamolum [inn-latin]
butamol
zaperin
asmadil
gerivent
servitamol
suprasma
dl-n-tert-butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine
volare easi-breathe
vencronyl
respax
salbuvent
2-t-butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol
butohaler
asthalin
proventil inhaler
respolin
butovent
suxar
salbutalan
arubendol-salbutamol
bronter
volare albuterol hfa
broncho-spray
m-xylene-alpha,alpha'-diol, alpha-((tert-butylamino)methyl)-4-hydroxy-
ventamol
butotal
1-(tert-butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol
alpha'-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol
anebron
salvent
bugonol
salbu-basf
ventodisks
1,3-benzenedimethanol, alpha(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-
SGCUT00011
EU-0101090
SPECTRUM_000200
SPECTRUM5_001059
PRESTWICK_665
BIO1_000935
BIO1_000446
BIO1_001424
CHEBI:2549 ,
4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
proventil
LOPAC0_001090
BSPBIO_000155
PRESTWICK3_000198
PDSP1_000623
PDSP2_000620
SMP1_000268
IDI1_000943
LOPAC0_001098
BPBIO1_000171
PRESTWICK2_000198
BCBCMAP01_000116
bdbm25769
salbutamol,(+/-)
.alpha.1'-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol, hemisulfate
18559-94-9
salbutamol
4-[2-(tert-butylamino)-1-hydroxy-ethyl]-2-(hydroxymethyl)phenol
albuterol
AB00052154
TO_000081
DB01001
D02147
proventil (tn)
albuterol (usp)
NCGC00024698-07
NCGC00024698-04
NCGC00024698-03
KBIO2_005816
KBIOGR_001294
KBIO2_003248
KBIOSS_000680
KBIO2_000680
SPECTRUM2_001350
SPBIO_001539
PRESTWICK1_000198
NINDS_000943
PRESTWICK0_000198
SPECTRUM4_000887
SPBIO_002076
SPECTRUM1500677
NCGC00024698-02
NCGC00024698-05
NCGC00024698-06
NCGC00015955-04
AC-10286
HMS2089I19
S 8260 ,
HMS2092I08
NCGC00015955-11
NCGC00015955-10
sch 13949w
etinoline
salbutamolum
nsc-757417
sch-13949w
CHEMBL714
ksc-11-222-1
KUC106739N
VU0243312-5
L000531
HMS502P05
HMS1568H17
HMS1921C04
NCGC00015955-09
HMS2095H17
AKOS007930174
salbutamol [inn:ban]
nsc 757417
qf8svz843e ,
albuterol [usan:usp]
unii-qf8svz843e
airomir
eolene
ec 242-424-0
4-{2-[(tert-butyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
tox21_200800
NCGC00258354-01
4-[2-(tert-butylamino)-1-oxidanyl-ethyl]-2-(hydroxymethyl)phenol
A812971
nsc757417
pharmakon1600-01500677
dtxcid001255
tox21_110266
dtxsid5021255 ,
CCG-39288
NCGC00015955-07
NCGC00015955-12
NCGC00015955-13
NCGC00015955-05
NCGC00015955-14
NCGC00015955-06
NCGC00015955-08
ventalin inhaler
solbutamol
alpha-[(tert-butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol
S5494
albuterol [mi]
albuterol [hsdb]
albuterol [orange book]
salbutamol [ep impurity]
35763-26-9
salbutamol [who-dd]
salbutamolum [who-ip latin]
salbutamol [ep monograph]
albuterol [usp monograph]
salbutamol [inn]
albuterol [usp-rs]
salbutamol [mart.]
albuterol [vandf]
salbutamol [who-ip]
1,3-benzenedimethanol, .alpha.(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-
(+/-)-1,3-benzenedimethanol, .alpha.(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-
SCHEMBL4913
NCGC00015955-16
tox21_110266_1
KS-5209
AB00052154-08
CS-4556
racemic salbutamol
4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol
SCHEMBL10025126
Q-201696
Q-201695
.alpha.'-((tert-butylamino)methyl)-4-hydroxy-m-xylene-.alpha.,.alpha.'-diol
1,3-benzenedimethanol, .alpha.1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-
salamol eb
4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol #
m-xylene-.alpha.,.alpha.-diol, .alpha.-1-((tert-butylamino)methyl)-4-hydroxy-
4-hydroxy-3-hydroxymethyl-.alpha.-((tert-butylamino)methyl)benzyl alcohol
m-xylene-.alpha.,.alpha.'-diol, .alpha.'-((tert-butylamino)methyl)-4-hydroxy-
1-(tert-butylaminomethyl)-4-hydroxy-m-xylene-.alpha.1,.alpha.3-diol
venetlin (salt/mix)
.alpha.1-[(tert-butylamino)methyl]-4-hydroxy-m-xylene-.alpha.,.alpha.'-diol
1,3-benzenedimethanol, .alpha.(1)-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-
albuterol (+/-)
HY-B1037
AB00052154_10
AB00052154_11
mfcd00148978
1219798-60-3
salbutamol, vetranal(tm), analytical standard
albuterol, united states pharmacopeia (usp) reference standard
salbutamol free base
salbutamol, european pharmacopoeia (ep) reference standard
salbutamol 100 microg/ml in acetonitrile
SR-01000075161-3
SR-01000075161-8
SR-01000075161-4
sr-01000075161
SR-01000075161-11
SR-01000075161-5
SBI-0051060.P005
HMS3712H17
2-(tert-butylamino)-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethanol
salbutamol, british pharmacopoeia (bp) reference standard
FT-0770967
FT-0661467
Q410358
salbutamol-(tert-butyl-d9) acetate
148563-15-9
BCP28423
BRD-A88254928-001-05-3
SB19749
SDCCGSBI-0051060.P006
NCGC00015955-28
HMS3886I08
AMY38245
(+)-5,6-o-cyclohexylidene-l-ascorbicacid
F15026
alpha-[(tert-butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha1-diol
BA164143
EN300-365894
(+/-)-albuterol-d3
salbutamol (ep monograph)
alpha1-
salbutamol (mart.)
4-hydroxy-3-hydroxymethyl-alpha-
salbutamolum (inn-latin)
salbutamol (ep impurity)
albuterol (usp-rs)
albuterol (usp monograph)
albuterol (usan:usp)
salbutamolo
Z2301287926
d,l-salbutamol, 1mg/ml in ethanol
d,l-salbutamol

Research Excerpts

Overview

Levalbuterol is a cost-saving option for treating hospitalized patients with COPD in China. LevalbuterOL is an alternative to racemic al buterol with potential to improve patient outcomes and reduce costs in the treatment of acute asthma exacerbations.

Excerpt	Reference	Relevance
"Levalbuterol is a cost-saving option for treating hospitalized patients with COPD in China."	( Levalbuterol Chen, L; Chen, X; Hu, Y; Li, X; Zhi, C, )	1.37
"Levalbuterol is a single isomer beta2-agonist that differs from racemic albuterol by elimination of (S)-albuterol. "	( Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Berger, WE, 2003)	1.56
"Albuterol is an effective treatment for hyperkalemia through beta-adrenergic induction of potassium (K+) uptake. "	( Levalbuterol is as effective as racemic albuterol in lowering serum potassium. Evans, E; LaFlamme, M; Pancu, D; Reed, J, 2003)	2.38
"Albuterol is a beta 2-agonist with rapid onset of action and a duration of approximately 6 hours."	( Formoterol vs. albuterol administered via Turbuhaler system in the emergency treatment of acute asthma in children. Avila-Castañón, L; Casas-Becerra, B; Del Río-Navarro, BE; Sienra-Monge, JJ; Velázquez-Armenta, Y, )	1.21
"Albuterol is a selective beta2-agonist that is widely used in the prevention and treatment of reactive airway disease. "	( The cost effectiveness of levalbuterol versus racemic albuterol. Quinn, C, 2004)	2.06
"Levalbuterol is an alternative to racemic albuterol with the potential to improve patient outcomes and reduce costs in the treatment of acute asthma exacerbations."	( Asthma pathophysiology and evidence-based treatment of severe exacerbations. Schreck, DM, 2006)	0.96
"Albuterol is a beta-2 agonist that has been demonstrated to increase muscle strength in studies in animals and humans. "	( Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Fowler, EG; Graves, M; Skura, CL; Spencer, MJ; Wetzel, GT, 2008)	3.23
"Albuterol is a long-acting beta 2-adrenergic receptor-selective drug that relaxes airway smooth muscle. "	( Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. Ahrens, RC; Smith, GD, )	3.02
"Albuterol is a beta2-adrenergic agonist commonly used as a bronchodilator for the treatment of patients with asthma. "	( Determination of albuterol in plasma after aerosol inhalation by gas chromatography-mass spectrometry with selected-ion monitoring. Anderson, P; Breen, P; Compadre, CM; Gann, L; Hiller, C; Logsdon, TW; Zhou, X, 1997)	2.08
"Albuterol is a quickly acting beta-2 adrenergic agonist bronchodilator widely used by asthmatics. "	( Cardiovascular effects after inhalation of large doses of albuterol dry powder in rats, monkeys, and dogs: a species comparison. Banks, CM; Beattie, JG; Lulham, GW; Mirro, EJ; Pai, S; Petruska, JM; Stuart, BO; Walters, KM, 1997)	1.98
"Albuterol is a safe drug for the treatment of mild to moderate asthma exacerbations in pediatric patients."	( Metabolic and electrocardiographic effects of albuterol in pediatric asthmatic patients treated in an emergency room setting. Del Río-Navarro, B; Gazca-Aguilar, A; Quibrera Matienzo, JA; Rodríguez Galván, Y; Sienra-Monge, JJ, )	1.11
"Albuterol is a 50:50 mixture of R-albuterol, the active enantiomer, and S-albuterol, which appears to be inactive in humans. "	( Levalbuterol nebulizer solution: is it worth five times the cost of albuterol? Asmus, MJ; Hendeles, L, 2000)	2.37
"Albuterol is a specific beta-2 agonist that has been reported to be effective in treating infants and children with bronchospastic pulmonary disease. "	( A randomized placebo-controlled study to evaluate the effects of oral albuterol on pulmonary mechanics in ventilator-dependent infants at risk of developing BPD. Bhutani, VK; Fox, WW; Stefano, JL, 1991)	1.96

Effects

The albuterol mDPI has an efficacy/tolerability profile consistent with other inhaled forms of al buterol. The drug is reliable, easy to use, and associated with a high level of patient satisfaction.

The albuterol mDPI has an efficacy/tolerability profile consistent with other inhaled forms of al buterol, and is reliable, easy to use, and associated with a high level of patient satisfaction. AlbuterOL has been reformulated in the non-ozone-depleting propellant, hydrofluoroalkane-134a (HFA al Buterol)

Excerpt	Reference	Relevance
"The albuterol mDPI has an efficacy/tolerability profile consistent with other inhaled forms of albuterol, and is reliable, easy to use, and associated with a high level of patient satisfaction. "	( Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClick(™) dry-powder inhaler in the treatment of asthma. Welch, MJ, 2016)	1.23
"HFA albuterol has a safety profile similar to that of CFC albuterol during chronic, scheduled use, and both drugs are well tolerated. "	( Safety of long-term treatment with HFA albuterol. Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1999)	1.13
"Oral albuterol has worse efficacy and side effects compared with inhaled albuterol, and thus its use has been discouraged for decades. "	( Association between dispensing of low-value oral albuterol and removal from Medicaid preferred drug lists. Chua, KP; Ciaccio, C; Conti, R; Pelczar, A; Volerman, A, 2022)	1.49
"Albuterol has been a cornerstone of asthma treatment for several decades, but evidence suggests that it may be overused at the expense of more efficacious treatment. "	( Albuterol: Still first-line in rescue therapy? Pitonzo, DG, 2022)	3.61
"The albuterol mDPI has an efficacy/tolerability profile consistent with other inhaled forms of albuterol, and is reliable, easy to use, and associated with a high level of patient satisfaction. "	( Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClick(™) dry-powder inhaler in the treatment of asthma. Welch, MJ, 2016)	1.23
"Albuterol has been used for more than 40 years to treat acute asthma exacerbations as a racemic mixture of isomers: the active form, (R)-albuterol, or levalbuterol, and (S)-albuterol, classically considered inert. "	( Levalbuterol versus albuterol. Ameredes, BT; Calhoun, WJ, 2009)	2.42
"Albuterol has been used in the acute treatment of asthma exacerbations for over 25 years. "	( Albuterol enantiomers: pre-clinical and clinical value? Ameredes, BT; Calhoun, WJ, 2010)	3.25
"Albuterol has been proven to be a vital component in the management of severe, acute asthma in children and adults. "	( Administration of albuterol by continuous nebulization. Buck, ML, 1995)	2.07
"albuterol, Airomir, 3M) has been approved for marketing in over 35 countries."	( The change to non-CFC metered dose inhalers. Rubinfeld, A, 1997)	1.02
"Albuterol has been reformulated in the non-ozone-depleting propellant, hydrofluoroalkane-134a (HFA albuterol)."	( Safety of long-term treatment with HFA albuterol. Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1999)	1.29
"HFA albuterol has a safety profile similar to that of CFC albuterol during chronic, scheduled use, and both drugs are well tolerated. "	( Safety of long-term treatment with HFA albuterol. Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1999)	1.13
"(S)-albuterol has distinctive pharmacologic properties that are unrelated to activation of beta(2 )-adrenoceptors."	( Contrasting properties of albuterol stereoisomers. Morley, J; Page, CP, 1999)	1.08
"R-albuterol has greater bronchodilatory effects than the racemate and may have anti-inflammatory properties."	( Levalbuterol hydrochloride. Colin, AA; Slattery, D; Wong, SW, 2002)	1.49

Actions

Albuterol reduces lower esophageal sphincter (LES) pressure in normal volunteers, although the effects of al buterol on esphageal function in asthmatic patients are not known. The drug can also cause hypokalemia and other metabolic and electrical changes, including prolonged QT interval.

Excerpt	Reference	Relevance
"Albuterol can also cause hypokalemia and other metabolic and electrical changes, including prolonged QT interval."	( Acute myocardial infarction associated with albuterol. Davis, MW; Fisher, AA; McGill, DA, 2004)	1.31
"Albuterol reduces lower esophageal sphincter (LES) pressure in normal volunteers, although the effects of albuterol on esophageal function in asthmatic patients are not known. "	( The effects of nebulized albuterol on esophageal function in asthmatic patients. DesBiens, J; Lacy, BE; Liu, MC; Mathis, C, 2008)	2.09
"Albuterol can also produce undesirable dose-related effects: metabolic effects including decreased levels of plasma potassium, phosphate, calcium and magnesium; increased levels of plasma glucose, insulin, renin, lactate and ketones; peripheral vasodilation and perhaps some direct cardiac stimulation resulting in decreased systemic and pulmonary vascular resistance, increased pulse pressure and tachycardia; and skeletal muscle tremor."	( Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. Ahrens, RC; Smith, GD, )	2.3
"Albuterol at a lower dose (0.1 mg/kg) had no significant effect on erythrocyte mass."	( beta 2-Adrenergic stimulation of erythropoiesis in busulfan treated mice. Bauer, C; Jelkmann, W, 1980)	0.98
"(S)-albuterol does not activate beta(2 )-adrenoceptors and does not modify activation of beta(2 )-adrenoceptors by (R)-albuterol so that for many years it was presumed to be biologically inert."	( Contrasting properties of albuterol stereoisomers. Morley, J; Page, CP, 1999)	1.08
"Albuterol did not produce any significant changes in blood pressure and pulse rate, thus confirming its selectivity for beta2 receptors."	( Comparative study of acute effects of albuterol and isoproterenol sulphate aerosols in bronchial asthma. Huber, GL; Mahajan, VK; Tomashefski, JF, 1977)	1.25
"With albuterol mean percent increase in FEV1 fell to 15% over baseline at 5 hr after a dose."	( Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma. Kemp, JP; Orgel, HA; Tinkelman, DG; Webb, DR, 1985)	1.08

Treatment

Levalbuterol treatment in the ED for patients with acute asthma resulted in higher patient discharge rates and may be a cost-effective alternative to racemic al buterol. The albuters demonstrated reduced parkinsonian symptoms and an increased ability to tap their index finger between two points 20 cm apart.

Excerpt	Reference	Relevance
"Albuterol treatment caused a small but significant increase in FEV(1) and FVC, a significant decrease of Vcw at FRC (VcwFRC), but no changes of Vcw at TLC (VcwTLC) and breathing pattern variables. "	( Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. Bianchi, R; Brusasco, V; Duranti, R; Filippelli, M; Pellegrino, R; Romagnoli, I; Scano, G, 2002)	2
"Levalbuterol-treated patients required significantly fewer treatments with beta-agonists (mean [+/- SD] number of treatments, 19.0 +/- 12.7 vs 30.8 +/- 24.0; p < 0.001) and ipratropium bromide (mean number of treatments, 9.4 +/- 11.5 vs 23.2 +/- 25.1; p < 0.001) than did racemic albuterol-treated patients."	( Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Halpern, M; Truitt, T; Witko, J, 2003)	1.45
"Levalbuterol treatment in the ED for patients with acute asthma resulted in higher patient discharge rates and may be a cost-effective alternative to racemic albuterol."	( Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Babin, S; Schreck, DM, 2005)	1.26
"The albuterol-treated patients demonstrated reduced parkinsonian symptoms and an increased ability to tap their index finger between two points 20 cm apart, and were able to perform a "walk test" in 70% of their control time."	( Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease. Alexander, GM; Grothusen, JR; Hooker, MD; Nukes, TA; Schwartzman, RJ, 1994)	0.77
"Albuterol treatment significantly increased the LAR compared to placebo treatment (p = 0.003) and significantly enhanced the number of sputum eosinophils (p = 0.009) and sputum ECP (p = 0.04) at 7 h but not 24 h post-allergen (p > 0.05)."	( Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Cockroft, DW; Gauvreau, GM; Jordana, M; O'Byrne, PM; Watson, RM, 1997)	1.32
"Albuterol treatment significantly reduced the median thickness of subepithelial Tn expression from 9.7 to 6.3 microns (P = 0.023) and macrophage numbers in the epithelium (P = 0.034), lamina propria (P = 0.039) and entire mucosa (P = 0.033), whereas nedocromil sodium had no effect."	( Regular albuterol or nedocromil sodium--effects on airway subepithelial tenascin in asthma. Altraja, A; Laitinen, A; Laitinen, LA; Marran, S; Märtson, T; Meriste, S; Sillastu, H, 1999)	1.46
"Albuterol pretreatment resulted in modest but significant bronchodilation as compared to placebo."	( Inhaled albuterol does not protect against ozone toxicity in nonasthmatic athletes. Bedi, JF; Gong, H; Horvath, SM, )	1.29
"Albuterol treatment produced significant bronchodilation and also prevented SO2-induced bronchoconstriction."	( The effects of albuterol on sulfur dioxide-induced bronchoconstriction in allergic adolescents. Bierman, CW; Furukawa, CT; Horike, M; Koenig, JQ; Marshall, SG; Pierson, WE; Shapiro, GG, 1987)	1.35
"Albuterol/theophylline treatment produced peak expiratory flow rates 2 hours after administration that were significantly higher than in the theophylline/placebo-treated group (119.3 L/min versus 83 L/min) p less than 0.01."	( Albuterol syrup in the treatment of asthma. Bierman, CW; Furukawa, CT; Pierson, WE; Shapiro, GG, 1985)	2.43
"Treatment with albuterol (8 mg/kg/day) during the two-week anti-MuSK injection series reduced the degree of weakness and weight loss, compared to vehicle-treated mice."	( Effects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis. Ghazanfari, N; Morsch, M; Phillips, WD; Reddel, SW; Tse, N, 2014)	1.01
"Treatment with albuterol resulted in progressive improvement of muscle strength, exercise tolerance, and ophthalmoplegia."	( Neuromuscular junction acetylcholinesterase deficiency responsive to albuterol. Chan, SH; Engel, AG; Wong, VC, 2012)	0.95
"Pretreatment with albuterol is more effective than montelukast for prevention of exercise-induced bronchospasm in children with asthma."	( Pretreatment with albuterol versus montelukast for exercise-induced bronchospasm in children. Harkins, M; Kelly, F; Kelly, HW; Raissy, HH, 2008)	1.01
"Treatment with albuterol decreased markedly both LTC4 secretion to 144 +/- 54.0 pg/ml (P < .05 vs."	( Beta adrenergic modulation of formyl-methionine-leucine-phenylalanine-stimulated secretion of eosinophil peroxidase and leukotriene C4. Leff, AR; McAllister, K; Munoz, NM; Neeley, SP; Spaethe, SM; Vita, AJ; White, SR, 1994)	0.63
"Pretreatment with albuterol, cromolyn, and a combination of albuterol and cromolyn 30 minutes before ETS exposure significantly diminished airway reactivity to ETS."	( Asthmatic responses to passive cigarette smoke: persistence of reactivity and effect of medications. Lehrer, SB; Menon, PK; Rando, RJ; Salvaggio, JE; Stankus, RP, 1991)	0.6
"Pretreatment with albuterol (1 microgram/kg) or aminophylline significantly attenuated the pulmonary response to methacholine in the mongrels but was without effect in the BGs."	( Reduced sensitivity to beta-adrenergic agonists in Basenji-Greyhound dogs. Hirshman, CA; Sauder, RA; Tobias, JD, 1990)	0.6
"Pretreatment with albuterol abolished any significant bronchoconstriction, with mean maximal falls in SGaw and FEV1 after challenge of 7.5 and 1.4%, respectively."	( Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Church, MK; Durham, SR; Holgate, ST; Howarth, PH; Kay, AB; Lee, TH, 1985)	0.96
"Pretreatment with albuterol attenuated both the cough and the drop in FEV1."	( Cough and wheezing from beclomethasone aerosol. Shim, C; Williams, MH, 1987)	0.6

Toxicity

Two very large, randomized, double-blind clinical trials performed in the United Kingdom and in the U.S. have suggested that addition of salmeteräE to usual asthma therapy is associated with a significant increase in the incidence of serious adverse events and asthma-related deaths.

Excerpt	Reference	Relevance
" Tremor was found to be the dose-limiting side effect with both modes of administration."	( Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol in asthmatics. Larsson, S; Svedmyr, N, 1977)	0.26
" Safety was determined by monitoring adverse events and standard biochemical, haematological and cardiovascular parameters."	( Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms). Palmer, JB; Shepherd, GL; Stuart, AM; Viskum, K, 1992)	0.28
" Although the number of subjects studied is small, our data suggest that air-driven nebulised high-dose salbutamol may be safe in the treatment of severe chronic obstructive airway disease but when combined with oral theophylline, a significant fall in plasma potassium may occur."	( Air-driven nebulised high-dose salbutamol in severe chronic obstructive airways disease: is it safe? Friend, JA; Lai, CK; Legge, JS, 1991)	0.28
" The study which is the first report in Africa to assess this novel formulation of salbutamol in a group of African patients, demonstrates that controlled release salbutamol 8 mg administered twice daily is safe and effective, offering benefits over current therapies in the treatment of asthma."	( The efficacy and safety of a controlled release formulation of salbutamol in the management of patients with asthma in Nairobi, Kenya. Aluoch, JA; Gathua, SN, 1990)	0.28
" The purpose of the present study was to assess the pharmacokinetics, efficacy and adverse effects of standard salbutamol tablets given by this route to patients with asthma."	( Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. Clark, GA; Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Moreland, TA; Struthers, AD, 1989)	0.28
" Although it is safe to use oxygen as the driving gas for nebulisers in patients with obstructive airways disease with normal Pco2, caution should be exercised in those who already have carbon dioxide retention."	( Oxygen as a driving gas for nebulisers: safe or dangerous? Campbell, IA; Gunawardena, KA; MacDonald, JB; Patel, B; Smith, AP, 1984)	0.27
"The incidence of potentially drug-related adverse events was similar among the treatment groups (range: 22% to 23%), with headache being the most commonly reported (range: 9% to 10%)."	( Safety of salmeterol in the maintenance treatment of asthma. Alexander, WJ; Chervinsky, P; Kemp, JP; Liddle, R; Mills, R; Nathan, RA; Seltzer, JM, 1995)	0.29
" Extensive cardiovascular monitoring revealed no significant cardiovascular adverse effects or arrhythmogenic effects associated with salmeterol over 12 weeks."	( Safety of salmeterol in the maintenance treatment of asthma. Alexander, WJ; Chervinsky, P; Kemp, JP; Liddle, R; Mills, R; Nathan, RA; Seltzer, JM, 1995)	0.29
" Cough, headache and itchy throat were adverse events possibly related to the use of Salmeterol."	( Efficacy and safety of inhaled Salmeterol (Serevent) as maintenance therapy for asthma in Nairobi. Gikonyo, BM; Nganga, LW; Odhiambo, JA, 1994)	0.29
" The outcome variables were: duration of hospitalization, percent of predicted peak expiratory flow rates recorded at 12-hour intervals, number of albuterol treatments required, and adverse effects."	( Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994)	0.49
" In the Am group, 6 of the 14 patients who entered the study experienced significant adverse effects consisting of nausea, emesis, headache, abdominal pain, and palpitations."	( Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994)	0.29
"There is no benefit and considerable risk of adverse effects associated with the use of Am in hospitalized asthmatic children."	( Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994)	0.29
" These aerosolized medications are not without the potential for adverse effects."	( Unexpected adverse effects of Freon 11 and Freon 12 as medication propellants. Oenbrink, RJ, 1993)	0.29
"Continuous albuterol therapy appears to be safe in our patient population as there was no significant evidence of cardiotoxicity."	( Safety of continuous nebulized albuterol for bronchospasm in infants and children. Crowley, MR; Grad, R; Katz, RW; Kelly, HW; McWilliams, BC; Murphy, SJ, 1993)	0.96
" In addition, all adverse effects were noted."	( The efficacy and safety of a continuous albuterol protocol for the treatment of acute adult asthma attacks. Barish, RA; Brandt, G; Hooper, F; Jerrard, D; Olshaker, J, 1993)	0.55
" This study shows that acute inhalation of HFA-134a in a CFC-free system is as safe as a CFC propellant system."	( Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. Cooper, KM; Donnell, D; Ekholm, BP; Harrison, LI; Klinger, NM; McEwen, J; Porietis, I; Ward, S, 1995)	0.29
" The only notable adverse experiences in the azelastine group were alterations in taste perception and a small mean increase in body weight."	( An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. , 1996)	0.29
" Salmeterol was well tolerated as assessed by pulse, blood pressure, haematological and biochemical variables and number of adverse events."	( The efficacy and safety of inhaled salmeterol 50 microg bd in older patients with reversible airflow obstruction. Luce, P; Starke, ID, 1996)	0.29
" We feel that CAN is safe for use in children diagnosed with status asthmaticus."	( Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus. Bigos, D; Brilli, RJ; Craig, VL, 1996)	0.57
" This study does not exclude the possibility that adverse cardiac events could occur with severe hypoxemia."	( Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Abboud, RT; Bowie, DM; Chapman, KR; Hodder, RV; McCallum, AL; Mesic-Fuchs, H; Molfino, NA; Newhouse, MT; Paré, PD, 1996)	0.54
" Both studies were continued for a further 9 months during which time exacerbation rates, lung function at the clinic and adverse events were monitored."	( Efficacy and safety of salmeterol in childhood asthma. Boner, AL; Ebbutt, A; Jenkins, MM; Lenney, W; Pedersen, S, 1995)	0.29
" No serious drug-related adverse events occurred."	( Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Goldstein, MF; Hamedani, AG; Kellerman, DJ; Noonan, MJ; Pearlman, DS; Schaberg, A; Tashkin, DP, 1997)	0.3
" No adverse events of clinical relevance were reported."	( Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma. Bondesson, E; Friberg, K; Löfdahl, CG; Soliman, S, 1998)	0.3
"Proportions of patients who were: admitted to hospital for respiratory diseases, reported adverse side effects, or withdrew because of adverse affects."	( Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines. Ayres, JG; Frost, CD; Holmes, WF; Ward, SM; Williams, DR, 1998)	0.3
"08) or the proportions who reported adverse events (1."	( Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines. Ayres, JG; Frost, CD; Holmes, WF; Ward, SM; Williams, DR, 1998)	0.3
"The hydrofluoroalkane inhaler was as safe as the chlorofluorocarbon inhaler when judged by hospital admissions and adverse affects."	( Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines. Ayres, JG; Frost, CD; Holmes, WF; Ward, SM; Williams, DR, 1998)	0.3
" Adverse events and changes in clinical laboratory values, vital signs, ECG results, and physical examinations were reported with similar incidence in each of the three treatment groups."	( Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma. Bieler, S; Hill, MR; Kemp, JP; Nelson, H; Vaughan, LM, 1999)	0.58
"Cardiovascular safety was regularly assessed by 12-lead ECG with a 15-s lead II rhythm strip, 24-h continuous ambulatory ECG (Holter) monitoring, serial vital sign measurements, and review of adverse cardiovascular events."	( Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial. Arledge, T; Chervinsky, P; Galant, S; Goldberg, P; Stahl, E; Wang, Y; Welch, MB, 1999)	0.3
"Long-term, twice-daily pharmacotherapy with salmeterol powder is safe and is not associated with unfavorable clinically significant changes in cardiac function or increases in cardiovascular adverse effects."	( Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial. Arledge, T; Chervinsky, P; Galant, S; Goldberg, P; Stahl, E; Wang, Y; Welch, MB, 1999)	0.3
" The incidence and severity of adverse events were similar across groups."	( Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. Brown, A; Finn, A; Galant, SP; Gross, G; Hamedani, AG; Harding, SM; Pleskow, W; van Bavel, J, 1999)	0.3
"As no cardiac side effects were detected, it could be concluded that salmeterol is quite a safe drug for use in childhood asthma treatment."	( Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children. Demirsoy, S; Olguntürk, R; Tunaoğlu, FS; Türktaş, I, 1999)	0.3
" Adverse events were recorded at clinic visits."	( Safety of long-term treatment with HFA albuterol. Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1999)	0.57
" Total reported adverse events were similar for the two treatments."	( Safety of long-term treatment with HFA albuterol. Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1999)	0.57
" Safety measurements included vital signs, physical examination, and reports of clinical adverse events at baseline and after 4, 8, and 12 weeks of treatment."	( Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma. Busse, WW; Casale, TB; Cox, F; Murray, JJ; Petrocella, V; Rickard, K, 1998)	0.3
" Pulmonary function, symptom control, frequency of asthma exacerbations, bronchial hyperresponsiveness (BHR) to methacholine challenge, and adverse events were assessed."	( A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma. Emmett, AH; Grossman, J; Nathan, RA; Pinnas, JL; Rickard, KA; Schwartz, HJ; Yancey, SW, 1999)	0.3
" We conclude that sputum induction using a relatively low output ultrasonic nebulizer with premedication with salbutamol is successful and safe in the majority of patients with asthma and other airway conditions."	( The safety and success rate of sputum induction using a low output ultrasonic nebuliser. Hunter, CJ; Pavord, ID; Ward, R; Wardlaw, AJ; Woltmann, G, 1999)	0.3
" Our findings indicate that TAA-HFA is a safe and effective replacement for the currently marketed CFC-containing product."	( Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group. Banerji, D; Chervinsky, P; Jacobson, K; Kane, RE; Noonan, M; Uryniak, T, 1999)	0.3
" Safety assessments included monitoring of adverse events and morning serum cortisol concentrations."	( Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Anttila, H; Davies, PI; Hederos, CA; Ossip, MS; Ribeiro, BL; Van den Berg, NJ, 2000)	0.31
" Frequent adverse events were exacerbations of the underlying airway disease (24%) and infections (12%), while typical pharmacological side-effects like tremor or tachycardia where reported in less than 1% of all patients."	( [efficacy and safety of salmeterol in long-term therapy in patients with chronic obstructive airway diseases]. Beeh, KM; Buhl, R; Salem, AE; Wiewrodt, R, 2000)	0.31
" Fluticasone propionate treatment over a 54-week period was well tolerated, with few drug-related adverse events, which were primarily topical effects of inhaled corticosteroids."	( Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000)	0.31
" Maternal side effects, particularly cardiovascular adverse events (8."	( Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group. , 2001)	0.31
" The extrapulmonary responses of (R)-albuterol and adverse effects were similar for single R-enantiomer or the racemic mixture."	( Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. DeGraw, S; Gumbhir-Shah, K; Jusko, WJ; Kellerman, DJ; Koch, P, 1998)	0.8
" In addition, GCD is relatively safe in the rat if the amount of GCD in the formulation is similar to this experiment."	( Cyclodextrin as a potential drug carrier in salbutamol dry powder aerosols: the in-vitro deposition and toxicity studies of the complexes. Reanmongkol, W; Srichana, T; Suedee, R, 2001)	0.31
" Outcomes assessed were completion of the test protocol, adequacy of sputum samples, decrease in FEV1, and adverse effects during the procedure."	( The tolerability, safety, and success of sputum induction and combined hypertonic saline challenge in children. Gibson, PG; Hankin, R; Henry, RL; Jones, PD; Simpson, J, 2001)	0.31
"Sputum induction is a safe and effective technique to study airway inflammation in stable asthma."	( Safety of sputum induction with isotonic saline in adults with acute severe asthma. Gibson, PG; Hensley, MJ; Simpson, JL; Wark, PA, 2001)	0.31
" Adverse events, clinical laboratory test results, vital signs, and electrocardiograms were evaluated for safety."	( Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. Baumgartner, RA; Bensch, G; Claus, R; Kim, KT; Milgrom, H; Skoner, DP, 2001)	0.69
" Lung function, quality of life and adverse events were evaluated as primary outcome variables."	( [Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma]. Beeh, KM; Beier, J; Buhl, R; Kornmann, O; Wiewrodt, R, 2002)	0.31
" Frequent adverse events included symptoms of asthma (5."	( [Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma]. Beeh, KM; Beier, J; Buhl, R; Kornmann, O; Wiewrodt, R, 2002)	0.31
" The main outcome measures were: indication for use of Ventolin MDI, assessment of disease severity, event rates during each period of observation; deaths, pregnancies, reported adverse drug reactions and reasons for discontinuation of MDI."	( Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England. Craig-McFeely, PM; Maier, WC; Shakir, SA; Soriano, JB; Wilton, LV, 2003)	0.32
" No serious adverse events, abnormal pregnancy outcomes or deaths have been related to Ventolin MDI or Ventolin Evohaler."	( Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England. Craig-McFeely, PM; Maier, WC; Shakir, SA; Soriano, JB; Wilton, LV, 2003)	0.32
" The incidence of adverse effects (except for an increase in oral candidiasis with FSC and FP) were similar among the treatment groups."	( The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Darken, P; Davis, S; Hanania, NA; Horstman, D; Lee, B; Reisner, C; Shah, T, 2003)	0.32
" Primary safety variables were asthma-related and nonasthma-related serious adverse events (SAE)s and adverse events (AE)s resulting in discontinuation (DAE)s."	( Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Aubier, M; Bengtsson, T; Campbell, M; Huang, S; Lindh, A; Pauwels, RA; Petermann, W; Schwabe, G; Sears, MR; Villasante, C, 2003)	0.32
"Despite concerns in the 1970s and 1980s about the safety of short-acting beta2-agonists, it is now generally accepted that these agents, used at appropriate doses, provide safe and effective treatment for asthma symptoms."	( State of the art in beta2-agonist therapy: a safety review of long-acting agents. Rabe, KF, 2003)	0.32
" Forced expiratory volume in 1 s (FEV1), pulse, blood pressure, electrocardiogram, adverse events and urine formoterol were assessed."	( Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Honomichlová, H; Kopriva, F; Matulka, M; Pohunek, P; Rybnícek, O; Svobodová, T, 2004)	0.32
" Our aim was to establish whether adverse effects of SABAs are greater at higher than normal doses and after withdrawing inhaled corticosteroid (ICS) therapy."	( Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate. Cowan, JO; Flannery, EM; Herbison, GP; Smith, AD; Taylor, DR; Wraight, JM, 2004)	0.32
" No patients discontinued due to treatment-related adverse events."	( Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma. Ayre, G; Dobson, C; Horowitz, A; Kruse, M; Rosenkranz, B, 2005)	0.33
" Both treatments were well tolerated, and the adverse reactions showed no significant difference between the two groups."	( [Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhaler compared to budesonide turbuhalar in the control of adult asthma]. Cai, BQ; Chen, BY; Chen, XD; Feng, YL; Guo, XJ; Kang, J; Li, Q; Lin, YP; Qiu, C; Shen, HH; Sun, TY; Tao, JJ; Wang, DQ; Xiao, BR; Xie, CM; Xu, YP; Yin, KS; Zhang, DP; Zheng, JP; Zhong, NS; Zhou, JY; Zhou, X, 2005)	0.33
"Sputum induction was found to be a safe procedure for obtaining clinical samples from children and adolescents even during exacerbations, allowing for clinical and functional limitations."	( [Induced sputum in children and adolescents with asthma: safety, clinical applicability and inflammatory cells aspects in stable patients and during exacerbation]. Bussamra, MH; Martins, MA; Nunes, Mdo P; Palomino, AL; Rodrigues, JC; Saraiva-Romanholo, BM, )	0.13
" Safety was assessed according to adverse events recorded."	( Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. Du, X; Humphries, M; Jiang, J; Wang, L; You-Ning, L, 2005)	0.33
" Safety evaluations were based on clinical adverse events and COPD exacerbations."	( The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Brown, CP; Emmett, A; Hanania, NA; Kalberg, C; Knobil, K; Make, B; ZuWallack, R, 2005)	0.55
" The type and incidence of adverse events were similar between the 2 groups."	( The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Brown, CP; Emmett, A; Hanania, NA; Kalberg, C; Knobil, K; Make, B; ZuWallack, R, 2005)	0.55
"Although large surveys have documented the favourable safety profile of beta(2)-adrenoceptor agonists (beta(2)-agonists) and, above all, that of the long-acting agents, the presence in the literature of reports of adverse cardiovascular events in patients with obstructive airway disease must induce physicians to consider this eventuality."	( Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Cazzola, M; Donner, CF; Matera, MG, 2005)	0.33
" The overall incidence of adverse events was 59% for fluticasone propionate-salmeterol and 57% for fluticasone propionate."	( The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Dorinsky, P; Ellsworth, A; House, K; LaForce, C; Malone, R; Nimmagadda, S; Schoaf, L, 2005)	0.33
" Treatment with high-dose formoterol and salbutamol was equally well tolerated, with no reports of serious adverse events."	( Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. Ayre, G; Dobson, C; Fitoussi, S; Horowitz, A; Kruse, M; Rosenkranz, B; Rouzier, R, 2006)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" While the exact mechanism for this known adverse effect of albuterol is not known, awareness of this adverse effect can be life saving to the patient."	( Paradoxical bronchospasm: a potentially life threatening adverse effect of albuterol. Nagajothi, N; Raghunathan, K, 2006)	0.81
" Safety assessments included adverse events, 12-hour urinary cortisol excretion, and growth."	( Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. Baker, JW; Blake, KV; Crim, C; Faris, MA; Kim, KT; Scott, CA; Wasserman, RL; Wu, W, 2006)	0.33
" There is much to suggest that the adverse outcomes associated with LABA monotherapy have been due to "masking of inflammation" rather than a toxic effect of the drugs."	( Long-acting beta-agonists in adult asthma: Evidence that these drugs are safe. Nelson, HS, 2006)	0.33
"Two very large, randomized, double-blind clinical trials performed in the United Kingdom and in the United States have suggested that addition of salmeteräE to usual asthma therapy is associated with a significant increase in the incidence of serious adverse events and asthma-related deaths compared with addition of albuterol or placebo to usual therapy in the same type of patients."	( Serious adverse events and death associated with treatment using long-acting beta-agonists. Martinez, FD, )	0.3
" The percentage of patients who experienced at least 1 adverse event was similar in the 2 groups."	( Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. Ceruti, E; Crim, C; Kleha, JF; Maspero, JF; Mehta, R; Qaqundah, PY; Scott, CA; Sugerman, RW; Wu, W, 2006)	0.33
" The overall rate of adverse events was PBO 56."	( Evaluation of the efficacy and safety of levalbuterol in subjects with COPD. Andrews, C; Baumgartner, RA; Claus, R; D'Urzo, T; Donohue, JF; Parsey, MV; Schaefer, K; Sharma, S, 2006)	0.59
" LABAs are well-tolerated in patients with COPD, with a low incidence of reported adverse events (AEs)."	( Clinical safety of long-acting beta2-agonist and inhaled corticosteroid combination therapy in COPD. Decramer, M; Ferguson, G, 2006)	0.33
" Few adverse events were reported; all were mild or moderate in severity."	( Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Barbier, M; Brookman, LJ; Elharrar, B; Fuhr, R; Knowles, LJ; Pascoe, S, 2007)	0.34
" The sustained bronchodilation of indacaterol 1000 microg was not associated with sustained systemic adverse effects."	( Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Barbier, M; Brookman, LJ; Elharrar, B; Fuhr, R; Knowles, LJ; Pascoe, S, 2007)	0.34
"To compare the risk of total mortality and certain respiratory and cardiac adverse events among users of the two types of recommended long-acting bronchodilators, we conducted a cohort study."	( Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Jara, M; Kesten, S; Lanes, SF; May, C; Wentworth, C, 2007)	0.34
" The primary end point was the incidence of postrandomization adverse events."	( Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Baumgartner, RA; D'Urzo, A; Hamilos, DL; Levy, RJ; Marcus, M; McVicar, WK; Parsey, M; Tripp, K, 2007)	0.63
"The overall incidence of adverse events was similar for levalbuterol (72."	( Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Baumgartner, RA; D'Urzo, A; Hamilos, DL; Levy, RJ; Marcus, M; McVicar, WK; Parsey, M; Tripp, K, 2007)	0.87
"The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular salmeterol versus placebo or regular short-acting beta(2)-agonists."	( Regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ, 2008)	0.35
" Unpublished data on mortality and serious adverse events was sought."	( Regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ, 2008)	0.35
" In 6 trials (2,766 patients), no serious adverse event data could be obtained."	( Regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ, 2008)	0.35
"In comparison with placebo, we have found an increased risk of serious adverse events with regular salmeterol."	( Regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ, 2008)	0.35
" This is a non-inferiority study where safety and efficacy outcomes were serially assessed, including adverse events, Baseline (BDI)/Transition Dyspnea Index (TDI), St."	( A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pul Balkissoon, R; Make, B, 2008)	0.56
"Acute administration of 3% and 7% HS appears to be safe and well-tolerated in most young children with CF."	( Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Davis, SD; Dellon, EP; Donaldson, SH; Johnson, R, 2008)	0.35
"The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular formoterol versus placebo or regular short-acting beta(2)-agonists."	( Regular treatment with formoterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ; Lasserson, TJ, 2008)	0.35
" Unpublished data on mortality and serious adverse events were sought."	( Regular treatment with formoterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ; Lasserson, TJ, 2008)	0.35
" Non-fatal serious adverse event data could be obtained for all participants from published studies comparing formoterol and placebo but only 80% of those comparing formoterol with salbutamol or terbutaline."	( Regular treatment with formoterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ; Lasserson, TJ, 2008)	0.35
"In comparison with placebo, we have found an increased risk of serious adverse events with regular formoterol, and this does not appear to be abolished in patients taking inhaled corticosteroids."	( Regular treatment with formoterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ; Lasserson, TJ, 2008)	0.35
" Subgroup analysis suggests that children, patients receiving salmeterol, and a duration of treatment>12 weeks are associated with a higher risk of serious adverse effects; also there was a protective effect of concomitant use of ICS."	( Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Castro-Rodriguez, JA; Marcos, LG; Moral, VP; Rodrigo, GJ, 2009)	0.35
" Nevertheless, in spite of the protective effect of the ICS, children and salmeterol use still show an increased risk of non-fatal serious adverse events."	( Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Castro-Rodriguez, JA; Marcos, LG; Moral, VP; Rodrigo, GJ, 2009)	0.35
" The incidence of adverse events was low and similar between the two groups and events were of the type expected in this population."	( Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea. Chan, R; Jung, KS; Lee, YC; Park, SK; Shim, JJ; Uh, ST; Williams, AE, 2008)	0.35
" Whether this association represents adverse effects of beta -agonist use or is entirely due to disease severity is a matter of ongoing debate."	( Safety of long-acting beta2-agonists in the treatment of asthma. Cazzola, M; Matera, MG, 2007)	0.34
" The frequency of adverse events, COPD exacerbations, and use of short-acting bronchodilator agents were assessed throughout the study period."	( Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Baumgartner, RA; Donohue, JF; Goodwin, E; Grogan, DR; Hanania, NA; Hanrahan, JP; Sciarappa, KA, 2008)	0.35
"Among treated subjects, the frequency of adverse events was similar for those taking arformoterol (90."	( Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Baumgartner, RA; Donohue, JF; Goodwin, E; Grogan, DR; Hanania, NA; Hanrahan, JP; Sciarappa, KA, 2008)	0.35
"Increased BDNF concentrations may underly the adverse effects of salmeterol monotherapy on airway responsiveness in asthma."	( Adverse effects of salmeterol in asthma: a neuronal perspective. Bratke, K; Edner, A; Kuepper, M; Lindner, Y; Lommatzsch, M; Virchow, JC, 2009)	0.35
" Adverse events, clinical laboratory test results, and vital signs were recorded throughout the 2 clinical studies."	( Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propiona Daley-Yates, PT; Gillett, B; House, KW; Ortega, HG; Parkins, DA; Thomas, MJ, 2009)	0.35
" Drug-related adverse events occurred in both groups (2 [dysphagia and tremor] in the RPID group and 3 [2 cases of dysphonia, 1 case of mucous-membrane irritation] in the Diskus group)."	( Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propiona Daley-Yates, PT; Gillett, B; House, KW; Ortega, HG; Parkins, DA; Thomas, MJ, 2009)	0.35
" The 2 SFC 50/250 inhalers were well tolerated and had comparable safety profiles; no serious adverse events were attributed to the study product."	( Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propiona Daley-Yates, PT; Gillett, B; House, KW; Ortega, HG; Parkins, DA; Thomas, MJ, 2009)	0.35
" Adverse effects linked to tocolysis were recorded."	( Nicardipine versus salbutamol in the treatment of premature labor: comparison of their efficacy and side effects. Abdennadheur, W; Amouri, H; Ben Amar, H; Gargouri, A; Guermazi, M; Hadj Taib, H; Kallel, W; Trabelsi, K; Zribi, A, 2008)	0.35
" Overall, 37% of formoterol plus tiotropium recipients experienced adverse events versus 51% of those receiving placebo plus tiotropium."	( Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Boota, A; Denis-Mize, K; Hanania, NA; Kerwin, E; Tomlinson, L, 2009)	0.35
"The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular salmeterol with inhaled corticosteroids versus the same dose of inhaled corticosteroids alone."	( Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cates, CJ; Jaeschke, R; Lasserson, TJ, 2009)	0.35
" Unpublished data on mortality and serious adverse events were obtained from the sponsors, and from FDA submissions."	( Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cates, CJ; Jaeschke, R; Lasserson, TJ, 2009)	0.35
" The overall risk of bias was low and data on serious adverse events were obtained from all studies."	( Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cates, CJ; Jaeschke, R; Lasserson, TJ, 2009)	0.35
"No significant differences have been found in fatal or non-fatal serious adverse events in trials in which regular salmeterol has been randomly allocated with inhaled corticosteroids, in comparison to inhaled corticosteroids at the same dose."	( Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cates, CJ; Jaeschke, R; Lasserson, TJ, 2009)	0.35
" Although, the response to bronchoconstriction in dogs and rats was different from humans, the two species presented ventilatory changes that highlight the potential adverse effect of test articles."	( Respiratory safety pharmacology: positive control drug responses in Sprague-Dawley rats, Beagle dogs and cynomolgus monkeys. Authier, S; Gauvin, D; Legaspi, M; Troncy, E, 2009)	0.35
"An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews."	( Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2009)	0.35
"We set out to compare the risks of mortality and non-fatal serious adverse events in trials which have randomised patients with chronic asthma to regular formoterol versus regular salmeterol."	( Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2009)	0.35
" Unpublished data on mortality and serious adverse events were sought from the sponsors and authors."	( Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2009)	0.35
" All studies were open label and recruited patients who were already taking inhaled corticosteroids for their asthma, and all studies contributed data on serious adverse events."	( Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2009)	0.35
" Asthma-related serious adverse events were rare, and there were no reported asthma-related deaths."	( Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2009)	0.35
"An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2010)	0.36
"We set out to compare the risks of mortality and non-fatal serious adverse events in trials which have randomised patients with chronic asthma to regular formoterol versus regular salmeterol, when each are used with an inhaled corticosteroid as part of the randomised treatment."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2010)	0.36
" Unpublished data on mortality and serious adverse events were sought from the sponsors and authors."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2010)	0.36
" Asthma-related serious adverse events were rare, and there were no reported asthma-related deaths."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2010)	0.36
" Food and Drug Administration and featured in the labeling of drugs associated with serious adverse reactions."	( FDA boxed warnings: how to prescribe drugs safely. O'Connor, NR, 2010)	0.36
" Assessments included adverse events, signs of adrenergic stimulation, electrocardiograms, and blood glucose and potassium levels."	( Repeat dosing of albuterol via metered-dose inhaler in infants with acute obstructive airway disease: a randomized controlled safety trial. Davis, AM; Ellsworth, A; Goodman, B; Kaashmiri, M; Lincourt, WR; Shepard, J; Trivedi, R, 2010)	0.7
"Overall, adverse events occurred in 4 (9%) and 3 (7%) subjects in the 180-microg and 360-microg groups, respectively."	( Repeat dosing of albuterol via metered-dose inhaler in infants with acute obstructive airway disease: a randomized controlled safety trial. Davis, AM; Ellsworth, A; Goodman, B; Kaashmiri, M; Lincourt, WR; Shepard, J; Trivedi, R, 2010)	0.7
"an increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2010)	0.36
" Unpublished data on mortality and serious adverse events were sought from the sponsors and authors."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2010)	0.36
" Asthma-related serious adverse events were rare, and there were no reported asthma-related deaths."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2010)	0.36
" Adverse events (AEs) were analysed overall and according to Anti-Platelet Trialists' Collaboration (APTC) criteria and baseline cardiovascular risk factors."	( Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Chung, KF; Felser, JM; Hu, H; Rueegg, P; Worth, H, 2011)	0.37
" However, several studies have indicated an increased risk of asthma mortality and asthma-related serious adverse events and the FDA recently mandated restrictions to the use of LABAs in asthma."	( Safe use of long-acting β-agonists: what have we learnt? Sears, MR, 2011)	0.37
" Add-on therapy with LABA is effective and safe if the dose of ICS is adequate to treat airway inflammation."	( Safe use of long-acting β-agonists: what have we learnt? Sears, MR, 2011)	0.37
" Other endpoints included adverse events and pulmonary function."	( A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma. Curry, L; Goodwin, E; Hanrahan, JP; Hinkle, J; Hinson, J; Kerwin, E; Sciarappa, K, 2011)	0.37
" Adverse events were infrequent and differences in forced expiratory volume in 1 sec and peak expiratory flow across treatment groups were not clinically meaningful."	( A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma. Curry, L; Goodwin, E; Hanrahan, JP; Hinkle, J; Hinson, J; Kerwin, E; Sciarappa, K, 2011)	0.37
" Adverse events (mostly mild or moderate) were reported for 52% and 46% of patients receiving indacaterol and placebo, respectively, and serious adverse events for 4% and 5%."	( Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data. Bleecker, ER; Kramer, B; Owen, R; Siler, T, 2011)	0.37
" Treatment time and adverse events were recorded."	( A prospective, comparative trial of standard and breath-actuated nebulizer: efficacy, safety, and satisfaction. Arunthari, V; Bruinsma, RS; Johnson, MM; Lee, AS, 2012)	0.38
" Additionally, the BAN was associated with a lower occurrence of adverse events."	( A prospective, comparative trial of standard and breath-actuated nebulizer: efficacy, safety, and satisfaction. Arunthari, V; Bruinsma, RS; Johnson, MM; Lee, AS, 2012)	0.38
" Pre- and post-treatment vital signs did not differ between groups, but use of the BAN was associated with a shorter duration and a lower occurrence of adverse events."	( A prospective, comparative trial of standard and breath-actuated nebulizer: efficacy, safety, and satisfaction. Arunthari, V; Bruinsma, RS; Johnson, MM; Lee, AS, 2012)	0.38
"An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews."	( Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2012)	0.38
"We set out to compare the risks of mortality and non-fatal serious adverse events in trials which have randomised patients with chronic asthma to regular formoterol versus regular salmeterol."	( Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2012)	0.38
" We sought unpublished data on mortality and serious adverse events from the sponsors and authors."	( Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2012)	0.38
" All studies were open label and recruited patients who were already taking inhaled corticosteroids for their asthma, and all studies contributed data on serious adverse events."	( Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2012)	0.38
" Asthma-related serious adverse events were rare and there were no reported asthma-related deaths."	( Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2012)	0.38
" Secondary endpoints included pulmonary function, plethysmography, pharmacokinetics of GSK233705 and salmeterol, adverse events (AEs), electrocardiograms (ECGs), vital signs, and laboratory parameters."	( Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients. Baggen, S; Beier, J; Brooks, J; Cahn, A; Deans, A; Maden, C; Mehta, R; van Noord, J, 2012)	0.38
"This study concludes that sublingual immunotherapy is safe during pregnancy and is also safe when initiated for the first time in a pregnant patient."	( A prospective study on the safety of sublingual immunotherapy in pregnancy. Shaikh, SW; Shaikh, WA, 2012)	0.38
"The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular formoterol versus placebo or regular short-acting beta(2)-agonists."	( Regular treatment with formoterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ, 2012)	0.38
" We sought unpublished data on mortality and serious adverse events."	( Regular treatment with formoterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ, 2012)	0.38
" Non-fatal serious adverse event data could be obtained for all participants from published studies comparing formoterol and placebo but only 80% of those comparing formoterol with salbutamol or terbutaline."	( Regular treatment with formoterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ, 2012)	0.38
"In comparison with placebo, we have found an increased risk of serious adverse events with regular formoterol, and this does not appear to be abolished in patients taking inhaled corticosteroids."	( Regular treatment with formoterol for chronic asthma: serious adverse events. Cates, CJ; Cates, MJ, 2012)	0.38
" We extracted the data relating to children from each review and from new trials found in the updated searches (including risks of bias, study characteristics, serious adverse event outcomes, and control arm event rates)."	( Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cates, CJ; Oleszczuk, M; Stovold, E; Wieland, LS, 2012)	0.38
" There are probably an additional three children per 1000 who suffer a non-fatal serious adverse event on combination therapy in comparison to ICS over three months."	( Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cates, CJ; Oleszczuk, M; Stovold, E; Wieland, LS, 2012)	0.38
" We summarized data relating to exacerbations and adverse events, particularly events related to COPD."	( The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Decramer, ML; Hanania, NA; Lötvall, JO; Yawn, BP, 2013)	0.39
"From 20 studies examined (8774 LABA-treated patients), there was no evidence of an association between LABA treatment and increased exacerbations, COPD-related adverse events, or deaths."	( The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Decramer, ML; Hanania, NA; Lötvall, JO; Yawn, BP, 2013)	0.39
" Secondary outcome measures included quality of life as measured by the Paediatric Asthma Quality of Life Questionnaire with Standardised Activities [PAQLQ(S)] and the Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ); time from randomisation to first exacerbation requiring treatment with a short course of oral corticosteroids; school attendance; hospital admissions; amount of rescue beta-2 agonist therapy prescribed; time from randomisation to treatment withdrawal (because of lack of efficacy or side effects); lung function at 48 weeks (as assessed by spirometry); cost-effectiveness; adverse events."	( Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. James, M; Lenney, W; McKay, AJ; Price, D; Tudur Smith, C; Williamson, PR, 2013)	0.39
" Adverse events were similar between the groups except for nervous system disorders, which were more frequently reported on fluticasone plus montelukast."	( Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. James, M; Lenney, W; McKay, AJ; Price, D; Tudur Smith, C; Williamson, PR, 2013)	0.39
" Systemic pharmacodynamics (potassium, heart rate, glucose and QTc), adverse events and systemic pharmacokinetics were also assessed."	( Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD. Ambery, C; Norris, V, 2013)	0.39
"To assess the risk of mortality and non-fatal serious adverse events in trials which randomised patients with chronic asthma to regular salmeterol and inhaled corticosteroids in comparison to the same dose of inhaled corticosteroids."	( Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cates, CJ; Ferrer, M; Jaeschke, R; Schmidt, S, 2013)	0.39
" We obtained unpublished data on mortality and serious adverse events from the sponsors, and from FDA submissions."	( Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cates, CJ; Ferrer, M; Jaeschke, R; Schmidt, S, 2013)	0.39
" We judged that the overall risk of bias was low, and we obtained data on serious adverse events from all studies."	( Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cates, CJ; Ferrer, M; Jaeschke, R; Schmidt, S, 2013)	0.39
"We found no statistically significant differences in fatal or non-fatal serious adverse events in trials in which regular salmeterol was randomly allocated with ICS, in comparison to ICS alone at the same dose."	( Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cates, CJ; Ferrer, M; Jaeschke, R; Schmidt, S, 2013)	0.39
"The adverse environmental effects of CFC-pMDIs stimulated the invention of novel delivery systems including the Respimat SMI."	( Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease. Panos, RJ, 2013)	0.61
" The two groups were compared with respect to symptom scores of cough, wheeze, respiratory rate, wheezing sound, three depression sign and peak expiratory flow, as well as adverse events."	( [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study]. Bao, YX; Lin, Q; Liu, QH, 2013)	0.39
" One child developed hand trembling in the salbutamol group, while no adverse event occurred in the tulobuterol group."	( [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study]. Bao, YX; Lin, Q; Liu, QH, 2013)	0.39
" Both treatments were well tolerated, with no clinically relevant effect on urinary cortisol excretion or vital signs and no treatment-related serious adverse events."	( Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Bateman, ED; Bleecker, ER; Busse, WW; Ellsworth, A; Jacques, L; Lötvall, J; Medley, H; O'Byrne, PM; Woodcock, A, 2013)	0.39
" Six patients in the FF/VI (2%) and three in the FP/SAL (1%) arm experienced serious adverse events, none of which were considered to be drug related."	( A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Agustí, A; Barnes, N; Bourbeau, J; Crim, C; De Backer, W; de Teresa, L; Locantore, N; Zvarich, MT, 2014)	0.4
"Our findings suggest that BT is safe for 5 years after BT in patients with severe refractory asthma."	( Safety of bronchial thermoplasty in patients with severe refractory asthma. Armstrong, B; Chung, KF; Corris, PA; Cox, G; Laviolette, M; Niven, RM; Pavord, ID; Shargill, NS; Thomson, NC, 2013)	0.39
" Overall incidence of adverse events (including COPD exacerbations) was 55·4% (143 of 258) for the QVA149 group and 60·2% (159 of 264) for the SFC group."	( Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Alagappan, VK; Banerji, D; Bateman, ED; Chen, H; D'Andrea, P; Pallante, J; Vogelmeier, CF, 2013)	0.39
" Ascoril expectorant caused no adverse reactions and was well tolerated by the patients."	( [Results of international multicentre non-interventional clinical study of the effectiveness and safety of ascoril expectorant for the treatment of cough in Kazakhstan and Uzbekistan]. Abuova, GT; An, ÉA; Ermekbaeva, BA; Guliaev, AE; Nurgozhin, TS; Zhaugasheva, SK, 2013)	0.39
" Clinical trials record these safety outcomes as non-fatal and fatal serious adverse events (SAEs), respectively."	( Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cates, CJ; Kew, KM; Oleszczuk, M; Wieland, LS, 2014)	0.4
"To assess the risk of serious adverse events in adults with asthma treated with regular maintenance formoterol or salmeterol compared with placebo, or when randomly assigned in combination with regular ICS, compared with the same dose of ICS."	( Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cates, CJ; Kew, KM; Oleszczuk, M; Wieland, LS, 2014)	0.4
"Available evidence from the reviews of randomised trials cannot definitively rule out an increased risk of fatal serious adverse events when regular formoterol or salmeterol was added to an inhaled corticosteroid (as background or as randomly assigned treatment) in adults or adolescents with asthma."	( Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cates, CJ; Kew, KM; Oleszczuk, M; Wieland, LS, 2014)	0.4
"All airway adverse events (AEs) were of mild or moderate severity."	( Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials. Cassella, JV; Fishman, RS; Greos, LS; Gross, N; Meltzer, EO; Spangenthal, S; Spyker, DA, 2014)	0.4
" Pooled adverse events (FF/VI 27%; FP/SAL 28%) and serious adverse events (FF/VI 2%; FP/SAL 3%) were similar between treatments."	( Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Crim, C; Dransfield, MT; Feldman, G; Korenblat, P; LaForce, CF; Locantore, N; Martinez, FJ; Pistolesi, M; Watkins, ML, 2014)	0.4
" The profile of treatment-emergent adverse events judged as related to abediterol was consistent with that seen after adrenergic stimulation and occurred exclusively in patients who received abediterol 10 μg or 25 μg."	( Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma. Beier, J; de Miquel, G; Fuhr, R; Jiménez, E; Massana, E; Ruiz, S; Seoane, B, 2014)	0.4
" This systematic review tested the hypothesis that the bronchodilator effect of the LABA/LAMA combination, umeclidinium (UMEC)/vilanterol (VIL), would translate into better outcomes without incurring increased adverse events (AEs)."	( A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD. Neffen, H; Rodrigo, GJ, 2015)	0.42
" Primary outcomes were trough FEV1, serious adverse events (SAEs), and serious cardiovascular events (SCVEs)."	( A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD. Neffen, H; Rodrigo, GJ, 2015)	0.42
" The incidence of on-treatment adverse events (AEs) was 48% with FF/VI 200/25 mcg and 37-40% with other treatments."	( Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Crim, C; de Guia, T; Newlands, AH; Wang, C; Wang-Jairaj, J; Zheng, J; Zhong, N, 2015)	0.42
" Long-acting β-2 agonists (LABAs) used in combination with inhaled corticosteroids (ICS) don't appear to increase all-cause mortality or serious adverse events in patients with persistent asthma compared with ICS alone."	( HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma? Madlon-Kay, DJ; Townsend, L, 2015)	0.42
" The efficacy and adverse events of SI were analyzed."	( Diagnostic yield and safety of sputum induction with nebulized racemic salbutamol versus hypertonic saline in smear-negative pulmonary tuberculosis. Keeratichananont, S; Keeratichananont, W; Nilmoje, T; Rittatorn, J, 2015)	0.42
"During both 12-week studies and the 12-week double-blind phase of the 52-week study, adverse events were more common with placebo MDPI (50%; n = 333) than albuterol MDPI (40%; n = 321); most frequent were upper respiratory tract infection (placebo MDPI 11%, albuterol MDPI 10%), nasopharyngitis (6%, 5%), and headache (6%, 4%)."	( Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma. Iverson, H; Miller, D; O'Brien, C; Raphael, G; Taveras, H, 2016)	0.92
" In conclusion, the proposed hydrogels represent a safe and efficient buccal drug delivery platform."	( Poloxamer bioadhesive hydrogel for buccal drug delivery: Cytotoxicity and trans-epithelial permeability evaluations using TR146 human buccal epithelial cell line. Boudy, V; Dumortier, G; Maury, M; Mignet, N; Olivier, E; Rat, P; Scherman, D; Seguin, J; Zeng, N, 2015)	0.42
" Adverse events were comparable across groups."	( Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. Bleecker, ER; Busse, WW; Donohue, JF; Garfinkel, S; Ghafouri, M; Manuel, RC; Schlenker-Herceg, R; Wise, R; Zubek, VB, 2016)	0.7
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."	( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016)	0.43
" Efficacy and safety were evaluated by measuring the baseline-adjusted percent-predicted FEV1 (PPFEV1) area under the time curve over 6 hours (AUC0-6) after the dose and adverse events, respectively."	( Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma. Iverson, H; LaForce, C; Shore, P; Taveras, H, 2017)	1.9
"Sputum induction is successful and safe in COPD."	( The success and safety profile of sputum induction in patients with chronic obstructive pulmonary disease: An Indian experience. Fernandes, L; Mesquita, AM, 2017)	0.46
"Perioperative respiratory adverse events (PRAE) remain the leading cause of morbidity and mortality in the paediatric population."	( Premedication with salbutamol prior to surgery does not decrease the risk of perioperative respiratory adverse events in school-aged children. Drake-Brockman, TFE; Hall, GL; Ramgolam, A; Slevin, L; Sommerfield, D; von Ungern-Sternberg, BS; Zhang, G, 2017)	0.46
" Safety in terms of adverse events (AEs) was also examined."	( Real-life effectiveness and safety of salbutamol Steri-Neb™ vs. Ventolin Nebules® for exacerbations in patients with COPD: Historical cohort study. Davis, E; Gefen, E; Gopalan, G; McDonald, R; Ming, SWY; Price, DB; Thomas, V, 2018)	0.48
" OBJECTIVES: To assess risks of mortality and non-fatal serious adverse events (SAEs) in trials that randomised participants with chronic asthma to regular salmeterol and ICS versus the same dose of ICS."	( Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. Cates, CJ; Ferrer, M; Sayer, B; Schmidt, S; Waterson, S, 2018)	0.48
"Non-fatal serious adverse eventsA total of 332 adults receiving regular salmeterol with ICS experienced a non-fatal SAE of any cause, compared to 282 adults receiving regular ICS."	( Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. Cates, CJ; Ferrer, M; Sayer, B; Schmidt, S; Waterson, S, 2018)	0.48
"We did not find a difference in the risk of death or serious adverse events in either adults or children."	( Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. Cates, CJ; Ferrer, M; Sayer, B; Schmidt, S; Waterson, S, 2018)	0.48
" Up to half of children having this procedure experience a perioperative respiratory adverse event."	( Effect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial. Drake-Brockman, TFE; Hall, GL; Slevin, L; Sommerfield, D; von Ungern-Sternberg, BS; Zhang, G, 2019)	0.92
"To determine whether inhaled albuterol sulfate (salbutamol sulfate) premedication decreases the risk of perioperative respiratory adverse events in children undergoing anesthesia for tonsillectomy."	( Effect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial. Drake-Brockman, TFE; Hall, GL; Slevin, L; Sommerfield, D; von Ungern-Sternberg, BS; Zhang, G, 2019)	1.21
"Occurrence of perioperative respiratory adverse events (bronchospasm, laryngospasm, airway obstruction, desaturation, coughing, and stridor) until discharge from the postanesthesia care unit."	( Effect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial. Drake-Brockman, TFE; Hall, GL; Slevin, L; Sommerfield, D; von Ungern-Sternberg, BS; Zhang, G, 2019)	0.92
" Perioperative respiratory adverse events occurred in 67 of 241 children (27."	( Effect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial. Drake-Brockman, TFE; Hall, GL; Slevin, L; Sommerfield, D; von Ungern-Sternberg, BS; Zhang, G, 2019)	0.92
"Albuterol premedication administered before tonsillectomy under general anesthesia in young children resulted in a clinically significant reduction in rates of perioperative respiratory adverse events compared with the rates in children who received placebo."	( Effect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial. Drake-Brockman, TFE; Hall, GL; Slevin, L; Sommerfield, D; von Ungern-Sternberg, BS; Zhang, G, 2019)	2.36
" First and second groups served as normal and toxic control were given distilled water 6 ml/ kg while third, fourth and fifth experimental groups were given N-acetylcysteine (300 mg/ kg), prazosin (0."	( Hepatoprotective Effect Of Prazosin Is Comparable To N-Acetylcysteine In Acetaminophen Induced Hepatotoxicity In Mice. Chiragh, S; Hussain, M; Shad, MN; Sulaiman, S, )	0.13
" Secondary outcomes included risk of hospitalization, pulmonary function, asthma control level, quality of life, and adverse events (AEs)."	( Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis. Hong, JG; Lu, J; Qin, Z; Zhou, XJ, 2021)	0.62
" During the treatment, the remission time of typical respiratory manifestations was recorded, and the adverse reactions were observed."	( Efficacy and safety of combined doxofylline and salbutamol in treatment of acute exacerbation of chronic obstructive pulmonary disease. Bao, H; Du, X; Zhao, D, 2021)	0.62
" In addition, the adverse reaction rate had no significant difference between two groups (p>0."	( Efficacy and safety of combined doxofylline and salbutamol in treatment of acute exacerbation of chronic obstructive pulmonary disease. Bao, H; Du, X; Zhao, D, 2021)	0.62
"Use of an RT-driven, score-based pathway for initiation and discontinuation of continuous albuterol for treatment of pediatric asthma exacerbation was safe and effective in the PICU and step-down unit."	( Safe and Effective Use of Score-Based Continuous Albuterol Therapy in a Pathway for Treatment of Pediatric Asthma Exacerbation. Berlinski, A; Carper, NL; Danner, NP; Lloyd, TL; Willis, LD, 2022)	1.2
"In contrast to published literature showing that benzalkonium chloride may be associated with a longer duration of continuous albuterol nebulization and hospital LOS, our study demonstrated that benzalkonium chloride-containing albuterol is safe for continuous nebulization in critically ill children and not associated with worse outcomes."	( Effectiveness and Safety of Albuterol Solutions With and Without Benzalkonium Chloride. Adams, CK; Al-Subu, AM; Bogenschutz, MC; DeSanti, RL; Friestrom, E; Langkamp, MR; Lasarev, MR; Terry, E; Vanderloo, JP; Yngsdal-Krenz, RA, 2023)	1.41
" The primary safety outcome was a composite of serious adverse events (SAEs) and/or adverse events leading to discontinuation (DAEs); the primary effectiveness outcome was time-to-first exacerbation."	( Safety and Effectiveness of As-Needed Formoterol in Asthma Patients Taking Inhaled Corticosteroid (ICS)-Formoterol or ICS-Salmeterol Maintenance Therapy. Anderson, GP; Brusselle, G; Gustafson, P; Jorup, C; Lamarca, R; Reddel, HK, 2023)	0.91

Pharmacokinetics

Sensitivity was assessed in terms of magnitudes of ED(50), the estimated albuterol dose required to achieve 50 % of the fitted maximal value of the pharmacodynamic effect above baseline, and change in response as a function of dose. Separate population pharmacokinetic models were developed for (R)- and (S)-al buterol.

Excerpt	Reference	Relevance
" Patients with renal failure but not asthmatics show changed pharmacokinetic profiles."	( Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Hochhaus, G; Möllmann, H, 1992)	0.28
"The study represents the investigation on pharmacodynamic lung function testing in 40 patients (21 with extrinsic asthma and 19 with intrinsic asthma)."	( [Pharmacokinetic testing of patients with bronchial asthma]. Kotarac, S; Lucić, S; Muhić, H; Pavicić, F; Popović-Grle, S, )	0.13
" The time to peak concentration, half-life and peak-to-trough ratio were similar for both formulations."	( Pharmacokinetic characteristics of a novel controlled-release sprinkle formulation of salbutamol. Devane, J; Martin, M; Mulligan, S, 1991)	0.28
" The mean Cmax for Volmax; administered after a meal was 19% lower than that of the drug administered in a fasting state (3."	( Albuterol extended-release products: effect of food on the pharmacokinetics of single oral doses of Volmax and Proventil Repetabs in healthy male volunteers. Donn, KH; Hussey, EK; Lahey, AP; Pakes, GE; Powell, JR, 1991)	1.72
" The steady-state pharmacokinetic profile of Volmax 8 mg orally every 12 hours for 3 days was compared with that of Proventil Repetabs 8 mg orally every 12 hours for 3 days in a randomized, two-way, crossover study in 23 healthy men."	( Albuterol extended-release products: a comparison of steady-state pharmacokinetics. Donn, KH; Hussey, EK; Powell, JR, 1991)	1.72
" The isolated vagus nerve-trachea tube preparation of the guinea-pig is well suited for the concommitant study of pharmacodynamic and pharmacokinetic properties of bronchodilator drugs."	( Pharmacodynamic and pharmacokinetic aspects on the transport of bronchodilator drugs through the tracheal epithelium of the guinea-pig. Jeppsson, AB; Roos, C; Waldeck, B; Widmark, E, 1989)	0.28
"Salbutamol was administered intravenously to 5 patients with renal function impairment for estimation its pharmacokinetic parameters."	( Pharmacokinetics of intravenous salbutamol in renal insufficiency and its biological effects. Luquel, L; Mory, B; Offenstadt, G; Olive, G; Rey, E; Richard, MO, 1989)	0.28
" There were no differences between O and SL for any of the pharmacodynamic parameters."	( Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. Clark, GA; Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Moreland, TA; Struthers, AD, 1989)	0.28
" Thus a stimulation of the mucociliary transport rate by the other major pharmacodynamic mechanisms, secretagogue activity and stimulation of pulmonary surfactant, has to be considered."	( Pharmacodynamic mechanism and therapeutic activity of ambroxol in animal experiments. Disse, BG; Ziegler, HW, 1987)	0.27
" Limited pharmacokinetic data suggest a long distribution phase, a terminal half-life of 3-8 hours, and 10-20% oral bioavailability."	( Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. Ahrens, RC; Smith, GD, )	1.57
"The safety, tolerability and systemic pharmacodynamic activity of the salmeterol/HFA134a inhaler, the current salmeterol inhaler, and placebo (HFA134a) were compared in 12 healthy volunteers in a double blind, randomised crossover study using a cumulative dosing design."	( Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers. Kirby, SM; Smith, J; Ventresca, GP, 1995)	0.29
"In healthy volunteers the salmeterol/HFA134a inhaler is at least as safe and well tolerated as the current salmeterol inhaler, and has similar systemic pharmacodynamic activity."	( Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers. Kirby, SM; Smith, J; Ventresca, GP, 1995)	0.29
" The plasma pharmacokinetic profiles of nedocromil sodium and the pharmacodynamic effect (bronchodilation) of salbutamol were evaluated."	( Equivalence of pharmacokinetic characteristics and bronchodilating effect between two combined formulations of nedocromil sodium and salbutamol: MDI and nebulizer solution. Bustacchini, S; Pistelli, R; Reggio, S; Valente, S, 1996)	0.29
"001) were found between the NebuChamber (N) and the Turbuhaler (T) for salbutamol Cmax and Cav."	( Lung delivery of salbutamol by dry powder inhaler (Turbuhaler) and small volume antistatic metal spacer (Airomir CFC-free MDI plus NebuChamber). Clark, DJ; Lipworth, BJ, 1997)	0.3
" Apart from causing a small increase in plasma potassium, the distomer had no effect on any pharmacodynamic parameter."	( Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Boulton, DW; Fawcett, JP, 1997)	0.54
"In order to obtain pharmacokinetic data from studies in humans, a sensitive and selective assay for the quantification of salbutamol in human plasma samples was required."	( Rapid pharmacokinetic screening of salbutamol in plasma samples by column-switching high-performance liquid chromatography-electrospray mass spectrometry. Sauter, T; Schmeer, K; Schmid, J, 1997)	0.3
" The mean half-life of distribution was 17."	( Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers. Anderson, PJ; Breen, P; Compadre, CM; Gann, L; Hiller, FC; Logsdon, TW; Zhou, X, 1998)	0.6
" Future pharmacodynamic studies of beta2-agonists should include determination of 02-adrenergic receptor genotype."	( Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Eberle, LV; Johnson, JA; Lima, JJ; Mohamed, MH; Self, TH; Thomason, DB, 1999)	0.54
" The purpose of this study was to test the hypothesis that numerical descriptors of powder flow properties predict aerosol dispersion and pharmacodynamic effect."	( Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Concessio, NM; Hickey, AJ; Knowles, MR; VanOort, MM, 1999)	0.3
" Pharmacodynamic evaluations of bronchodilation were performed in guinea pigs, for selected formulations."	( Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Concessio, NM; Hickey, AJ; Knowles, MR; VanOort, MM, 1999)	0.3
" A proportionality between aerosol dispersion and pharmacodynamic effect was observed in preliminary in vivo evaluations, which demonstrates the potential of these techniques for correlation studies between in vitro powder properties and in vivo effect."	( Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Concessio, NM; Hickey, AJ; Knowles, MR; VanOort, MM, 1999)	0.3
" The pharmacokinetic parameters were determined by noncompartmental analysis and model-fitting."	( Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. DeGraw, S; Gumbhir-Shah, K; Jusko, WJ; Kellerman, DJ; Koch, P, 1999)	0.3
"To investigate the potential for systemic pharmacodynamic and pharmacokinetic interactions between inhaled salmeterol and fluticasone propionate when repeat doses of the two drugs are given in combination to healthy subjects."	( Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Daniel, MJ; Falcoz, C; Kirby, S; Milleri, S; Squassante, L; Ventresca, GP; Ziviani, L, )	0.13
" The systemic pharmacodynamic effects of inhaled salmeterol were not affected by the co-administration of fluticasone propionate."	( Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Daniel, MJ; Falcoz, C; Kirby, S; Milleri, S; Squassante, L; Ventresca, GP; Ziviani, L, )	0.13
"These results in healthy subjects indicate that there is no systemic pharmacodynamic or pharmacokinetic interaction between inhaled salmeterol and fluticasone propionate when given in combination."	( Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Daniel, MJ; Falcoz, C; Kirby, S; Milleri, S; Squassante, L; Ventresca, GP; Ziviani, L, )	0.13
" The pharmacokinetic parameters of each enantiomer were determined by noncompartmental and model-fitting analyses."	( Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. DeGraw, S; Gumbhir-Shah, K; Jusko, WJ; Kellerman, DJ; Koch, P, 1998)	0.53
"To examine whether systemic beta2-adrenoceptor responses, such as tachycardia, tremor and hypokalaemia, can be used as a surrogate for the 20 min pharmacokinetic profile of inhaled salbutamol."	( Pharmacokinetics and systemic beta2-adrenoceptor-mediated responses to inhaled salbutamol. Fowler, SJ; Lipworth, BJ, 2001)	0.31
"To compare the lung and systemic delivery of salbutamol following inhalation from a metered dose inhaler (MDI), a MDI attached to a spacer (MDI+SP) and a nebuliser (NEB) using a urinary pharmacokinetic method."	( Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser. Chrystyn, H; Corlett, SA; Silkstone, VL, 2002)	0.31
" The concentrations of salbutamol in plasma were assessed with non-compartment model to obtain the pharmacokinetic parameters."	( Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. Du, XL; Fu, Q; Li, DK; Xu, WB; Zhu, Z, 2002)	0.31
" Sensitivity was assessed in terms of magnitudes of ED(50), the estimated albuterol dose required to achieve 50 % of the fitted maximal value of the pharmacodynamic effect above baseline, and change in response as a function of dose, with emphasis on 1 and 2 actuations."	( A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers. Adams, WP; Creticos, PS; Khattignavong, AP; Lewis, LD; Lietman, PS; Martinez, MN; Molzon, JA; Petty, BG; Singh, GJ; Williams, RL, 2002)	0.76
" The concentrations of salbutamol in plasma were determined by HPLC, and then assessed with PCNONLIN software to obtain the pharmacokinetic parameters and relative bioavailability of aerosol versus water solution."	( [Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. Du, XL; Fu, Q; Li, DK; Xu, WB; Zhu, Z, 2001)	0.31
" The pharmacokinetics of salbutamol aersol was described well with a two-compartment model, and the parameters for salbutamol inhaled and orally administered were assessed as follows: Tmax were (0."	( [Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. Du, XL; Fu, Q; Li, DK; Xu, WB; Zhu, Z, 2001)	0.31
" The tablets coated to 3% and 4% levels exhibited the release rates within the range calculated from pharmacokinetic data."	( Design of salbutamol EOP tablets from pharmacokinetics parameters. Limsuwan, P; Mitrevej, A; Pongwai, S; Sinchaipanid, N, 2003)	0.32
"Transdermal drug delivery formulation containing 5 mg/patch of salbutamol sulfate (SS), providing an input rate of 100 microg/h of SS was formulated and subjected for pharmacokinetic and pharmacodynamic evaluation in moderately asthmatic patients (n=6)."	( Clinical pharmacokinetic and pharmacodynamic evaluation of transdermal drug delivery systems of salbutamol sulfate. Hiremath, SR; Narasimha Murthy, S, 2004)	0.32
" The peak concentration was reached within 15-20 min."	( The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. Muanpanarai, D; Srichana, T; Suedee, R; Tanmanee, N, 2005)	0.55
"This was a randomised, double-blind, placebo-controlled, cross-over study comparing the systemic pharmacodynamic effects (heart rate and serum potassium) and pharmacokinetics of salmeterol delivered by the non-CFC hydrofluoralkane (HFA) propellant 134a and the CFC propellant (propellant 11/12) metered dose inhalers (MDI) in healthy subjects."	( Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. Daley-Yates, P; De Silva, M; Handel, M; Kempsford, R; Mehta, R, 2005)	0.33
" Separate population pharmacokinetic models were developed for (R)- and (S)-albuterol using the NOMNEM((R)) computer program."	( Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma. Baumgartner, RA; Grasela, T; Hsu, R; Maier, G; Rubino, C, 2007)	0.85
" Therefore, this study investigated the pharmacokinetic characteristics of roflumilast and its pharmacodynamically active metabolite roflumilast N-oxide when co-administered with orally inhaled salbutamol in healthy subjects."	( Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects. Bethke, TD; David, M; Giessmann, T; Hauns, B; Hauschke, D; Hermann, R; Lahu, G; Siegmund, W; Weinbrenner, A; Westphal, K; Zech, K, 2006)	0.33
"There were no relevant pharmacokinetic interactions between roflumilast and salbutamol at therapeutically effective doses."	( Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects. Bethke, TD; David, M; Giessmann, T; Hauns, B; Hauschke, D; Hermann, R; Lahu, G; Siegmund, W; Weinbrenner, A; Westphal, K; Zech, K, 2006)	0.33
"24, Cmax (ng/ml) 172."	( The investigation of the pharmacokinetics of pulsatile-release salbutamol sulfate with pH-sensitive ion exchange resin as the carriers in beagle dogs. Guo, H; Liu, H; Pan, W; Sun, T; Yu, F; Zhao, X, 2007)	0.34
"This study evaluated pharmacokinetic and glucodynamic responses to AIR inhaled insulin relative to subcutaneous insulin lispro, safety, pulmonary function, and effects of salbutamol coadministration."	( AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. Berclaz, PY; de la Peña, A; Gates, JR; Muchmore, DB; Tibaldi, FS; Wolzt, M, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"Because interpatient variability in bronchodilation from inhaled albuterol is large and clinically important, we characterized the albuterol dose/response relationship by pharmacodynamic modeling and quantified variability."	( Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma. Blake, K; Derendorf, H; Lima, J; Madabushi, R, 2008)	0.82
"This study was designed to compare the pharmacokinetic (PK), pharmacodynamic (PD), efficacy, and safety data for 2 DPIs delivering a combination of salmeterol 50 microg plus fluticasone propionate (FP) 250 microg (SFC 50/250) to investigate assumptions of bioequivalence."	( Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propiona Daley-Yates, PT; Gillett, B; House, KW; Ortega, HG; Parkins, DA; Thomas, MJ, 2009)	0.35
" The pharmacokinetic parameters obtained are explained in relation to the compound's metabolism by sulfotransferases."	( Pharmacokinetic parameters and a theoretical study about metabolism of BR-AEA (a salbutamol derivative) in rabbit. Correa-Basurto, J; Elizalde-Solis, O; Galicia-Luna, LA; Romero-Huerta, J; Soriano-Ursúa, MA; Trujillo-Ferrara, JG, 2010)	0.36
"Airway absorption and bioavailability of inhaled corticosteroids (ICSs) may be influenced by differences in pharmacokinetic properties such as lipophilicity and patient characteristics such as lung function."	( The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Borgström, L; Dalby, C; Edsbäcker, S; Harrison, TW; Larsson, T; Polanowski, T, 2009)	0.35
" In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15."	( The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Borgström, L; Dalby, C; Edsbäcker, S; Harrison, TW; Larsson, T; Polanowski, T, 2009)	0.35
" In addition, the strengths and limitations of the PK approach to detect differences in product performance compared with in vitro and pharmacodynamic (PD)/clinical/therapeutic equivalence (TE) studies were discussed."	( Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. Adams, WP; Chen, ML; Daley-Yates, P; Davis, J; Derendorf, H; Ducharme, MP; Fuglsang, A; Herrle, M; Hochhaus, G; Holmes, SM; Lee, SL; Li, BV; Lyapustina, S; Newman, S; O'Connor, D; Oliver, M; Patterson, B; Peart, J; Poochikian, G; Roy, P; Shah, T; Sharp, SS; Singh, GJ, 2011)	0.37
" Pharmacokinetic results showed a greater initial absorption of salmeterol with DPI-C but greater continued absorption and a 40% greater AUC with DPI-A, which we attribute to slower but more extensive oral absorption because of the greater mass of swallowed large particles of salmeterol generated by DPI-A."	( Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. Harrison, LI; Needham, MJ; Novak, CC; Ratner, P, 2011)	0.37
" This method has been successfully applied to the pharmacokinetic study of compound ipratropium bromide aerosol mainly containing ipratropium bromide (IB) and salbutamol sulphate (SS) after inhalation in rats."	( Simultaneous determination of ipratropium and salbutamol in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. Ding, C; Ge, Q; Li, Z; Wu, J; Zhi, X; Zhou, Z, 2011)	0.37
"Prediction of pharmacokinetic (PK) profile for inhaled drugs in humans provides valuable information to aid toxicology safety assessment, evaluate the potential for systemic accumulation on multiple dosing and enable an estimate for the clinical plasma assay requirements."	( A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats. Harrison, A; Jones, RM, 2012)	0.38
"A sensitive and selective liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) was developed and validated for the determination of salbutamol in human plasma and urine, and successfully applied to the pharmacokinetic study of salbutamol in Chinese healthy volunteers after inhalation of salbutamol sulfate aerosol."	( Determination of salbutamol in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry and its pharmacokinetic study. Chen, K; Guo, R; Liu, S; Liu, X; Teng, Y; Wang, B; Wei, C; Yuan, G; Zhang, D; Zhang, R, 2012)	0.38
"We found no significant difference in pharmacokinetic profile of inhaled and oral salbutamol between elite athletes with asthma and nonasthmatic subjects."	( The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects. Backer, V; Dalhoff, K; Elers, J; Hemmersbach, P; Henninge, J; Pedersen, L, 2012)	0.38
" No clinically relevant systemic pharmacodynamic effects were observed."	( Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Ambery, C; Bateman, ED; Kornmann, O; Norris, V, 2013)	0.39
"The in vitro tests and systemic pharmacodynamic endpoints revealed no major differences between the two inhalers, but lacked predictive power and sensitivity to guide in vivo drug delivery performance and systemic exposure."	( Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. Chan, RH; Daley-Yates, PT; Despa, SX; Louey, MD; Mehta, R, 2014)	0.4
" Twenty-five subjects with asthma were recruited and underwent SULT1A3 genotyping, from which four SNP homozygote (GG) subjects and nine wild-type (AA) subjects were selected to participated in the pharmacokinetic investigation."	( SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? Jacobson, GA; Walters, EH; Wood-Baker, R; Yee, KC, 2015)	0.42
" However, studies on the pharmacokinetic profile of orally inhaled salbutamol doses used in clinical practice have not yet been reported in Chinese subjects."	( Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. Chen, J; Jiang, B; Jin, F; Lou, H; Ruan, Z; Shao, R; Shen, H, 2016)	0.43
" Pharmacokinetic parameters, including AUC0-0."	( Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. Chen, J; Jiang, B; Jin, F; Lou, H; Ruan, Z; Shao, R; Shen, H, 2016)	0.43
"The mean (SD) pharmacokinetic parameters of the reference drug were AUC0-0."	( Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers. Chen, J; Jiang, B; Jin, F; Lou, H; Ruan, Z; Shao, R; Shen, H, 2016)	0.43
"Fifteen children, ages 6-11 years, were included (PK, n = 13 for time to Cmax and terminal half-life of elimination; n = 12 for AUC and Cmax due to incomplete data)."	( Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma. Iverson, H; Ratnayake, A; Shore, P; Taveras, H, 2016)	0.7
"Predicting local lung tissue pharmacodynamic (PD) responses of inhaled drugs is a longstanding challenge related to the lack of experimental techniques to determine local free drug concentrations."	( Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms. Boger, E; Fridén, M, 2019)	0.51
"Intravenous salbutamol is used to treat children with refractory status asthmaticus, however insufficient pharmacokinetic data are available to guide initial and subsequent dosing recommendations for its intravenous use."	( Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. Boehmer, ALM; Boeschoten, SA; Buysse, CMP; de Hoog, M; de Wildt, SN; de Winter, BCM; Knibbe, CAJ; Koch, BCP; Koninckx, M; Plötz, FB; Vaessen-Verberne, AA; van der Nagel, BCH; Verhallen, JT; Vet, NJ, 2020)	0.56
"Our aim was to develop a population pharmacokinetic model to characterize the pharmacokinetic profile for intravenous salbutamol in children with status asthmaticus admitted to the pediatric intensive care unit (PICU), and to use this model to study the effect of different dosing schemes with and without a loading dose."	( Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. Boehmer, ALM; Boeschoten, SA; Buysse, CMP; de Hoog, M; de Wildt, SN; de Winter, BCM; Knibbe, CAJ; Koch, BCP; Koninckx, M; Plötz, FB; Vaessen-Verberne, AA; van der Nagel, BCH; Verhallen, JT; Vet, NJ, 2020)	0.56
"The pharmacokinetic model of intravenous R- and S-salbutamol described the data well and showed that a loading dose should be considered in children."	( Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. Boehmer, ALM; Boeschoten, SA; Buysse, CMP; de Hoog, M; de Wildt, SN; de Winter, BCM; Knibbe, CAJ; Koch, BCP; Koninckx, M; Plötz, FB; Vaessen-Verberne, AA; van der Nagel, BCH; Verhallen, JT; Vet, NJ, 2020)	0.56
" The aim of this study is to assess the potential of exhaled breath condensate (EBC) as a matrix for pharmacokinetic analysis of inhaled and intravenous medication."	( Pharmacokinetics of intravenous and inhaled salbutamol and tobramycin: An exploratory study to investigate the potential of exhaled breath condensate as a matrix for pharmacokinetic analysis. Birkhoff, WAJ; Cholewinski, T; Cohen, AF; Dröge, MJ; Klarenbeek, NB; Kruizinga, MD; Nelemans, T; van Esdonk, MJ; Zuiker, RGJA, 2020)	0.56
" Values for total clearance of compounds from plasma should be one of the most important pharmacokinetic parameters for predictions."	( Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data. Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N, 2020)	0.56
"Human pharmacokinetic studies of lung-targeted drugs are typically limited to measurements of systemic plasma concentrations, which provide no direct information on lung target-site concentrations."	( Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation. Badorrek, P; Ellinghusen, BD; Eriksson, UG; Faulenbach, C; Fridén, M; Hohlfeld, JM; Holz, O; Lundqvist, AJ; Müller, M; Sadiq, MW; Stomilovic, S, 2021)	0.62
" Pharmacokinetic profiles were generated by combining data from multiple individuals, covering all sample timings."	( Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation. Badorrek, P; Ellinghusen, BD; Eriksson, UG; Faulenbach, C; Fridén, M; Hohlfeld, JM; Holz, O; Lundqvist, AJ; Müller, M; Sadiq, MW; Stomilovic, S, 2021)	0.62
"Combining pharmacokinetic data derived from several individuals and techniques sampling different lung compartments enabled generation of pharmacokinetic profiles for evaluation of lung targeting after inhaled and oral drug delivery."	( Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation. Badorrek, P; Ellinghusen, BD; Eriksson, UG; Faulenbach, C; Fridén, M; Hohlfeld, JM; Holz, O; Lundqvist, AJ; Müller, M; Sadiq, MW; Stomilovic, S, 2021)	0.62

Compound-Compound Interactions

The objective of this study was to determine whether a combination of nebulized albuterol and ipratropium with warmed humidified oxygen would be more beneficial when compared to the same combination at room temperature.

Excerpt	Reference	Relevance
"Effects of flutropium bromide, a new bronchodilator with an anticholinergic action, alone or in combination with other antiasthma drugs were investigated in guinea pigs by using an index of inhibition of the acetylcholine (ACh)-induced bronchoconstriction."	( [Effects of flutropium bromide, a new anti-asthma drug, alone or in combination with salbutamol, aminophylline and disodium cromoglycate on the acetylcholine induced bronchoconstriction]. Misawa, M; Mizuno, H; Ohno, H; Takahashi, Y, 1990)	0.28
" It is concluded that IPB alone is less effective than beta-adrenoceptor agonist, but its combination with SAS would be an effective and safe treatment in acute asthmatic attack."	( [Effects of ipratropium bromide (IPB) and its combination with salbutamol sulfate (SAS) in acute asthmatic attack]. Chen, L; Deng, K; Ye, YQ, 1989)	0.28
" In a single-blind study of 14 normal volunteers, we infused salbutamol in doses used in clinical practice and examined the effects of the addition of theophylline alone or combined with (-)-adrenaline on plasma potassium levels, heart rate and blood pressure."	( Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline. Addis, GJ; Reid, C; Reid, JL; Whitesmith, R; Whyte, KF, 1988)	0.27
" 12 patients received during a month salbutamol combined with nedocromil (Tilade 8 mg per day)."	( [Bronchial hyperreactivity in patients with bronchial asthma treated with salbutamol and salbutamol combined with beclocort or nedocromil]. Krasnowska, M; Liebhart, E; Małolepszy, J, 1994)	0.29
" This study shows that the additive bronchodilating effect of theophylline, when used in combination with salbutamol, 200 micrograms, and ipratropium, 40 micrograms, is significant but small in stable COPD."	( Is oral theophylline effective in combination with both inhaled anticholinergic agent and inhaled beta 2-agonist in the treatment of stable COPD? Ikeda, A; Izumi, T; Koyama, H; Nishimura, K, 1993)	0.29
"The bronchodilator effect of the salbutamol alone and in combination with bromide of ipratropio is similar in intensity and in action time demonstrated by the VEF1."	( [Degree and duration of bronchodilatation with an agonist beta 2 administered alone versus an agonist beta 2 administered with ipratropium bromide in children with acute asthma]. Bermejo Guevara, MA; del Río Navarro, BE; Reyes Ruiz, NI; Rosas Vargas, MA; Sienra Monge, JJ, )	0.13
"The enantiomeric separation of a series of basic pharmaceuticals (beta-blockers, local anesthetics, sympathomimetics) has been investigated in nonaqueous capillary electrophoresis (NACE) systems using heptakis(2,3-di-O-methyl-6-O-sulfo)-beta-cyclodextrin (HDMS-beta-CD) in combination with potassium camphorsulfonate (camphorSO3-)."	( Enantiomeric separation of basic compounds using heptakis(2,3-di-O-methyl-6-O-sulfo)-beta-cyclodextrin in combination with potassium camphorsulfonate in nonaqueous capillary electrophoresis: optimization by means of an experimental design. Chiap, P; Crommen, J; Dewé, W; Fillet, M; Hubert, P; Servais, AC, 2004)	0.32
"Salmeterol (S) and montelukast (M) individually inhibit the obstructive consequences of thermal stimuli such as exercise and hyperventilation (HV), but there is no information on whether these drugs can interact positively."	( Bronchoprotective effects of single doses of salmeterol combined with montelukast in thermally induced bronchospasm. Coreno, A; El-Ekiaby, A; McFadden, ER; Skowronski, M; West, E, 2005)	0.33
" In a sample of children with acute asthma and initial mean PEF<50% predicted, LEV was associated with less tachycardia but had no other advantage over RAC combined with IB."	( Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. Cline, SM; Coakley, TA; Euwema, MS; Knecht, KR; Ralston, ME; Ziolkowski, TJ, 2005)	0.67
" Whether inhaled corticosteroids by themselves or in combination with a long-acting beta2-adrenoceptor agonist repress systemic inflammation in chronic obstructive pulmonary disease is unknown."	( Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. Cowie, RL; FitzGerald, M; Ford, G; Mainra, RR; Man, SF; Marciniuk, DD; Melenka, LS; Ramesh, W; Rousseau, R; Sin, DD; Wilde, E; Williams, D; Wong, E; York, E, 2006)	0.33
"If inhaled corticosteroids by themselves or in combination with a long-acting beta2-adrenoceptor agonist could repress systemic inflammation, they might greatly improve clinical prognosis by reducing various complications in chronic obstructive pulmonary disease."	( Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. Cowie, RL; FitzGerald, M; Ford, G; Mainra, RR; Man, SF; Marciniuk, DD; Melenka, LS; Ramesh, W; Rousseau, R; Sin, DD; Wilde, E; Williams, D; Wong, E; York, E, 2006)	0.33
"The objective of this study was to determine whether a combination of nebulized albuterol and ipratropium with warmed humidified oxygen would be more beneficial when compared to the same combination with humidified oxygen at room temperature."	( Beneficial effects of warmed humidified oxygen combined with nebulized albuterol and ipratropium in pediatric patients with acute exacerbation of asthma in winter months. Hassen, GW; Nibhanipudi, K; Smith, A, 2009)	0.81
"Our study shows that warmed humidified oxygen given along with the combination of nebulized albuterol and ipratropium is more beneficial for pediatric patients having an acute exacerbation of bronchial asthma in the winter months when compared to nebulized albuterol alone with warmed humidified oxygen, nebulized albuterol alone with room temperature humidified oxygen, or a combination of nebulized albuterol and ipratropium with room temperature humidified oxygen."	( Beneficial effects of warmed humidified oxygen combined with nebulized albuterol and ipratropium in pediatric patients with acute exacerbation of asthma in winter months. Hassen, GW; Nibhanipudi, K; Smith, A, 2009)	0.81
" We examined the effect of inhaled salmeterol, alone and in combination with fluticasone propionate, on the management of patients with COPD."	( The effect of inhaled salmeterol, alone and in combination with fluticasone propionate, on management of COPD patients. Boskabady, M; Boskabady, MH; Mansori, F; Nemat Khorasani, A, 2010)	0.36
" Two LABAs (salmeterol and formoterol) are currently licensed for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide respectively)."	( The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis. Cave, AC; Hurst, MM, 2011)	0.37
" The GLISTEN trial compared the efficacy of two long-acting anti-muscarinic antagonists (LAMA), when combined with an inhaled corticosteroid (ICS) and a long-acting β2 agonist (LABA)."	( Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Bremner, P; Chang, CL; Day, P; Frenzel, C; Frith, PA; Kurstjens, N; Ratnavadivel, R; Thompson, PJ, 2015)	0.42
"This randomised, blinded, placebo-controlled trial in moderate/severe COPD patients compared once-daily glycopyrronium (GLY) 50 µg, once-daily tiotropium (TIO) 18 µg or placebo (PLA), when combined with salmeterol/fluticasone propionate (SAL/FP) 50/500 µg twice daily."	( Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Bremner, P; Chang, CL; Day, P; Frenzel, C; Frith, PA; Kurstjens, N; Ratnavadivel, R; Thompson, PJ, 2015)	0.42
"To compare the efficacy of nebulised salbutamol alone and in combination with ipratropium bromide in acute severe asthma in children."	( Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. Ahmed Khan, KM; Bai, C; Gowa, MA; Memon, BN; Parkash, A, 2016)	0.43
"The effect of three amino acid coatings (L-leucine, L-valine and L-phenylalanine) on particle integrity, aerosolization properties, cellular interaction, cytocompatibility, and drug permeation properties of drug combination powder particles (beclomethasone dipropionate and salbutamol sulphate) for dry powder inhalation (DPI) was investigated."	( Drug permeation and cellular interaction of amino acid-coated drug combination powders for pulmonary delivery. Bimbo, LM; Hirvonen, J; Kauppinen, EI; Raula, J; Vartiainen, V, 2016)	0.43
"Evaluation of the efficacy of nebulized magnesium sulfate (MgSO4) alone and in combination with salbutamol in acute asthma."	( The efficacy of nebulized magnesium sulfate alone and in combination with salbutamol in acute asthma. Ali, MA; El-Garhy, OH; Sarhan, HA; Youssef, NA, 2016)	0.43
"Nebulized MgSO4 alone or combined with salbutamol has a clinically significant bronchodilator effect in acute asthma and leads to clinical improvement, increase in PEFR, reduction in HR, and reduction in RR."	( The efficacy of nebulized magnesium sulfate alone and in combination with salbutamol in acute asthma. Ali, MA; El-Garhy, OH; Sarhan, HA; Youssef, NA, 2016)	0.43
"To evaluate and contrast the therapeutic effect and safety of fluticasone aerosol combined with theophylline tablets in patients with moderate to severe asthma, compared with salmeterol/fluticasone propionate aerosol."	( Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β Chen, P; Dai, A; Kong, L; Shang, S; Wang, Y, 2016)	0.43
"After a screening period, patients meeting the inclusion criteria were randomly assigned to the experiment group (fluticasone aerosol combined with theophylline tablets) or the control group (salmeterol/fluticasone aerosol combined with placebo tablets) for 12 weeks of treatment."	( Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β Chen, P; Dai, A; Kong, L; Shang, S; Wang, Y, 2016)	0.43
"There was no significant difference in therapeutic effect and safety between the 2 groups in treating patients with moderate to severe persistent asthma, which suggests that fluticasone aerosol combined with theophylline tablets is worth considering for use in primary hospitals or for low-income populations."	( Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β Chen, P; Dai, A; Kong, L; Shang, S; Wang, Y, 2016)	0.43
"The aims of the study were to investigate the potential drug-drug interaction between salbutamol and ambroxol, the bioequivalence of the new fixed-dose combination containing salbutamol and ambroxol compared with co-administration of the two separate formulations, and to describe the safety and tolerability of the fixed-dose combination formulation in healthy Chinese volunteers."	( Investigation of a potential drug-drug interaction between salbutamol and ambroxol and bioequivalence of a new fixed-dose combination containing these two drugs in healthy Chinese subjects. Ding, L; Li, T; Liu, L; Lu, J; Shi, X; Wang, Y; Yang, W; Zhao, S, 2018)	0.48
"An open-label, single-dose, four-treatment, four-period crossover study for evaluation of drug-drug interaction and bioequivalence (n = 24) was performed."	( Investigation of a potential drug-drug interaction between salbutamol and ambroxol and bioequivalence of a new fixed-dose combination containing these two drugs in healthy Chinese subjects. Ding, L; Li, T; Liu, L; Lu, J; Shi, X; Wang, Y; Yang, W; Zhao, S, 2018)	0.48
"There were no significant drug-drug pharmacokinetic interactions between salbutamol and ambroxol after oral administration."	( Investigation of a potential drug-drug interaction between salbutamol and ambroxol and bioequivalence of a new fixed-dose combination containing these two drugs in healthy Chinese subjects. Ding, L; Li, T; Liu, L; Lu, J; Shi, X; Wang, Y; Yang, W; Zhao, S, 2018)	0.48
"The primary purpose of this study was to identify the most common drug-drug interactions (DDI'S) in patients prescribed medications upon discharge from the emergency department."	( Descriptive study of drug-drug interactions attributed to prescriptions written upon discharge from the emergency department. Bridgeman, PJ; Jawaro, T; Mele, J; Wei, G, 2019)	0.51
" The primary endpoint is the identification and characterization of drug-drug interactions caused by discharge prescriptions written by the treating physician."	( Descriptive study of drug-drug interactions attributed to prescriptions written upon discharge from the emergency department. Bridgeman, PJ; Jawaro, T; Mele, J; Wei, G, 2019)	0.51
"The aim of this study was to investigate and discuss the salbutamol combined with budesonide in treatment of pediatric bronchial asthma (BA) and its effect on eosinophils (EOS)."	( Salbutamol combined with budesonide in treatment of pediatric bronchial asthma and its effect on eosinophils. Fan, C; Huang, X; Li, S; Mei, Q; Qian, D; Quan, J, 2021)	0.62
" The children in control group were treated with budesonide and those in observation group were treated with salbutamol combined with budesonide."	( Salbutamol combined with budesonide in treatment of pediatric bronchial asthma and its effect on eosinophils. Fan, C; Huang, X; Li, S; Mei, Q; Qian, D; Quan, J, 2021)	0.62
"The treatment of salbutamol combined with budesonide for pediatric BA has significant therapeutic effects; it can restore the pulmonary functions rapidly and improve the immunity of the lung, reduce the levels of eotaxin, ECP and EOS of the child patients and promote EOS apoptosis."	( Salbutamol combined with budesonide in treatment of pediatric bronchial asthma and its effect on eosinophils. Fan, C; Huang, X; Li, S; Mei, Q; Qian, D; Quan, J, 2021)	0.62
" In an attempt to prevent PTB in singleton pregnancies, cervical cerclage, in combination with other treatments, has been advocated."	( Cervical stitch (cerclage) in combination with other treatments for preventing spontaneous preterm birth in singleton pregnancies. Eke, AC; Eleje, GU; Ezebialu, IU; Ikechebelu, JI; Ilika, CP; Okam, PC, 2020)	0.56
" We included studies comparing cervical cerclage in combination with one, two or more interventions with cervical cerclage alone in singleton pregnancies."	( Cervical stitch (cerclage) in combination with other treatments for preventing spontaneous preterm birth in singleton pregnancies. Eke, AC; Eleje, GU; Ezebialu, IU; Ikechebelu, JI; Ilika, CP; Okam, PC, 2020)	0.56
" One study (20 women), conducted in the UK, comparing cervical cerclage in combination with a tocolytic (salbutamol) with cervical cerclage alone in women with singleton pregnancy did not provide any useable data for this review."	( Cervical stitch (cerclage) in combination with other treatments for preventing spontaneous preterm birth in singleton pregnancies. Eke, AC; Eleje, GU; Ezebialu, IU; Ikechebelu, JI; Ilika, CP; Okam, PC, 2020)	0.56
" We did not identify any studies looking at other treatments in combination with cervical cerclage."	( Cervical stitch (cerclage) in combination with other treatments for preventing spontaneous preterm birth in singleton pregnancies. Eke, AC; Eleje, GU; Ezebialu, IU; Ikechebelu, JI; Ilika, CP; Okam, PC, 2020)	0.56

Bioavailability

The chemical modifications that make albuterol beta 2-selective also promote oral bioavailability and increased duration of action by decreasing sensitivity to degradative enzymes. A two-way-crossover bioavailability study was completed with 15 healthy male volunteers to evaluate the relative bioavailability of an orally administered controlled-release (CR) formulation of al buterol.

Excerpt	Reference	Relevance
" The bioavailability of po and it salbutamol was approximately 1 and 20%, respectively."	( Salbutamol disposition and dynamics in conscious rabbits: influence of the route of administration and of the dose. du Souich, P; Ong, H; Perreault, S, 1992)	0.28
") relative bioavailability of 92."	( Determination of the relative bioavailability of salbutamol to the lung following inhalation. Chrystyn, H; Hindle, M, 1992)	0.28
"We compared in this double-blind crossover study the bioavailability of dextromethorphan from a dextromethorphan-salbutamol combination tablet (Redol comp) and from a plain dextromethorphan tablet (Extuson) by determining dextrorphan concentrations after single-dose oral administration in 10 healthy volunteers."	( Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet. Happonen, P; Karttunen, P; Mykkänen, M; Romppanen, T; Silvasti, M; Tukiainen, H, 1990)	0.28
" In these experiments, fenoterol and orciprenaline showed better bioavailability than salbutamol."	( Determination of bioavailability on the basis of tachycardia after intravenous and oral administration of fenoterol, orciprenaline and salbutamol in non-anaesthetized rats. Muacevic, G, 1985)	0.27
" Relative bioavailability was assessed by comparing areas under the plasma-albuterol concentration time curves as well as peak concentrations and time to peak concentration."	( Influence of food on the absorption of albuterol Repetabs. Affrime, MB; Bolinger, AM; Gambertoglio, JG; Leung, P; Newth, CJ; Patrick, JE; Powell, M; Symchowicz, S; Young, KY; Zureikat, G, 1989)	0.78
"A two-way-crossover bioavailability study was completed with 15 healthy male volunteers to evaluate the relative bioavailability of an orally administered controlled-release (CR) formulation of albuterol as compared to the immediate-release (IR) formulation of albuterol."	( Relative bioavailability of a controlled-release albuterol formulation for twice-daily use. Chubb, JM; Meyer, MC; Reese, ME; Sykes, RS, )	0.58
" The absolute bioavailability of each of the oral preparations was 44%."	( Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. Goldstein, DA; Soldin, SJ; Tan, YK, 1987)	0.27
"In a single dose cross-over experiment in twelve healthy adults a comparison of the absorption profiles and the relative bioavailability was made between a new salbutamol containing tablet (preparation A = Salbutax) and a commercially available and accepted formulation as reference (preparation B), both containing 4 mg salbutamol."	( Single dose absorption profiles and bioavailability of two different salbutamol tablets. Freie, HM; Grasmeijer, G; Jonkman, JH; van der Boon, WJ, 1986)	0.27
" These results suggest a better bioavailability of Th, likely accounted for by a more advanced pharmaceutical technology."	( Serum theophylline and ventilatory function in chronic obstructive lung disease. Comparison between two slow-release formulations of theophylline. Cornelli, U; Grassi, V; Sorbini, CA; Tantucci, C; Verdecchia, P, 1985)	0.27
" The bioavailability of two 4-mg tablet formulations, differing in their inactive excipients, and a syrup formulation, was evaluated."	( Comparative bioavailability and pharmacokinetics of three formulations of albuterol. Chung, M; Gural, R; Patrick, JE; Powell, ML; Radwanski, E; Symchowicz, SS; Weisberger, M, 1985)	0.5
" The chemical modifications that make albuterol beta 2-selective also promote oral bioavailability and increased duration of action by decreasing sensitivity to degradative enzymes."	( Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. Ahrens, RC; Smith, GD, )	1.85
" Given via the trachea, salbutamol bioavailability was decreased by hypoxia."	( Influence of hypoxia and hypercapnia on the kinetics and hypokaliaemic effect of salbutamol in the rabbit. Du Souich, P; Ong, H; Perreault, S; Saunier, C, 1995)	0.29
" In dogs, Cmax was higher and reflected the greater oral bioavailability in this species."	( Disposition of salmeterol xinafoate in laboratory animals and humans. Barrow, A; Colthup, PV; Kulkarni, S; Maconochie, JG; Manchee, GR; Oxford, J; Palmer, E; Tarbit, MH, )	0.13
"04), a relative oral bioavailability of 104%, indicating equivalent total salbutamol output, was also obtained in the human subjects."	( Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs. Chang, C; Simon, OR, 1994)	0.29
" From these samples the relative bioavailability to the lung (urinary salbutamol excretion 30 minutes after dosing) and the systemic bioavailability of the dose (24 hour urinary excretion of salbutamol and its metabolite) for each inhalation method was obtained."	( Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. Chrystyn, H; Hindle, M, 1994)	0.29
" The nebuhaler and Bricanyl Spacer spacer devices were found to increase the relative bioavailability of salbutamol to the lung compared with the MDI alone."	( Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. Chrystyn, H; Hindle, M, 1994)	0.29
"Spacer devices improve pulmonary bioavailability of salbutamol and reduce the systemically available dose."	( Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. Chrystyn, H; Hindle, M, 1994)	0.29
" Based on these observations, considerably higher bioavailability of (+)- than of (-)-albuterol may be anticipated after oral or inhaled doses of this drug."	( Stereoselective sulfation of albuterol in humans. Biosynthesis of the sulfate conjugate by HEP G2 cells. Schey, KL; Thornburg, KR; Walle, T; Walle, UK, )	0.65
" Since IA salbutamol administration generated 100% bioavailability (F), AUCIA was used as a reference for comparison."	( Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. Adam, A; du Souich, P; Dumont, L; Ong, H; Perreault, S; Villiere, V, )	0.13
"To understand the previous result of higher bioavailability of rectal salbutamol (SB) compared with oral SB, in situ experiments using rabbit duodenal and rectal loop were carried out."	( [Absorption and first-pass-effect of salbutamol after intraduodenal and intrarectal administration in rabbits]. Ito, K; Kurosawa, N; Owada, E, 1993)	0.29
"A simple non-invasive method, in which a urine sample is taken 30 minutes after drug administration, has previously been shown to be a measure of the relative bioavailability of salbutamol to the lungs."	( Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Chrystyn, H; Hindle, M; Newton, DA, 1993)	0.29
" Each inhaled 4 x 100 micrograms salbutamol in a series of experiments to examine the relative bioavailability to the lung after different respiratory manoeuvres."	( Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Chrystyn, H; Hindle, M; Newton, DA, 1993)	0.29
"There was significantly greater elimination of unchanged salbutamol 30 minutes after administration, indicating a greater relative bioavailability of salbutamol to the lungs after (1) exhaling gently to residual volume rather than to functional residual capacity before inhalation; (2) slow inhalation (10 l/min) compared with fast inhalation (50 l/min); (3) breath holding for 10 seconds after inhalation compared with no breath holding."	( Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Chrystyn, H; Hindle, M; Newton, DA, 1993)	0.29
" The oral bioavailability of the beta 2-adrenoceptor agonist salbutamol has been proposed to be stereoselective, presumably due to presystemic sulphate conjugation."	( Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Pesola, GR; Walle, T; Walle, UK, 1993)	0.29
"In order to obtain a basic knowledge for developing the rectal dosage form of salbutamol (SB), a comparison of the bioavailability was made between oral and rectal administrations."	( [Comparison of bioavailability of salbutamol between oral and rectal administration in rabbits]. Ito, K; Kurosawa, N; Morishima, S; Owada, E, 1993)	0.29
"The aim of this study was to determine whether significant differences exist in lung bioavailability between generic (Salamol, Salbulin) and innovator (Ventolin) formulations of inhaled salbutamol given by metered dose inhalers."	( Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Clark, DJ; Clark, G; Gordon-Smith, J; Lipworth, BJ; McPhate, G, 1996)	0.29
" Salbutamol, 1200 micrograms, was given with mouth rinsing and lung bioavailability was assessed by measuring plasma salbutamol levels and urine excretion of salbutamol."	( Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Clark, DJ; Clark, G; Gordon-Smith, J; Lipworth, BJ; McPhate, G, 1996)	0.29
" The most significant features of the enantioselective disposition of albuterol are the relatively rapid plasma clearance and low bioavailability of the eutomer."	( Enantioselective disposition of albuterol in humans. Boulton, DW; Fawcett, JP, 1996)	0.81
"With the future advent of a world wide ban on chlorofluorocarbon containing aerosols, a study was designed to compare the in vivo lung bioavailability of salbutamol via chlorofluorocarbon-containing metered-dose inhaler (CFC), chlorofluorocarbon-free metered-dose inhaler (CFC-free), and dry powder inhaler (DPI)."	( Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Clark, DJ; Lipworth, BJ, 1996)	0.29
" In summary, administration of albuterol with a MDI achieved a profile of serum levels in mechanically ventilated patients similar to that in healthy control subjects, but the peak serum level and systemic bioavailability (AUC0-30) were lower in the patients."	( Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered-dose inhaler administration. Dhand, R; Duarte, AG; Fahey, PJ; Fink, JB; Jenne, JW; Reid, R; Tobin, MJ, 1996)	1.06
" An in vivo study of lung bioavailability of salbutamol from a large volume (Volumatic) spacer was conducted."	( Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Clark, DJ; Lipworth, BJ, 1996)	0.29
" Measurements of lung bioavailability were made at five, 10, and 20 minutes after inhalation to determine peak (Cmax) and average (Cav) plasma salbutamol levels."	( Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Clark, DJ; Lipworth, BJ, 1996)	0.29
" Using urinary excretion, the relative bioavailability of salbutamol to the lungs and the body for a prototype DPI has been compared with an MDI."	( Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler. Chrystyn, H; Hindle, M; Parry-Billings, M; Peers, EM, 1997)	0.3
" The amount of salbutamol and its metabolite, the ester sulphate conjugate, renally excreted up to 24 h post inhalation was also determined to evaluate the relative bioavailability of salbutamol to the body."	( Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler. Chrystyn, H; Hindle, M; Parry-Billings, M; Peers, EM, 1997)	0.3
"Fluticasone propionate, an inhaled corticosteroid with negligible systemic bioavailability via the oral route, is efficacious in the treatment of asthma when administered via metered-dose inhaler."	( Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Goldstein, MF; Hamedani, AG; Kellerman, DJ; Noonan, MJ; Pearlman, DS; Schaberg, A; Tashkin, DP, 1997)	0.3
" It has a bioavailability of 50% and sulphation is the main route of its metabolism."	( (-)-salbutamol sulphation in the human liver and duodenal mucosa: interindividual variability. Giulianetti, B; Giuliani, L; Gomeni, R; Nervi, M; Pacifici, GM; Quilici, MC; Spisni, R, 1997)	0.3
" The bioavailability of the eutomer was less than that of the distomer after administration of pure enantiomers and racemate."	( Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Boulton, DW; Fawcett, JP, 1997)	0.54
"A study was undertaken to test the hypothesis that airway calibre may alter lung deposition and therefore lung bioavailability of inhaled drugs as a result of narrowed airways reducing peripheral drug delivery."	( Effects of airway calibre on lung delivery of nebulised salbutamol. Clark, DJ; Lipworth, BJ, 1997)	0.3
" The systemic effects of salbutamol are limited by its fairly high first-pass metabolism, but the oral bioavailability of salmeterol is unknown."	( The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects. Bennett, JA; Harrison, TW; Tattersfield, AE, 1999)	0.3
"For inhaled formulations of a drug substance, the balance between desired local activity and undesired systemic activity can be expressed with an L:T ratio, where L stands for the local bioavailability and T stands for the total systemic bioavailability."	( Local versus total systemic bioavailability as a means to compare different inhaled formulations of the same substance. Borgström, L, 1998)	0.3
" The purpose of this study was to compare the pulmonary bioavailability of albuterol delivered by the nebulizer, the metered-dose inhaler (MDI) and spacer, and the right-angle MDI adaptor in ventilated patients using urinary analysis of drug levels."	( A comparison of bronchodilator therapy delivered by nebulization and metered-dose inhaler in mechanically ventilated patients. Hogan, J; Krikorian, J; Marik, P, 1999)	0.53
" The pulmonary bioavailability was poor with the right-angle MDI port."	( A comparison of bronchodilator therapy delivered by nebulization and metered-dose inhaler in mechanically ventilated patients. Hogan, J; Krikorian, J; Marik, P, 1999)	0.3
" The bioavailability of S-salbutamol was significantly higher than that of R-salbutamol after the different modes of administration."	( Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Ahlner, J; Andersson, RG; Norlander, B; Rydberg, I; Schmekel, B; Sjöswärd, KN, 1999)	0.3
" The principles of establishing bioequivalence on the basis of bioavailability and pharmacokinetics may not be applicable to inhaled medications with predominantly topical and minimal systemic effects."	( Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane beta-agonists. Parameswaran, K, 1999)	0.3
" The different 30-min urinary excretions following inhalation of the two formulations suggest a link between the relative bioavailability of salbutamol to the lung and the respirable dose, and that a slow inhalation rate should be used when using a Clickhaler."	( The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation. Chege, JK; Chrystyn, H, 2000)	0.31
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
"The 30 min urinary salbutamol method can be used for an inhalation period of up to 8 min to identify the relative bioavailability to the lung."	( Relative bioavailability of salbutamol to the lung following inhalation when administration is prolonged. Chrystyn, H; Corlett, SA; Silkstone, VL; Tomlinson, HS, 2000)	0.31
"Blood samples for plasma salbutamol concentrations were taken at 5 min, 10 min, and 20 min after inhalation, to measure lung bioavailability as a surrogate for relative lung dose."	( Comparative in vivo lung delivery of hydrofluoroalkane-salbutamol formulation via metered-dose inhaler alone, with plastic spacer, or with cardboard tube. Fowler, SJ; Griffiths, EA; Lipworth, BJ; Wilson, AM, 2001)	0.31
" There were no differences in pharmacokinetics of (R)-albuterol when administered as (R)- or (RS)-albuterol at the 5-mg dose with equivalent relative bioavailability as seen from maximum concentration (Cmax) and area under the concentration-time curve (AUC)."	( Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. DeGraw, S; Gumbhir-Shah, K; Jusko, WJ; Kellerman, DJ; Koch, P, 1998)	0.78
" This leads to a secretion-limited peroral absorption of salbutamol, which contributes to the poor oral bioavailability of the drug."	( The influence of active secretion processes on intestinal absorption of salbutamol in the rat. Casabó, VG; Martín-Villodre, A; Nácher, A; Valenzuela, B, 2001)	0.31
"To study the pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler (MDI) in healthy volunteers."	( Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. Du, XL; Fu, Q; Li, DK; Xu, WB; Zhu, Z, 2002)	0.31
" The relative bioavailability of MDI versus water solution was calculated."	( Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. Du, XL; Fu, Q; Li, DK; Xu, WB; Zhu, Z, 2002)	0.31
" The relative bioavailability of salbutamol MDI was 57 %+/-24 % compared with oral solution."	( Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. Du, XL; Fu, Q; Li, DK; Xu, WB; Zhu, Z, 2002)	0.31
"The 30 min urinary recovery of salbutamol, an index of the relative systemic bioavailability of salbutamol following inhalation, can be used to compare the lung deposition of nebulized systems."	( Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. Chrystyn, H; Corlett, SA; Silkstone, VL, 2002)	0.31
"02) correlation between the in vitro respirable dose and the amount of salbutamol excreted in the urine 30 min after the start of nebulization (relative bioavailability of salbutamol to the lung)."	( An investigation of in vitro/in vivo correlations for salbutamol nebulized by eight systems. Chrystyn, H; Dennis, JH; Pieron, CA; Silkstone, VL, 2002)	0.31
" Blood samples were taken for plasma salbutamol at 5, 10, 15 and 20 min after inhalation to measure lung bioavailability as a surrogate for relative lung dose."	( Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children. Anhøj, J; Bisgaard, H; Lee, DK; Lipworth, BJ, 2002)	0.31
"To study the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers."	( [Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. Du, XL; Fu, Q; Li, DK; Xu, WB; Zhu, Z, 2001)	0.31
" The concentrations of salbutamol in plasma were determined by HPLC, and then assessed with PCNONLIN software to obtain the pharmacokinetic parameters and relative bioavailability of aerosol versus water solution."	( [Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. Du, XL; Fu, Q; Li, DK; Xu, WB; Zhu, Z, 2001)	0.31
" The relative bioavailability of salbutamol aerosol was 57."	( [Studies on the pharmacokinetics and relative bioavailability of salbutamol aerosol in healthy volunteers]. Du, XL; Fu, Q; Li, DK; Xu, WB; Zhu, Z, 2001)	0.31
"The purpose of this investigation was to evaluate the bioavailability of three salbutamol sulfate suppository formulations."	( Bioavailability assessment of salbutamol sulfate suppositories in human volunteers. Al-Saidan, S; Kassem, AA; Khan, MA; Samy, AM; Taha, EI; Zaghloul, AA, 2004)	0.32
" The observed intra-subject in health volunteers is similar to the reported intra-subject variability of bioavailability for a number of oral medications."	( Intra-subject variability in lung dose in healthy volunteers using five conventional portable inhalers. Aswania, O; Bhatt, J; Everard, ML; Iqbal, SM; Rigby, AS; Ritson, S, 2004)	0.32
"The impact of intestinal conjugative metabolism on oral bioavailability was assessed by sequential and simultaneous analyses of the reported data in humans."	( Differentiation of organ availability by sequential and simultaneous analyses: intestinal conjugative metabolism impacts on intestinal availability in humans. Hayashi, M; Kawashima, K; Mizuma, T; Sakaguchi, S; Sakai, S, 2005)	0.33
"The relative lung bioavailability of salbutamol sulfate particles produced using supercritical fluids (SEDS) and delivered by dry powder inhaler (DPI) was compared with the performance of a conventional micronized drug DPI using the same device design (Clickhaler, Innovata Biomed)."	( Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization. Chrystyn, H; de Matas, M; Hosker, H; Mukherjee, R; Richardson, CH; Wong, I, 2007)	0.34
"Twelve healthy volunteers and 11 mild asthmatic patients completed separate four-way randomised cross-over studies, assessing the relative bioavailability of salbutamol sulfate (urinary excretion method), formulated as SEDS particles (three batches) and micronized particles (Asmasal inhaler, UCB Pharma Ltd)."	( Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization. Chrystyn, H; de Matas, M; Hosker, H; Mukherjee, R; Richardson, CH; Wong, I, 2007)	0.34
"There was no significant difference in the relative lung bioavailability of salbutamol and its bronchodilator response between the best performing SEDS formulation and the Asmasal inhaler in volunteers and patients, respectively."	( Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization. Chrystyn, H; de Matas, M; Hosker, H; Mukherjee, R; Richardson, CH; Wong, I, 2007)	0.34
"Active Pharmaceutical Ingredient (API) manufactured using supercritical fluids and delivered by DPI can provide similar lung bioavailability and clinical effect to the conventional micronized commercial product."	( Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization. Chrystyn, H; de Matas, M; Hosker, H; Mukherjee, R; Richardson, CH; Wong, I, 2007)	0.34
" In this regard, ANNs have been used to model historical data exploring the relative lung bioavailability of salbutamol from several different nebulizers."	( Evaluation of an in vitro in vivo correlation for nebulizer delivery using artificial neural networks. Chrystyn, H; de Matas, M; Shao, Q; Silkstone, VL, 2007)	0.34
"The aim of these experiments was to investigate the use of artificial neural networks (ANNs) for generating models able to predict the relative lung bioavailability and clinical effect of salbutamol when delivered to healthy volunteers and asthmatic patients from dry powder inhalers (DPIs)."	( Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks. Chrystyn, H; de Matas, M; Richardson, CH; Shao, Q, 2008)	0.35
"Although hepatic availability has been extensively studied to assess the oral bioavailability of drugs, intestinal availability has not, especially that related to conjugative metabolism (phase II metabolism)."	( Assessment of presystemic and systemic intestinal availability of orally administered drugs using in vitro and in vivo data in humans: intestinal sulfation metabolism impacts presystemic availability much more than systemic availability of salbutamol, SUL Mizuma, T, 2008)	0.35
" The objective of this study was to make nano-salbutamol sulphate (SBS) DPI, radiolabel it with Tc-99m using a novel surface labeling methodology, characterize the formulation and assess its in vitro and in vivo deposition in healthy human volunteers to estimate its bioavailability in the target area."	( Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Ahmad, FJ; Bhatnagar, A; Jain, GK; Khar, RK; Malhotra, G; Mittal, G, 2009)	0.35
" Using a urinary pharmacokinetic method we have measured the relative lung and systemic bioavailability from urinary salbutamol excretion 30 min (USAL0."	( Salbutamol relative lung and systemic bioavailability of large and small spacers. Chrystyn, H; Mazhar, SH, 2008)	0.35
" Furthermore, 29b was found to have low oral bioavailability in rat and dog and also to have long duration of action in an in vivo model of bronchodilation."	( Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups. Barrett, VJ; Bevan, NJ; Biggadike, K; Butchers, PR; Coe, DM; Conroy, R; Edney, DD; Field, RN; Ford, AJ; Guntrip, SB; Looker, BE; McLay, IM; Monteith, MJ; Morrison, VS; Mutch, PJ; Procopiou, PA; Richards, SA; Sasse, R; Smith, CE, 2009)	0.35
" The relative bioavailability to the lung of inhaled fluticasone and salmeterol combination is primarily dependent on respirable dose delivery and can be reliably quantified using adrenal suppression and early fall in serum potassium (marker of systemic beta-2 adrenoreceptor response) as surrogate markers for delivered lung dose."	( A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. Clearie, K; Lipworth, BJ; McFarlane, L; Meldrum, K; Menzies, D; Nair, A, 2009)	0.35
"To compare the in vivo relative bioavailability to the lung of Hydrofluoroalkane(HFA) Seretide delivered via Synchro-Breathe (SB); an optimally prepared 750 ml large volume plastic spacer, Volumatic (VM); and conventional Evohaler pMDI (EH)."	( A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. Clearie, K; Lipworth, BJ; McFarlane, L; Meldrum, K; Menzies, D; Nair, A, 2009)	0.35
"The breath-actuated Synchro-Breathe device was comparable to an optimally prepared Volumatic spacer, and resulted in commensurate improvement in relative lung bioavailability for both fluticasone and salmeterol moieties compared to pMDI."	( A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. Clearie, K; Lipworth, BJ; McFarlane, L; Meldrum, K; Menzies, D; Nair, A, 2009)	0.35
"Airway absorption and bioavailability of inhaled corticosteroids (ICSs) may be influenced by differences in pharmacokinetic properties such as lipophilicity and patient characteristics such as lung function."	( The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Borgström, L; Dalby, C; Edsbäcker, S; Harrison, TW; Larsson, T; Polanowski, T, 2009)	0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" The aim of this study was to investigate the relevance of this apical liquid film on the drug absorption rate when deposited as a dry powder formulation on pulmonary epithelial cells in vitro."	( Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique. Bur, M; Huwer, H; Lehr, CM; Muys, L, 2010)	0.36
" Two separate randomized cross-over studies were performed to compare the systemic bioavailability of test vs."	( Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. Clearie, KL; Du Bois, J; Lipworth, BJ; Nell, H; Vaidyanathan, S; Williamson, PA, 2010)	0.36
"This study compares the in vivo relative lung bioavailability of Hydrofluoroalkane (HFA) Seretide delivered via unprimed and unwashed Aerochamber Plus (AP) or Volumatic (VM) spacers, a integrated breath-actuated vortex Synchro-Breathe (SB) device and an Evohaler pMDI (EH) device using adrenal suppression and early fall in serum potassium (K) as surrogates for respirable dose."	( Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers. Burns, P; Lipworth, BJ; McKinlay, L; Nair, A; Short, P; Williamson, P, 2011)	0.37
"The breath-actuated SB device was comparable to 'out of the box' small and large volume spacers and produced similar improvements in relative systemic lung bioavailability for fluticasone and salmeterol."	( Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers. Burns, P; Lipworth, BJ; McKinlay, L; Nair, A; Short, P; Williamson, P, 2011)	0.37
" It had lower oral absorption and bioavailability than salmeterol in both rat and dog."	( The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group. Barrett, VJ; Ford, AJ; Looker, BE; Lunniss, GE; Needham, D; Procopiou, PA; Smith, CE; Somers, G, 2011)	0.37
" Administering as a dry powder formulation slowed the rat lung absorption rate of the least soluble compound (fluticasone propionate), impacting the prediction of C(max) and MRT."	( A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats. Harrison, A; Jones, RM, 2012)	0.38
"The main objective of this study was to develop a novel aerosolized liposome formulation for pulmonary delivery of anti-asthmatic medication and to explore the relationship between the bioavailability and anti-asthmatic efficacy of such a formulation."	( Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Chen, X; Huang, W; Wong, BC; Wong, YF; Xu, M; Yang, Z; Yin, L, 2012)	0.38
"This study presents an application of the piecewise rational quadratic interpolant to the AUC calculation in the bioavailability study."	( Application of the piecewise rational quadratic interpolant to the AUC calculation in the bioavailability study. Ahmad, M; Akhter, KP; Javed, Z; Khan, SA; Murtaza, G; Muryam, B; Ramzan, M; Shafi, I, )	0.13
" Using SBS as the model drug in this study, we developed SBS-loaded liposomes for oral administration and explored the relationship between their bioavailability and anti-asthmatic efficacy."	( Effect of liposomes on the absorption of water-soluble active pharmaceutical ingredients via oral administration. Bian, Z; Chen, H; Chen, X; Huang, W; Lu, A; Wong, BC; Xu, M; Yang, Z; Zhang, G; Zhao, Z, 2013)	0.39
"This was a randomized, double-blind, double-dummy, replicate treatment design comparative bioavailability study of SFC 50/250 delivered in a capsule-based inhaler (Rotahaler®) and a multidose dry powder inhaler (Diskus®)."	( Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. Chan, RH; Daley-Yates, PT; Despa, SX; Louey, MD; Mehta, R, 2014)	0.4
" Data mining based on artificial neural networks and genetic algorithms were used to model in vitro inhalation process, predict and optimize bioavailability from inhaled doses delivered by metered dose inhaler (MDI) using different spacers in NIV."	( In vitro/in vivo correlation and modeling of emitted dose and lung deposition of inhaled salbutamol from metered dose inhalers with different types of spacers in noninvasively ventilated patients. Abdelrahim, MEA; Abdelrahman, MM; Hussein, RRS; M A Ali, A; Said, ASA; Salem, HF, 2017)	0.46
"Salbutamol sulphate (SS) is a model short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm having poor bioavailability (50%) due to its extensive first-pass effect."	( Development of Salbutamol Sulphate Sublingual Films in Pullulan Matrix for Enhanced Bioavailability & Clinical Efficacy. Kharshoom, RM; Sallam, NM; Sanad, RA; Zeneldin, MA, 2017)	0.46
"FDSFs significantly improved the bioavailability of SS and resulted in dramatic improvement in its clinical efficacy."	( Development of Salbutamol Sulphate Sublingual Films in Pullulan Matrix for Enhanced Bioavailability & Clinical Efficacy. Kharshoom, RM; Sallam, NM; Sanad, RA; Zeneldin, MA, 2017)	0.46
" Data mining technology based on artificial neural networks and genetic algorithms were used here to model in-vitro inhalation process and predict bioavailability from inhaled doses delivered by three different vibrating mesh nebulisers (VMNs) in NIV."	( Modelling of in-vitro and in-vivo performance of aerosol emitted from different vibrating mesh nebulisers in non-invasive ventilation circuit. Abdelrahim, ME; Abdelrahman, MM; Ali, AM; Rabea, H; Said, AS; Salah Eldin, R, 2017)	0.46
" This trend did not extend to the 24-h levels, in which bioavailability with the large spacer plus pMDI (49."	( Performance of Large Spacer Versus Nebulizer T-Piece in Single-Limb Noninvasive Ventilation. Abdelrahim, ME; Elberry, AA; Fathy, M; Harb, HS; Rabea, H, 2018)	0.48
" Adding a preliminary bronchodilator dose by pMDI prenebulization showed a trend toward greater pulmonary bioavailability of nebulized salbutamol and may be worth considering to maximize delivery of salbutamol to patients who are severely ill."	( Performance of Large Spacer Versus Nebulizer T-Piece in Single-Limb Noninvasive Ventilation. Abdelrahim, ME; Elberry, AA; Fathy, M; Harb, HS; Rabea, H, 2018)	0.48
"The motive behind present work was to discover a solution for overcoming the problems allied with a deprived oral bioavailability of salbutamol sulfate (SS) due to its first pass hepatic metabolism, shorter half-life, and systemic toxicity at high doses."	( Lung delivery of nanoliposomal salbutamol sulfate dry powder inhalation for facilitated asthma therapy. Hajare, A; Honmane, S; More, H; Osmani, RAM; Salunkhe, S, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" This study evaluated the relative lung and systemic bioavailability and oropharyngeal deposition of salbutamol post-inhalation from Ventolin® Evohaler® (GlaxoSmithKline) either alone following verbal inhaler technique counselling (VC) or connected to a newly improved Able Spacer® (AS)."	( Comparative pharmacokinetics of salbutamol inhaled from a pressurized metered dose inhaler either alone or connected to a newly enhanced spacer design. Ammari, WG; Oriquat, GA; Sanders, M, 2020)	0.56
" The relative lung bioavailability (0-0."	( Comparative pharmacokinetics of salbutamol inhaled from a pressurized metered dose inhaler either alone or connected to a newly enhanced spacer design. Ammari, WG; Oriquat, GA; Sanders, M, 2020)	0.56
" Thus, this study aimed to assess the relative lung deposition and systemic bioavailability and compare bronchodilator response of salbutamol delivered using different accessory devices attached to pMDIs."	( Effect of different accessory devices on the dose delivered from pressurised metred-dose inhalers. Abdelrahim, M; Hussein, RRS; Nicola, M; Soliman, YMA, 2021)	0.62
"5)] and systemic bioavailability [0."	( Effect of different accessory devices on the dose delivered from pressurised metred-dose inhalers. Abdelrahim, M; Hussein, RRS; Nicola, M; Soliman, YMA, 2021)	0.62
"61-fold enhancement in SB bioavailability from optimized formula (F13) compared to market tablet."	( Superhydrophobic Surface for Enhancing the Bioavailability of Salbutamol Sulfate from Cross-Linked Microspheres: Formulation, Characterization, and in vivo Evaluation. Abdoun, S; Alfuraihy, A; Alsubaiyel, A; Altasan, B; Gaber, D, 2021)	0.62

Dosage Studied

Albuterol syrup over metaproterenol syrup in currently recommended doses. Study compared single daily versus twice daily dosing with a 24-hour theophylline, Uniphyl.

Excerpt	Relevance	Reference
" In contrast to other broncholytic substances, a very small dosage of clenbuterol is sufficient to protect rats against the liberation of histamine and serotonin caused by the anaphylactic reaction."	( [Profile of pharmacological actions of NAB 365 (clenbuterol), a novel broncholytic agent with selective activity on adrenergic beta2-receptors (author's transl)]. Engelhardt, G, 1976)	0.26
"3 Dose-response curves to the four drugs for tracheal relaxation were almost parallel."	( Assessment of the selectivity of OPC-2009, a new beta2-adrenoceptor stimulatn, by the use of the blood-perfused trachea in situ and of the isolated blood-perfused papillary muscle of the dog. Himori, N; Taira, N, 1977)	0.26
" The slopes of the salbutamol dose-response curves were flatter than those for isoprenaline and noradrenaline; the slopes of the procaterol dose-response curves were flatter than those for salbutamol."	( Comparative study of chronotropic and inotropic responses to 5-(-hydroxy-2-isopropylaminobutyl)-8-hydroxycarbostyril hydrochloride hemihydrade (procaterol), salbutamol, noradrenaline and isoprenaline in the dog heart. Chiba, S, )	0.13
"The authors report two cases of severe non-obstructive cardiomyopathy presenting at the end of pregnancy in young women treated for long periods and at high dosage with beta 2-adrenoceptor stimulants, prescribed for threatened abortion or premature labour."	( [Myocardiopathies during pregnancy. Possible role of beta-mimetics]. Bourdonnec, C; Daubert, JC; Gosse, P; Gouffault, J; Grall, JY; Pony, JC; Rio, M, 1978)	0.26
" Increase of dosage did not lead to improved effectiveness."	( [Parasympathicolytic drugs in treatment of obstructive lung diseases (author's transl)]. Gonsior, E; Meier-Sydow, J; Schultze-Werninghaus, G, 1979)	0.26
" Specific airway conductance is measured after increasing doses of inhaled salbutamol and the extent to which the dose-response curve is displaced to the right after beta-adrenoceptor blocking drugs is used to assess bronchial beta-adrenoceptor blockade."	( Quantitative assessment of bronchial beta-adrenoceptor blockade in man. Baldwin, CJ; Gribbin, HR; Tattersfield, AE, 1979)	0.26
" The dose-response curves for the two agonists were parallel, but salbutamol was approximately 1/15 as potent as isoprenaline on a weight basis."	( Profile of beta-adrenoceptors in femoral, superior mesenteric and renal vascular beds of dogs. Taira, N; Yabuuchi, Y; Yamashita, S, 1977)	0.26
" Construction of dose-response curves, however, revealed antagonism of all three parameters by propranolol and different sensitivities of the parameters to isoprenaline."	( The beta-adrenoceptors responsible for a direct relaxation of the uncontracted nictitating membrane of the anaesthetized cat. Broadley, KJ, 1977)	0.26
"13 The vasoconstrictor actions of phenylephrine, noradrenaline and adrenaline were all antagonized by the systemic administration of phentolamine, all three dose-response curves being shifted to the right."	( The role of beta-adrenoceptors in the responses of the hepatic arterial vascular bed of the dog to phenylephrine, isoprenaline, noradrenaline and adrenaline. Richardson, PD; Withrington, PG, 1977)	0.26
" Isoprenaline, salbutamol and ritodrine caused a dose-dependent reduction of the spontaneous contractions of the pregnant myometrium and a dose-related and parallel shift to the right of the isoprenaline dose-response curve was obtained with butoxamine but not with practolol."	( Beta-adrenoceptors in the pregnant and non-pregnant myometrium of the goat and cow. Larsen, JJ, 1979)	0.26
"3 Propranolol caused a parallel shift to the right of the noradrenaline dose-response curve which was not changed by phentolamine."	( alpha And beta-adrenoceptors in the detrusor muscle and bladder base of the pig and beta-adrenoceptors in the detrusor muscle of man. Larsen, JJ, 1979)	0.26
" Dose-response curves for acetylcholine with and without dopamine, isoprenaline, phenylephrine and noradrenaline were obtained."	( The depressor effect of dopamine on the electrical and mechanical activities of cat small intestine. Okawa, H; Wantanabe, M, 1975)	0.25
" The shape of the salbutamol dose-response curve was not altered by aminophylline pre-treatment--it is therefore argued that the drugs are additive but not synergistic on the basis of this preliminary study."	( Additive interaction of aminophylline and salbutamol in asthma: an in vivo study using dose-response curves. Handslip, P; Leopold, D, 1979)	0.26
" Salbutamol powder in a dose of 200 micrograms per capsule was able to control asthma as well as the aerosol, but some patients needed to increase the frequency of dosage when using the powder."	( Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients. Hartley, JP; Nogrady, SG; Seaton, A, 1979)	0.26
" Adequate theophylline dosage is an effective bronchodilator."	( Treatment of asthma in children. Hobday, JD, 1978)	0.26
" Administration of a standard premedication dosage to patients sedated for other reasons occasionally led to worsened respiratory status; pre-medication should be reduced or eliminated in sedated patients."	( Bronchofiberscopy in the postoperative management of lung surgery patients. Nakhosteen, JA, 1979)	0.26
"Salbutamol in a powder aerosol from the Rotahaler insufflator was compared, with equal doses of the conventional pressurized aerosol by dose-response curves and in a 1 month open trial, in the treatment of asthma patients with good inhalation technique."	( Comparison of salbutamol Rotahaler with conventional pressurized aerosol. Clark, TJ; Hetzel, MR, 1977)	0.26
" In the dosage used an increase in maternal and fetal heart rate was observed, more frequently in the patients receiving salbutamol compared with those receiving terbutaline."	( The effect of salbutamol and terbutaline in the management of premature labour. Rydén, G, 1977)	0.26
" Salbutamol was given as an infusion in the same dosage as is used to inhibit uterine contractions in cases of premature labor and in obstetric emergencies."	( The immediate effect of a beta-adrenergic agonist (salbutamol) on carbohydrate and lipid metabolism during the third trimester of pregnancy. Joelsson, I; Larsson, A; Lunell, NO; Persson, B, 1977)	0.26
" Reproduceable responses sufficient for calculating dose-response curves, could be obtained up to 30 h after death."	( Physiological and pharmacological studies on isolated human bronchial preparations. Berlin, E; Boe, J; Thulesius, O, 1978)	0.26
"In human adipose tissue in vitro, dose-response curves were followed for different adrenomimetics releasing free fatty acids and glycerol into an albumin-containing medium."	( Some adrenomimetic drugs affecting lipolysis in human adipose tissue in vitro. Kuhn, E; Wenke, M; Wenkeová, J, 1976)	0.26
" Drug dosage was one 4-mg tablet, of two inhalations of 100 mug of salbutamol aerosol or a combination of both, four times daily."	( The efficacy, as modified by the circadian rhythm of salbutamol administered by different routes. Alanko, K; Lahdensuo, A, 1976)	0.26
"1 Dose-response curves for the positive inotropic and chronotropic responses to isoprenaline were obtained in atria from untreated guinea-pigs and those receiving various reserpine pretreatments."	( Selective reserpine-induced supersensitivity of the positive inotropic and chronotropic responses to isoprenaline and salbutamol in guinea-pig isolated atria. Broadley, KJ; Lumley, P, 1977)	0.26
" Cumulative dose-response curves for the positive inotropic and chronotropic responses of isolated guinea-pig atria to isoprenaline and the partial agonist salbutamol were plotted as a percentage of the maximum response to isoprenaline."	( The influence of temperature upon reserpine-induced supersensitivity of guinea-pig isolated atria to isoprenaline and salbutamol. Broadley, KJ; Duncan, C, 1977)	0.26
"Cumulative dose-response curves for orally administered fenoterol and salbutamol concerning effects of FEV1, heart rate, blood pressure and tremor were constructed."	( Cumulative dose-response curves for comparison of oral bronchodilating drugs. A study of salbutamol and fenoterol. Larsson, S; Svedmyr, N, 1977)	0.26
" Cumulative dose-response curves for both routes of administration concerning 1-sec forced expiratory volume, forced vital capacity, heart rate, blood pressure, and tremor were constructed."	( Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol in asthmatics. Larsson, S; Svedmyr, N, 1977)	0.26
" In this dosage it was found that the peak effect of the two drugs was the same but that the effect of rimiterol was less prolonged than that of sulbutamol."	( Comparison between the bronchodilator and cardiovascular effects of inhaling 0.5 mg. rimiterol ('Pulmadil') and 0.2 mg. salbutamol. Bianco, S; Kamburoff, PL; Prime, FJ, 1975)	0.25
" In the present study, log dose-response lines were obtained for dl-isoprenaline (ISO), l-adrenaline (ADR) l-noradrenaline (NOR), salbutamol (SALB), and orciprenaline on isolated tracheal chains prepared from both the laryngeal (L) and bronchial (B) ends of the trachea."	( The effect of cocaine on the responses of the differently innervated laryngeal and bronchial ends of the guinea pig trachea in vitro to clinically used bronchodilators. Hamilton, JT; Jones, TR; Lefcoe, NM, 1975)	0.25
" Given orally, RP 58802B (5 mg/kg, 60 min before challenge) produced a greater than three-fold shift to the right of the dose-response curve and depressed the maximum response to histamine by 39 +/- 11%."	( RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. Lewis, SA; Raeburn, D; Underwood, SL, 1992)	0.28
" The dose-response curves for change in PC20 indicated that the higher doses of the nebulizer solution delivered more drug to beta 2 receptors in the lung than the lower doses from the MDI."	( Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution. Bioassay by histamine bronchoprovocation. Blake, KV; Harman, E; Hendeles, L; Hoppe, M, 1992)	0.61
" Bronchial lability was characterized by (1) variability in mean daily peak expiratory flow rate and (2) bronchial responsiveness to either carbachol (as assessed by the threshold dose and the slope of the dose-response curve) or salbutamol (as assessed by the threshold dose and maximal response)."	( Relationship between spontaneous dyspnoea and lability of airway obstruction in asthma. Lockhart, A; Marsac, J; Peiffer, C; Razzouk, H; Toumi, M, 1992)	0.28
" All changes were dosed related."	( Dose-response study with high-dose inhaled salmeterol in healthy subjects. Forster, JK; Maconochie, JG, 1992)	0.28
" Dose-response curves show similar sensitivity, but decreased responsiveness in the lean animal."	( Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists. Bray, GA; Tsujii, S, 1992)	0.28
" Before salmeterol treatment was initiated and after 3, 6, 9 and 12 months of salmeterol treatment, a cumulative dose-response curve to inhaled salbutamol (100, 300 and 900 micrograms) was performed, and FEV1 measured."	( Twelve months, treatment with inhaled salmeterol in asthmatic patients. Effects on beta 2-receptor function and inflammatory cells. Lötvall, J; Lunde, H; Svedmyr, N; Törnqvist, H; Ullman, A, 1992)	0.28
" Microcapsules were compressed into tablets to get a controlled release oral dosage form."	( Release kinetics of salbutamol sulphate from wax coated microcapsules and tableted microcapsules. Jayaswal, SB; Raghuvanshi, RS; Singh, J; Tripathi, KP, )	0.13
"To study the dose-response relationship of salmeterol for protection against a naturally occurring stimulus, isocapnic hyperventilation tests of cold air were done in 16 asthmatic patients."	( Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours. Jörres, R; Lüthke, M; Magnussen, H; Nowak, D; Rabe, KF; Wiessmann, J, 1992)	0.28
" Such patients may require theophylline dosage adjustment as a result of this interaction."	( Enhancement of theophylline clearance by oral albuterol. Amitai, Y; Glustein, J; Godfrey, S, 1992)	0.54
" After each period, dose-response curves were measured on 4 study days with doubling doses of salbutamol, ipratropium, a combination of salbutamol and ipratropium, and placebo until a plateau in FEV1 was reached."	( Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma. Alting-Hebing, D; Breederveld, N; Koëter, GH; Postma, DS; van der Mark, TW; Wempe, JB, 1992)	0.28
" dosage regimen."	( Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma. Mazza, JA; Reed, CE; Tashkin, DP, 1992)	0.57
" On the other day, the patients received sustained-release theophylline, 200 mg twice a day, or in a dosage taken previously to achieve a serum theophylline level of 55 to 110 mumol/L."	( The effects of inhaled albuterol and oral theophylline on gastroesophageal reflux in patients with gastroesophageal reflux disease and obstructive lung disease. Austin, J; Rohwedder, JJ; Ruzkowski, CJ; Sanowski, RA; Waring, JP, 1992)	0.59
"Reversed-phase high-performance liquid chromatography (RP-HPLC), isotachophoresis (ITP) and capillary zone electrophoresis (CZE) were applied to the determination of salbutamol, terbutaline sulphate and fenoterol hydrobromide in commercially available pharmaceutical dosage forms."	( Comparison of isotachophoresis, capillary zone electrophoresis and high-performance liquid chromatography for the determination of salbutamol, terbutaline sulphate and fenoterol hydrobromide in pharmaceutical dosage forms. Ackermans, MT; Beckers, JL; Everaerts, FM; Seelen, IG, 1992)	0.28
"We used a placebo-controlled standardized protocol to define the dose-response relationship to the beta-adrenergic bronchodilator salbutamol (albuterol) in 10 ventilator-dependent premature infants at a postnatal age of 13."	( Dose-related bronchodilator response to aerosolized salbutamol (albuterol) in ventilator-dependent premature infants. Dehan, M; Denjean, A; Gaultier, C; Guimaraes, H; Migdal, M; Miramand, JL, 1992)	0.72
" Thirty minutes later a beta 2-agonist dose-response curve was performed by inhaling salbutamol in cumulative doses of 200, 400 and 800 micrograms."	( Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast--MK-0679) in asthmatic patients. Buntinx, A; De Lepeleire, I; Decramer, M; Friedman, B; Lammers, JW; Van Daele, P; Van den Elshout, FM, 1992)	0.28
" Regression analysis also showed no evidence of a dose-response relationship for Ros."	( Measurement of normal human airways response to beta-adrenoceptor stimulation using a forced oscillation technique. Clark, RA; Lipworth, BJ; McDevitt, DG, 1991)	0.28
" Forced expiratory volume in one second (FEV1) dose-response curves for inhaled salbutamol were repeatedly recorded during the study, and no tachyphylaxis was found."	( Inhaled formoterol during one year in asthma: a comparison with salbutamol. Arvidsson, P; Larsson, S; Löfdahl, CG; Melander, B; Svedmyr, N; Wåhlander, L, 1991)	0.28
" During the high dosing the secretion rate of parotid saliva decreased and the concentrations of its total protein, amylase, hexosamine and the ratio of hexosamine/total protein were lowered."	( Saliva composition in asthmatic patients after treatment with two dose levels of a beta 2-adrenoceptor agonist. Ericson, T; Möller, C; Ryberg, M, 1990)	0.28
" The initially used intravenous dosage (0."	( [The treatment of hyperkalemia with salbutamol]. Muñoz, R; Velásquez, L, 1991)	0.28
" The following observations were made: four patients had sinus tachycardia and another suffered from ventricular extrasystoles as seen in the electrocardiographic register; another two patients had sinus tachycardia when the bronchial dilator dosage was doubled."	( [Electrocardiographic changes with the use of aminophylline and salbutamol in adult patients with chronic bronchial asthma]. Esquer Flores, J; Gálvez Gudiño, VJ; Orea Solano, M, )	0.13
" A need therefore exists for a pediatric salbutamol dosage form, which not only controls asthma but is also convenient and acceptable to use."	( Pharmacokinetic characteristics of a novel controlled-release sprinkle formulation of salbutamol. Devane, J; Martin, M; Mulligan, S, 1991)	0.28
" Dose-response curves were obtained for the inotropic, chronotropic and pressor responses to cumulative infusions of noradrenaline (n = 6) and dobutamine (n = 6)."	( The effects of neuropeptide Y on myocardial contractility and coronary blood flow. Awad, SJ; Einstein, R; Potter, EK; Richardson, DP, 1991)	0.28
" These findings imply therapeutic advantages of albuterol syrup over metaproterenol syrup in currently recommended doses with respect to improvement in pulmonary function, chronotropic effects, and frequency of dosing required to maintain optimum bronchodilation over a 24-hour period."	( Comparison of albuterol and metaproterenol syrup in the treatment of childhood asthma. Ratner, PH; Shapiro, GG; Wolfe, JD, 1991)	0.9
" To determine whether these drugs also protect against excessive airway narrowing, the effect of inhaled salbutamol on the position and shape of the dose-response curves for histamine or methacholine was investigated in 12 patients with asthma and 11 with chronic obstructive lung disease."	( The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Bel, EH; Dijkman, JH; Sterk, PJ; Timmers, MC; Zwinderman, AH, 1991)	0.28
"5 x 10(-7) M) and matched placebo were administered by identical metered dose inhaler 15 min before a dose-response to sodium metabisulphite (1."	( Salbutamol inhibits metabisulphite-induced bronchoconstriction. Dixon, CM; Ind, PW; Iredale, MJ, 1991)	0.28
" Dose-response curves were measured after three weeks of treatment with ipratropium bromide and again after a three-week course of inhaled salbutamol."	( Tolerance to beta 2-agonists in patients with chronic obstructive pulmonary disease. Anthonisen, NR; Georgopoulos, D; Wong, D, 1990)	0.28
" One subject developed moderate drowsiness during multiple dosing with cetirizine."	( Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. Dauphinee, B; Djahed, B; Gong, H; Tashkin, DP; Wu, TC, 1990)	0.28
" Dose-response curves to inhaled SB were obtained the day before and the day after each treatment period."	( Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. Hedner, J; Svedmyr, N; Ullman, A, 1990)	0.28
" The dose of hyperventilation of cold air causing a 20% fall in FEV1 (PD20) was interpolated on the dose-response curve."	( Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. Cartier, A; Ghezzo, H; Gontovnick, L; Malo, JL; Trudeau, C, 1990)	0.5
" The dose-response curves for these agonists were shifted slightly to the right when the amplitude of the twitch was increased up to twice its original size."	( Dissociation constants and relative efficacies estimated from the functional antagonism of beta-adrenoceptor agonists on transmural stimulation in rat vas deferens. Diaz-Toledo, A; Jurkiewicz, A, 1990)	0.28
" Results were determined for both daytime and nighttime dosing intervals."	( Albuterol extended-release products: a comparison of steady-state pharmacokinetics. Donn, KH; Hussey, EK; Powell, JR, 1991)	1.72
" Although cromolyn sodium significantly decreased the severity of antigen-induced bronchoconstriction, it did not affect T-cell subset composition changes at the dosage used."	( Antigen-induced T-cell changes: modulation by pharmacologic agents. Gerblich, A; Salik, H; Schuyler, M; Varghese, J, 1990)	0.28
" The drug dosage was controlled by limiting the inspired volumes of gas (single and cumulative) to the pretested inspiratory capacity."	( Single breath versus panting technique in salbutamol delivery through a 750 mL spacing device. James, RW; Masters, IB, 1990)	0.28
"Cardioselectivity of a single oral dose of metoprolol oral osmotic (OROS) (14/190 mg) and atenolol (100 mg) was compared in 12 patients with reversible obstructive airway disease by assessing the dose-response curve to increasing doses of inhaled salbutamol."	( Comparative evaluation of cardioselectivity of metoprolol OROS and atenolol: a double-blind, placebo-controlled crossover study. Bruni, B; Dottorini, ML; Grassi, V; Lecaillon, JB; Motolese, M; Peccini, F; Sorbini, CA; Tantucci, C, 1990)	0.28
" In phase 1, maximal bronchodilation was determined by dose-response studies on separate days."	( Efficacy of atropine methylnitrate alone and in combination with albuterol in children with asthma. Hill, MR; Nelson, HS; Sladek, WA; Sur, S; Szefler, SJ; Vichyanond, P, 1990)	0.52
"The purpose of the present study was to compare the efficacy and systemic effects of 4 mg and 8 mg doses of salbutamol controlled release (SCR) after single dosing and at steady state in patients with asthma."	( Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma. Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Palmer, JB, 1990)	0.28
" Salbutamol did not influence the caffeine dose-response curves in any of the groups (n = 14 in the MH-non-susceptible (MHN) group)."	( Influence of salbutamol on the in vitro muscle response to caffeine and halothane in malignant hyperthermia. Bendixen, D; Ording, H, 1990)	0.28
" The beta-antagonist effects of the three substances were also studied, by running a dose-response curve to noradrenaline or adrenaline as appropriate following the addition of the substance of interest."	( Effects of dilevalol on human atrial muscle. Brown, MJ; Sanders, L, 1990)	0.28
" In vivo X-ray studies of the abdomen were carried out to locate the floating and non-floating (fabricated) dosage forms at various time intervals of uniform duration."	( In vitro and in vivo studies of sustained-release floating dosage forms containing salbutamol sulfate. Babu, VB; Khar, RK, 1990)	0.28
" We determined the inhaled adenosine dose-response curves after no treatment and after treatment with aminophylline (240 mg in 10 min), reproterol (90 mcg in 2 min) and salbutamol (100 mcg in 2 min) administered intravenously 15 min before adenosine and reproterol (500 mcg) and salbutamol (200 mcg) administered by inhalation from a metered aerosol 30 min before adenosine on separate days."	( Role of purinergic system in tracheobronchial reactivity of healthy and bronchopathic subjects. Carapella, N; Filippelli, A; Loffreda, A; Marmo, E; Matera, MG; Montanaro, C; Santagata, A; Servodio, R; Susanna, V, 1990)	0.28
" However, the dose-response curves of salbutamol on the venous and arterial systems overlapped, indicating that the increase in venous return represents a combination of properties common to both beta 1 and beta 2 adrenoceptors."	( Dopamine and norepinephrine increase venous return by stimulating alpha and beta adrenoceptors in the dog. Banning, JW; Morgan, JP; Roebel, LE; Van Maanen, EF, 1988)	0.27
"05) greater at all dosage levels with the Turret."	( Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. Bloom, R; Clarke, SW; Johnson, MA; Newman, SP; Talaee, N, 1989)	0.66
" On the day salbutamol was given, surface area under the dose-response curve to PGF2 alpha was significantly higher and the final drop of FEV1 significantly lower than those observed on days when placebo, ipratropium bromide and cromolyn sodium were given."	( Effect of salbutamol, ipratropium bromide and cromolyn sodium on prostaglandin F2 alpha-induced bronchospasm. Georgopoulos, D; Giulekas, D; Ilonidis, G; Sichletidis, L, 1989)	0.28
"In a randomized, double-blind, double-dummy, crossover study consisting of two 1-month periods with a 2-week 'run-in' we compared the effects of a combination of fenoterol with ipratropium bromide (Duovent, Boehringer Ingelheim) and salbutamol administered by standard metered dose inhalers in conventional dosage in young adults with nocturnal asthma."	( Comparison of a combination of fenoterol with ipratropium bromide (Duovent) and salbutamol in young adults with nocturnal asthma. Shettar, SP; Wolstenholme, RJ, 1989)	0.28
" Dose-response curves were made for the beta 2-sympathicomimetic salbutamol."	( In vivo beta 2-adrenoceptor hyporesponsiveness in the cardiovascular system of the pig after Bordetella pertussis. De Wildt, DJ; Nijkamp, FP; Schoute, E; Van Heuven-Nolsen, D; Verdouw, PD, 1989)	0.28
" In contrast to airways effects, systemic beta-adrenoceptor responses did not occur until 500 micrograms, and a ceiling in the dose-response curve was not reached."	( Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Lipworth, BJ; McDevitt, DG, 1989)	0.28
" Comparison of dose-response curves for MDI alone and with PSS showed no significant differences, for any of the variables measured."	( Systemic beta-adrenoceptor responses to salbutamol given by metered-dose inhaler alone and with pear shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects. Lipworth, BJ; McDevitt, DG; Struthers, AD, 1989)	0.28
" Comparison with dose-response curves in a group of young (Y) subjects (24 +/- 3 years) given an identical dose protocol of salbutamol showed no evidence of subsensitivity of beta 2-adrenoceptor responses in the elderly (E) group (mean and 95% confidence intervals for maximum responses): delta K -0."	( Beta-adrenoceptor responses to inhaled salbutamol in the elderly. Lipworth, BJ; McDevitt, DG; Tregaskis, BF, 1989)	0.28
" Three hours after drug ingestion, dose-response curves were constructed using cumulative doses of inhaled salbutamol: 200 micrograms, 700 micrograms, 1700 micrograms, 3200 micrograms, 6200 micrograms."	( Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade. Brown, RA; Lipworth, BJ; McDevitt, DG, 1989)	0.28
"Patients with severe chronic airways obstruction often respond poorly to inhaled salbutamol in conventional dosage from a pressurized aerosol."	( High dose salbutamol in chronic airflow obstruction: comparison of nebulizer with Rotacaps. Assoufi, BK; Hodson, ME, 1989)	0.28
" The concentration-time profiles at steady-state showed little fluctuation in plasma salbutamol levels over the twelve hour dosing interval."	( Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. Charter, MK; Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Palmer, JB, 1989)	0.28
" Plasma glucose, potassium, and magnesium were measured at each step of the dose-response curve."	( The biochemical effects of high-dose inhaled salbutamol in patients with asthma. Clark, RA; Fraser, CG; Lipworth, BJ; McDevitt, DG, 1989)	0.28
" At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms)."	( Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Lipworth, BJ; McDevitt, DG; Struthers, AD, 1989)	0.28
"Sixteen patients suffering from bronchial asthma, with or without chronic bronchitis, sufficiently severe to be treated with inhaled corticosteroids, were studied in a single-blind trial (blind observer) of beclomethasone dipropionate (BDP) given in three randomized dosage regimens: 500, 1000 and 2000 micrograms per day, each for 4 weeks."	( Effects of inhaled beclomethasone dipropionate on beta 2-receptor function in the airways and adrenal responsiveness in bronchial asthma. Folgering, HT; Lammers, JW; Molema, J; van Herwaarden, CL, 1988)	0.27
" There was a linear log dose-response relationship for each airways parameter (FEV1, VC, sGaw, FEF 50%)."	( Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. Brown, RA; Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG, 1988)	0.27
"25 mg/kg), the dose-response curve of clenbuterol (0."	( Does a single priming injection of clenbuterol alter behavioral response to beta-adrenoceptor agonists and antagonists in mice through a time-dependent process? Martin, P; Simon, P; Soubrie, P, 1985)	0.27
" We investigated whether the maximal response plateau or the position of the dose-response curve is due to functional inhibition by neurogenic mechanisms or to prostaglandin release."	( Limited maximal airway narrowing in nonasthmatic subjects. Role of neural control and prostaglandin release. Daniel, EE; Hargreave, FE; Sterk, PJ; Zamel, N, 1985)	0.27
" Biotransformations are determined by environmental or genetic factors and by the associated therapy and can change dramatically from one patient to another (interindividual variability) or for the same patient by multiple dosing (intra-individual variability)."	( [Metabolism of beta-adrenergic substances. Therapeutic implications]. Brès, J; Bressolle, F; Clauzel, AM; Pistre, MC; Rachmat, H, )	0.13
" Treatment of intact vasa deferentia with increasing concentrations of BAAM resulted in a progressive rightward shift in the dose-response curve to isoprenaline or salbutamol followed by a decreased maximum response."	( Binding of agonists and antagonists to beta-adrenoceptors in rat vas deferens: relationship to functional response. Abel, PW; May, JM; Minneman, KP, 1985)	0.27
" The slow-release tablets were preferred by 15 of 18 children and their families when the effects, side effects and dosage were evaluated."	( Terbutaline slow-release tablets in children with asthma. A comparison with t.i.d. beta 2-agonist therapy. Croner, S; Gustafsson, M; Kjellman, NI; Säwedal, L, 1986)	0.27
" With currently used dosing regimens, theophylline appears to produce relatively constant levels of effect on airway responsiveness and clinical efficacy around the clock, while inhaled beta 2 agonists appear to have insufficient effects at the end of longer dosing intervals."	( The effect of theophylline and beta 2 agonists on airway reactivity. Ahrens, RC; Joad, J; Milavetz, G, 1987)	0.27
" The suggestion is made that failure to recognize the nonlinearity of the dose-response curves for bronchodilators has resulted in underestimating their combined action."	( Theophylline as a bronchodilator in COPD and its combination with inhaled beta-adrenergic drugs. Jenne, JW, 1987)	0.27
" Dose-response curves were plotted upon the inhalation of salbutamol in two-week intervals in patients treated with betamimetics."	( Development of drug tachyphylaxis in asthmatic patients treated with beta-adrenergic drugs. Böszörményi-Nagy, G; Debreczeni, LA; Herjavecz, I; Szeitz, A, 1987)	0.27
" Dose-response effects were clearly seen with salbutamol but not with ipratropium bromide."	( Nebulized salbutamol and ipratropium bromide in asthmatic children. Evans, NA; Lenney, W, 1986)	0.27
" Then salbutamol was administered by a dosimetric aerosol (DA) at the usual dosage (200 micrograms) and the change in FEV1 was observed at 60 min; thereafter 40 micrograms of ipratropium bromide (IB) were administered by DA and FEV1 was measured after 60 min."	( Influence of pindolol on asthmatics and effect of bronchodilators. Antoniadou, H; Georgopoulos, D; Giulekas, D; Papakosta, D; Sotiropoulou, E; Vamvalis, C, 1986)	0.27
" Airway dose-response curves to timolol (0-2%), L-714,465 (0-4%), and placebo (methyl cellulose) eye drops were performed in a double-blind randomised study in which airway response was measured as change in FEV1 and specific airway conductance (sGaw)."	( Comparison of the airway response to eye drops of timolol and its isomer L-714,465 in asthmatic subjects. Richards, R; Tattersfield, AE, 1987)	0.27
" In fifteen selected chronic asthmatics, individual cumulative dose-response curves to S and IB were performed on two separate days (linear regression of bronchodilator response (delta FEV1) between 20 and 80% of maximal response, versus log dose), and the dose of S equipotent to the IB dose giving the maximal bronchodilator effect (IBopt) was calculated by interpolation of each S curve."	( Cumulative dose-response curves for assessing combined effects of salbutamol and ipratropium bromide in chronic asthma. de Lauture, D; Grandordy, BM; Marsac, J; Thomas, V, 1988)	0.27
" Dose-response curves were obtained for inhaled salbutamol and inhaled ipratropium bromide."	( Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Agusti-Vidal, A; Campistol, J; Lloberes, P; Montserrat, JM; Picado, C; Ramis, L; Serra, J, 1988)	0.27
" Despite this, the duration of the bronchodilator effect of procaterol on a twice daily dosage did not seem to be long enough in all patients."	( Comparison between oral procaterol and salbutamol in patients with bronchial asthma. Jaakkola, J; Terho, EO; Torkko, M; Tukiainen, H, 1988)	0.27
" Pulse rate, blood pressure and blood levels of cyclic GMP, free fatty acid, cyclic AMP, glucose and lactic acid were measured in order to evaluate efficacy and dosage of Formoterol and to compare efficacy of this drug with that of Salbutamol."	( Evaluation of a new bronchodilator, Formoterol, using biochemical parameters. Ikuta, T; Inamizu, T; Nishimoto, Y; Onari, K; Tanabe, M; Yamakido, M, 1985)	0.27
" Dose-response studies of the effect of epinephrine on adenosine-deaminase or isoproterenol-stimulated fat-cells demonstrate an inhibitory effect of epinephrine on lipolysis promoted by stimulation of alpha 2-adrenoceptors which occurs before the commonly described beta 1-adrenergic effect which promotes stimulation of lipolysis."	( Fat cell adrenoceptors: inter- and intraspecific differences and hormone regulation. Berlan, M; Carpene, C; Lafontan, M, 1985)	0.27
" The air pollution dosage during exercise is much higher than during rest because of a higher ventilatory rate and both nasal and oral breathing in the former case."	( Implications of air pollution effects on athletic performance. Covert, DS; Kim, YS; Koenig, JQ; Namekata, T; Pierson, WE, 1986)	0.27
" When 2 or 4 weeks of continuous cromolyn therapy was given in addition to a dosage 15 minutes prior to exercise, there was no significant difference compared with acute cromolyn administration alone."	( A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm. Katz, RM; Lanier, R; Rachelefsky, GS; Rohr, AS; Siegel, SC; Spector, SL, 1987)	0.58
" No statistically significant differences were observed in mean steady-state values for Cmax, Cmin, AUC(0-12 h) and peak-to-trough fluctuations (PTF) in comparing the two dosage formulations."	( Relative bioavailability of a controlled-release albuterol formulation for twice-daily use. Chubb, JM; Meyer, MC; Reese, ME; Sykes, RS, )	0.39
" Ten subjects became tachyphylactic to inhaled salbutamol, assessed by a dose-response curve, before and after the 2 weeks of treatment from a metered-dose inhaler."	( The effect of ketotifen on bronchial beta-adrenergic tachyphylaxis in normal human volunteers. Pauwels, R; Van der Straeten, M, 1988)	0.27
" Airway responsiveness thus appears to be a useful tool for evaluating inhaled beta 2-agonists and designing beta 2-agonist dosing regimens."	( Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. Ahrens, RC; Annis, L; Harris, JB; Milavetz, G; Ries, R, 1987)	0.5
" The antagonistic component of a partial agonist is seen as a parallel shift of the agonist curve to the right from a constructed additive dose-response curve, from which a dose ratio (DR) was determined for calculation of graphic estimation of KB or pA2 of partial agonists."	( Simple pA2 estimation of partial agonists: comparison with the Kaumann-Blinks method. Pöch, G; Zimmermann, I, 1988)	0.27
" This required a threefold increase in theophylline dosage to maintain therapeutic serum theophylline concentrations."	( Enhancement of theophylline clearance by intravenous albuterol. Amirav, I; Amitai, Y; Avital, A; Godfrey, S, 1988)	0.52
" A similar excretion pattern exhibiting a far more extensive distortion in the enantiomeric ratio was found in three subjects dosed with a single 4-mg tablet of racemic salbutamol."	( Analysis of salbutamol enantiomers in human urine by chiral high-performance liquid chromatography and preliminary studies related to the stereoselective disposition kinetics in man. Soldin, SJ; Tan, YK, 1987)	0.27
" The doses of salbutamol inhaled via the nebulizer and MDI producing maximal bronchodilation were established by cumulative dose-response curves."	( Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Fulton, TJ; Heaton, RW; Jenkins, SC; Moxham, J, 1987)	0.27
" 4 The systemic availability (n = 3), urinary recovery of unchanged oral salbutamol and area under the plasma curve during the oral dosage interval (n = 5) were all only slightly lower (10-20%) than control values, suggesting slightly lower oral absorption."	( Pharmacokinetics and metabolism of salbutamol in premature labour. Hutchings, MJ; Morgan, DJ; Paull, JD; Wilson-Evered, E, 1987)	0.27
" While statistically significant differences in lag time and time to peak concentration were noted among the various oral preparations, the drug is rapidly absorbed in all three dosage forms and the observed differences are unlikely to be of clinical significance."	( Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. Goldstein, DA; Soldin, SJ; Tan, YK, 1987)	0.27
" The bronchodilator effect of the two aerosols was determined from cumulative dose-response studies."	( Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma. Mitchell, DM; Short, M; Solomon, MA; Spiro, SG; Tolfree, SE, 1987)	0.27
" This study was undertaken to compare the clinical effectiveness and toxicity of these two drugs and to try to establish dosage schedules of inhaled salbutamol with spacer in the treatment of acute asthma."	( [Subcutaneous adrenaline versus inhaled salbutamol in the treatment of childhood asthmatic crisis]. Bonal de Falgas, J; Farré Riba, R; Ferrés Mataró, J; Juliá Brugues, A; Mangues Bafalluy, MA, 1987)	0.27
"A new controlled-release (CR) dosage formulation of albuterol has been developed which is suitable for twice-a-day dosing."	( Comparative steady state bioavailability of conventional and controlled-release formulations of albuterol. Dowdy, Y; Gural, R; Patrick, JE; Powell, ML; Symchowicz, S; Weisberger, M, )	0.6
" The results suggest that enhancement of the early bronchodilator response obtained by adding oxitropium bromide to a conventional dose of salbutamol in patients with stable asthma reflects suboptimal dosing of salbutamol rather than differences between the agents in mechanisms of action, whereas enhancement in duration of response is related also to the pharmacological characteristics of oxitropium bromide."	( Combination of oxitropium bromide and salbutamol in the treatment of asthma with pressurized aerosols. Laitinen, LA; Poppius, H, 1986)	0.27
"The sensitivity of the uterus to the inhibition of contractions by salbutamol, diltiazem or nifedipine was assessed in the ovariectomized, post-partum rat by dose-response curves following bolus intravenous (i."	( The effects of long-term infusion of salbutamol, diltiazem and nifedipine on uterine contractions in the ovariectomized, post-partum rat. Abel, MH; Hollingsworth, M, 1986)	0.27
" Then after a further 3 wk of dosing 3 times a day of the second medication (10 patients received each medication), they were challenged once more 16 h after the last dose."	( Comparison of tremor responses to orally administered albuterol and terbutaline. Druz, WS; Jenne, JW; Shaughnessy, TK; Starkey, PW; Valcarenghi, G; Yu, C, 1986)	0.52
" This study compared single daily versus twice daily dosing with a 24-hour theophylline, Uniphyl, in asthma and further evaluated for the additional effect of metered-dose albuterol on each theophylline regimen."	( The use of a single daily theophylline dose and metered-dose albuterol in asthma treatment. Bush, RK; Busse, WW; Smith, A, 1986)	0.71
" Steady-state plasma levels were predictable from the kinetic data and were reached by the third day of dosing (ninth and tenth dose)."	( Multiple-dose albuterol kinetics. Chung, M; Gural, R; Patrick, JE; Powell, ML; Radwanski, E; Symchowicz, S; Weisberger, M, )	0.49
" Statistical analyses of FEV1, FEF25-75, and FVC revealed that all doses of albuterol powder were superior to placebo within 5 min with a log dose-response trend for both degree and duration of bronchodilation."	( Inhaled albuterol powder for the treatment of asthma--a dose-response study. Kemp, JP; Meltzer, EO; Orgel, HA; Welch, MJ, 1985)	0.93
" Both contractile cholinergic responses and relaxant nonadrenergic noncholinergic dose-response data were obtained for the in vitro bronchial specimens by electrical field stimulation."	( Airway reactivity in chronic obstructive pulmonary disease. Failure of in vivo methacholine responsiveness to correlate with cholinergic, adrenergic, or nonadrenergic responses in vitro. Armour, CL; Hogg, JC; Paré, PD; Schellenberg, RR; Taylor, SM, 1985)	0.27
" The addition of albuterol to theophylline improved control of severe asthma in children 2 to 6 years of age demonstrated by improvement in pulmonary function, decrease in theophylline dosage requirement, and improvement in symptoms."	( Albuterol syrup in the treatment of asthma. Bierman, CW; Furukawa, CT; Pierson, WE; Shapiro, GG, 1985)	2.05
" 10 micrograms of clenbuterol revealed no significant differences when compared to placebo, whereas the 20 micrograms dosage as usually administered in clinical routine demonstrated significant--but only slight--differences to placebo-baseline."	( [Novel quantitative assessment of the tremorogenic effects of the beta 2-mimetics clenbuterol and salbutamol after oral administration]. Schaffler, K; Schuster, D, 1985)	0.27
" Side effects were noted in 5 patients taking nifedipine, leading to a decrease in the dosage to 30 mg per day in 3, and in one patient taking placebo."	( Nifedipine in chronic bronchial asthma: a randomized double-blind crossover trial against placebo. Boismare, F; Lemercier, JP; Leprevost, A; Moore, ND; Ozenne, G; Pasquis, P; Tardif, C, 1985)	0.27
" The dosage of salbutamol was the one normally used and supplementary treatment was standardized."	( Salbutamol vs. placebo for treatment of pertussis. Krantz, I; Norrby, SR; Trollfors, B, )	0.13
" These findings imply possible therapeutic advantages of oral albuterol and terbutaline with respect to dosing frequency, while the more rapid onset of oral metaproterenol suggests that it may have an advantage when used on an as-needed basis."	( Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics. Biedermann, AA; Chu, TJ; Wolfe, JD; Yamate, M, 1985)	0.76
" No significant differences were observed between the three dosage groups."	( Nebulised salbutamol without oxygen in severe acute asthma: how effective and how safe? Crompton, GK; Douglas, JG; Fergusson, RJ; Grant, IW; Prescott, RJ; Rafferty, P, 1985)	0.27
" The three dosage forms were orally administered to 12 normal male volunteers in a randomized three-way crossover study."	( Comparative bioavailability and pharmacokinetics of three formulations of albuterol. Chung, M; Gural, R; Patrick, JE; Powell, ML; Radwanski, E; Symchowicz, SS; Weisberger, M, 1985)	0.5
" Ketotifen in the higher dosage caused a slight reduction in salbutamol usage and a modest improvement in breathing in patients not already receiving inhaled corticosteroids."	( Ketotifen in adult asthma. Dyson, AJ; Mackay, AD, 1980)	0.26
" Diabetic patients treated with salbutamol should therefore be under close surveillance and have their insulin dosage increased."	( [Metabolic risks of salbutamol in diabetic patients. A study using somatostatin (author's transl)]. Compagnie, MJ; Dellenbach, P; Schlienger, JL; Stephan, F, 1980)	0.26
" Dose-response curves to a beta agonist, albuterol, were obtained in six normal subjects by measuring specific airway conductance (sGaw) after increasing doses of inhaled albuterol."	( Assessment of bronchial beta blockade after oral bevantolol. Baldwin, CJ; Gribbin, HR; Mackay, AD; Tattersfield, AE, 1981)	0.53
" Dose-response curves to the relaxant effects of isoprenaline, salbutamol, adrenaline and noradrenaline were determined on the partially contracted smooth muscles of the cat nictitating membrane following alpha-adrenoreceptor blockade in order to test the hypothesis of a causal relationship between the inhibition of neuronal uptake and denervation supersensitivity."	( Denervation and beta-adrenoreceptors of the cat nictitating membrane. Nickerson, M; Varma, DR, 1981)	0.26
"We have compared bronchodilator dose-response curves to inhaled salbutamol in seven normal and eight asthmatic subjects."	( Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects. Barnes, PJ; Pride, NB, 1983)	0.27
" sGaw was measured before dosing and after 2 h, just before salbutamol was inhaled."	( Time course of the bronchial response to salbutamol after placebo, betaxolol and propranolol. Kaik, G; Palminteri, R, 1983)	0.27
"The dose-response curves of the beta-adrenergic agonists isoprenaline (mixed beta 1 and beta 2), prenalterol (beta 1-selective), noradrenaline (more beta 1 than beta 2) and salbutamol (beta 2-selective) were studied on adipose cells of the rat, in vitro."	( Characterization of the beta-adrenoceptor of the adipose cell of the rat. Curtis-Prior, PB; Tan, S, 1983)	0.27
" Ipratropium bromide in adequate dosage appears to be effective in reducing morning dipping in asthma."	( Ipratropium bromide in patients with nocturnal asthma. Cox, ID; Hughes, DT; McDonnell, KA, 1984)	0.27
" dosage with salbutamol (1-10 micrograms/kg), aminophylline (5-20 mg/kg) or ipratropium bromide (1-10 micrograms/kg) on total lung resistance in the anaesthetised state."	( Pulmonary responses of salbutamol tolerant guinea-pigs to aminophylline and ipratropium bromide. Tomlinson, DR; Ward, MJ, 1984)	0.27
" This provides a simple, rapid and reproducible way of obtaining linear dose-response curves by plotting times of exposures against absolute or percent increases in sRaw."	( Drug effect on bronchial response to PGF2 alpha and water inhalation. Bianco, S; Damonte, C; Robuschi, M, 1983)	0.27
" Cumulative log dose-response curves were constructed."	( Methacholine dose-response curves in normal and asthmatic man: effect of starting conductance and pharmacological antagonism. Chung, KF; Snashall, PD, 1984)	0.27
"A dose-response study of the effect of naloxone on schedule-induced drinking confirmed that this type of drinking is resistant to the opiate antagonist at doses which depressed drinking induced by water-deprivation, hypertonic saline and salbutamol."	( The effect of naloxone on schedule-induced and other drinking. Singer, G; Wallace, M; Willis, G, 1984)	0.27
" Nineteen aerobic, non-atopic, athletes (10 females, 9 males) were studied in a double-blind fashion to determine the effect of a therapeutic dosage of salbutamol on pulmonary function, oxygen consumption (VO2max), heart rate (HR), and anaerobic threshold (AT)."	( Salbutamol and treadmill performance in non-atopic athletes. Dunwoody, DW; Filsinger, IB; Jang, F; McKenzie, DC; Rhodes, EC; Stevens, A; Stirling, DR; Wiley, JP, 1983)	0.27
" On each occasion a regression line for the descending part of the log-cumulative dose-response curve was computed."	( Prostaglandins and the control of airways responses to histamine in normal and asthmatic subjects. Walters, EH, 1983)	0.27
" Analysis of variance of the results indicated significant dose-response relationships and showed the larger doses to have a longer duration of action."	( Dose-response study of inhaled salbutamol powder in chronic airflow obstruction. Corris, PA; Gibson, GJ; Nariman, S; Neville, E, 1983)	0.27
" The FEV1 dose-response curves were almost identical indicating bronchodilating equipotency between the two modes of administration."	( The effect of powder aerosol compared to pressurized aerosol. Löfdahl, CG; Svedmyr, K; Svedmyr, N, 1982)	0.26
" Nine patients participated in a dose-response study."	( A comparison between inhaled clenbuterol and salbutamol in chronic bronchitis with reversible airway obstruction. Baronti, A; Grieco, A; Vibelli, C, 1980)	0.26
" The development of resistance was assessed from salbutamol dose-response studies in which the airway response was measured as specific airway conductance (sGaw)."	( Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Harvey, JE; Tattersfield, AE, 1982)	0.26
"Cumulative inhalation dose-response curves for the response to prostaglandin E2 (PGE2) have been constructed in normal subjects and patients with mild, stable asthma."	( Interactions between response to inhaled prostaglandin E2 and chronic beta-adrenergic agonist treatment. Bevan, M; Davies, BH; Walters, EH, 1982)	0.26
" We constructed cumulative log dose-response curves and determined the steepest slope and the provocative dose of histamine (PD35) needed to cause a 35% fall in specific airway conductance (SGaw)."	( Histamine dose-response relationships in normal and asthmatic subjects. The importance of starting airway caliber. Chung, KF; Keyes, SJ; Morgan, B; Snashall, PD, 1982)	0.26
" The dose-response curve for non-esterified fatty acids and insulin, though displaced downwards, did not indicate an impaired response to salbutamol since the shape was unchanged."	( Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol. Alberti, KG; Baldwin, CJ; Harvey, JE; Tattersfield, AE; Wood, PJ, 1981)	0.26
"We examined the use of partial expiratory flow-volume (PEFV) curves to obtain dose-response curves to an inhaled beta 2-adrenoceptor agonist (salbutamol) in eight normal subjects."	( Partial flow-volume curves to measure bronchodilator dos-response curves in normal humans. Barnes, PJ; Gribbin, HR; Osmanliev, D; Pride, NB, 1981)	0.26
" At no dosage level was there synergy between the two agents in terms of either mean percentage increase in FEV1 or the integrated response."	( Intravenous salbutamol and aminophylline in asthma: a search for synergy. Dart, AM; Davies, BH; Handslip, PD, 1981)	0.26
" So with the dosage used here no implication of central beta-adrenoceptors in sleep mechanisms and production of epileptic activity are suggested."	( Effect of salbutamol, a putative cerebral beta agonist on sleep stages and interictal epileptic discharges. Autret, A; DEgiovanni, E; Laffont, F; Lucas, B, 1981)	0.26
"1 Cumulative dose-response curves (FEV1) to pressurized aerosol salbutamol were established in 17 patients admitted to hospital with acute severe asthma."	( Comparative efficacy of salbutamol by pressurized aerosol and wet nebulizer in acute asthma. Madsen, BW; Paterson, JW; Tarala, RA, 1980)	0.26
" The highest dose used in the dose-response trials (=0."	( Inhalation of racemic epinephrine in children with asthma. Dose-response relation and comparison with salbutamol. Kjellman, B; Tollig, H; Wettrell, G, 1980)	0.26
" On the last day of each period a cumulative dose-response experiment with terbutaline in the doses 50, 100, 250 and 500 micrograms (cumulative dose 900 micrograms) was performed."	( Influence of budesonide on the response to inhaled terbutaline in children with mild asthma. Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1995)	0.29
" A histamine challenge test was done 12 h after the last dose of each treatment period, and dose-response curves to inhaled salbutamol (200-3200 micrograms) were constructed 36 h after the last dose."	( Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Grove, A; Lipworth, BJ, 1995)	0.29
" A dose-response curve for nebulized ipratropium was determined."	( [Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience]. Beck, R, 1995)	0.29
"05), which is consistent with albuterol's recommended dosing frequency of every 4 to 6 hours."	( Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. Corren, J; Katz, RM; Nicodemus, CF; Rachelefsky, GS; Schanker, HM; Siegel, SC; Spector, SL, 1995)	0.82
"When testing the response to beta 2-agonist drugs in severe chronic obstructive pulmonary disease (COPD), a dose-response assessment should be undertaken."	( Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Cazzola, M; D'Amato, G; Matera, MG; Rossi, F; Santangelo, G; Vinciguerra, A, 1995)	0.29
"The safety, tolerability and systemic pharmacodynamic activity of the salmeterol/HFA134a inhaler, the current salmeterol inhaler, and placebo (HFA134a) were compared in 12 healthy volunteers in a double blind, randomised crossover study using a cumulative dosing design."	( Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers. Kirby, SM; Smith, J; Ventresca, GP, 1995)	0.29
" Bronchodilator dose-response studies were performed by administering increasing doses of isuprel intravenously before and after treatment with salbutamol."	( [Bronchial reactivity after regular inhalation of salbutamol]. Krasnowska, M; Małlolepszy, J; Passowicz-Muszyńska, E, 1995)	0.29
" The dose-response curve for each subject was measured by a log transformation and linear regression analysis as well as a formula fitted to the data points to obtain values for a (slope) and b (position)."	( Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction. Huang, TJ; Kuo, HP; Lin, HC; Shieh, WB; Wang, CH; Yang, CT; Yu, CT, 1995)	0.29
" Maximum plasma concentrations attained at 1 h after dosing ranged between 35."	( The determination in human plasma of 1-hydroxy-2-naphthoic acid following administration of salmeterol xinafoate. Carey, PF; Chilton, AS; Godward, RE, 1995)	0.29
" In conclusion, combining the standard dosages of ipratropium bromide and salbutamol may provide greater bronchodilation than doubling the standard dosage of ipratropium bromide in patients with COPD."	( Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Ikeda, A; Izumi, T; Koyama, H; Nishimura, K, 1995)	0.29
" Dosing intervals and the use of other medications were determined by the treating physician."	( Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. Chou, KJ; Crain, EF; Cunningham, SJ, 1995)	0.29
" Isolated atrial strips showed a right shift of their dose-response curve to isoprenaline in the presence of the highly selective beta 2-AR antagonist ICI 118,551 at concentrations above 1 x 10(-8) mol/L."	( The effects of sympathomimetics on the cardiovascular system of sheep. Allen, R; Alley, MR; Baxter, S; Burgess, C; Crane, J; Dallimore, JA; Davie, PS; Kealey, AS; Lapwood, KR; Pack, RJ, 1994)	0.29
" Dose-response curves were constructed using cumulative doses of 100 micrograms, 200 micrograms, 400 micrograms, 1000 micrograms, 2000 micrograms, and 4000 micrograms, and airways and systemic responses were measured 20 minutes after each dose with 40 minute increments."	( Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Newnham, DM; Winter, JH, 1995)	0.29
"01), but significant differences between salmeterol doses were no longer evident, despite an apparent dose-response effect."	( A 1-week dose-ranging study of inhaled salmeterol in patients with asthma. Bierman, CW; Bronsky, EA; Kemp, JP; Liddle, RF; Orgel, HA; Tinkelman, DG; van As, A, 1994)	0.29
" Salmeterol, 42 micrograms twice daily, is a safe and effective dosage for patients with mild-to-moderate asthma who are persistently symptomatic and require maintenance bronchodilator therapy."	( A 1-week dose-ranging study of inhaled salmeterol in patients with asthma. Bierman, CW; Bronsky, EA; Kemp, JP; Liddle, RF; Orgel, HA; Tinkelman, DG; van As, A, 1994)	0.29
" Subjects received cumulative doses of up to 400 micrograms (50 + 50 + 100 + 100 + 100 micrograms at 45 min intervals) inhaled salmeterol prior to a 13 day dosing schedule of twice-daily inhaled salmeterol 100 micrograms or placebo."	( Does tachyphylaxis occur to the non-pulmonary effects of salmeterol? Chilton, JE; Keene, ON; Maconochie, JG; Minton, NA, 1994)	0.29
"The purpose of the present study was to assess the degree of protection of inhaled salmeterol against exercise-induced bronchoconstriction (EIB) after chronic compared with single dosing in patients with asthma."	( Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Cree, IA; Dhillon, DP; Ingram, CG; Lipworth, BJ; Ramage, L, 1994)	0.29
"This study investigated the effects of an osmotic release oral drug delivery system of metoprolol on the changes induced by cumulative doses of inhaled salbutamol on bronchomotor tone, skeletal muscle, and the circulatory system after single (day 1) and multiple (day 7) dosing in 18 hypertensive asthmatic patients (forced expiratory volume in 1 second > 50% predicted; diastolic blood pressure > 90 mm Hg)."	( Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors. Bauer, K; Kaik, B; Kaik, G, 1994)	0.29
" The dose-response curve to methacholine reached a plateau in all the responders."	( Evaluation of asymptomatic subjects with low forced expiratory ratios (FEV1/VC). Kivity, S; Schwarz, Y; Solomon, A; Topilsky, M; Trajber, I, 1994)	0.29
" These results indicate that inhalational administration of a selective PDE isoenzyme type III/IV inhibitor, SDZ ISQ 844 decreases airway responsiveness at dosage which does not affect the base-line respiratory resistance."	( [Effects of inhaled SDZ ISQ 844, a cyclic nucleotide phosphodiesterase isoenzyme type III/IV inhibitor, on airway responsiveness in beagles]. Adachi, M; Horikoshi, S; Idaira, K; Imai, T; Okamoto, M, 1994)	0.29
" They are an expression of pharmacological activity brought about by the excessive beta stimulant action of high dosage with the drug."	( A review of the toxicology of salbutamol (albuterol). Libretto, SE, 1994)	0.55
" This emphasizes the need for well-designed research to develop optimal dosage regimens in paediatric patients with bronchiolitis."	( Pattern of drug usage in bronchiolitis. Nahata, MC; Schad, PA, 1994)	0.29
"This study investigated the effects of isamoltane on the changes induced by cumulative doses of inhaled albuterol (salbutamol) on bronchomotor tone, skeletal muscle, circulatory system, and metabolism after single (day 1) and multiple dosing (day 7) in 15 healthy subjects."	( Assessment of beta-adrenergic receptor blockade after isamoltane, a 5-HT1-receptor active compound, in healthy volunteers. Bauer, K; Dietersdorfer, F; Kaik, G, 1993)	0.5
" The PD20 (dose of histamine causing a 20% fall in FEV1) was measured before and 11, 35, and 59 h after cessation of treatment and a bronchodilator dose-response study before and 83 h after cessation of treatment."	( Asthma control during and after cessation of regular beta 2-agonist treatment. Pavord, ID; Tattersfield, AE; Wahedna, I; Wisniewski, AF; Wong, CS, 1993)	0.29
" The lung function parameters after cumulative dosing of salbutamol were equal during each study day."	( A novel multiple dose powder inhaler. Salbutamol powder and aerosol give equal bronchodilatation with equal doses. Haahtela, T; Korhonen, P; Laurikainen, K; Nyberg, A; Silvasti, M; Vidgren, M, 1994)	0.29
" The main finding was that older children had higher concentrations than younger children, despite similar dosage regimens."	( Systemic absorption of salbutamol following nebulizer delivery in acute asthma. Dawson, KP; Manglick, P; Penna, AC; Tam, J, 1993)	0.29
"The study deals with the effect of salbutamol powder (Ventodisk) administered with Diskhaler device comparatively to salbutamol dosed aerosols."	( [Effectiveness of salbutamol powder (Ventodisk Glaxo) compared to dosed aerosols (sultanol)]. Duţu, S; Ionescu, AA; Macri, A; Popescu, O; Stoicescu, P, )	0.13
" A further 416 (57) micrograms reduction in inhaled corticosteroid dosage was possible during the treatment phase but this was almost identical in the WEB 2086 and placebo-treated groups, amounting to 353 (92) and 481 (65) micrograms/day respectively (not significant [NS])."	( The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. Calverley, PM; Dhillon, P; Higgins, C; Holgate, ST; Johnston, SL; Ramhamadany, E; Spence, DP; Turner, S; Winning, A; Winter, J, 1994)	0.29
" No patient required escalation of dosage or additional intervention such as intravenous beta-agonist therapy or mechanical ventilation."	( Low-dose beta-agonist continuous nebulization therapy for status asthmaticus in children. Eid, NS; Montgomery, VL, 1994)	0.29
"The relative bronchodilator (delta FEV1, V25, V50) potency and side effect profile (delta tremor, heart rate, breathlessness, BP) of nebulized salbutamol and fenoterol were evaluated by means of a randomized, double-blind, crossover, cumulative (50 to 2,500 micrograms) dose-response study."	( Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma. Dolovich, MB; Kazim, F; Newhouse, MT, 1994)	0.29
"8) and less total dosage (34 +/- 16 mg compared with 70 +/- 34 mg; mean difference, -36 mg; CI, -60."	( Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma? Aull, L; Harman, E; Hendeles, L; Huang, D; O'Brien, RG; Reents, S; Shieh, G; Visser, J, 1993)	0.29
") dosing of SB, fraction of dose which avoids the hepatic first-pass-effect (Fh) was calculated from the areas under the blood concentration-time curve (AUC)."	( [Absorption and first-pass-effect of salbutamol after intraduodenal and intrarectal administration in rabbits]. Ito, K; Kurosawa, N; Owada, E, 1993)	0.29
" Drugs were dosed as dry powders directly into the tracheobronchial tree and MVL was assessed by using the fluorescent macromolecule fluorescein isothiocyanate-dextran (FITC-dextran, 150 kD)."	( Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo. Karlsson, JA; Raeburn, D, 1993)	0.29
"The authors compared the effectiveness and advantages of the powdered inhalation variety of the preparation Ventodisc (Glaxo) with the "classical" dosed inhalation form of Salbutamol (Polfa) in 21 patients with bronchial asthma."	( [The bronchodilator agent, Ventodisk, in the powdered inhalation form without freon is better]. Malý, M; Reisová, M; Vondra, V, 1993)	0.29
" Although transient, the dose-response relationship and duration of effect is unknown."	( Hypokalemia after pediatric albuterol overdose: a case series. Leikin, JB; Linowiecki, KA; Paloucek, F; Soglin, DF, 1994)	0.58
" We compared the dose-response relationship to albuterol by wet nebulization or metered dose inhaler in acute asthma."	( A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. Afilalo, M; Colacone, A; Kreisman, H; Wolkove, N, 1993)	0.89
" The cumulative dose-response technique is applicable in the emergency department setting and is helpful in comparing the relative utility of various bronchodilator regimens."	( A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. Afilalo, M; Colacone, A; Kreisman, H; Wolkove, N, 1993)	0.63
" These data indicate that the acute effect of albuterol inhalation at twice the recommended dosage has no positive effect on endurance performance measures or pulmonary function in athletes who are not asthmatic."	( Effects of acute inhalation of albuterol on submaximal and maximal VO2 and blood lactate. Fleck, SJ; Lucia, A; Storms, WW; Vint, PF; Wallach, JM; Zimmerman, SD, 1993)	0.83
" The slopes of the dose-response curves of FEV1 and plasma cAMP to intravenous S were unaffected by the two treatment courses."	( Effects of therapeutic doses of salbutamol alone and combined with beclomethasone dipropionate on airway responsiveness and cyclic AMP plasma levels in asthmatic patients. Adami, S; Ferrari, M; Lo Cascio, V; Olivieri, M; Prior, M; Romito, D; Squassante, L; Testi, R, 1993)	0.29
" The method was applied, without any interferences from the excipients, to the determination of the drug in a tablet dosage form and in drug dissolution studies."	( Voltammetric study of salbutamol and application to its determination in a tablet dosage form and dissolution profiles for the dosage form. Munden, R; Sagar, KA; Smyth, MR, 1993)	0.29
" Optimal dosing will be obtained when the catheter extends the full length of the tracheal tube."	( Dosing efficiency and particle-size characteristics of pressurized metered-dose inhaler aerosols in narrow catheters. Chambers, C; Dolovich, M; Lerman, J; Taylor, RH, 1993)	0.29
"In order to evaluate rectal administration of salbutamol (SB), five healthy volunteers were dosed orally and rectally with racemic SB (0."	( Serum concentration and cardiovascular effects of salbutamol after oral and rectal administration in healthy volunteers. Bando, K; Ito, K; Kato, A; Kurosawa, N; Kurosawa, S; Owada, E, 1993)	0.29
" The aim of this study was to seek such a relationship in young asthmatic children using dose-response curves (DRC)."	( The effect of age on bronchodilator responsiveness. Landau, LI; LeSouëf, PN; Turner, DJ, 1993)	0.29
"In order to obtain a basic knowledge for developing the rectal dosage form of salbutamol (SB), a comparison of the bioavailability was made between oral and rectal administrations."	( [Comparison of bioavailability of salbutamol between oral and rectal administration in rabbits]. Ito, K; Kurosawa, N; Morishima, S; Owada, E, 1993)	0.29
" The dose-response curve for melatonin shows an approximate 1000-fold shift in potency in the RCS rat."	( Agonist-induced effects on cyclic AMP metabolism are affected in pigment epithelial cells of the Royal College of Surgeons rat. Nash, MS; Osborne, NN, 1995)	0.29
" Dosage of isoprenaline increased from 1 to 12 micrograms/min, and salbutamol increased from 4 to 64 micrograms/min during the trial."	( Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. Allan, LD; Groves, AM; Rosenthal, E, 1995)	0.29
"We studied three doses of inhaled salbutamol, 200, 400, and 800 micrograms/day, to determine dose-response curves for these two adverse effects."	( Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. Bhagat, R; Cockcroft, DW; Swystun, VA, 1996)	0.29
" In addition, agents that can be dosed as needed (i."	( Cost comparison of beta 2-agonist bronchodilators used in the treatment of asthma. Nightingale, CH, )	0.13
") dosing was compared to one dose at night and to placebo."	( Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients. Ariaansz, M; Nauta, JJ; Postmus, PE; Raaijmakers, JA; Van Keimpema, AR, 1996)	0.53
"This study compares the safety and efficacy of HFA 134a salbutamol sulfate (Airomir in the 3M CFC-free system [3M Pharmaceuticals]) and CFC 11/12 salbutamol (Ventolin [Allen & Hanburys]) in a cumulative dose-response (1, 1, 2, 4, 8 inhalations at 30-min intervals) study in asthmatic patients."	( Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Cline, AC; Ekholm, BP; Kleerup, EC; Tashkin, DP, 1996)	0.29
" Both HFA 134a salbutamol sulfate and CFC 11/12 salbutamol displayed a significant dose-response for FEV1, FEF25-75%, FVC, serum potassium, heart rate, and systolic BP."	( Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Cline, AC; Ekholm, BP; Kleerup, EC; Tashkin, DP, 1996)	0.29
") provide a convenient, twice-daily dosing regimen, but are indicated only for patients > or = 12 years of age."	( Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children. Boltansky, H; Harrison, JE; Kobayashi, RH; Lorber, RR; Pearlman, DS; Shapiro, G; Skoner, DP; Trochelmann, LM, 1996)	0.63
" Hypothetically, twice daily dosing of salmeterol may result in continuous protection."	( Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. Creyghton, FB; de Jongste, JC; Hop, WC; Kerrebijn, KF; van den Berg, M; van Rooij, RW; Verberne, AA, 1996)	0.29
" One hour after inhaling single doses of placebo, salmeterol 25 micrograms, or formoterol 12 micrograms, dose-response curves to repeated doses of inhaled fenoterol were constructed (cumulative doses of 100-3200 micrograms)."	( Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol. Grove, A; Lipworth, BJ, 1996)	0.29
" There were no significant differences in the area under the dose-response curve for any of the parameters during the dose-response curve following treatment with salmeterol or formoterol compared with placebo."	( Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol. Grove, A; Lipworth, BJ, 1996)	0.29
"Prior treatment with low doses of salmeterol or formoterol does not significantly alter bronchodilator dose-response curves to repeated doses of fenoterol in stable asthmatic patients."	( Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol. Grove, A; Lipworth, BJ, 1996)	0.29
"The purpose of this study was to evaluate the effect of albuterol dosing schedule on clinical outcome in subjects with moderate to severe stable asthma."	( The effect of inhaled albuterol in moderate to severe asthma. Apter, AJ; Clive, J; McNally, D; Metersky, M; Reisine, ST; Wells, M; Willard, A; ZuWallack, RL, 1996)	0.85
"In our sample of patients with moderate to severe asthma, four times daily dosing of albuterol did not lead to deterioration of asthma control."	( The effect of inhaled albuterol in moderate to severe asthma. Apter, AJ; Clive, J; McNally, D; Metersky, M; Reisine, ST; Wells, M; Willard, A; ZuWallack, RL, 1996)	0.83
"1% predicted were studied in a randomised double blind single dosing crossover study."	( Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Clark, DJ; Clark, G; Gordon-Smith, J; Lipworth, BJ; McPhate, G, 1996)	0.29
" We wanted to assess whether the combination of a beta 2-bronchodilator with an anti-inflammatory treatment in the same metered-dose inhaler (MDI) with a regular dosing schedule might improve compliance."	( Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Compliance Working Group. Braunstein, GL; Harper, AE; Trinquet, G, 1996)	0.29
" The longer dosing intervals, which may enhance compliance, encourage its administration in patients with COPD."	( A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Calderaro, F; Caputi, M; Cazzola, M; Di Perna, F; Matera, MG; Rossi, F; Vinciguerra, A, 1995)	0.29
" Salmeterol and salbutamol produced the same maximal increase in sGAW and had the same area under the dose-response curves."	( Airway effects of salmeterol in healthy individuals. Bake, B; Bergendal, A; Johansson, A; Löfdahl, CG; Lötvall, J; Skoogh, BE, 1995)	0.29
"6 mg) and oral (4 mg) dosing with racemic drug to seven normal male volunteers."	( Enantioselective disposition of salbutamol in man following oral and intravenous administration. Boulton, DW; Fawcett, JP, 1996)	0.29
" While trypan blue potentiated the effect of histamine and shifted its dose-response curve to the left, it did not affect the contractile effects of acetylcholine."	( Effect of trypan blue on the action of acetylcholine, histamine and salbutamol in the isolated guinea-pig ileum. Damankeshideh, M; Mahmoudian, M, 1996)	0.29
" Additionally, during dosing with TBH, fewer patients experienced adverse events than during dosing with RH or DH."	( Relative efficacy of three different inhalers containing salbutamol in patients with asthma. Hamersma, WB; Mahadewsingh, JV; Schreurs, AJ, 1996)	0.29
" It is also important when considering new dosage routes or formulations in order to optimize therapeutic plasma concentrations of the active enantiomer."	( Enantioselective disposition of albuterol in humans. Boulton, DW; Fawcett, JP, 1996)	0.58
"The aim of this study was to evaluate the effects of single and chronic dosing with salmeterol on exercise capacity and lung function in patients with chronic obstructive pulmonary disease."	( Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Dhillon, DP; Grove, A; Ingram, CG; Jenkins, RJ; Lipworth, BJ; Ramage, L; Reid, P; Smith, RP; Winter, JH, 1996)	0.29
" When selecting a 15-min pretreatment interval with equieffective anti-WFR doses from the first dose-response experiments (i."	( Effects of local treatment with salmeterol and terbutaline on anti-IgE-induced wheal, flare, and late induration in human skin. Grönneberg, R; Raud, J, 1996)	0.29
"In human subjects, chronic beta2-agonist dosing reduces mononuclear leukocyte (MNL) beta-adrenoceptor numbers."	( In vivo quantification of human pulmonary beta-adrenoceptors: effect of beta-agonist therapy. Hayes, MJ; Hughes, JM; Ind, PW; Jones, T; Qing, F; Rahman, SU; Rhodes, CG; Sriskandan, S, 1996)	0.29
"These results confirm that there is activation of the RAS in asthmatic subjects by single doses of nebulized beta 2-agonists and that repeated dosing with nebulized albuterol has further, additive effects on plasma Ang II levels."	( The effect of nebulized albuterol on the activity of the renin-angiotensin system in asthma. Connell, JM; Millar, EA; Thomson, NC, 1997)	0.8
" An appropriate dosing schedule for fenoterol needs to be redefined."	( Oral fenoterol versus sustained release theophylline in adult asthmatics. Almagro, J; Andrade, RJ; Hidalgo Sanchez, R; Lucena, MI; Sanchez de la Cuesta, F, 1997)	0.3
" A dose-response increase in pulmonary function was found, but only 66% of the subjects improved sufficiently to be sent home."	( Observations on the effects of aerosolized albuterol in acute asthma. Dixon, L; Galan, G; Hejal, R; McFadden, ER; Strauss, L, 1997)	0.56
"This was a 1-week study evaluating the safety and efficacy of two dosage regimens of salmeterol in children with asthma."	( A one-week dose-ranging study of inhaled salmeterol in children with asthma. Bronsky, EA; Chervinsky, P; Howland, WC; Liddle, R; Nathan, RA; Pollard, SJ; Prenner, B; Stahl, E; Weinstein, S, 1997)	0.3
" The aim of this study was to determine the effects of regular treatment with the long-acting beta-agonist, salmeterol, on the methacholine dose-response curve (DRC) in mild-to-moderate asthmatics."	( Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics. O'Shaughnessy, AD; Sears, MR; Walker, CM; Wong, AG, 1997)	0.3
"The purpose of this study was to evaluate the feasibility of switching to once-daily (qd) administration of flunisolide in patients with asthma that was controlled by twice-daily (bid) dosing of this inhaled steroid."	( The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. Bodenheimer, S; Bronsky, EA; Chervinsky, P; Cohen, L; Corren, J; Goldsobel, AB; Gong, H; Kaliner, MA; Lotner, GZ; Rachelefsky, GS; Rosen, JP; White, MV; ZuWallack, RL, 1997)	0.3
" The shape of the dose-response curves and the magnitude of the total increase in the forced expiratory volume in one second (FEV1) was identical for CPAP and control conditions."	( Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask. Bersten, AD; Parkes, SN, 1997)	0.3
"Short-term salmeterol use within the prescribed dosage was not shown to increase short-term power output in nonasthmatic cyclists."	( The effects of salmeterol on power output in nonasthmatic athletes. Fleck, SJ; McDowell, SL; Storms, WW, 1997)	0.3
"We conclude that a single 50-microg dose of salmeterol has an excellent protective effect against exercise-induced asthma for at least 9 hours, but that this effect may wane during regular once-daily salmeterol treatment, despite the reduced frequency of dosing and despite concomitant use of inhaled glucocorticoids."	( Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Cheang, MS; Gerstner, TV; Simons, FE, 1997)	0.3
" L-NMMA coinfusion inhibited responses (area under the dose-response curve) to isoproterenol (0."	( Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm. Chowienczyk, PJ; Dawes, M; Ritter, JM, 1997)	0.3
"The use of inhaled antibiotics in the treatment of cystic fibrosis has become widespread despite controversy in the literature as to the appropriate dosing regimen and its effectiveness."	( The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Coates, AL; Kelemen, S; MacDonald, J; MacNeish, CF; Meisner, D; Thibert, R; Vadas, E, 1997)	0.54
" For secondary end points salmeterol treatment was associated with higher morning and evening peak expiratory flow and forced expiratory volume in one second; a reduction in symptoms, bronchodilator use and airway responsiveness to methacholine; and no effect on serum potassium concentration, 24 hour heart rate, or the final forced expiratory volume in one second achieved during a salbutamol dose-response study."	( Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. Bennett, J; Clark, M; Cooper, S; Lewis, S; Oborne, J; Rushton, L; Tattersfield, AE; Thompson Coon, J; Wilding, P, 1997)	0.3
" Interactive mixtures of micronized Salmeterol Xinafoate adhered to irrespirable lactose monohydrate carrier particles were used as model dosage forms."	( The development of a cascade impactor simulator based on adhesion force measurements to aid the development of dry powder inhalations. Podczeck, F, 1997)	0.3
"), the heart rate dose-response curves to isoprenaline were shifted to the right of those determined in matched groups of vehicle-pretreated animals."	( Celiprolol: agonist and antagonist effects at cardiac beta 1- and vascular beta 2-adrenoceptors determined under in vivo conditions in the rat. Alda, O; Alvarez-Guerra, M; Garay, RP, 1997)	0.3
"A group of 20 patients with moderate bronchial asthma aged 18 through 65, previously treated with Becotide inhaler for 4 weeks was given Serevent in regular dosage for 4 weeks."	( [Serevent in the treatment of moderate bronchial asthma]. Acasandri, E; Arghir, O; Filip, G; Floca, L; Mihai, D; Panghea, P; Voicu, G, )	0.13
" Beta 2 adrenoceptor function was evaluated by measuring lymphocyte beta 2 adrenoceptor parameters and constructing dose-response curves to salbutamol (100-1600 micrograms)."	( Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Lipworth, BJ; McFarlane, LC; Tan, KS, 1997)	0.3
"05) in terms of the calculation method used (relation of the areas under the plasma level curve Loo-Riegelman, deconvolution) nor in terms of the dosage form (Ventolin Volmax, SG7 and SG14)."	( Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol. Calvo, MB; Caramella, C; Conte, U; Domínguez-Gil, A; Gascón, AR; Hernández, RM; Pedraz, JL, )	0.13
" Dose-response curves for the effects of isoprenaline (non selective beta-agonist), salbutamol (beta2-agonist), dobutamine (beta1-agonist) on ICa were obtained in the absence and presence of various concentrations of ICI 118551 (beta2-antagonist), metoprolol (beta1-antagonist) and xamoterol (partial beta1-agonist) to derive EC50 (i."	( Pharmacological characterization of the receptors involved in the beta-adrenoceptor-mediated stimulation of the L-type Ca2+ current in frog ventricular myocytes. Fischmeister, R; Jurevicius, J; Skeberdis, VA, 1997)	0.3
" Even when controlling for dosage in the preceding 24 h, there was a 262-fold and 810-fold variation in the urinary concentrations for unchanged and total salbutamol, respectively, among the community patients."	( Investigation of urinary levels of salbutamol in asthmatic patients receiving inhaled therapy. Jacobson, GA; McLean, S; Peterson, GM, 1997)	0.3
" The purpose of this study was to evaluate the dose-response effects of racemic (+/-) salbutamol and its R(-) and S(+) isomers in terms of pharmacokinetics and pharmacodynamics at extrapulmonary beta 2 adrenoceptors when given by the inhaled route to healthy volunteers."	( Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Arbeeny, C; Clark, DJ; Koch, P; Lipworth, BJ, 1997)	0.3
" This method was applied to evaluate the enantioselective release of salbutamol and taking into account the hypothesis that one enantiomer of a chiral drug would be released faster than the other from a pharmaceutical dosage form containing a racemic drug and a chiral excipient."	( Determination of salbutamol enantiomers by high-performance capillary electrophoresis and its application to dissolution assays. Calvo, B; Esquisabel, A; Gascón, AR; Hernández, RM; Igartua, M; Pedraz, JL, 1997)	0.3
"5%) in matched normal subjects, but had no effect on TLCO and KCO in EH patients prior to TS; and (2) subsequent inhalation of the beta 2-adrenoreceptor agonist salbutamol in a dosage suspected to cause alveolar beta-receptor stimulation had no effect on TLCO and KCO, neither in the normal subjects, nor in EH patients (before and after TS)."	( Partial pulmonary sympathetic denervation by thoracoscopic D2-D3 sympathicolysis for essential hyperhidrosis: effect on the pulmonary diffusion capacity. Noppen, MM; Vincken, WG, 1997)	0.3
" A dose-response curve (DRC) for systemic beta2-responses to inhaled salbutamol (800 to 3,200 microg) was constructed before and after each treatment period (ie, FM + PL or FM + PRED)."	( Concomitant administration of low-dose prednisolone protects against in vivo beta2-adrenoceptor subsensitivity induced by regular formoterol. Lipworth, BJ; McFarlane, LC; Tan, KS, 1998)	0.3
" This study assesses the effect of long-term beta2-agonist dosing on cardiac beta-adrenoceptors."	( Effect of long-term beta2-agonist dosing on human cardiac beta-adrenoceptor expression in vivo: comparison with changes in lung and mononuclear leukocyte beta-receptors. Hayes, MJ; Hughes, JM; Ind, PW; Jones, T; Qing, F; Rahman, SU; Rhodes, CG, )	0.13
"Serum sex hormones, lymphocyte beta2-adrenoceptor parameters, and bronchodilator and systemic dose-response curves (DRCs) to albuterol (Salbutamol) (100 to 1,600 microg) were measured at both on and off periods."	( Beta2-adrenoceptor regulation and function in female asthmatic patients receiving the oral combined contraceptive pill. Lipworth, BJ; McFarlane, LC; Tan, KS, 1998)	0.51
"At weeks 0, 4, 8, and 12, spirometry was performed predose and serially over 6 h after dosing with study drug."	( Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics. Bleecker, ER; Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, J; Slade, HB; Tinkelman, DG, 1998)	0.3
" Vital signs were recorded over 6 h after dosing with study drug at weeks 0, 4, 8, and 12."	( Proventil HFA and ventolin have similar safety profiles during regular use. Bleecker, ER; Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, J; Slade, HB; Tinkelman, DG, 1998)	0.3
" Changes in heart rate and BP were small after dosing with study drug and tended to be similar for the active treatments and HFA-134a placebo groups."	( Proventil HFA and ventolin have similar safety profiles during regular use. Bleecker, ER; Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, J; Slade, HB; Tinkelman, DG, 1998)	0.3
" A dosage of 16 puffs per day of propellant HFA-134a was well tolerated by asthmatics."	( Proventil HFA and ventolin have similar safety profiles during regular use. Bleecker, ER; Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, J; Slade, HB; Tinkelman, DG, 1998)	0.3
"A dose-response increase in pulmonary function was found, but only 70% improved sufficiently to be discharged."	( Therapeutic response patterns to high and cumulative doses of salbutamol in acute severe asthma. Rodrigo, C; Rodrigo, G, 1998)	0.3
" Lymphocyte beta2-adrenoceptor parameters and a dose-response curve to inhaled albuterol (200 to 1600 microg) were evaluated at 36 hours after the last dose of each treatment period."	( Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. Aziz, I; Hall, IP; Lipworth, BJ; McFarlane, LC, 1998)	0.53
"There were no significant differences in the mean values for albuterol dose-response effects among the three treatment regimens."	( Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. Aziz, I; Hall, IP; Lipworth, BJ; McFarlane, LC, 1998)	0.54
"1 microM), both caused rightward shifts in the dose-response curve for the inhibition of histamine release by isoprenaline."	( Salmeterol inhibition of mediator release from human lung mast cells by beta-adrenoceptor-dependent and independent mechanisms. Chong, LK; Cooper, E; Peachell, PT; Vardey, CJ, 1998)	0.3
" Consistent in vitro fine particle dosing from the Diskus inhaler translates into a consistent clinical effect at low and high flow rates in children."	( Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Auk, IL; Bisgaard, H; Bojsen, K; Ifversen, M; Klug, B; Nielsen, KG, 1998)	0.3
" Twice daily dosing may increase compliance with therapy."	( A multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 microg per day) for the treatment of patients with mild-to-moderate asthma. Bernstein, DI; Cohen, R; Ginchansky, E; Pedinoff, AJ; Tinkelman, DG; Winder, JA, 1998)	0.3
" The accuracy of dosing and the technically perfect use of devices are extremely important, especially when drugs with potential systemic side effects are administered."	( Inhalation devices in childhood asthma. Gács, E; Göndöcs, R; Jákly, A; Uhereczky, G, 1998)	0.3
" Peak inspiratory flow (PIF) through Turbuhaler was measured on each dosing occasion."	( Beta 2-agonists administered by a dry powder inhaler can be used in acute asthma. Boe, J; Löfdahl, CG; Maranetra, N; Nana, A; Selroos, O; Ståhl, E; Youngchaiyud, P, 1998)	0.3
"The aim of this study was to investigate whether regular treatment with inhaled salmeterol modifies the dose-response curve to the inhaled short-acting beta2-agonist terbutaline or affects the concentration of nitric oxide (NO) in exhaled air of children with asthma."	( Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1998)	0.3
"We examined whether a pretreatment with formoterol, oxitropium bromide, or salmeterol might modify the dose-response curves to inhaled salbutamol in patients with stable and partially reversible chronic obstructive pulmonary disease (COPD)."	( Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Calderaro, F; Cazzola, M; Di Perna, F; Girbino, G; Matera, MG; Noschese, P; Vinciguerra, A, 1998)	0.3
" Concentrations of 1, 10 and 100 nM of BAAM caused dose-dependent rightward shifts in the dose-response curve for the isoprenaline inhibition of histamine release."	( Influence of receptor reserve on beta-adrenoceptor-mediated responses in human lung mast cells. Chong, LK; Drury, DE; Ghahramani, P; Peachell, PT, 1998)	0.3
" PD20 FEV1 and dose-response slope [DRS; maximal change in FEV1 (%)/dose of Mch (mumol)] were used to evaluate efficacy."	( The bronchoprotective efficacy of salbutamol inhaled from a new metered-dose powder inhaler compared with a conventional pressurized metered-dose inhaler connected to a spacer. Alanko, K; Hedman, J; Herrala, J; Liipo, K; Nieminen, MM; Nyholm, JE; Pietinalho, A; Seppälä, OP; Terho, E, 1998)	0.3
" The patients attended the laboratory during both treatment periods at 0730 hours, when a dose-response curve for systemic beta2-adrenoceptor responses to inhaled salbutamol (0."	( Concomitant inhaled corticosteroid resensitises cardiac beta2-adrenoceptors in the presence of long-acting beta2-agonist therapy. Aziz, I; Lipworth, BJ; McFarlane, LC, 1998)	0.3
" The number of rescue medication inhaled, side effects, heart rate, blood pressure, serum potassium dosage and electrocardiograms, did no show significative differences between the groups."	( [Efficacy of and tolerance to salmeterol compared to salbutamol in patients with bronchial asthma]. De Oliveira, MA; Faresin, SM; Jardim, JR; Lucas, SR; Nery, LE, )	0.13
"This study showed that in mild to moderate asthmatic patients, salmeterol in the dosage of 100 mg/day raised the FEV1 and the morning PEF and led to pronounced decrease in the nocturnal symptoms as compared to salbutamol."	( [Efficacy of and tolerance to salmeterol compared to salbutamol in patients with bronchial asthma]. De Oliveira, MA; Faresin, SM; Jardim, JR; Lucas, SR; Nery, LE, )	0.13
" Assessment of 1-second forced expiratory volume (FEV1) curves before and after dosing on the last day of each 2-week period indicated that the combination was superior to either single agent in peak effect and area under the curve up to 8 h after dosing (FEV1-AUC0-8), in both phases of the trial."	( Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Coleman, W; Gross, N; Linberg, S; Miller, R; Oren, J; Tashkin, D, 1998)	0.59
" Pulmonary function and safety measures were assessed after each dosing interval."	( Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1998)	0.55
"Recent studies have raised concern that regular inhalation of beta2 -agonists may cause a worsening of asthma control compared with on-demand dosing regimens."	( Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. Brambilla, R; Chapman, KR; Della Cioppa, G; Fairbarn, MS; FitzGerald, JM; Stubbing, D; Till, MD, 1999)	0.3
" Safety was assessed by measuring changes in pulse rate, blood pressure, and electrocardiogram (ECG) intervals after dosing with study drug, monitoring adverse events, and performing prestudy and poststudy laboratory testing and physical examinations."	( Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. Bronsky, E; Colice, GL; Ekholm, BP; Klinger, NM, 1999)	0.54
" HFA134a was rapidly absorbed after inhalation with dose-related blood concentrations which declined rapidly after dosing (t1/2 = 31 min)."	( Clinical pharmacology of HFA134a. Ventresca, GP, 1995)	0.29
"Limited dose-response information is available for nebulized beta2 -agonists, especially in young children."	( The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. DeGraw, SS; Gawchik, SM; Noonan, M; Reasner, DS; Saccar, CL, 1999)	0.57
" Metered dosing (metered-dosing inhaler or premixed solution) were chosen by 22 caregivers (54%), calibrated measuring tools (droppers, syringes) by 15 (37%), and noncalibrated delivery devices (teaspoon) by 4 (10%)."	( Caregiver knowledge and delivery of a commonly prescribed medication (albuterol) for children. Simon, HK, 1999)	0.54
"Metered dosing and calibrated measuring devices aided in the accurate delivery of this prescription medication."	( Caregiver knowledge and delivery of a commonly prescribed medication (albuterol) for children. Simon, HK, 1999)	0.54
" Patients on inhaled corticosteroids, cromolyn, and nedocromil were allowed into the study if their dosing remained constant throughout the study."	( Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. Mende, CN; Petrocella, VJ; Rickard, KA; Wiegand, L; Yancey, SW; Zaidel, G; Zwillich, CW, 1999)	0.3
" Salmeterol, however, showed a flatter dose-response curve, and a significantly weaker maximal protective effect (2."	( Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Ibsen, T; Lötvall, J; Mellén, A; Palmqvist, M, 1999)	0.3
"Current evidence suggests that addition of the long-acting beta2-agonist salmeterol to an inhaled corticosteroid in patients with persistent asthma symptoms provides greater clinical benefit than doubling the dosage of the inhaled corticosteroid."	( Salmeterol/fluticasone propionate combination. Jarvis, B; Spencer, CM, 1999)	0.3
" Each agent was given in recommended dosage on separate days in a double-blind, crossover format, and the patients' arterial blood gases (ABGs) were measured at baseline and at intervals to 120 min."	( Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium. Gross, NJ; Khoukaz, G, 1999)	0.51
" Exercise challenge was repeated at day 3, week 4, and week 8 after randomization near the end of the dosing interval for both drugs."	( Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. Chuchalin, AG; Gunawardena, KA; Helbling, A; Jasan, J; Langley, SJ; Laurenzi, M; Lee, TH; Leff, JA; Menten, J; O'Neill, SJ; Suskovic, S; van Noord, JA; Villaran, C, 1999)	0.3
"There were no differences between regular treatment with formoterol and salmeterol in their effects on lymphocyte beta2-adrenoceptor regulation at the end of a 12-h dosing interval, with both drugs exhibiting a residual degree of bronchodilator activity at the same time point."	( Comparative trough effects of formoterol and salmeterol on lymphocyte beta2-adrenoceptor--regulation and bronchodilatation. Aziz, I; Lipworth, BJ; McFarlane, LC, 1999)	0.3
"We investigated the bronchodilator dose-response to nebulized albuterol and the dose of albuterol which produces maximal bronchodilation in the acutely ill, hospitalized asthmatic."	( Dose-response characteristics of nebulized albuterol in the treatment of acutely ill, hospitalized asthmatics. Brennan, K; Ciccolella, DE; Criner, GJ; Kelsen, SG, 1999)	0.81
" Dose-response curves were compared using an analysis of covariance."	( Tolerance to beta-agonists during acute bronchoconstriction. Aldridge, RE; Cowan, JO; Flannery, EM; Hancox, RJ; Herbison, GP; McLachlan, CR; Taylor, DR; Town, GI, 1999)	0.3
"6 microgram/kg) and aminophylline (25 mg/kg), which were determined by the dose-response curves for inhibition of histamine-induced bronchoconstriction, were intravenously administered 5 minutes before the propranolol inhalation."	( Difference in bronchoprotective effects of bronchodilators on postallergic propranolol-induced bronchoconstriction. Fujimura, M; Ishiura, Y; Matsuda, T; Mizuhashi, K; Myou, S, 1999)	0.3
"Different mixed-effects models were compared to evaluate the population dose-response and relative potency of two albuterol inhalers."	( Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability. Hill, MR; Kimanani, EK; Lalonde, RL; Ouellet, D; Potvin, D; Vaughan, LM, 1999)	0.51
" A spacer device has been shown to further enhance the dosing characteristics."	( A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. Grant, AC; Prime, D; Slater, AL; Woodhouse, RN, 1999)	0.3
" Two hours after inhalation a dose-response curve to inhaled oxitropium bromide (100 microg/puff) or placebo was constructed using one puff, one puff, two puffs, and two puffs-that is, a total cumulative dose of 600 microg oxitropium bromide."	( Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease. Califano, C; Cazzola, M; Centanni, S; D'Amato, G; D'Amato, M; Di Perna, F; Donner, CF, 1999)	0.3
"This study shows that acute pretreatment with 50 microg salmeterol does not block the possibility of inducing more bronchodilation with an anticholinergic agent when a higher than normal dosage of the muscarinic antagonist is used."	( Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease. Califano, C; Cazzola, M; Centanni, S; D'Amato, G; D'Amato, M; Di Perna, F; Donner, CF, 1999)	0.3
" The t(max)of about 2 h reflected serial dosing rather than delayed absorption."	( Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. DeGraw, S; Gumbhir-Shah, K; Jusko, WJ; Kellerman, DJ; Koch, P, 1999)	0.3
" Twelve subjects would suffice for a cumulative dose-response study for bronchodilator bioequivalence."	( Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane beta-agonists. Parameswaran, K, 1999)	0.3
"046], but was far lower following oral dosing [0."	( Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man--no evidence of enantioselective lung metabolism. Dallow, N; Dow, J; Eynott, P; Milleri, S; Ventresca, GP; Ward, JK, 2000)	0.31
" Patients received treatments each for 2 weeks followed by a bolus (IV/inhaled) of corticosteroid or placebo: (1) placebo inhaler bid + bolus placebo; (2) formoterol Turbuhaler 24 microg metered dosage bid (delivered dosage 18 microg bid) + placebo; (3) formoterol 24 microg bid + bolus IV hydrocortisone, 200 mg; or (4) formoterol 24 microg bid + bolus inhaled budesonide, 1,600 microg."	( Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Aziz, I; Lipworth, BJ, 2000)	0.6
" Long-term administration of montelukast provided consistent inhibition of exercise-induced bronchoconstriction at the end of the 8-week dosing interval without tolerance."	( Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Bronsky, EA; DeLucca, PT; Edelman, JM; Ghannam, AF; Gormley, GJ; Grossman, J; Kemp, JP; Pearlman, DS; Turpin, JA, 2000)	0.31
" However, these studies were conducted in patients with stable asthma (at the top of the dose-response curve), whereas a nebulized bronchodilator most likely would be used by patients with an acute exacerbation."	( Levalbuterol nebulizer solution: is it worth five times the cost of albuterol? Asmus, MJ; Hendeles, L, 2000)	0.93
" A new propellant, hydrofluoroalkane (HFA), incorporates a re-engineered delivery system associated with dosing reproducibility throughout the life of the canister."	( Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. Boccuzzi, SJ; Roehm, JB; Wogen, J, 2000)	0.55
" This improvement in dosing characteristics has the potential to translate into enhanced economic outcomes."	( Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. Boccuzzi, SJ; Roehm, JB; Wogen, J, 2000)	0.55
" Depending on the intensity of allergen exposure, complaints now occur in February/March only, requiring updating of the therapy in respect of dosage and number of drugs used."	( [Two out-of-the-ordinary (?) case reports an asthmatic disease]. Hausen, T, 2000)	0.31
" As opposed to data from an adult population, no plateau was reached in the dose-response curve using the above doses over time."	( Is nebulized aerosol treatment necessary in the pediatric emergency department? Gilad, E; Houri, S; Mandelberg, A; Morag, B; Priel, IE; Tsehori, S, 2000)	0.31
"To test the lower range of the dose-response curve, effects of MF delivered by dry powder inhaler (DPI) on AMP-induced bronchoconstriction were compared with those of placebo."	( Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. Arshad, H; Harrison, JE; Holgate, ST; Stryszak, P, 2000)	0.31
" Ratios of PCwheeze between treatment and placebo challenges were calculated for each dosage group."	( The bronchoprotective effect of inhaled salmeterol in preschool children: a dose-ranging study. Brown, R; Efthimiou, J; Kurian, M; Primhak, RA; Smith, CM; Wach, R; Yong, SC, 1999)	0.3
" In contrast to benzalkonium chloride, the dose-response curves for secretostatic and celltoxic effects of salmeterol markedly overlapped."	( Influence of salmeterol and benzalkonium chloride on G-protein-mediated exocytotic responses of rat peritoneal mast cells. Krebs, D; Seebeck, J; Ziegler, A, 2000)	0.31
"Our purpose was to evaluate the effectiveness of fluticasone propionate powder 200 microg/d administered as a once- or twice-daily dosage regimen in patients who were currently being treated with bronchodilators only (BD patients) and in patients who required inhaled corticosteroids for maintenance treatment of asthma (ICS patients)."	( Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. Duke, S; Grady, J; Harding, S; Munk, ZM; Prillaman, B; Rooklin, A; Stevens, A; Wolfe, J, 2000)	0.31
" Subsequent experiments under prazosin treatment established the apoptosis dose-response curves for the increasingly beta(2)-selective AR agonists isoproterenol (ISO) (beta(1) approximately beta(2)) and albuterol (ALB) (beta(2)>beta(1))."	( Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. Jamali, NZ; Lucchinetti, E; Shafiq, SA; Siddiqui, MA; Xu, W; Zaugg, M, 2000)	0.49
" Mean maximum (or minimum) absolute values were used to construct dose-response curves to calculate the relative dose potency of the two drugs."	( Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Bennett, J; Cooper, S; Guhan, AR; Lewis, S; Oborne, J; Tattersfield, AE, 2000)	0.31
" Each of the products provided an emitted dose which was within +/- 25% of the mean value indicating accurate and consistent dosing (93, 112 and 221 microg per metered dose for the salbutamol 100 microg and fluticasone propionate 125 and 250 microg HFA 134a pMDIs, respectively)."	( Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Cripps, A; Riebe, M; Schulze, M; Woodhouse, R, 2000)	0.31
" No dose-response effect or clinically relevant differences were observed in morning plasma cortisol concentrations or after cosyntropin stimulation."	( A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Finn, A; Harding, SM; Jones, R; Li, JT; Nathan, RA; Payne, JE; Wolford, JP, 2000)	0.31
" When comparing the two active dosing regimens, significant differences in favor of twice-daily dosing were noted in FEV(1), albuterol use, and withdrawal due to lack of efficacy."	( Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000)	0.51
"Fluticasone propionate powder improved lung function when administered either qd or bid over a 1-year period to patients with moderate asthma, with twice-daily dosing demonstrating significantly greater improvement in some efficacy parameters than once-daily dosing over the first 12 weeks of treatment."	( Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000)	0.31
"Our results showed no difference between formoterol and salmeterol in the degree of functional antagonism against methacholine-induced bronchoconstriction at the end of a 12-h dosing interval in patients who expressed the homozygous glycine-16 genotype."	( Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. Aziz, I; Dempsey, OJ; Lipworth, BJ, 2000)	0.31
"Homozygous Arg-16 patients are susceptible to clinically important increases in asthma exacerbations during chronic dosing with the short acting beta(2) agonist salbutamol."	( Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Drazen, JM; Hancox, RJ; Herbison, GP; Taylor, DR; Town, GI; Yandava, CN, 2000)	0.31
" Urine was also obtained from subjects who had received the maximum dosage of inhaled salbutamol advisable for competing athletes to provide protection from exercise-induced asthma and treatment of asthma (1600 microgram in 24 h, 800 microgram being in the last 4 h)."	( Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. Bergés, R; de La Torre, X; Farré, M; Fitch, KD; Mas, M; Morton, AR; Segura, J; Ventura, R, 2000)	0.31
"The safety and efficacy of two once daily dosing regimens (200 microg and 400 microg) of mometasone furoate (MF) administered in the morning by using a dry-powder inhaler (DPI) were compared with those of a twice daily dosing regimen (200 microg administered twice daily) in patients with mild-to-moderate persistent asthma previously taking only inhaled beta(2)-adrenergic agonists."	( Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. Berkowitz, RB; Harrison, JE; Kemp, JP; Miller, SD; Murray, JJ; Nolop, K, 2000)	0.31
" The dose-response curve for L-750355-induced glycerolemia lies to the left of that for tachycardia."	( L-750355, a human beta3-adrenoceptor agonist; in vitro pharmacology and profile of activity in vivo in the rhesus monkey. Bach, T; Candelore, MR; Cascieri, MA; Cioffe, C; Deng, L; Fisher, MH; Forrest, MJ; Hegarty-Friscino, B; Hom, G; MacIntyre, E; Marko, O; Ok, HO; Strader, C; Szumiloski, J; Tota, L; Vicario, P; Weber, AE; Wyvratt, M, 2000)	0.31
"The present study was designed to evaluate the bronchodilating role of zafirlukast, a CysLT(1)receptor antagonist, at the standard dosage currently recommended in the marketing of this agent in smokers with COPD."	( Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist. Allegra, L; Boveri, B; Carlucci, P; Cazzola, M; Centanni, S; DiMarco, F; Santus, P, 2000)	0.31
" At each visit, a dose-response curve to inhaled salbutamol was constructed using a total cumulative dose of 800 microg."	( Additive effects of salmeterol and fluticasone or theophylline in COPD. Calderaro, F; Cazzola, M; Centanni, S; Di Lorenzo, G; Di Perna, F; Testi, R, 2000)	0.31
"5 mg albuterol by jet nebulization in a dosing schedule determined by the ACA phase."	( Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. Craven, D; Golonka, G; Kercsmar, CM; Moore, S; Myers, TR; O'riordan, MA, 2001)	1.1
" This dosage is also as effective when added to low-dosage inhaled corticosteroid therapy as doubling of corticosteroid dosages."	( Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Dunn, CJ; Goa, KL, 2001)	0.31
" Dosing continued on the evening of day 10 and on day 11, and on day 12 the effect of repeat-dose treatment with salmeterol and salmeterol/fluticasone propionate on the systemic effects of cumulative doses of inhaled salbutamol (up to a total dosage of 3,200 microg) was evaluated."	( Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Daniel, MJ; Falcoz, C; Kirby, S; Milleri, S; Squassante, L; Ventresca, GP; Ziviani, L, )	0.13
" For fluticasone propionate, there were no statistically significant differences between salmeterol/fluticasone propionate and fluticasone propionate with respect to Cmax, plasma concentration at the end of the dosing interval (Ct), terminal elimination half-life (t1/2) or time to Cmax (tmax)."	( Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Daniel, MJ; Falcoz, C; Kirby, S; Milleri, S; Squassante, L; Ventresca, GP; Ziviani, L, )	0.13
" WCV for the area under dose-response curve (AUC) for absolute blood flow was 18% and 13% for acetylcholine and albuterol, respectively."	( Assessment of forearm vasodilator responses to acetylcholine and albuterol by strain gauge plethysmography: reproducibility and influence of strain gauge placement. Chowienczyk, PJ; Jackson, G; Ritter, JM; Walker, HA, 2001)	0.76
" The long duration of action of salmeterol offers the advantage of twice daily dosing compared with the required four times a day dosing with ipratropium."	( Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Anderson, W; Bailey, W; Broughton, J; Friedman, M; Rennard, SI; Rickard, K; Wisniewski, M; ZuWallack, R, 2001)	0.31
" Dose-response curves for change in FEV1 with salbutamol were compared using analysis of covariance to take account of methacholine-induced changes in spirometry."	( Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Cowan, JO; Flannery, EM; Hancox, RJ; Herbison, GP; Jones, SL; Taylor, DR, 2001)	0.31
" The primary end point was mean morning peak expiratory flow (PEF) measured 5 minutes after dosing and entered in a patient diary each day during the first 4 weeks of treatment."	( Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial. Condemi, JJ, 2001)	0.31
" In a patient subset with severe asthma, a dose-response relationship was observed for levalbuterol, indicating that higher doses were more effective."	( Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. Baumgartner, RA; Bensch, G; Claus, R; Kim, KT; Milgrom, H; Skoner, DP, 2001)	0.91
" These results indicate that the difference in FPM does not warrant a change in the recommended dosage of salmeterol administered when using the VHCs tested."	( Evaluation of particle size distribution of salmeterol administered via metered-dose inhaler with and without valved holding chambers. Ahrens, RC; Garris, T; Holmes, M; Kelly, HW; Reisner, C; Stevens, AL; Vandermeer, AK, 2001)	0.31
" The difference in percent change in FEV1 between the Taifun and the other devices was statistically significant at the two first dose levels, but diminished towards the higher doses when the plateau of the dose-response curve was reached."	( The efficacy of a new salbutamol metered-dose powder inhaler in comparison with two other inhaler devices. Aalto, E; Hakonen, T; Jouhikainen, T; Liipp, K; Lukkari-Lax, E; Nieminen, MM; Seppälä, OR, 2001)	0.31
" The retention of water within recently crystallised salbutamol is potentially important to the behaviour of dosage forms containing the amorphous (or partially amorphous) form of this drug."	( A study of the crystallisation of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy. Buckton, G; Columbano, A; Wikeley, P, 2002)	0.31
"A dose-response curve to formoterol via Turbuhaler or salbutamol via pressurized metered-dose inhaler (pMDI) was constructed."	( Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Calderaro, E; Califano, C; Cazzola, M; D'Amato, G; D'Amato, M; Di Perna, F; Matera, MG, 2002)	0.31
"This study was designed to compare the efficacy and tolerability of single doses of albuterol/HFA 134a with albuterol/CFC and to demonstrate a dose-response among the different doses of both formulations."	( A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. Batty, EP; Langley, SJ; Masterson, CM; Sykes, AP; Woodcock, A, 2002)	0.77
" Triplicate measurements of forced expiratory volume in 1 second (FEV1) were made immediately before dosing and 15 minutes, 30 minutes, 1, 2, 3, 4, 5, and 6 hours postdose."	( A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. Batty, EP; Langley, SJ; Masterson, CM; Sykes, AP; Woodcock, A, 2002)	0.55
" There were significant differences in T(max) and AUC0-20 min between the two dosage forms."	( Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. Du, XL; Fu, Q; Li, DK; Xu, WB; Zhu, Z, 2002)	0.31
" The new device, Airmax, uses proprietary technologies known as the X-ACT system to provide accurate and consistent dosing and excellent lung deposition--even at low inspiratory flow rates--combined with ease of use by the patient."	( Delivery of salbutamol and of budesonide from a novel multi-dose inhaler Airmax. Colledge, J; Jones, S; O'Leary, D; Phelan, M; Zeng, XM, 2002)	0.31
" A bivariate dose-response model based on these principles was fitted simultaneously to all data."	( Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Böcskei, C; Juhász, G; Larsson, R; Poczi, M; Rosenborg, J; Rott, Z, 2002)	0.31
" Each study phase was separated by 7 days and the order of dosing was randomized."	( Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. Chrystyn, H; Corlett, SA; Silkstone, VL, 2002)	0.31
") excretion of salbutamol plus its metabolite over 24 h post ORAL, MDI, NEB and NEBC dosing was 297."	( Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. Chrystyn, H; Corlett, SA; Silkstone, VL, 2002)	0.31
" A bivariate dose-response model based on these principles was fitted simultaneously to all data."	( Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients. Böcskei, C; Juhász, G; Larsson, P; Poczi, M; Rosenborg, J; Rott, Z, 2002)	0.54
" Cumulative dose-response curves (200, 400, 800 and 1600 microg) were constructed."	( Metal versus plastic spacers: an in vitro and in vivo comparison. Ekkelenkamp, MB; Janssen, R; Lammers, JW; Weda, M; Zanen, P, 2002)	0.31
" Unfortunately the most effective dosage of beta2-agonists may increase above that recommended during acute exacerbations."	( Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. Califano, C; Cazzola, M; D'Amato, G; D'Amato, M; Di Perna, F; Marsico, SA; Matera, MG; Terzano, C, 2002)	0.31
"In an effort to develop a sensitive method to document bioequivalence, bronchoprovocation with methacholine chloride was used to assess the dose-response relationship of albuterol as delivered by MDI."	( A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers. Adams, WP; Creticos, PS; Khattignavong, AP; Lewis, LD; Lietman, PS; Martinez, MN; Molzon, JA; Petty, BG; Singh, GJ; Williams, RL, 2002)	0.72
"The methacholine bronchoprovocation model is safe and useful in the study of albuterol MDI dose-response in asthmatic subjects."	( A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers. Adams, WP; Creticos, PS; Khattignavong, AP; Lewis, LD; Lietman, PS; Martinez, MN; Molzon, JA; Petty, BG; Singh, GJ; Williams, RL, 2002)	0.75
"Systemic corticosteroids and inhaled beta(2) agonists are accepted first line treatments for acute severe asthma, but there is no consensus on their optimum dosage and frequency of administration."	( Randomised pragmatic comparison of UK and US treatment of acute asthma presenting to hospital. Daynes, TJ; Harrison, BD; Innes, NJ; Stocking, JA, 2002)	0.31
" The dose-response curve to isoproterenol in naive sphincters or sphincters pre-treated with atropine indicated that muscarinic blockade decreased the EC(50) rather than potentiated maximal beta-adrenergic relaxation."	( Muscarinic blockers potentiate beta-adrenergic relaxation of bovine iris sphincter. Barilan, A; Geyer, O; Nachman-Rubinstein, R; Oron, Y, 2003)	0.32
"To prepare and evaluate a suppository dosage form of salbutamol sulfate."	( Salbutamol sulfate suppositories: influence of formulation on physical parameters and stability. Kassem, AA; Khan, MA; Taha, EI; Zaghloul, AA, 2003)	0.32
"Rectal suppository of salbutamol sulfate could be prepared as an alternative to the oral dosage form to circumvent the first-pass metabolism."	( Salbutamol sulfate suppositories: influence of formulation on physical parameters and stability. Kassem, AA; Khan, MA; Taha, EI; Zaghloul, AA, 2003)	0.32
" Significant benefit was gained from adding salmeterol in a group of patients who appeared to have been at the top of their steroid dose-response curve receiving FP250."	( Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Browning, D; Colman, NC; Dal Negro, R; Fletcher, CP; Ind, PW; James, MH, 2003)	0.32
"To determine the magnitude of residual bronchoprotection after chronic dosing with long-acting beta(2)-agonists."	( Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids. Currie, GP; Jackson, CM; Lipworth, BJ; Ogston, SA, 2003)	0.32
"Three different methods developed for the determination of salbutamol sulfate (SBS), in pure drug form and in dosage forms, are discussed."	( Three useful bromimetric methods for the determination of salbutamol sulfate. Basavaiah, K; Prameela, HC, 2003)	0.32
" These findings suggest that ways need to be found: (i) to increase the use of current asthma management guidelines by practitioners; (ii) to improve documentation of prescribed medications and their dosage and; (iii) to improve education of parents in home management measures."	( Prescribing for asthmatic children in primary care. Are we following guidelines? Dashash, NA; Mukhtar, SH, 2003)	0.32
"To determine the reproducibility and dose-response relationship for urinary salbutamol excretion post inhalation."	( Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. Chrystyn, H; Corlett, SA; Tomlinson, HS, 2003)	0.32
"The cumulative dose-response study compared the biological effects (pulmonary function, respiratory muscle function, systemic effects) of an equal dose of salbutamol delivered via four different devices in 23 patients with asthma and 21 patients with moderate or severe chronic obstructive pulmonary disease (COPD)."	( Does the inhalation device affect the bronchodilatory dose response curve of salbutamol in asthma and chronic obstructive pulmonary disease patients? Broeders, ME; Folgering, HT; Hop, WC; Molema, J; Vermue, NA, 2003)	0.32
" Dose-response curves (DRC) were constructed with the following cumulative doses of salbutamol: 200 microg, 600 microg (200 microg + 400 microg), 1400 microg (600microg + 800 microg) ad 2600 microg (1400 + 1200 microg)."	( Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device. Lipworth, BJ; McDevitt, DG; Newnham, DM, 1993)	0.29
" Dose-response curves showed that Salm, at concentration >1."	( Cytokine release and adhesion molecule expression by stimulated human bronchial epithelial cells are downregulated by salmeterol. Di Blasi, P; Rossi, GA; Sabatini, F; Sale, R; Serpero, L; Silvestri, M, 2003)	0.32
" This randomized, placebo-controlled, multicenter, crossover study investigated the efficacy, dose-response and safety of HFA-albuterol delivered via a breath-actuated Autohaler inhalation device in comparison with the same medication delivered using a conventional P&B device."	( Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma. Cohen, RM; Gross, G; Guy, H, 2003)	0.81
" No significant correlations were found between FP dosage and height SDS, OC, AKP, IGFBP-3, and SC."	( Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. Bergadá, I; Colom, AJ; Kofman, CD; Maffey, AF; Teper, AM; Vidaurreta, SM, 2004)	0.32
"if patients with asthma remain symptomatic in spite of chronic treatment with inhaled corticosteroids (ICS), increasing the ICS dosage or adding another drug to the treatment regimen are possible therapeutic alternatives."	( Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. Bergmann, KC; Braun, R; Lindemann, L; Steinkamp, G, 2004)	0.32
"5 microg) according to asthma severity compared with traditional fixed dosing (FD) regimens."	( Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Aalbers, R; Backer, V; Jorup, C; Kava, TT; Omenaas, ER; Sandström, T; Welte, T, 2004)	0.32
"5, mean inhaled corticosteroids 735 microg/day, mean forced expiratory volume in 1 second [FEV(1)] 84% predicted) were randomised after 2 weeks' run-in to either: budesonide/formoterol adjustable maintenance dosing (AMD), budesonide/formoterol FD or salmeterol/fluticasone (Seretide Diskus dagger 50/250 microg) FD."	( Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Aalbers, R; Backer, V; Jorup, C; Kava, TT; Omenaas, ER; Sandström, T; Welte, T, 2004)	0.32
"Adjustable maintenance dosing with budesonide/formoterol provides more effective asthma control by reducing exacerbations and reliever medication usage compared with fixed-dose salmeterol/fluticasone."	( Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Aalbers, R; Backer, V; Jorup, C; Kava, TT; Omenaas, ER; Sandström, T; Welte, T, 2004)	0.32
"Since beta1-blockade by nebivolol is larger after repeated dosing than after a single oral intake, we have explored its effect on pulmonary function after a 2-week treatment in hypertensive patients with mild to moderate COPD."	( Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. Cazzola, M; Girbino, G; Matera, MG; Ruggeri, P; Sanduzzi, A; Spicuzza, L; Vatrella, A, )	0.13
" The effect on dispersion efficiency of jet velocity, nozzle location, reservoir size and shape, and the loaded dose is investigated for possible design of new dosing methods or inhalers."	( Use of an impinging jet for dispersion of dry powder inhalation aerosols. Finlay, WH; Lange, CF; Wang, Z, 2004)	0.32
" IC was recorded before dosing and at 5, 10, 15 and 30 min and 1, 2, 3 and 4 h post-dose."	( Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility. Bouros, D; Della Cioppa, G; Kottakis, J; Le Gros, V; Overend, T; Siafakas, N, 2004)	0.32
"To determine whether albuterol helps REX attenuate unloading-induced KE losses, two groups of subjects strength trained their left thigh three times per week, and otherwise refrained from ambulatory and weight-bearing activity for 40 d while receiving a capsule dosing treatment (albuterol, placebo) with no crossover."	( Albuterol helps resistance exercise attenuate unloading-induced knee extensor losses. Caruso, JF; Cook, TD; Elias, J; Hamill, JL; Keller, CP; Mercado, DR; Montgomery, AG; Yamauchi, M, 2004)	2.09
" The in vivo performance of mucoadhesive microspheres formulations showed prolonged and controlled release of salbutamol as compared with oral administration of conventional dosage form."	( Development and characterization of mucoadhesive microspheres bearing salbutamol for nasal delivery. Chourasia, MK; Jain, AK; Jain, RK; Jain, SK; Shrivastava, AK, )	0.13
" The nocturnal dose-response curve was shifted to the right."	( Response to inhaled albuterol during nocturnal asthma. Ahrens, R; Beaty, R; Harman, EM; Hendeles, L; Stevens, G, 2004)	0.65
"The earlier described faster onset-of-action of formoterol as compared to a equipotent dosage of salmeterol was confirmed in this study."	( Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma. Creemers, JP; Greefhorst, AP; Hoff, WJ; Schermer, TR; Sips, AP; van Herwaarden, CL; Westbroek, J, 2004)	0.32
"Recently, dry powder inhaler (DPI) was more available than pressure metered dosed inhaler (pMDI) for the inhalation therapy of the respiratory disease."	( [Comparison of the bronchodilator effect of salbutamol between pressure metered dosed inhaler and dry powder inhaler in patients with stable bronchial asthma]. Fujimura, M; Kasahara, K; Nakao, S; Yasui, M; Yoshimi, Y, 2004)	0.32
"Pulmonary function methods which are able to detect small pharmacological effects may be useful for assessing the full dose-response curve of bronchodilatators."	( A comparison of lung function methods for assessing dose-response effects of salbutamol. Houghton, CM; Singh, D; Woodcock, AA, 2004)	0.32
" The once-a-day dosing and easy-to-use HandiHaler device should improve patient compliance."	( Tiotropium: a new, long-acting agent for the management of COPD--a clinical review. Crutchfield, D, 2004)	0.32
" In the US, twice-daily salmeterol/fluticasone propionate 50/250 microg is approved for use in adults with chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis, and in the EU, the twice-daily 50/500 microg dosage is approved for use in patients with severe COPD, repeat exacerbations and significant symptoms despite bronchodilator therapy."	( Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease. Fenton, C; Keating, GM, 2004)	0.32
" DPIVM may allow significant financial savings in centers and hospital departments using high-cost pharmaceuticals susceptible of customized dosing --e."	( [Financial assessment of device for the preparation of intravenous mixtures in hospital pharmacy]. Bonafont Pujol, X; Casado Collado, A; Clemente Bautista, S; Herdman, M; Jódar Masanés, R; Luengo Pascual, L; Napal Lecumberri, V; Serrano Padilla, G, )	0.13
" The lack of differences in FEV(1) increases observed after 200 and 400 microg salbutamol may reflect attainment of the flat portion of the dose-response curve using either device."	( Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction. Fontana, GA; Geri, P; Lavorini, F; Luperini, M; Maluccio, NM; Mariani, L; Marmai, C; Pistolesi, M, 2004)	0.32
" Fixed dosing with budesonide/formoterol or salmeterol/fluticasone provides effective asthma control in line with guideline goals."	( Combination therapy in asthma--fixed or variable dosing in different patients? Lötvall, J, 2004)	0.32
" However, in view of the steep bronchodilator dose-response curve for salbutamol, further studies are needed to determine whether such device care is clinically necessary."	( Effect of mouthpiece washing on aerosol performance of CFC-free Ventolin. Bosnic-Anticevich, SZ; Chan, HK; Chew, NY; Reddel, HK, 2004)	0.32
" This study compared the dose-response of salbutamol delivered by the Aerodose Inhaler (Aerogen Inc."	( Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics. Cockburn, W; Fishman, R; Lipworth, BJ; Sims, EJ; Taylor, K, 2005)	0.33
" Subjects performed left leg REX, which otherwise refrained from ambulatory and weight-bearing activity for 40 days, while randomized to a capsule (placebo, albuterol) dosing regimen with no crossover to note whether albuterol helps REX mitigate unloading-induced AE losses."	( Albuterol aids resistance exercise in reducing unloading-induced ankle extensor strength losses. Caruso, J; Cook, T; Elias, J; Hamill, J; Higginson, B; Mercado, D; O'Meara, S; Siconolfi, S; Yamauchi, M, 2005)	1.97
" The efficacy, dosing flexibility, and improved side effect profile of levalbuterol were the sources of greatest satisfaction for parents/ caregivers in the levalbuterol group."	( A patient satisfaction survey comparing levalbuterol with racemic albuterol in children. Ames, DE; Berger, WE; Harrison, D, )	0.62
" In most SFC patients the fluticasone dosage can be reduced by 50 % without losing asthma control."	( [Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment]. Liefring, E; Molitor, S; Trautmann, M, 2005)	0.33
" Oral absorption of swallowed albuterol was eliminated by oral dosing of 560 mg activated charcoal 1 h prior to albuterol aerosol administration."	( The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. Muanpanarai, D; Srichana, T; Suedee, R; Tanmanee, N, 2005)	0.84
"Bronchodilator tolerance, assessed by a reduction of the area under the salbutamol dose-response curve, occurred after 1 dose of formoterol (28% reduction, 95% CI 12, 45%), increased up to 1 week and plateaued between 1 and 2 weeks (58% reduction, 95% CI 38, 78%)."	( Rapid onset of tolerance to beta-agonist bronchodilation. Hancox, RJ; Haney, S, 2005)	0.33
"Greater clinical benefit in controlling the symptoms of asthma is frequently observed through combining moderate doses of inhaled glucocorticoids together with long-acting beta(2)-agonists, as compared with increasing glucocorticoid dosage alone."	( Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-agonists. Corrigan, CJ; Faith, A; Hawrylowicz, CM; Lavender, P; Lee, TH; Peek, EJ; Richards, DF, 2005)	0.33
" Drug use in the 6 months before and after step-up in treatment from inhaled corticosteroids [ICs; total daily dosage of < or =1000 microg beclomethasone dipropionate (BDP) or equivalent] to either salmeterol/fluticasone propionate combination (SFC) or concurrent BDP and long-acting beta(2)-agonists (LABAs) given in separate inhalers was compared."	( Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. Angus, R; Cheesbrough, A; Reagon, R, 2005)	0.33
" The addition of a low-dose long-acting beta(2) agonist is superior to the simple increase of the dosage of inhaled corticosteroids."	( [Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhaler compared to budesonide turbuhalar in the control of adult asthma]. Cai, BQ; Chen, BY; Chen, XD; Feng, YL; Guo, XJ; Kang, J; Li, Q; Lin, YP; Qiu, C; Shen, HH; Sun, TY; Tao, JJ; Wang, DQ; Xiao, BR; Xie, CM; Xu, YP; Yin, KS; Zhang, DP; Zheng, JP; Zhong, NS; Zhou, JY; Zhou, X, 2005)	0.33
" Seventy-two hours after the last OVA challenge, guinea pigs were anesthetized and tracheostomized, respiratory system resistance and elastance were measured and a dose-response curve to inhaled methacholine chloride was obtained."	( Effect of salbutamol on pulmonary responsiveness in chronic pulmonary allergic inflammation in guinea pigs. Arantes-Costa, FM; Kasahara, DI; Lopes, FD; Martins, MA; Nunes, MP; Perini, A, 2005)	0.33
"A patient-driven, adjustable maintenance dosing (AMD) approach to asthma therapy, in which the dose is adjusted by patients according to the severity of their symptoms, has recently been compared with fixed-dose therapy in open-label studies."	( The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast Boulet, LP; FitzGerald, JM; Follows, RM, 2005)	0.33
"This study used a double-blind, double-dummy design to compare the efficacy of 2 treatment approaches: stable dosing of salmeterol/fluticasone propionate (SAL/FP) and AMD of formoterol/budesonide (FOR/BUD)."	( The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast Boulet, LP; FitzGerald, JM; Follows, RM, 2005)	0.33
" After 4 weeks of stable dosing in both groups, eligible patients continued the study for an additional 48 weeks, receiving either a stable dose of SAL/FP or AMD of FOR/BUD."	( The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast Boulet, LP; FitzGerald, JM; Follows, RM, 2005)	0.33
" Over weeks 1 through 52, patients receiving stable dosing of SAL/FP had a significantly greater percentage of symptom-free days compared with those receiving AMD of FOR/BUD (median, 58."	( The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast Boulet, LP; FitzGerald, JM; Follows, RM, 2005)	0.33
"In this adult population with persistent asthma, stable dosing of SAL/FP 50/250 microg BID resulted in significantly greater increases in symptom-free days, days free of rescue medication, and morning PEE, as well as almost halving the exacerbation rate, compared with AMD of FOR/BUD 6/200 microg."	( The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast Boulet, LP; FitzGerald, JM; Follows, RM, 2005)	0.33
" Dose-response curves were constructed based on FEV(1) and peak expiratory flow rate (PEFR) recorded after each incremental dose."	( A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Henry, MT; Nair, S; Pearson, SB; Thomas, E, 2005)	0.55
" Over 97% of GPs ranked development of paediatric formulations and clearer dosage information more highly than clinical trials as a means to reducing off-label prescribing."	( Off-label prescribing to children: attitudes and experience of general practitioners. Ekins-Daukes, S; Helms, PJ; McLay, JS; Taylor, MW, 2005)	0.33
"Our objective was to determine if nebulized racemic epinephrine is more efficacious than nebulized albuterol or saline placebo in the treatment of bronchiolitis in the outpatient setting when dosing is equivalent in terms of beta-2 agonist potency."	( Randomized, placebo-controlled trial of albuterol and epinephrine at equipotent beta-2 agonist doses in acute bronchiolitis. Anaya, T; Hartenberger, C; Kelly, HW; Qualls, C; Ralston, S, 2005)	0.81
" From these data, acute salbutamol intake at therapeutical dosage did appear to improve peak power and mean power during a supramaximal exercise, but the mechanisms involved need further investigation."	( Effects of acute salbutamol intake during a Wingate test. Beaupied, H; Benhamou, L; Collomp, K; Courteix, D; De Ceaurriz, J; Jaffre, C; Le Panse, B; Lecoq, AM; Portier, H; Richard, O, 2005)	0.33
" the dose-response curve of salbutamol on L-type calcium current was shifted to the higher concentration range and maximal increase in contraction force was diminished in human atrial cells."	( Changes of beta2-adrenergic stimulation induced by hyperosmosis in human atrium. Benetis, R; Gendviliene, V; Jurevicius, J; Kanaporis, G; Macianskiene, R; Skeberdis, VA; Zablockaite, D, 2005)	0.33
" Dose-response curves were constructed based on skeletal and cardiac muscle hypertrophy."	( Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Lynch, GS; Ryall, JG; Sillence, MN, 2006)	0.33
" Effective maintenance therapywith the correct dosage ofinhalational corticosteroids administered correctly can probably stop the potentially fatal asthma type II from developing."	( [Fatal asthma in childhod preventable by recognizing risk factors and presenting features]. Corel, LJ; de Hoog, M; Joosten, KF; Tiddens, HA; Verbruggen, SC, 2006)	0.33
" We theorized that this lack of demonstrable benefit resulted from variations in dosing and titration, rather than the drug per se, and that intensive care unit (ICU) LOS would be shortened by the administration of terbutaline according to a protocol incorporating a quantitative assessment of severity of illness."	( Protocol-based titration of intravenous terbutaline decreases length of stay in pediatric status asthmaticus. Carroll, CL; Schramm, CM, 2006)	0.33
" The results highlight a more significant effect of inspiratory flow on variable dosage emission when using the Symbicort Turbuhaler compared with the Seretide Diskus."	( Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Assi, KH; Chrystyn, H; Pearson, SB; Tarsin, WY, 2006)	0.33
" According to the dose-response curve to methacholine, they were categorized as having either unlimited airway narrowing (UAN group) (n = 20) or response plateau (RP group) (n = 18)."	( Dyspnea perception and reversibility of methacholine-induced unlimited airway narrowing in asthmatics. Malakauskas, K; Sakalauskas, R; Sitkauskiene, B; Stravinskaite, K, 2006)	0.33
"Response to salmeterol does not vary between ADRB2 genotypes after chronic dosing with an inhaled corticosteroid."	( Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. Anderson, WH; Baitinger, LA; Bleecker, ER; Dorinsky, PM; Edwards, LD; Klotsman, M; Yancey, SW, 2006)	0.33
"The purpose of this study was to examine the relationship between the specific types of medication, length of use, frequency of use, and dosing time of day on the dental caries of children diagnosed with asthma."	( A cross-sectional study of medication-related factors and caries experience in asthmatic children. Chen, JW; Donovan, K; Lee, JY; Milano, M, )	0.13
" The 95% CI exceeded the pre-determined margin of 100ml by 2 ml, so that the statistical hypothesis of non-inferiority of once daily dosing was not confirmed."	( Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD--a double-blind, randomised, controlled trial. Hartmann, U; Metzenauer, P; Welte, T, 2008)	0.35
"Based on a comparable efficacy and tolerability, the dosing schedule with formoterol via Novolizer as once daily in the morning seems to be an alternative compared to twice daily treatment."	( Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD--a double-blind, randomised, controlled trial. Hartmann, U; Metzenauer, P; Welte, T, 2008)	0.35
"R-albuterol (levalbuterol) is a drug used for asthma therapy and some formulations of it are in solid dosage forms."	( Solid-state characterization of two polymorphic forms of R-albuterol sulfate. Badini, R; Cuffini, S; Karlsson, A; Palacio, MA; Palacios, SM, 2007)	1.3
" The strategy of adjustable maintenance dosing (AMD) involves adjustment of the maintenance dose, (using a single combination [budesonide/formoterol] inhaler, Symbicort((R))) in response to variability of asthma control over time."	( Inhaled Glucocorticosteroid and Long-Acting beta(2)-Adrenoceptor Agonist Single-Inhaler Combination for Both Maintenance and Rescue Therapy : A Paradigm Shift in Asthma Management. D'Urzo, AD, 2006)	0.33
"We conducted a double blind, randomised, placebo-controlled, crossover study evaluating the effects of halving inhaled steroid dosage plus salmeterol, or salmeterol and tiotropium."	( A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Fardon, T; Haggart, K; Lee, DK; Lipworth, BJ, 2007)	0.34
" Lactic acidosis improved within 24 h after discontinuation or decrease in the dosage of beta2-agonists."	( Lactic acidosis in children with acute exacerbation of severe asthma. Koul, PB; Minarik, M; Totapally, BR, 2007)	0.34
" The results showed that the test dosage forms was bioequivalent with reference dosage form, and had an obviously pulsatile-release effect."	( The investigation of the pharmacokinetics of pulsatile-release salbutamol sulfate with pH-sensitive ion exchange resin as the carriers in beagle dogs. Guo, H; Liu, H; Pan, W; Sun, T; Yu, F; Zhao, X, 2007)	0.34
"For similar systemic exposure, dosing should be adjusted to age or size but not on a fixed microg kg(-1) basis, which may lead to unnecessary suboptimal dosing."	( Age dependent systemic exposure to inhaled salbutamol. Bisgaard, H; Bønnelykke, K; Jespersen, JJ, 2007)	0.34
") completely reversed the rightward shift of the formoterol dose-response curve due to beta(2)-receptor desensitisation."	( Formoterol and beclomethasone dipropionate interact positively in antagonising bronchoconstriction and inflammation in the lung. Bergamaschi, M; Berti, F; Bolzoni, P; Civelli, M; Razzetti, R; Rossoni, G; Villetti, G, 2007)	0.34
" An increased frequency of dosing with these drugs seems preferable for cases of severe or uncontrolled asthma."	( Optimization of dosing schedule of daily inhalant dexamethasone to minimize phase shifting of clock gene expression rhythm in the lungs of the asthma mouse model. Hayasaka, N; Honma, K; Honma, S; Kudo, T; Kuwaki, T; Shibata, S; Yaita, T, 2007)	0.34
" The aims of this study were to evaluate the long-term efficacy (including symptom-free days and exacerbations) and impact on HRQoL of a stable-dose regimen of salmeterol/fluticasone propionate (SAL/FP) and an adjustable maintenance dosing (AMD) regimen of formoterol/budesonide (FOR/BUD) where treatment is adjusted based on symptoms [SAM40056]."	( Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. Price, DB; Williams, AE; Yoxall, S, 2007)	0.34
"Transdermal beta 2-agonist tulobuterol showed an improvement in FEV1, FVC and IC after dosing compared with those at baseline."	( Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. Akamatsu, K; Hirano, T; Ichikawa, T; Ichinose, M; Matsunaga, K; Minakata, Y; Nakanishi, M; Sugiura, H; Ueshima, K; Yamagata, T; Yanagisawa, S, 2008)	0.35
" At the baseline visit 2-6 days later, the provocative concentration of methacholine to induce a 30% decrease in forced expiratory volume in 1 second (FEV(1) PC(30)) was determined, followed by a nebulized racemic albuterol dose-response study with three doses of albuterol, to familiarize patients with the procedures."	( Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction. Esparham, A; Harkins, M; Kelly, HW; Raissy, HH, 2007)	0.8
"Electrostatic forces arising from charge accumulation on drug and excipient powders cause agglomeration and adhesion of particles to solid surfaces and problems during the manufacture and use of many pharmaceutical dosage forms, including dry powder inhalers (DPIs)."	( The effect of relative humidity on electrostatic charge decay of drugs and excipient used in dry powder inhaler formulation. Carter, P; Elajnaf, A; Rowley, G, 2007)	0.34
" Studies have shown that a large volume spacer attached to a metered dose inhaler provides similar bronchodilator effects to nebulized dosing during the management of patients following an acute exacerbation."	( Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation. Chrystyn, H; Ismail, NE; Mazhar, SH; Newton, DA, 2008)	0.35
" For patients in group A, a fixed dosage was maintained for 18 months, while those in group B received tailored dosage or withdrawal of therapy according to the clinical control level (well or total control)."	( [A clinical study on the significance of airway hyperresponsiveness monitoring in the adjustment of combined therapy for asthmatic patients]. Liu, CT; Pang, YM; Tan, CW; Wang, G; Wang, YM, 2007)	0.34
" Further studies are needed to elucidate the clinical benefit of combination inhalers versus the individual components in different inhalers, and to investigate the clinical benefit of flexible dosing of combination inhalers in patients with COPD."	( Comparison and optimal use of fixed combinations in the management of COPD. Aalbers, R; Mensing, M, 2007)	0.34
"This study determined the dose-response effects of inhaled salbutamol (SAL) on time-trial performance and urine concentrations of SAL (cSAL)."	( Dose response of inhaled salbutamol on exercise performance and urine concentrations. McKenzie, DC; Sheel, AW; Sporer, BC, 2008)	0.35
" The two FSC treatments were similar except that QD dosing did not maintain improvements in lung function for 24h compared with twice daily dosing."	( Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. Dorinsky, PM; Kerwin, EM; Meltzer, EO; Nathan, RA; Ortega, HG; Schoaf, L; Yancey, SW, 2008)	0.35
" Few studies have explored the safety of at least 1 year of use of racemic albuterol, and none have examined long-term dosing of levalbuterol."	( Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Baumgartner, RA; D'Urzo, A; Hamilos, DL; Levy, RJ; Marcus, M; McVicar, WK; Parsey, M; Tripp, K, 2007)	0.86
" Mean percentage of predicted FEV1 improved after dosing and was stable for both groups."	( Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Baumgartner, RA; D'Urzo, A; Hamilos, DL; Levy, RJ; Marcus, M; McVicar, WK; Parsey, M; Tripp, K, 2007)	0.63
" The compression of these particles into tablets revealed that desirable controlled released dosage forms could be prepared."	( Preparation of functional composite particles of salbutamol sulfate using a 4-fluid nozzle spray-drying technique. Chen, R; Danjo, K; Okamoto, H, 2008)	0.35
" Traditional press-and-breathe Metered Dose Inhalers (pMDIs) have recently improved their ecological appeal, can be used in every clinical and environmental situation, their dosing is convenient and highly reproducible, but their efficient delivery remains highly technique dependent."	( Inhalatory therapy training: a priority challenge for the physician. Melani, AS, 2007)	0.34
" In severe to critical asthma, differences between sites were common and related to recommendations for: ipratropium use; metered-dose inhaler versus nebulised delivery of salbutamol in severe asthma; use of intravenous aminophylline, intravenous magnesium and dosing of intravenous salbutamol in critical asthma."	( Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines. Acworth, J; Babl, FE; Borland, M; Cotterell, E; Francis, P; Jamison, S; Krieser, D; Neutze, J; Ngo, P; Schutz, J; Sheriff, N; Thomson, F, 2008)	0.35
" Therefore, we infused salbutamol at a higher dosage (23."	( Effect of salbutamol on respiratory muscle function and ventilation in awake canines. Easton, PA; Holroyde, MC; Johnson, MW; Katagiri, M; Kusuhara, N; Rothwell, BC, 2008)	0.35
"The present study was designed to examine the dose-response relationship of inhaled salbutamol and its concentration in the urine while resting at various times after inhalation, and to compare these values against the current World Anti-Doping Code limits."	( Inhaled salbutamol and doping control: effects of dose on urine concentrations. McKenzie, DC; Rupert, JL; Sheel, AW; Sporer, BC; Taunton, J, 2008)	0.35
"The present study relates to enhancing the dosing efficiency of pharmaceutical dry powder formulations administered by pulmonary inhalation."	( Techniques to develop and characterize nanosized formulation for salbutamol sulfate. Ahmad, FJ; Bhatnagar, A; Khar, RK; Sultana, S, 2009)	0.35
" During the 40-day period, subjects performed resistance exercise (REX) with their unloaded leg on an inertial resistance ergometer and, as part of a double-blind design, consumed the maximal oral therapeutic dosage of albuterol (i."	( Temporal strength changes from resistance exercise and albuterol on unloaded muscle. Caruso, JF; Cook, TD; Hamill, JL; Mercado, DR; Saito, K; Yamauchi, M, 2008)	0.78
"The National Heart, Lung, and Blood Institute guideline recommends that dosing racemic albuterol be administered every 1 to 4 hours for treating patients with asthma or chronic obstructive pulmonary disease (COPD) in the hospital."	( Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Andrews, WT; Ciubotaru, RL; Claus, R; Donohue, JF; Hanania, NA; Noe, L; Pasta, DJ; Roach, J; Schaefer, K, 2008)	0.91
" (R)-albuterol plasma levels ranged from 10% to 18% higher after racemic albuterol HFA MDI dosing versus after levalbuterol HFA MDI."	( A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. Baumgartner, RA; Corren, J; Goodwin, E; Hanrahan, JP; McVicar, WK; Nair, P; Pleskow, WW; Tripp, K, 2008)	1.15
"In this study single-day cumulative dosing of asthmatic subjects with levalbuterol HFA MDI or racemic albuterol HFA MDI resulted in similar improvements in FEV(1) and tolerability."	( A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. Baumgartner, RA; Corren, J; Goodwin, E; Hanrahan, JP; McVicar, WK; Nair, P; Pleskow, WW; Tripp, K, 2008)	0.87
" These powders would be anticipated to deposit predominately in the lower regions of the lung following inhalation and then undergo delayed rather than instantaneous drug release, offering the potential to reduce dosing frequency and improve patient compliance."	( Carbomer-modified spray-dried respirable powders for pulmonary delivery of salbutamol sulphate. Alhusban, FA; Seville, PC, 2009)	0.35
" Venezuela's Ministry of Health ambulatory facilities care for 80 % or more of a mostly urban and impoverished population of 26 million inhabitants, registering close to a million acute asthma visits per year; a nebulised fixed fenoterol-ipratropium bromide combination (Bero-dual, Boehringer-Ingelheim) in repeated dosing is the standard treatment."	( Equivalence of a single saline nebulised dose of formoterol powder vs three doses of nebulised Albuterol every twenty minutes in acute asthma in children: a suitable cost effective approach for developing nations. Abate, J; Capriles-Hulett, A; Ferro, S; Manrique, J; Perez-Puigbo, A; Rodriguez, E; Vera, V, )	0.35
"It is concluded that four puffs of salmeterol delivered with an MDI and a spacer device induces significant bronchodilation in mechanically ventilated patients with COPD exacerbation, the duration of which is highly variable, precluding definite conclusions in regard to optimum dosing schedules."	( Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstructive pulmonary disease patients: a prospective clinical study. Gavriilidis, G; Georgopoulos, D; Linardakis, M; Malliotakis, P, 2008)	0.35
" On 3 separate days, a dose-response curve to inhaled salbutamol (100 microg puff-1), ipratropium bromide (20 microg puff-1) or placebo was constructed 3h after inhalation of the last dose of tiotropium, using one puff, one puff, two puffs and two puffs, for a total cumulative dose of 600 microg salbutamol or 120 microg ipratropium bromide."	( Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. Cazzola, M; Centanni, S; D'Adda, A; Di Marco, F; Pizzolato, S; Santus, P, 2009)	0.35
"4% predicted) were randomized to receive mono-therapy (either arformoterol 15microg BID [n=76] or tiotropium 18microg QD [n=80]), or combined therapy (sequential dosing of arformoterol 15microg BID and tiotropium 18microg QD [n=78])."	( Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Andrews, WT; Donohue, JF; Goodwin, E; Hanrahan, JP; Huang, H; Mahler, DA; Schaefer, K; Tashkin, DP, 2009)	0.35
"In subjects with persistent asthma, the ADRB2 Arg16Gly polymorphism does not alter lung function responses to SAL or FSC over the 12 hour dosing interval following acute and chronic dosing."	( Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms. Anderson, WH; Edwards, LD; Klotsman, M; Ortega, HG; Yancey, SW, 2009)	0.35
"Chronic dosing with fluticasone propionate/salmeterol in a single device provides superior protection compared with an inhaled corticosteroid alone in protecting against exercise-induced asthma in children with persistent asthma."	( Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. Matz, J; Ortega, HG; Pearlman, D; Qaqundah, P; Stempel, DA; Yancey, SW, 2009)	0.35
"Mucoadhesive patch releasing the drug in the oral cavity at predetermined rate may present distinct advantages over traditional dosage forms such as tablets, gels and solutions."	( Development and characterization of mucoadhesive buccal patches of salbutamol sulphate. Patel, RS; Poddar, SS, 2009)	0.35
" Using the data collected with the USP II apparatus, the plasma profiles were simulated and compared with human plasma profiles obtained after administration of the same dosage forms to healthy fasted volunteers."	( A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations. Aivaliotis, A; Butler, J; Dressman, J; Fischbach, M; Fotaki, N; Hempenstall, J; Klein, S; Reppas, C, 2009)	0.35
"This study was carried out to compare the rate and extent of absorption of a generic salbutamol in oral dosage form (Brethmol, 4 mg) with the proprietary equivalent product (Ventolin, 4 mg), in healthy adult subjects, under fasting conditions."	( Comparative bioavailability study of two salbutamol tablets in healthy adult volunteers. Basu, RC; Chik, Z; Lee, TC; Mohamed, Z; Pendek, R, 2009)	0.35
"The purpose of this study was to examine safety during the initial escalation day, buildup phase, and home dosing phase in subjects enrolled in a peanut OIT study."	( Safety of a peanut oral immunotherapy protocol in children with peanut allergy. Burks, AW; Hofmann, AM; Jones, SM; Kamilaris, J; Lokhnygina, Y; Palmer, KP; Scurlock, AM; Steele, PH, 2009)	0.35
" Two recently completed trials have demonstrated that with respect to asthma control the combination of inhaled steroid (400 - 800 microg/d) plus theophylline is at least as effective as doubling the dose of inhaled steroid in patients who remain symptomatic on a dosage of 400 - 800 microg daily."	( [Asthma therapy: combination of topical glucocorticosteroids and theophylline]. Ukena, D, 1997)	0.3
" The results suggest coacervation thermal change as an appropriate approach to develop slow-release multi-unit oral dosage form of salbutamol sulphate suggesting at least twice administration in every 24 hours."	( A comparative study of various microencapsulation techniques: effect of polymer viscosity on microcapsule characteristics. Ahamd, M; Akhtar, N; Murtaza, G; Rasool, F, 2009)	0.35
"Salbutamol (sustained released formulation) administered orally at a daily dose of 16 mg using a periodic dosage regimen (3 wks on, 1 wk off)."	( Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial. Attarian, S; Desnuelle, C; Doppler, V; Eymard, B; Hammouda, EH; Hogrel, JY; Lacomblez, L; Laforêt, P; Ollivier, G; Payan, CA; Pouget, J, 2009)	0.35
"One titrimetric and two spectrophotometric methods which are simple, sensitive and rapid are described for the assay of salbutamol sulphate (SBS) in bulk drug and in tablet dosage forms using N-bromosuccinimide (NBS) and two dyes, rhodamine-B and methylene blue, as reagents."	( Rapid titrimetric and spectrophotometric methods for salbutamol sulphate in pharmaceuticals using N-bromosuccinimide. Basavaiah, K; Ramakrishna, V; Somashekar, BC, 2007)	0.34
"A simple, sensitive and specific RP-HPLC method was developed for the quantification of related impurities of albuterol sulfate (AS) and ipratropium bromide (IB) in liquid pharmaceutical dosage form."	( Development and validation of a stability indicating RP-HPLC method for the simultaneous determination of related substances of albuterol sulfate and ipratropium bromide in nasal solution. Farooqui, M; Kasawar, GB, 2010)	0.78
" The CIC showed the least serum cortisol suppression of the tested dosing regimens."	( Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. Derendorf, H; Derom, E; Lahu, G; Nave, R; Xu, J, 2010)	0.36
"Cumulative dosing with albuterol HFA 180 microg or 360 microg via MDI-spacer and face mask in children younger than 2 years did not result in any significant safety issues and improved MTASS by at least 48%."	( Repeat dosing of albuterol via metered-dose inhaler in infants with acute obstructive airway disease: a randomized controlled safety trial. Davis, AM; Ellsworth, A; Goodman, B; Kaashmiri, M; Lincourt, WR; Shepard, J; Trivedi, R, 2010)	1.01
" The first step in outpatient management should be to increase the dosage of inhaled short-acting bronchodilators."	( Management of COPD exacerbations. Evensen, AE, 2010)	0.36
" The films were designed to release the drug for a prolonged period of time so as to reduce the frequency of administration of the available conventional dosage forms of SS."	( In vitro and in vivo evaluation of buccal bioadhesive films containing salbutamol sulphate. Deshpande, SB; Jain, A; Muthu, MS; Rawat, MK; Singh, S; Singh, SK; Soni, R, 2010)	0.36
" Levcromakalim produced concentration-dependent inhibitory effect on myometrial spontaneity and relaxant effect and the dose-response curve (DRC) was shifted towards right in the presence of glybenclamaide."	( Cellular coupling of potassium channels with beta2 adrenoceptors in mediating myometrial relaxation in buffaloes (Bubalus bubalis). Choudhury, S; Garg, SK; Mishra, SK; Singh, TU, 2010)	0.36
"Hydrophilic matrix formulations are important and simple technologies that are used to manufacture sustained release dosage forms."	( Swelling, erosion and drug release characteristics of salbutamol sulfate from hydroxypropyl methylcellulose-based matrix tablets. Chaibva, FA; Khamanga, SM; Walker, RB, 2010)	0.36
" No significant dose-response or difference in T : R ratio was noted for OUCC."	( Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. Clearie, KL; Du Bois, J; Lipworth, BJ; Nell, H; Vaidyanathan, S; Williamson, PA, 2010)	0.36
" Single dosing studies with fluticasone/salmeterol 250/25 microg via pMDI or with spacer showed pharmacokinetic equivalence with FP, but not SM."	( Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. Clearie, KL; Du Bois, J; Lipworth, BJ; Nell, H; Vaidyanathan, S; Williamson, PA, 2010)	0.36
" All three children received inhaled colistin at a dosage of 75 mg diluted in 3 ml of normal saline twice daily (1,875,000 IU of colistin daily), for a duration of 25, 32, and 15 days, respectively."	( Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. Falagas, ME; Kafetzis, DA; Korbila, IP; Papadatos, JH; Sideri, G; Vouloumanou, EK, 2010)	0.36
" dosing schedule, formulation, etc."	( Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Blanchette, CM; Charles, MS; Dalal, AA; Lavallee, D; Mapel, D; Silver, H, 2010)	0.36
"5, 3 and 6 μm mass median aerodynamic diameter in a cumulative dosing schedule of 10, 20, 40 and 100 μg."	( Predicting the clinical effect of a short acting bronchodilator in individual patients using artificial neural networks. Biddiscombe, MF; Chrystyn, H; de Matas, M; Meah, S; Shao, Q; Usmani, OS, 2010)	0.36
" Known adverse effects of propranolol treatment include transient bradycardia, hypotension, hypoglycemia, and bronchospasm (in patients with underlying spastic respiratory illnesses), which led to a general recommendation to gradually increase propranolol dosage and closely monitor patients' hemodynamics at the onset of therapy."	( Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Kietz, S; Lakomek, M; Lauerer, P; Pavlakovic, H; Zutt, M, 2010)	0.36
" Statistical design and response surface methodology have been successfully used to understand and optimize formulation factors and interactions that impact the in vitro release characteristics of salbutamol sulfate from a potential multisource sustained release dosage form."	( The use of response surface methodology for the formulation and optimization of salbutamol sulfate hydrophilic matrix sustained release tablets. Chaibva, FA; Walker, RB, )	0.13
" The greatest challenge in the use of PD measurements with some OIPs (particularly inhaled corticosteroids) is the demonstration of a dose-response relationship (for local effects), without which the bioassay, and hence a PD study, may not have sufficient sensitivity to detect differences in product performance."	( Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. Adams, WP; Chen, ML; Daley-Yates, P; Davis, J; Derendorf, H; Ducharme, MP; Fuglsang, A; Herrle, M; Hochhaus, G; Holmes, SM; Lee, SL; Li, BV; Lyapustina, S; Newman, S; O'Connor, D; Oliver, M; Patterson, B; Peart, J; Poochikian, G; Roy, P; Shah, T; Sharp, SS; Singh, GJ, 2011)	0.37
" Under-treatment with ICS and differential dosing of ICS in many trials are major factors driving the LABA safety concern."	( Safe use of long-acting β-agonists: what have we learnt? Sears, MR, 2011)	0.37
"To evaluate the use of thermal ink-jetting as a method for dosing drugs onto oral films."	( Preparation of personalized-dose salbutamol sulphate oral films with thermal ink-jet printing. Basit, AW; Buanz, AB; Gaisford, S; Saunders, MH, 2011)	0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" Determination of the significance of the observed differences in pharmacokinetics from this single-dose study requires further exploration in studies using clinically relevant dosing regimens."	( Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. Harrison, LI; Needham, MJ; Novak, CC; Ratner, P, 2011)	0.37
" The limitations of the analysis are that the results from a single study, TORCH, have a large bearing on the overall findings of the analysis, and that there is heterogeneity in the length and the dosing of the included studies, although it does not appear that heterogeneity affected the reported results."	( Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Edwards, SJ; Gray, J; Halpin, DM; Morais, J; Singh, D, 2011)	0.37
"We report in this manuscript, the use of direct ammonium persulfate-enhanced chemiluminescence (CL) imaging, to monitor changes to measure serum salbutamol concentration in subjects of different haptoglobin (Hp) phenotypes at different dosing time."	( Direct monitoring changes of salbutamol concentration in serum by chemiluminescent imaging. Delanghe, JR; Na, N; Ouyang, J; Zhang, C; Zhang, R, 2011)	0.37
"These results suggest that there are differences in lung diffusion and peripheral SaO(2) according to genetic variation of the ADRB2 at position 27 which could play a potential role in dosing options or adjustments that may be required according to genotype."	( Influence of genetic variation of the β2-adrenergic receptor on lung diffusion in patients with cystic fibrosis. Daines, CL; Foxx-Lupo, WT; Morgan, WJ; Patanwala, AE; Phan, H; Skrentny, TT; Snyder, EM; Sprissler, R; Traylor, BR; Wheatley, CM, 2011)	0.37
"Ten patients with COPD underwent a dose-response curve to salbutamol (until 800 μg of cumulative dose) after a 1-week washout (baseline), 8 hours after the first administration of formoterol 12 μg (day 1), and after a 12-week and 24-week period of treatment with formoterol (12 μg twice daily by dry powder inhaler)."	( Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD. Bertella, E; Corda, L; La Piana, GE; Montemurro, LT; Pini, L; Tantucci, C, 2011)	0.37
"5) concentrations were logged, suggesting a nonlinear dose-response relationship between particulate matter exposure concentrations and airway mediators of asthma, for which the relationship tends to flatten at higher concentrations."	( The response of children with asthma to ambient particulate is modified by tobacco smoke exposure. Gelfand, EW; Rabinovitch, N; Silveira, L; Strand, M, 2011)	0.37
" This negative interaction, the smaller effect of particulate matter exposure in children exposed to higher ETS, may be related to a nonlinear dose-response relationship between asthma mediators and particulate exposures."	( The response of children with asthma to ambient particulate is modified by tobacco smoke exposure. Gelfand, EW; Rabinovitch, N; Silveira, L; Strand, M, 2011)	0.37
" Intracoronary salbutamol demonstrated significant dose-response ΔSLV and ΔCBF from baseline, respectively (0."	( Coronary β2-adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: novel insights from an in vivo intravascular ultrasound study. Beltrame, JF; Carbone, A; Copus, B; Leong, DP; Liew, GY; Nelson, AJ; Nicholls, SJ; Puri, R; Wong, DT; Worthley, MI; Worthley, SG, 2012)	0.38
"FSC or other ICS exposure was not associated with an increased odds of cataracts or glaucoma, nor was a dose-response relationship observed in this population-based nested case-control study of COPD patients in the United Kingdom."	( Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. Davis, KJ; Miller, DP; Sampson, T; Watkins, SE, 2011)	0.37
"Prediction of pharmacokinetic (PK) profile for inhaled drugs in humans provides valuable information to aid toxicology safety assessment, evaluate the potential for systemic accumulation on multiple dosing and enable an estimate for the clinical plasma assay requirements."	( A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats. Harrison, A; Jones, RM, 2012)	0.38
"For the primary outcome there was significant protection after single and long-term dosing with fluticasone alone and fluticasone-salmeterol combination, whereas salmeterol alone only afforded protection after the first dose."	( Effects of intranasal salmeterol and fluticasone given alone and in combination in persistent allergic rhinitis. Burns, P; Lipworth, BJ; Nair, A; Short, P, 2012)	0.38
"Chronic dosing with fluticasone but not salmeterol confers anti-inflammatory activity against nasal AMP challenge, but there was no potentiation of fluticasone when given in combination with salmeterol."	( Effects of intranasal salmeterol and fluticasone given alone and in combination in persistent allergic rhinitis. Burns, P; Lipworth, BJ; Nair, A; Short, P, 2012)	0.38
" Normally, an increase in chlorine dosage and pH resulted in faster degradation of these pharmaceuticals."	( Reaction of β-blockers and β-agonist pharmaceuticals with aqueous chlorine. Investigation of kinetics and by-products by liquid chromatography quadrupole time-of-flight mass spectrometry. Cela, R; Quintana, JB; Rodil, R, 2012)	0.38
" Among them, C9 had highest affinity, best dose-response behavior, lowest limit of detection, and highest specificity and was chosen to be labeled with colloidal gold as the detector reagent and applied on the conjugate pad."	( A high-affinity anti-salbutamol monoclonal antibody: key to a robust lateral-flow immunochromatographic assay. Chen, FJ; Xie, CH; Yang, TB, 2012)	0.38
" In conclusion, our results suggest that abediterol has a preclinical profile for once-daily dosing in humans together with a fast onset of action and a favorable cardiovascular safety profile."	( Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. Aparici, M; Beleta, J; Carcasona, C; Cortijo, J; De Alba, J; Gavaldà, A; Gómez-Angelats, M; Gras, J; Miralpeix, M; Morcillo, E; Otal, R; Puig, C; Ramos, I; Ryder, H; Vilella, D; Viñals, M, 2012)	0.38
" As a result, asthma exacerbation can be treated with pMDIs used through holding chambers in emergency room successfully when applied with dosing scheme appropriate for the patient's age, weight and severity of exacerbation (usually 1/4th of nebule dosing) on the contrary to ordinary method of nebulizers."	( [Salbutamol in asthma treatment: with nebulizer or inhaler?]. Cavkaytar, O; Sekerel, BE, 2012)	0.38
"The objective of this work was to characterize the dose-response relationship between two inhaled long-acting beta agonists (PF-00610355 and salmeterol) and the forced expiratory volume in one second (FEV1) in order to inform dosing recommendations for future clinical trials in patients with chronic obstructive pulmonary disease (COPD)."	( Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease. Cleton, A; Hutmacher, MM; Martin, SW; Nielsen, JC; Ribbing, J, 2012)	0.38
" This pharmacological profile combined with clinical data is consistent with once a day dosing of vilanterol in the treatment of both asthma and chronic obstructive pulmonary disease (COPD)."	( In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. Barrett, VJ; Emmons, AJ; Ford, AJ; Knowles, RG; Morrison, VS; Slack, RJ; Sturton, RG, 2013)	0.39
" Treatment was twice-daily dosing with albuterol HFA MDI at 90 micrograms with dose counter for either 5 or 7 weeks."	( Prospective, open-label assessment of albuterol sulfate hydrofluoroalkane metered-dose inhaler with new integrated dose counter. Given, J; Iverson, H; Lepore, M; Taveras, H, )	0.67
" The secondary outcome was difference in symptom scores among the three treatment groups to determine if one dosing protocol was superior to another."	( Early intervention with high-dose inhaled corticosteroids for control of acute asthma exacerbations at home and improved outcomes: a randomized controlled trial. Hossain, J; Mannan, S; McGeady, S; Skorpinski, E; Yousef, E, )	0.13
" No effects were observed on glucose, potassium, heart rate, blood pressure and no dose-response effect was seen on corrected QT elongation."	( A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Baggen, S; Chan, R; Locantore, N; Ludwig-Sengpiel, A; Riley, JH; Wielders, PL, 2013)	0.39
" Assumed the importance of this topic and the lack of a clinical evaluation specifically designed to assess the impact of chronic administration of indacaterol on the response to salbutamol, we sought to compare the effect of 4-week treatment with indacaterol 150 μg once-daily versus formoterol 12 μg twice-daily on the dose-response curve to inhaled salbutamol (total cumulative dose of 800 μg) in a non-double-blinded, crossover, randomised, and controlled pilot trial that enrolled 20 outpatients with moderate to severe COPD."	( Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Cazzola, M; Matera, MG; Picciolo, S; Proietto, A; Rogliani, P; Ruggeri, P; Segreti, A, 2013)	0.39
" However, no specific dosing recommendations have been made for children admitted to the PICU."	( Corticosteroid therapy in critically ill pediatric asthmatic patients. Canarie, MF; Carroll, CL; Faustino, EV; Giuliano, JS; Li, S; Pinto, MG, 2013)	0.39
" Country of practice, years of experience, and PICU size were not associated with corticosteroid dosing preference."	( Corticosteroid therapy in critically ill pediatric asthmatic patients. Canarie, MF; Carroll, CL; Faustino, EV; Giuliano, JS; Li, S; Pinto, MG, 2013)	0.39
" Future research is needed to determine the most appropriate corticosteroid dosage in this critically ill patient population."	( Corticosteroid therapy in critically ill pediatric asthmatic patients. Canarie, MF; Carroll, CL; Faustino, EV; Giuliano, JS; Li, S; Pinto, MG, 2013)	0.39
" There is a need for long-term randomised controlled trials of these technologies to determine patient-focused outcomes (such as quality of life and burden of care), safe and effective dosing levels of medications and clinical outcomes (such as hospitalisations and need for antibiotics) and an economic evaluation of their use."	( Nebuliser systems for drug delivery in cystic fibrosis. Daniels, T; Mills, N; Whitaker, P, 2013)	0.39
" The Respimat SMI delivery device is a novel, efficient, and well-received system for the delivery of aerosolized albuterol and ipratropium bromide to patients with COPD; however, the presence of longer-acting, less frequently dosed respiratory medications provide patients and providers with other therapeutic options."	( Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease. Panos, RJ, 2013)	0.82
"The unintentional generation of amorphous character in crystalline active pharmaceutical ingredients (APIs) is an adverse consequence of mechanical activation during dosage form manufacture."	( Reducing mechanical activation-induced amorphisation of salbutamol sulphate by co-processing with selected carboxylic acids. Amharar, Y; Corcoran, S; Corrigan, OI; Curtin, V; Gallagher, KH; Healy, AM; Tajber, L, 2013)	0.39
" Patients remaining on FP-SAL (n=1,146) were compared with those switched to efBDP-FOR at an equivalent or lower inhaled corticosteroid (ICS) dosage (n=382)."	( Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Brockman, J; Burden, A; Gruffydd-Jones, K; Harris, T; Haughney, J; King, C; Lavorini, F; Papi, A; Price, D; Ryan, D; Small, I, 2013)	0.39
"05) odds of achieving overall asthma control (no asthma-related hospitalisations, bronchial infections, or acute oral steroids; salbutamol ≤200μg/day) and lower daily short-acting β2-agonist usage at a lower daily ICS dosage (mean -130μg/day FP equivalents; p<0."	( Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Brockman, J; Burden, A; Gruffydd-Jones, K; Harris, T; Haughney, J; King, C; Lavorini, F; Papi, A; Price, D; Ryan, D; Small, I, 2013)	0.39
"Asthma patients may be switched from FP-SAL to efBDP-FOR at an equivalent or lower ICS dosage with no reduction in clinical effectiveness but a significant reduction in cost."	( Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Brockman, J; Burden, A; Gruffydd-Jones, K; Harris, T; Haughney, J; King, C; Lavorini, F; Papi, A; Price, D; Ryan, D; Small, I, 2013)	0.39
" Controlling for FP dosage and baseline characteristics, FSC patients had lower risks of asthma-related exacerbations, fewer SABAs and systemic corticosteroids, higher costs of asthma medications and total asthma-related health care, and lower total asthma-related health-care costs excluding study medication cost."	( Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations. Delea, TE; Hagiwara, M; Stanford, RH, )	0.13
"Asthmatic athletes using salbutamol should receive clear dosing advise and education to minimize the risk of inhaling doses of salbutamol that may produce urine concentrations of salbutamol above 1200 ng/mL."	( Impact of ethnicity, gender, and dehydration on the urinary excretion of inhaled salbutamol with respect to doping control. Chester, N; Dickinson, J; Hu, J; Loosemore, M; Whyte, G, 2014)	0.4
" Initially oral dosing was undertaken in neonatal mice administered a maximum tolerable dose of racemic albuterol."	( Enantioselective disposition of (R/S)-albuterol in skeletal and cardiac muscle. Jacobson, GA; Premilovac, D; Rattigan, S; Yee, KC, 2014)	0.89
" A subsample of 259 families had controller medication use monitored objectively for approximately 1 month by MDILog (fluticasone propionate), TrackCap (montelukast), or dosage counter (fluticasone/salmeterol combination)."	( Complementary and alternative medicine use and adherence to asthma medications among Latino and non-Latino white families. Adams, SK; Canino, G; Fedele, DA; Fritz, GK; Jandasek, B; Koinis-Mitchell, D; Kopel, SJ; McQuaid, EL; Mitchell, J; Seifer, R, )	0.13
"The slope of the IV methacholine dose-response curve for Rrs was similar in dogs and monkeys and both species differed from minipigs, which showed greater reactivity."	( Respiratory mechanics: comparison of Beagle dogs, Göttingen minipigs and Cynomolgus monkeys. Authier, S; Bassett, L; Gold, L; Maghezzi, S; Robichaud, A; Schuessler, T; Troncy, E; Truchetti, G, )	0.13
" The dose-response relationship was similar within the non-asthma patients."	( Beta2-adrenergic agonist use and the risk of multiple sclerosis: a total population-based case-control study. Lee, CT; Lin, FC; Tsai, CP, 2014)	0.4
" An estimate of the urine average concentration at steady-state was collected by averaging the concentration measurements in the dosing period from -12 to 0 h relative to the last administered dose."	( Detection and pharmacokinetics of salbutamol in thoroughbred racehorses following inhaled administration. Hillyer, L; Hincks, PR; Paine, SW; Pearce, CM; Scarth, J; Wieder, ME, 2015)	0.42
" RESULTS were adjusted for initial prescriber, initial medication, dosing regimen and relevant comorbidities."	( Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β₂-agonists: a dispensing database analysis. Dekhuijzen, PN; Postma, MJ; van Boven, JF; van der Galiën, R; van der Molen, T; van Raaij, JJ; Vegter, S, 2014)	0.4
" Dose-response RL curves in affected and carrier mice indicated a lack of methacholine response."	( Plp1 gene duplication inhibits airway responsiveness and induces lung inflammation. Armani, MH; Hobson, GM; Kreiger, PA; Rodriguez, E; Sakowski, L; Shaffer, TH; Waldman, SA; Zhu, Y, 2015)	0.42
"The effectiveness of inhaled salbutamol in routine care depends particularly on prescribed dosage and applied inhalation technique."	( How to improve prescription of inhaled salbutamol by providing standardised feedback on administration: a controlled intervention pilot study with follow-up. Bertsche, A; Bertsche, T; Frontini, R; Kaune, A; Kiess, W; Musiol, J; Neininger, MP; Prenzel, F; Rink, J, 2015)	0.42
"The developed salbutamol sulfate matrix tablets might be beneficial over the conventional tablets to decrease the dosing frequency and enhanced patient compliance."	( In situ cross-linked matrix tablets for sustained salbutamol sulfate release - formulation development by statistical optimization. Das, K; Malakar, J; Nayak, AK, )	0.13
"5 mg four times daily (n = 57); dosage reductions and other respiratory therapies were permitted."	( Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. Brunetti, L; Dhanaliwala, F; Kang, H; Poiani, G; Poppiti, K; Suh, DC, 2015)	0.67
"The clinicians followed various respiratory trends monitored by the Servo-i ventilator after albuterol dosing to document the clinical utility of using albuterol in this infant."	( Assessing the Response to Inhaled Albuterol by Monitoring Patient Effort-Related Trends With a Servo-I Ventilator in Neurally Adjusted Ventilatory Assist Mode: A Case Presentation. Brinck, MJ; Snow, TM, 2015)	0.92
"The infant had a positive response to albuterol dosing that subsequently led to reduced length of stay, reduced costs, and reduced family anxiety."	( Assessing the Response to Inhaled Albuterol by Monitoring Patient Effort-Related Trends With a Servo-I Ventilator in Neurally Adjusted Ventilatory Assist Mode: A Case Presentation. Brinck, MJ; Snow, TM, 2015)	0.97
" In summary, the DPI formulation based on untreated lactose, especially by capsule filling using a dosing chamber to powder layer (compression) ratio of 1:2, proved to be superior in terms of the dosing accuracy (RSD<0."	( Carrier-based dry powder inhalation: Impact of carrier modification on capsule filling processability and in vitro aerodynamic performance. Faulhammer, E; Khinast, JG; Paudel, A; Wahl, V; Zellnitz, S, 2015)	0.42
" Incidences of β2-agonist-related events (excluding headache) during the pooled 12-week dosing periods were low (≤ 1%) in both groups."	( Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma. Iverson, H; Miller, D; O'Brien, C; Raphael, G; Taveras, H, 2016)	0.72
" The primary outcome will be measured by using the asthma control test and the secondary outcomes will be measured by using the percentage of symptom-free days, the average dosage of salbutamol aerosol and/or prednisone tablets, lung functions, daily asthma symptom scores, asthma quality of life questionnaire, and so on."	( Efficacy of acupuncture for chronic asthma: study protocol for a randomized controlled trial. Fan, L; Feng, JT; Hu, CP; Liu, YY; Shao, SJ; Wang, PY; Wang, WQ; Wang, Y; Xu, YD; Yang, YQ; Yin, LM; Zhang, TF, 2015)	0.42
" Primary efficacy endpoints were baseline-adjusted forced expiratory volume in 1 s (FEV1) at 30 min (30-min FEV1) after each cumulative dose (Study 1) and FEV1 area under the effect curve over 6 h (FEV1 AUEC0-6) after dosing (Study 2)."	( Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Albuterol (Salbuterol) Multi-dose Dry-Powder Inhaler and ProAir(®) Hydrofluoroalkane for the Treatment of Persistent Asthma: Results of Two Randomized Double-Blind Studies. Iverson, H; Kerwin, EM; Lepore, MS; Miller, DS; Shah, T; Taveras, H; Wayne, D, 2016)	0.68
" Our aim was to characterize dosing and timing of epinephrine, diphenhydramine, and albuterol in the pediatric patient with anaphylaxis."	( Prehospital Administration of Epinephrine in Pediatric Anaphylaxis. Barger, J; Carrillo, E; Hern, HG, 2016)	0.66
"In pre-clinical animal studies, the uniformity of dosing across subjects and routes of administration is a crucial requirement."	( Optimization and Dose Estimation of Aerosol Delivery to Non-Human Primates. de Swart, RL; Duprex, WP; Fink, JB; Janssens, HM; MacLoughlin, RJ; van Amerongen, G, 2016)	0.43
"Albuterol multidose dry powder inhaler (MDPI) with an integrated dose counter allows patients to track the number of remaining doses and to simplify dosing by eliminating the need to coordinate inhalation with actuation associated with metered-dose inhalers."	( Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter. Given, J; Iverson, H; Taveras, H, 2016)	2.14
" Patients who demonstrated adequate MDPI inhaler technique and ≥90% compliance with dosing and diary completion during a run-in period qualified for treatment with albuterol MDPI with a dose counter (2 inhalations/dose; 90 μg/inhalation) twice daily for up to 50 days."	( Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter. Given, J; Iverson, H; Taveras, H, 2016)	0.89
" For salbutamol and formoterol, urine thresholds have been adopted to limit supratherapeutic dosing and to discriminate between inhaled (permitted) and oral (prohibited) use."	( Beta2-Agonist Doping Control and Optical Isomer Challenges. Fawcett, JP; Jacobson, GA, 2016)	0.43
"The ideal dosing of albuterol via metered-dose inhalers for acute childhood asthma is not well established."	( Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe. da Silva Filho, LV; De Lalibera, IB; de Souza, AV; Muchão, FP; Rodrigues, JC; Schvartsman, C; Souza, JM; Torres, HC, 2016)	2.2
"Higher albuterol dosage regimens did not result in lower admission rate or shorter length of stay in the ER, but showed similar safety profile for children with moderate to severe acute asthma."	( Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe. da Silva Filho, LV; De Lalibera, IB; de Souza, AV; Muchão, FP; Rodrigues, JC; Schvartsman, C; Souza, JM; Torres, HC, 2016)	2.33
" The primary efficacy variable was the change in forced expiratory volume in one second from predose to 60 minutes after dosing on day 85."	( Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD. Bhargava, S; Bhattacharya, A; Gogtay, J; Purandare, S; Rebello, J; Singh, V; Talwar, D; Whig, J, 2016)	0.43
" Devices that are straightforward to use are less likely to result in dosing errors and can improve patients' satisfaction with therapy and adherence."	( Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClick(™) dry-powder inhaler in the treatment of asthma. Welch, MJ, 2016)	0.68
" We will measure urinary salbutamol levels 30 min after dosing as an estimate of salbutamol doses in the lungs, and also look for genetic polymorphisms linked to poor responses to inhaled salbutamol."	( How can we optimise inhaled beta2 agonist dose as 'reliever' medicine for wheezy pre-school children? Study protocol for a randomised controlled trial. Alberti, C; Beydon, N; Bremner, S; Earl, G; Lansley, A; Mukhopadhyay, S; Olden, C; Palmer, CN; Seddon, P; Symes, L; Wileman, E, 2016)	0.43
"To evaluate the efficacy and safety of albuterol MDPI versus placebo MDPI after chronic dosing in children with asthma."	( Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma. Iverson, H; LaForce, C; Shore, P; Taveras, H, 2017)	2.17
" The benefit of albuterol (mean change in PPFEV1) was evident 5 minutes after dosing and lasted several hours; the maximal effect was noted 1 to 2 hours after dosing."	( Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma. Iverson, H; LaForce, C; Shore, P; Taveras, H, 2017)	2.24
" Clinical efficacy was evident within 5 minutes of dosing and maintained for >2 hours."	( Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma. Iverson, H; LaForce, C; Shore, P; Taveras, H, 2017)	1.9
" The time to q2h dosing from initiation of CAN was compared between the baseline and SCAMP cohorts."	( A Critical Asthma Standardized Clinical and Management Plan Reduces Duration of Critical Asthma Therapy. Agus, MS; Graham, DA; Melendez, E; Wong, J, 2017)	0.46
" There was a decrease in median time to q2h dosing after the SCAMP (baseline, 21."	( A Critical Asthma Standardized Clinical and Management Plan Reduces Duration of Critical Asthma Therapy. Agus, MS; Graham, DA; Melendez, E; Wong, J, 2017)	0.46
" However, the mechanisms and dose-response relationships are poorly understood."	( Effects of nebulised magnesium sulphate on inflammation and function of the guinea-pig airway. Broadley, KJ; Ford, WR; Kidd, EJ; Powell, C; Turner, DL, 2017)	0.46
"Patients receiving noninvasive ventilation (NIV) may benefit from medical aerosol, but most guidance on dosing with different aerosol devices is limited to in-vitro studies."	( In-vitro/in-vivo comparison of inhaled salbutamol dose delivered by jet nebulizer, vibrating mesh nebulizer and metered dose inhaler with spacer during non-invasive ventilation. Abdelrahim, ME; Abdelrahman, MM; Hassan, A; Salah Eldin, R, 2017)	0.46
"Patient receiving invasive mechanical ventilation (IMV) may benefit from medical aerosol, but guidance on dosing with different aerosol devices is limited to in-vitro studies."	( Inhaled salbutamol dose delivered by jet nebulizer, vibrating mesh nebulizer and metered dose inhaler with spacer during invasive mechanical ventilation. Abdelrahim, ME; Abdelrahman, MM; Al-Kholy, MB; Boules, ME; El Essawy, AFM; ElHansy, MHE; Hussein, RRS; Said, ASA, 2017)	0.46
"5 h post dosing and pooled for the next 24 h."	( Lung deposition and systemic bioavailability of different aerosol devices with and without humidification in mechanically ventilated patients. Abdelrahim, MEA; Al Hallag, M; Ali, MRA; Dailey, P; Fink, JB; Moustafa, IOF; Rabea, H, )	0.13
" The assay was successfully applied to the quantification of blood salbutamol concentrations in three healthy volunteers dosed with 1 mg salbutamol by inhalation."	( Quantitation of salbutamol using micro-volume blood sampling - applications to exacerbations of pediatric asthma. Cordell, RL; Hawcutt, DB; Monks, PS; Pandya, HC; Semple, MG; Valkenburg, TSE, 2018)	0.48
" In this small pilot dose-response study, we aimed to explore whether addition of nebulized salbutamol to standard care might improve resuscitation."	( Salbutamol in acute organophosphorus insecticide poisoning - a pilotdose-response phase II study. Alam, MMJ; Bari, MS; Chowdhury, FR; Eddleston, M; Maruf, S; Patwary, MI; Rahman, MM; Ruhan, AM; Uddin, MM; Ullah, P, 2018)	0.48
" The new formulation was bioequivalent to the co-administration of two drugs in separate dosage forms."	( Investigation of a potential drug-drug interaction between salbutamol and ambroxol and bioequivalence of a new fixed-dose combination containing these two drugs in healthy Chinese subjects. Ding, L; Li, T; Liu, L; Lu, J; Shi, X; Wang, Y; Yang, W; Zhao, S, 2018)	0.48
" Subjects presenting with a Pediatric Asthma Score ranging from 5 to 11 received albuterol by BAN or MDI via standard weight-based and symptom severity dosing protocols."	( A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers. Arnold, SR; Gilmore, B; Jacobs, J; Kink, R; Snider, MA; Wan, JY, 2018)	0.71
" The current protocol for systemic reactions in immunotherapy is for the prescribing physician to reassess the dosing and schedule as well as the risk:benefit assessment for the therapy and determine whether or not to proceed."	( Neurologic manifestations in anaphylaxis due to subcutaneous allergy immunotherapy: A case report. Mangold, M; Qureshi, M, 2018)	0.48
" The Solo nebulizer-holding chamber had the highest aerosol emitted compared with all nebulizer-adapter combinations and higher urine samples 30 min after dosing and cumulatively collected urine for 24 h compared with the nebulizer-T-piece."	( Effect of a Nebulizer Holding Chamber on Aerosol Delivery. Abdelrahim, ME; Abdelwahab, NS; Elberry, AA; Rabea, H; Salem, MN; Sarhan, RM, 2018)	0.48
" A unique opportunity for PBPK model evaluation is provided by the clinical PD data for salbutamol, which in its inhaled dosage form (400 μg), produces a higher bronchodilatory effect than in its oral dosage form (2 mg) despite lower drug concentrations in blood."	( Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms. Boger, E; Fridén, M, 2019)	0.51
" Recent investigations also suggest that the optimal dosing of intravenous insulin may be lower than previously described."	( Acute Management of Hyperkalemia. Liu, M; Rafique, Z, 2019)	0.51
" Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazodone, significantly elevated FGF20 levels in the nigrostriatal tract."	( Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats. Doherty, P; Duty, S; Fletcher, EJR; Jamieson, AD; Williams, G, 2019)	0.51
" Commercially available syrup dosage form was successfully analyzed by the developed methods without interference from formulation additives."	( Bilinear and trilinear algorithms utilizing full and selected variables for resolution and quantitation of four components with overlapped spectral signals in bulk and syrup dosage form. Boltia, SA; Fayed, AS; Hegazy, MA; Musaed, A, 2019)	0.51
"This study aimed to investigate the dose-response and pharmacology of a range of single doses of nebulised ensifentrine (RPL554), an inhaled dual phosphodiesterase (PDE) 3/4 inhibitor in patients with asthma."	( Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. Abbott-Banner, K; Bjermer, L; Newman, K, 2019)	0.51
" For the two co-primary endpoints there was a clear ensifentrine dose-response relationship, with all treatments superior to placebo (p < 0."	( Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. Abbott-Banner, K; Bjermer, L; Newman, K, 2019)	0.51
"Intravenous salbutamol is used to treat children with refractory status asthmaticus, however insufficient pharmacokinetic data are available to guide initial and subsequent dosing recommendations for its intravenous use."	( Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. Boehmer, ALM; Boeschoten, SA; Buysse, CMP; de Hoog, M; de Wildt, SN; de Winter, BCM; Knibbe, CAJ; Koch, BCP; Koninckx, M; Plötz, FB; Vaessen-Verberne, AA; van der Nagel, BCH; Verhallen, JT; Vet, NJ, 2020)	0.56
"Our aim was to develop a population pharmacokinetic model to characterize the pharmacokinetic profile for intravenous salbutamol in children with status asthmaticus admitted to the pediatric intensive care unit (PICU), and to use this model to study the effect of different dosing schemes with and without a loading dose."	( Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. Boehmer, ALM; Boeschoten, SA; Buysse, CMP; de Hoog, M; de Wildt, SN; de Winter, BCM; Knibbe, CAJ; Koch, BCP; Koninckx, M; Plötz, FB; Vaessen-Verberne, AA; van der Nagel, BCH; Verhallen, JT; Vet, NJ, 2020)	0.56
" After validation, the model was used for simulations to evaluate the effect of different dosing regimens with or without a loading dose."	( Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. Boehmer, ALM; Boeschoten, SA; Buysse, CMP; de Hoog, M; de Wildt, SN; de Winter, BCM; Knibbe, CAJ; Koch, BCP; Koninckx, M; Plötz, FB; Vaessen-Verberne, AA; van der Nagel, BCH; Verhallen, JT; Vet, NJ, 2020)	0.56
"There has been increasing interest in transnasal pulmonary aerosol administration, but the dose-response relationship has not been reported."	( Dose Response to Transnasal Pulmonary Administration of Bronchodilator Aerosols via Nasal High-Flow Therapy in Adults with Stable Chronic Obstructive Pulmonary Disease and Asthma. Fink, JB; Hadeer, M; Li, J; Luo, J; Zhao, M, )	0.13
" Physical carrier and blend characterisation regarding particle size, morphology, density, shear cell testing and dosing behaviour were performed."	( Particle engineered mannitol for carrier-based inhalation - A serious alternative? Birk, G; Hertel, N; Scherließ, R, 2020)	0.56
" Conventional dosage schemes used in public health to cure various diseases generally lead to undesirable side effects and renders the overall treatment ineffective."	( An Efficient, Lung-Targeted, Drug-Delivery System To Treat Asthma Via Microparticles. Al-Dhubiab, BE; Attimarad, M; Handral, M; Haroun, M; Hiremath, JG; Nair, AB; Ramnarayanan, C; Roopashree, TS; Shinu, P; SreeHarsha, N; Tratrat, C; Venugopala, KN, 2019)	0.51
" For this reason, all beta2-agonists are currently on the Prohibited List issued by the World Anti-Doping Agency (WADA), regardless of dosing route with some exemptions for inhaled salbutamol, formoterol, and salmeterol when used at therapeutic inhaled doses."	( The salmeterol anomaly and the need for a urine threshold. Hostrup, M; Jacobson, GA, 2022)	0.72
" The observed differences may be caused by the difference in dosing between the two regimens."	( Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial. Carpaij, OA; Kerstjens, HAM; Niemeijer, A; Seigers, D; van Geffen, WH; Vonk, JM; Westbroek, LF, 2020)	0.56
" Inhaled salbutamol was administered via a pressurized metered dosed inhaler with a valved holding chamber."	( Effectiveness of hypertonic saline nebulization in airway clearance in children with non-cystic fibrosis bronchiectasis: A randomized control trial. Anuradha, KWDA; Gunathilaka, PKG; Wickramasinghe, VP, 2021)	0.62
" To prove the safety and efficacy of the dosage form, a new HPLC method for analysis of salbutamol sulfate impurities was developed and validated."	( Development and validation of a HPLC method for quantifica-tion of degradation impurities of salbutamol sulfate with following long-term stability studies in multicomponent cough syrup. Bezruk, I; Bunyatyan, V; Georgiyants, V; Gubar, S; Ivanauskas, L; Kovalenko, SM; Materiienko, A, 2020)	0.56
"Our aim was to survey treatment practices used for preschool children with wheezing in emergency rooms (ER) focussing on inhalation device choice and handling, face mask use, salbutamol dosing and written instructions."	( Heterogeneity of emergency treatment practices in wheezing preschool children. Csonka, P; Lehtimäki, L; Mäkelä, MJ; Tapiainen, T, 2021)	0.62
" MON, or combination of MFC, with no limitation of dosage or duration."	( Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis. Hong, JG; Lu, J; Qin, Z; Zhou, XJ, 2021)	0.62
"Beta 2 agonists are well known for their use in the treatment of asthma and COPD however in the last few years new indications of beta 2 agonist appeared like reduction of local fats and treatment of preterm labour which required the formulation of new dosage forms and administration strategies."	( Optimization of two charge transfer reactions for colorimetric determination of two beta 2 agonist drugs, salmeterol xinafoate and salbutamol, in pharmaceutical and biological samples. Abdelkawy, M; Salem, H; Samir, A, 2022)	0.72
" We sought to determine how many children required escalation of care once placed on every 4-h dosing of albuterol."	( Inpatient albuterol spacing as an indicator of discharge readiness. Aoyama, B; Lee, B; Shen, BH, 2023)	1.53
" Although systemic intake is banned, inhalation for asthma is permitted but with dosage restrictions."	( Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control. Biollaz, J; Buclin, T; Courlet, P; Guidi, M; Mazzoni, I; Rabin, O, 2022)	0.72
"More than fifty years after the commercialization of the Ventolin metered-dose inhaler (MDI), its constituent active ingredient, salbutamol sulfate (SS), remains the most prescribed short-acting beta agonist for the first-line treatment of acute asthma attacks and the metered-dose inhaler remains its primary dosage form."	( Development of an ethanol-free salbutamol sulfate metered-dose inhaler: Application of molecular dynamic simulation-based prediction of intermolecular interaction. Abdelwahed, W; Aldabet, A; Alkhayer, M; Golgoun, S; Haroun, M; Miller, JF; Soltani, S, 2022)	0.72
"The objective of the proposed work was to develop a rapid and new reverse phase ultra-performance liquid chromatographic (RP-UPLC) method for the simultaneous quantification of related impurities of ipratropium bromide and salbutamol sulfate in the combined inhalation dosage form."	( Development of a rapid and validated stability-indicating UPLC-PDA method for concurrent quantification of impurity profiling and an assay of ipratropium bromide and salbutamol sulfate in inhalation dosage form. Bapuji, AT; Kondra, S; Pawar, AKM; Shankar, PDS, 2023)	0.91
" Pharmacokinetic-pharmacodynamic (PKPD) models to guide paediatric dosing are lacking."	( Optimising intravenous salbutamol in children: a phase 2 study. Anderson, BJ; Kloprogge, F; Pan, S; Ramnarayan, P; Sheng, Y; Standing, JF; Walsh, S, 2023)	0.91
" To selectively determine albuterol and budesonide in both pure and pharmaceutical dosage forms, two analytical methods were developed: the zero-order absorption method and the dual-wavelength method."	( Development and validation of analytical methods for selective determination of albuterol and budesonide in Airsupra inhalation aerosol using spectrophotometry. Almalki, AH; Almrasy, AA; Ramzy, S, 2023)	1.44

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Role	Description
bronchodilator agent	An agent that causes an increase in the expansion of a bronchus or bronchial tubes.
beta-adrenergic agonist	An agent that selectively binds to and activates beta-adrenergic receptors.
environmental contaminant	Any minor or unwanted substance introduced into the environment that can have undesired effects.
xenobiotic	A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
phenylethanolamines	An ethanolamine compound having a phenyl (substituted or unsubstituted) group on the carbon bearing the hydroxy substituent.
secondary amino compound	A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
phenols	Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
glp-1 receptor, partial	Homo sapiens (human)	Potency	0.0134	0.0184	6.8060	14.1254	AID624148; AID743262
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	3.2357	0.1000	20.8793	79.4328	AID588453; AID588456
GLS protein	Homo sapiens (human)	Potency	7.1108	0.3548	7.9355	39.8107	AID624146; AID624170
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	13.3858	0.5318	15.4358	37.6858	AID504845
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	0.8152	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1259401
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	2.3891	0.0002	29.3054	16,493.5996	AID743075
arylsulfatase A	Homo sapiens (human)	Potency	8.4921	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	49.4892	0.0355	20.9770	89.1251	AID504332
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	0.0398	0.0016	28.0151	77.1139	AID1224843; AID1224895; AID1259393
flap endonuclease 1	Homo sapiens (human)	Potency	8.4368	0.1337	25.4129	89.1251	AID588795
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	9.0743	0.0056	12.3677	36.1254	AID624032
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	0.0601	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	711.0000	0.1100	7.1903	10.0000	AID1443987; AID1449628; AID1473738
Beta-2 adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	1.2618	0.0002	0.9326	7.2000	AID395056; AID625205; AID640201
Beta-2 adrenergic receptor	Homo sapiens (human)	Ki	0.8512	0.0000	0.6635	9.5499	AID1798855; AID395056; AID481516; AID625205
60 kDa heat shock protein, mitochondrial	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1700	4.5590	10.0000	AID1594139
10 kDa heat shock protein, mitochondrial	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1700	4.5590	10.0000	AID1594139
Thiosulfate sulfurtransferase	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0600	3.9631	9.7000	AID1594135
60 kDa chaperonin	Escherichia coli	IC50 (µMol)	175.0000	0.0390	3.5552	9.8000	AID1594140; AID1594141
10 kDa chaperonin	Escherichia coli	IC50 (µMol)	175.0000	0.0390	3.5552	9.8000	AID1594140; AID1594141
Beta-2 adrenergic receptor	Cavia porcellus (domestic guinea pig)	Ki	1.8280	0.0004	0.5902	2.5119	AID481516
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
NPYLR7B	Aedes aegypti (yellow fever mosquito)	EC50 (µMol)	20.0000	0.0390	2.2899	18.3000	AID1259426
Beta-2 adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.1088	0.0000	0.3111	10.0000	AID1760529; AID1906919; AID481517; AID606103; AID640202
Beta-2 adrenergic receptor	Homo sapiens (human)	Kd	14.2062	0.0000	0.6288	8.9130	AID1626022; AID1626023; AID1798580
Beta-1 adrenergic receptor	Homo sapiens (human)	EC50 (µMol)	0.5858	0.0001	0.4914	6.0000	AID1760528; AID1906920
Beta-1 adrenergic receptor	Homo sapiens (human)	Kd	23.1370	0.0001	0.8039	10.0000	AID1798580
Beta-3 adrenergic receptor	Homo sapiens (human)	Kd	23.1370	0.0001	0.7631	8.9130	AID1798580
Delta-type opioid receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0091	0.0005	0.3649	6.9000	AID395059
Beta-2 adrenergic receptor	Bos taurus (cattle)	Kd	0.5200	0.0006	1.4775	9.1200	AID40694
Beta-2 adrenergic receptor	Cavia porcellus (domestic guinea pig)	EC50 (µMol)	0.0386	0.0002	0.8843	8.2000	AID395059; AID481517
Beta-2 adrenergic receptor	Cavia porcellus (domestic guinea pig)	Kd	0.6348	0.0002	0.5477	4.4668	AID1190659; AID426241
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-2 adrenergic receptor	Bos taurus (cattle)	Concentration	30.0000	1.0000	5.5000	10.0000	AID40688
Beta-2 adrenergic receptor	Bos taurus (cattle)	KD app	0.5700	0.0370	1.1774	4.4800	AID40687
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
diet induced thermogenesis	Beta-2 adrenergic receptor	Homo sapiens (human)
regulation of sodium ion transport	Beta-2 adrenergic receptor	Homo sapiens (human)
transcription by RNA polymerase II	Beta-2 adrenergic receptor	Homo sapiens (human)
receptor-mediated endocytosis	Beta-2 adrenergic receptor	Homo sapiens (human)
smooth muscle contraction	Beta-2 adrenergic receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome to lysosome transport	Beta-2 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of protein kinase A signaling	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of bone mineralization	Beta-2 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-2 adrenergic receptor	Homo sapiens (human)
bone resorption	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Beta-2 adrenergic receptor	Homo sapiens (human)
negative regulation of smooth muscle contraction	Beta-2 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of mini excitatory postsynaptic potential	Beta-2 adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of autophagosome maturation	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of lipophagy	Beta-2 adrenergic receptor	Homo sapiens (human)
cellular response to amyloid-beta	Beta-2 adrenergic receptor	Homo sapiens (human)
response to psychosocial stress	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activity	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of AMPA receptor activity	Beta-2 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-2 adrenergic receptor	Homo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrine	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrine	Beta-1 adrenergic receptor	Homo sapiens (human)
diet induced thermogenesis	Beta-1 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-1 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-1 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-1 adrenergic receptor	Homo sapiens (human)
fear response	Beta-1 adrenergic receptor	Homo sapiens (human)
regulation of circadian sleep/wake cycle, sleep	Beta-1 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-1 adrenergic receptor	Homo sapiens (human)
regulation of postsynaptic membrane potential	Beta-1 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-1 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-1 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-1 adrenergic receptor	Homo sapiens (human)
protein folding	60 kDa chaperonin	Escherichia coli K-12
response to radiation	60 kDa chaperonin	Escherichia coli K-12
response to heat	60 kDa chaperonin	Escherichia coli K-12
virion assembly	60 kDa chaperonin	Escherichia coli K-12
chaperone cofactor-dependent protein refolding	60 kDa chaperonin	Escherichia coli K-12
protein refolding	60 kDa chaperonin	Escherichia coli K-12
chaperone cofactor-dependent protein refolding	60 kDa chaperonin	Escherichia coli K-12
response to heat	60 kDa chaperonin	Escherichia coli K-12
adhesion of symbiont to host	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of type II interferon production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
'de novo' protein folding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
response to unfolded protein	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
response to cold	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interferon-alpha production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of type II interferon production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-10 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-12 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-6 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein refolding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
B cell proliferation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
B cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of macrophage activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
negative regulation of apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
isotype switching to IgG isotypes	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein stabilization	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
chaperone-mediated protein complex assembly	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein maturation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
biological process involved in interaction with symbiont	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cellular response to interleukin-7	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein import into mitochondrial intermembrane space	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein folding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial unfolded protein response	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apoptotic mitochondrial changes	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
receptor-mediated endocytosis	Beta-3 adrenergic receptor	Homo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
diet induced thermogenesis	Beta-3 adrenergic receptor	Homo sapiens (human)
carbohydrate metabolic process	Beta-3 adrenergic receptor	Homo sapiens (human)
generation of precursor metabolites and energy	Beta-3 adrenergic receptor	Homo sapiens (human)
energy reserve metabolic process	Beta-3 adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Beta-3 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
response to cold	Beta-3 adrenergic receptor	Homo sapiens (human)
heat generation	Beta-3 adrenergic receptor	Homo sapiens (human)
negative regulation of multicellular organism growth	Beta-3 adrenergic receptor	Homo sapiens (human)
eating behavior	Beta-3 adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Beta-3 adrenergic receptor	Homo sapiens (human)
brown fat cell differentiation	Beta-3 adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-3 adrenergic receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Beta-3 adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	Beta-3 adrenergic receptor	Homo sapiens (human)
osteoblast differentiation	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein folding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
response to unfolded protein	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
chaperone cofactor-dependent protein refolding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
sulfur amino acid catabolic process	Thiosulfate sulfurtransferase	Homo sapiens (human)
cyanate catabolic process	Thiosulfate sulfurtransferase	Homo sapiens (human)
epithelial cell differentiation	Thiosulfate sulfurtransferase	Homo sapiens (human)
rRNA import into mitochondrion	Thiosulfate sulfurtransferase	Homo sapiens (human)
rRNA transport	Thiosulfate sulfurtransferase	Homo sapiens (human)
receptor-mediated endocytosis	Beta-2 adrenergic receptor	Bos taurus (cattle)
regulation of smooth muscle contraction	Beta-2 adrenergic receptor	Bos taurus (cattle)
positive regulation of MAPK cascade	Beta-2 adrenergic receptor	Bos taurus (cattle)
negative regulation of G protein-coupled receptor signaling pathway	Beta-2 adrenergic receptor	Bos taurus (cattle)
adenylate cyclase-activating adrenergic receptor signaling pathway	Beta-2 adrenergic receptor	Bos taurus (cattle)
positive regulation of autophagosome maturation	Beta-2 adrenergic receptor	Bos taurus (cattle)
positive regulation of lipophagy	Beta-2 adrenergic receptor	Bos taurus (cattle)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
amyloid-beta binding	Beta-2 adrenergic receptor	Homo sapiens (human)
beta2-adrenergic receptor activity	Beta-2 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-2 adrenergic receptor	Homo sapiens (human)
adenylate cyclase binding	Beta-2 adrenergic receptor	Homo sapiens (human)
potassium channel regulator activity	Beta-2 adrenergic receptor	Homo sapiens (human)
identical protein binding	Beta-2 adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Beta-2 adrenergic receptor	Homo sapiens (human)
protein-containing complex binding	Beta-2 adrenergic receptor	Homo sapiens (human)
norepinephrine binding	Beta-2 adrenergic receptor	Homo sapiens (human)
beta-adrenergic receptor activity	Beta-1 adrenergic receptor	Homo sapiens (human)
beta1-adrenergic receptor activity	Beta-1 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-1 adrenergic receptor	Homo sapiens (human)
PDZ domain binding	Beta-1 adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Beta-1 adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Beta-1 adrenergic receptor	Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential	Beta-1 adrenergic receptor	Homo sapiens (human)
magnesium ion binding	60 kDa chaperonin	Escherichia coli K-12
protein binding	60 kDa chaperonin	Escherichia coli K-12
ATP binding	60 kDa chaperonin	Escherichia coli K-12
isomerase activity	60 kDa chaperonin	Escherichia coli K-12
ATP hydrolysis activity	60 kDa chaperonin	Escherichia coli K-12
identical protein binding	60 kDa chaperonin	Escherichia coli K-12
unfolded protein binding	60 kDa chaperonin	Escherichia coli K-12
ATP-dependent protein folding chaperone	60 kDa chaperonin	Escherichia coli K-12
lipopolysaccharide binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
p53 binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
DNA replication origin binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
single-stranded DNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
RNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
double-stranded RNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
high-density lipoprotein particle binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
isomerase activity	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP hydrolysis activity	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
enzyme binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ubiquitin protein ligase binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apolipoprotein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apolipoprotein A-I binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
unfolded protein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-folding chaperone binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP-dependent protein folding chaperone	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
norepinephrine binding	Beta-3 adrenergic receptor	Homo sapiens (human)
beta-adrenergic receptor activity	Beta-3 adrenergic receptor	Homo sapiens (human)
protein binding	Beta-3 adrenergic receptor	Homo sapiens (human)
beta3-adrenergic receptor activity	Beta-3 adrenergic receptor	Homo sapiens (human)
beta-3 adrenergic receptor binding	Beta-3 adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Beta-3 adrenergic receptor	Homo sapiens (human)
epinephrine binding	Beta-3 adrenergic receptor	Homo sapiens (human)
RNA binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein folding chaperone	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
unfolded protein binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-folding chaperone binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
metal ion binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
thiosulfate sulfurtransferase activity	Thiosulfate sulfurtransferase	Homo sapiens (human)
5S rRNA binding	Thiosulfate sulfurtransferase	Homo sapiens (human)
3-mercaptopyruvate sulfurtransferase activity	Thiosulfate sulfurtransferase	Homo sapiens (human)
beta2-adrenergic receptor activity	Beta-2 adrenergic receptor	Bos taurus (cattle)
protein homodimerization activity	Beta-2 adrenergic receptor	Bos taurus (cattle)
norepinephrine binding	Beta-2 adrenergic receptor	Bos taurus (cattle)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
nucleus	Beta-2 adrenergic receptor	Homo sapiens (human)
lysosome	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome	Beta-2 adrenergic receptor	Homo sapiens (human)
early endosome	Beta-2 adrenergic receptor	Homo sapiens (human)
Golgi apparatus	Beta-2 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
endosome membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
apical plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
neuronal dense core vesicle	Beta-2 adrenergic receptor	Homo sapiens (human)
receptor complex	Beta-2 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-2 adrenergic receptor	Homo sapiens (human)
early endosome	Beta-1 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-1 adrenergic receptor	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Beta-1 adrenergic receptor	Homo sapiens (human)
neuronal dense core vesicle	Beta-1 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-1 adrenergic receptor	Homo sapiens (human)
cytoplasm	60 kDa chaperonin	Escherichia coli K-12
cytosol	60 kDa chaperonin	Escherichia coli K-12
membrane	60 kDa chaperonin	Escherichia coli K-12
GroEL-GroES complex	60 kDa chaperonin	Escherichia coli K-12
mitochondrial matrix	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular space	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cytoplasm	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrion	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial matrix	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
early endosome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cytosol	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
plasma membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
clathrin-coated pit	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cell surface	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
coated vesicle	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
secretory granule	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular exosome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
sperm midpiece	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
sperm plasma membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
migrasome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-containing complex	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
lipopolysaccharide receptor complex	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
plasma membrane	Beta-3 adrenergic receptor	Homo sapiens (human)
receptor complex	Beta-3 adrenergic receptor	Homo sapiens (human)
plasma membrane	Beta-3 adrenergic receptor	Homo sapiens (human)
mitochondrion	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
membrane	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular exosome	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial matrix	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular space	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrion	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrial matrix	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrion	Thiosulfate sulfurtransferase	Homo sapiens (human)
early endosome	Beta-2 adrenergic receptor	Bos taurus (cattle)
Golgi apparatus	Beta-2 adrenergic receptor	Bos taurus (cattle)
receptor complex	Beta-2 adrenergic receptor	Bos taurus (cattle)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1594141	Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1760528	Agonist activity at human beta1 adrenoceptor expressed in CHO cells assessed as increase in intracellular cAMP level incubated for 1 hr by alphascreen technology	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Recent Advances in β
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID481516	Displacement of [125I]cyanopindolol from human recombinant beta2 adrenergic receptor expressed in CHO cells by filtration assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID16044	The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.)	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1146065	Intrinsic activity at beta-adrenoceptor in guinea pig trachea assessed as relaxation of spontaneously contracted tracheal smooth muscle relative to papaverine	1977	Journal of medicinal chemistry, Aug, Volume: 20, Issue:8	Adrenergic agents. 6. Synthesis and potential beta-adrenergic agonist activity of some meta-substituted p-hydroxyphenylethanolamines related to salbutamol.
AID481513	Binding affinity to human serum albumin by UV/HPLC analysis	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1137785	Agonist activity at beta-2 adrenergic receptor in guinea pig tracheal rings assessed as time required to reach 90% of final relaxation of methacholine-constricted tracheal rings	2014	ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4	Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.
AID24177	log(1/ISA) value of the compound	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1906924	Bronchodilatory activity in rabbit model assessed as inhibition of acetylcholine-induced bronchoconstriction at 3 ug/kg, iv measured after 1 min by Konzett-Roessler methodology relative to control
AID1636357	Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1594135	Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID40690	Beta-2 adrenergic receptor intrinsic symphaticomimetic activity relative to salbutamol	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID481519	Agonist activity at beta2 adrenergic receptor in guinea pig tracheal strip assessed as inhibition of electrically-induced bronchocontractile response after 30 mins	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1774075	Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1223486	Intrinsic clearance in human hepatocytes from chimeric mouse with humanized liver assessed per 10'6 cells at 10 uM after 0.25 to 2 hrs by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID625278	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID40687	Apparent binding affinity constant to beta-2 adrenergic receptor determined using [3H]DHA	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID1906929	Bronchodilatory activity in rabbit model assessed as inhibition of acetylcholine-induced bronchoconstriction at 9 ug/kg, iv measured after 45 mins by Konzett-Roessler methodology relative to control
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1190659	Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring at basal tone assessed as bronchorelaxation activity	2015	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4	Insights on the role of boron containing moieties in the design of new potent and efficient agonists targeting the β2 adrenoceptor.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1443992	Total Cmax in human administered as single dose	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1774076	Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1906920	Agonist activity at beta1 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1906928	Bronchodilatory activity in rabbit model assessed as inhibition of acetylcholine-induced bronchoconstriction at 1 ug/kg, iv measured after 30 mins by Konzett-Roessler methodology relative to control
AID1594137	Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID467613	Volume of distribution at steady state in human	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID129460	Bronchosecretory activity measured as tracheal secretion of phenol red in mouse after oral administration	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	2-[(3-Pyridinylmethyl)thio]pyrimidine derivatives: new bronchosecretolytic agents.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1137808	Toxicity in iv dosed guinea pig assessed as change in plasma potassium level up to 60 mins	2014	ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4	Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.
AID771315	Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID77612	Intrinsic activity measured on Guinea pig tracheal spiral strips.	1990	Journal of medicinal chemistry, Nov, Volume: 33, Issue:11	Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID426144	Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring assessed as bronchorelaxation activity against carbachol-induced contraction	2009	European journal of medicinal chemistry, Jul, Volume: 44, Issue:7	Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
AID1906926	Bronchodilatory activity in rabbit model assessed as inhibition of acetylcholine-induced bronchoconstriction at 9 ug/kg, iv measured after 30 mins by Konzett-Roessler methodology relative to control
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID771316	Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID640202	Agonist activity at recombinant human beta2-adrenoceptor expressed in whole cells assessed as cAMP accumulation by homogeneous radioimmunoassay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD.
AID1146181	Agonist activity at beta-1 adrenergic receptor in guinea pig right atria assessed as increase in contraction rate of spontaneously beating right atria	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID481520	Agonist activity at beta2 adrenergic receptor in guinea pig tracheal strip assessed as time required to reach maximal inhibition of electrically-induced bronchoconstriction	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
AID1137784	Agonist activity at beta-2 adrenergic receptor in human bronchial rings assessed as time required to reach 90% of final relaxation of carbachol-constricted bronchial rings	2014	ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4	Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1594145	Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1774079	Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID513146	Binding affinity to human beta-2 adrenergic receptor delta 5-C271 mutant expressed in Spodoptera frugiperda Sf9 cells	2006	Nature chemical biology, Aug, Volume: 2, Issue:8	Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1626022	Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes by liquid scintillation counting	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID503294	Agonist activity at beta-2-adrenergic receptor expressed in HEK293 cells assessed as induction of receptor interaction with beta-arrestin by EYFP based reporter gene assay	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1906925	Bronchodilatory activity in rabbit model assessed as inhibition of acetylcholine-induced bronchoconstriction at 1 ug/kg, iv measured after 1 min by Konzett-Roessler methodology relative to control
AID41888	Tested for intrinsic sympathomimetic activity (ISA); Agonist	1988	Journal of medicinal chemistry, Nov, Volume: 31, Issue:11	Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID40694	Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1146180	Agonist activity at beta-2 adrenergic receptor in guinea pig tracheal chain assessed as relaxation of spontaneously contracted tracheal smooth muscle	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1146185	Intrinsic activity at beta-2 adrenergic receptor in guinea pig tracheal chain assessed as relaxation of spontaneously contracted tracheal smooth muscle relative to papaverine	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID1223483	Unbound fraction in iv dosed human plasma	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1123872	Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of anoxia at 1.25 mg/kg, po treated 30 mins before histamine challenge (Rvb = 5.08 mins)	1979	Journal of medicinal chemistry, Mar, Volume: 22, Issue:3	New bronchodilators. Synthesis and bronchodilating activity of some 3-(alkoxymethyl)-alpha-(N-substituted aminomethyl)-4-hydroxybenzyl alcohols.
AID1774078	Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1873863	Displacement of [3H]-CGP12,177 from immobilized Halo tag-fused beta2 adrenoceptor (unknown origin) expressed in Escherichia coli BL21 (DE3)
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1443987	Inhibition of recombinant human BSEP expressed in baculovirus infected sf21 cell membrane vesicles assessed as reduction in ATP-dependent [3H]-taurocholate uptake in to vesicles after 5 mins by TopCount method	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1636356	Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1223477	Total clearance in iv dosed human	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1626024	Binding affinity to inactive/G protein-uncoupled human beta2-AR by immobilized artificial membrane HPLC analysis	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1906919	Agonist activity at beta2 adrenoceptor (unknown origin) expressed in HEK293 cells assessed as cAMP accumulation incubated for 60 mins by microplate reader analysis
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1906921	Selectivity ratio of EC50 for beta1 adrenoceptor (unknown orgin) expressed in HEK293 cells to EC50 for human beta2 adrenoceptor (unknown orgin) expressed in HEK293 cells
AID395056	Displacement of [3H]CGP1217 from human recombinant adrenergic beta2 receptor transfected in insect Sf9 cells by scintillation counting	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID513152	Partial agonist activity at human biamane labelled beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as bimane response by fluorescence spectroscopy	2006	Nature chemical biology, Aug, Volume: 2, Issue:8	Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
AID426234	Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring assessed as bronchorelaxation activity against histamine-induced contraction	2009	European journal of medicinal chemistry, Jul, Volume: 44, Issue:7	Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1223478	Total clearance in chimeric mouse with humanized liver at 3 mg/kg, iv by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID395059	Agonist activity at adrenergic beta2 receptor in guinea pig trachea assessed as relaxation of carbachol-induced tissue contraction	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.
AID1906989	Bronchodilatory activity in iv dosed rabbit model assessed as inhibition of acetylcholine-induced bronchoconstriction measured after 1 min by Konzett-Roessler methodology relative to control
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1443995	Hepatotoxicity in human assessed as drug-induced liver injury	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1906923	Bronchodilatory activity in rabbit model assessed as inhibition of acetylcholine-induced bronchoconstriction at 9 ug/kg, iv measured after 1 min by Konzett-Roessler methodology relative to control
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1594139	Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID481518	Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay relative to formoterol	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
AID513154	Binding affinity to human beta-2 adrenergic receptor delta 5-C271/W135 mutant expressed in Spodoptera frugiperda Sf9 cells	2006	Nature chemical biology, Aug, Volume: 2, Issue:8	Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
AID76393	Inhibition of spontaneous tone in Guinea pig tracheal spiral strips.	1990	Journal of medicinal chemistry, Nov, Volume: 33, Issue:11	Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis.
AID481512	Chromatographic hydrophobicity index at 2 mg/ml at pH 7.4 by rapid gradient HPLC analysis	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
AID513148	Agonist activity at human Beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as decrease in bimane fluorescence intensity by fluorescence spectroscopy	2006	Nature chemical biology, Aug, Volume: 2, Issue:8	Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
AID218847	Change in Gibb's free energy at High affinity beta2- adrenoceptor in Chang living cells.	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID1190661	Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring assessed as bronchorelaxation activity against histamine-induced contraction relative to isoproterenol	2015	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4	Insights on the role of boron containing moieties in the design of new potent and efficient agonists targeting the β2 adrenoceptor.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1146179	Selectivity ratio of ED25 for beta-adrenergic receptor in guinea pig right atrial muscle to ED50 for beta-adrenergic receptor in guinea pig tracheal tissue	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Adrenerigic agents. 7.1 Synthesis and beta-adrenergic agonist activity of several 2-pyridylethanolamines.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID24440	Calculated partition coefficient (clogP)	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID41488	Selectivity for beta-2 adrenergic receptor	1988	Journal of medicinal chemistry, Nov, Volume: 31, Issue:11	Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID771317	Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID1137786	Agonist activity at beta-2 adrenergic receptor in guinea pig tracheal rings assessed as relaxation of methacholine-constricted tracheal rings	2014	ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4	Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.
AID40688	Concentration required for maximal (95-100%) beta-2 adrenergic receptor occupancy	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID1223475	Elimination half life in chimeric mouse with humanized liver at 3 mg/kg, iv by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1223481	Elimination half life iv dosed human	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1123873	Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of anoxia at 5 mg/kg, po treated 30 mins before histamine challenge (Rvb = 5.08 mins)	1979	Journal of medicinal chemistry, Mar, Volume: 22, Issue:3	New bronchodilators. Synthesis and bronchodilating activity of some 3-(alkoxymethyl)-alpha-(N-substituted aminomethyl)-4-hydroxybenzyl alcohols.
AID606104	Intrinsic activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr relative to formoterol	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID40536	Selectivity towards beta-1 adrenergic receptor; Nonselective towards beta-1 adrenoceptor	1988	Journal of medicinal chemistry, Nov, Volume: 31, Issue:11	Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1146066	Intrinsic activity at beta-adrenoceptor in guinea pig atria assessed as cardiac stimulant activity by measuring change in rate of contraction of right atrial muscle relative to isoproterenol	1977	Journal of medicinal chemistry, Aug, Volume: 20, Issue:8	Adrenergic agents. 6. Synthesis and potential beta-adrenergic agonist activity of some meta-substituted p-hydroxyphenylethanolamines related to salbutamol.
AID503306	Antiproliferative activity against human PC3 cells at 2 uM after 120 hrs by MTT assay relative to DMSO	2006	Nature chemical biology, Jun, Volume: 2, Issue:6	Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1906931	Bronchodilatory activity in rabbit model assessed as inhibition of acetylcholine-induced bronchoconstriction at 1 ug/kg, iv measured after 45 mins by Konzett-Roessler methodology relative to control
AID29812	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID467611	Dissociation constant, pKa of the compound	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID426240	Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring assessed as bronchorelaxation activity against histamine-induced contraction in presence of ICI-118551	2009	European journal of medicinal chemistry, Jul, Volume: 44, Issue:7	Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1146183	Intrinsic activity at beta-1 adrenergic receptor in guinea pig right atria assessed as increase in contraction rate of spontaneously beating right atria relative to isoproterenol	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID481521	Agonist activity at beta2 adrenergic receptor in guinea pig tracheal strip assessed as duration of maximal inhibitory action against electrically-induced bronchoconstriction	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
AID1137783	Intrinsic activity at beta-2 adrenergic receptor in guinea pig tracheal rings	2014	ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4	Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.
AID1146056	Agonist activity at beta-adrenoceptor in guinea pig trachea assessed as relaxation of spontaneously contracted tracheal smooth muscle	1977	Journal of medicinal chemistry, Aug, Volume: 20, Issue:8	Adrenergic agents. 6. Synthesis and potential beta-adrenergic agonist activity of some meta-substituted p-hydroxyphenylethanolamines related to salbutamol.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1906939	Relaxant activity in guinea pig smooth muscle cells assessed as decrease in intracellular calcium level at 1 umol/L incubated for 5 mins by Flura2AM staining based fluorescence assay
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1636440	Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1123875	Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of coughing at 5 mg/kg, po treated 30 mins before histamine challenge (Rvb = 6.13 mins)	1979	Journal of medicinal chemistry, Mar, Volume: 22, Issue:3	New bronchodilators. Synthesis and bronchodilating activity of some 3-(alkoxymethyl)-alpha-(N-substituted aminomethyl)-4-hydroxybenzyl alcohols.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1190660	Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring assessed as bronchorelaxation activity against histamine-induced contraction	2015	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4	Insights on the role of boron containing moieties in the design of new potent and efficient agonists targeting the β2 adrenoceptor.
AID1873862	Binding affinity to immobilized Halo tag-fused beta2 adrenoceptor (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as retention time by chromatographic analysis
AID426239	Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring assessed as bronchorelaxation activity against histamine-induced contraction in presence of propranolol	2009	European journal of medicinal chemistry, Jul, Volume: 44, Issue:7	Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
AID481517	Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
AID1626023	Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes assessed as intrinsic Kd by liquid scintillation counting	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID640201	Displacement of [3H]dihydroalprenolol from beta2-adrenoceptor after 90 mins by liquid scintillation counting	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1146059	Agonist activity at beta-adrenoceptor in guinea pig atria assessed as cardiac stimulant activity by measuring change in rate of contraction of right atrial muscle	1977	Journal of medicinal chemistry, Aug, Volume: 20, Issue:8	Adrenergic agents. 6. Synthesis and potential beta-adrenergic agonist activity of some meta-substituted p-hydroxyphenylethanolamines related to salbutamol.
AID1906930	Bronchodilatory activity in rabbit model assessed as inhibition of acetylcholine-induced bronchoconstriction at 3 ug/kg, iv measured after 45 mins by Konzett-Roessler methodology relative to control
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID426238	Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring assessed as maximum bronchorelaxation activity against carbachol-induced contraction at 100 uM	2009	European journal of medicinal chemistry, Jul, Volume: 44, Issue:7	Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1146184	Selectivity ratio of ED25 for beta-1 adrenergic receptor in guinea pig right atria to ED50 for beta-2 adrenergic receptor in guinea pig tracheal chain	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1594140	Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID218845	Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID40686	Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1146178	Intrinsic activity at beta-adrenergic receptor in guinea pig right atrial muscle assessed as rate of contraction of spontaneously beating atria relative to isoproterenol	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Adrenerigic agents. 7.1 Synthesis and beta-adrenergic agonist activity of several 2-pyridylethanolamines.
AID1443991	Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID426241	Binding affinity to adrenergic beta2 receptor in Hartley guinea pig tracheal ring	2009	European journal of medicinal chemistry, Jul, Volume: 44, Issue:7	Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
AID40695	Intrinsic activity was measured as concentration of beta-2 adrenergic receptor agonist required for cAMP production	1986	Journal of medicinal chemistry, Apr, Volume: 29, Issue:4	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.
AID467612	Fraction unbound in human plasma	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1760529	Agonist activity at human beta2 adrenoceptor expressed in CHO cells assessed as increase in intracellular cAMP level incubated for 1 hr by alphascreen technology	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Recent Advances in β
AID1594144	Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1146174	Agonist activity at beta-adrenergic receptor in guinea pig tracheal tissue assessed as bronchodilator activity	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Adrenerigic agents. 7.1 Synthesis and beta-adrenergic agonist activity of several 2-pyridylethanolamines.
AID606103	Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.
AID215614	Dissociation constant against a series of agonists of membranes of the turkey erythrocyte containing mainly beta-adrenoceptors was determined.	1982	Journal of medicinal chemistry, Dec, Volume: 25, Issue:12	Correlation between affinity toward adrenergic receptors and approximate electrostatic potentials of phenylethylamine derivatives. 1. Effects of the side chain.
AID1123874	Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of coughing at 1.25 mg/kg, po treated 30 mins before histamine challenge (Rvb = 6.13 mins)	1979	Journal of medicinal chemistry, Mar, Volume: 22, Issue:3	New bronchodilators. Synthesis and bronchodilating activity of some 3-(alkoxymethyl)-alpha-(N-substituted aminomethyl)-4-hydroxybenzyl alcohols.
AID218848	Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID1906927	Bronchodilatory activity in rabbit model assessed as inhibition of acetylcholine-induced bronchoconstriction at 3 ug/kg, iv measured after 30 mins by Konzett-Roessler methodology relative to control
AID771314	Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID1146175	Agonist activity at beta-adrenergic receptor in guinea pig right atrial muscle assessed as rate of contraction of spontaneously beating atria	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Adrenerigic agents. 7.1 Synthesis and beta-adrenergic agonist activity of several 2-pyridylethanolamines.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1146067	Separation ratio of ED25 at beta-adrenoceptor in guinea pig atria to ED50 for beta-adrenoceptor in guinea pig trachea	1977	Journal of medicinal chemistry, Aug, Volume: 20, Issue:8	Adrenergic agents. 6. Synthesis and potential beta-adrenergic agonist activity of some meta-substituted p-hydroxyphenylethanolamines related to salbutamol.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1223482	Ratio of drug level in blood to plasma in iv dosed human	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1594134	Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID426237	Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring assessed as maximum bronchorelaxation activity against histamine-induced contraction at 100 uM	2009	European journal of medicinal chemistry, Jul, Volume: 44, Issue:7	Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1798855	Beta-2 Adrenergic Receptor Binding Assay and Agonist Functionality Assay from Article 10.1021/jm801211c: \\Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.\\	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.
AID1798580	3H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: \\The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.\\	2005	British journal of pharmacology, Feb, Volume: 144, Issue:3	The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346250	Human beta2-adrenoceptor (Adrenoceptors)	2005	British journal of pharmacology, Feb, Volume: 144, Issue:3	The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID1346250	Human beta2-adrenoceptor (Adrenoceptors)	1999	Molecular pharmacology, Nov, Volume: 56, Issue:5	Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2044 (21.52)	18.7374
1990's	2513 (26.46)	18.2507
2000's	2629 (27.69)	29.6817
2010's	1890 (19.90)	24.3611
2020's	420 (4.42)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3,059 (30.26%)	5.53%
Reviews	587 (5.81%)	6.00%
Case Studies	582 (5.76%)	4.05%
Observational	38 (0.38%)	0.25%
Other	5,842 (57.80%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (393)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Evaluating Bronchodilator Response in Patients With Bronchiectasis [NCT05932316]		96 participants (Anticipated)	Interventional	2023-05-20	Recruiting
Mannitol-Induced Cough Challenge in Healthy Controls and Subjects With Mild Allergic Asthma [NCT03620422]		40 participants (Actual)	Interventional	2019-01-11	Completed
Double Blind, Double Dummy, Cross-over Study to Compare the Bronchodilator Effect of CHF1535 pMDI (Fixed Combination of Beclometasone 50 µg + Formoterol 6 µg) Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children [NCT01584492]	Phase 2	59 participants (Actual)	Interventional	2011-12-31	Completed
Comparison of Preoperative Inhaled Budesonide With Salbutamol on the Respiratory Adverse Effects in Children Undergoing Tonsillectomy [NCT06158893]	Phase 4	87 participants (Anticipated)	Interventional	2024-08-31	Not yet recruiting
Peak Inspiratory Flow (PIF) and Dry Powder Inhaler (DPI) Performance in Chronic Obstructive Pulmonary Disease (COPD) [NCT04606394]	Phase 4	30 participants (Actual)	Interventional	2020-12-02	Completed
A Phase II Study to Assess the Efficacy and Safety of a Single Inhaled Dose of Albuterol Sulfate Dry Powder Via the Trivair Deposition System Versus Albuterol Sulfate HFA pMDI in Patients With Intermittent or Persistent Mild Asthma [NCT01252758]	Phase 2	0 participants (Actual)	Interventional	2012-11-30	Withdrawn
Physiological Response to Salbutamol and Exercise [NCT03902106]		40 participants (Anticipated)	Interventional	2019-03-28	Recruiting
Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma [NCT00070707]	Phase 4	188 participants (Actual)	Interventional	2003-04-03	Completed
Asthma and Childhood Obesity: Understanding Potential Mechanisms and Identifying Strategies to Improve Respiratory Symptoms [NCT03586544]	Phase 4	34 participants (Actual)	Interventional	2018-09-18	Terminated(stopped due to The study was halted prematurely due to COVID 19.)
Comparative Study on the Efficacy and Safety of Procaterol vs Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room [NCT01091337]	Phase 4	96 participants (Actual)	Interventional	2006-05-31	Completed
A Multicentre, Randomised, Placebo-controlled, Double-blind (Sponsor Open), Parallel-group, 8-week Treatment Study Investigating the Efficacy and Safety of Intra-nasal GSK2245035 in Adults With Allergic Asthma Treated With Inhaled Corticosteroids (ICS) [NCT03707678]	Phase 2	0 participants (Actual)	Interventional	2019-01-21	Withdrawn(stopped due to After careful review of new data on GSK2245035, GlaxoSmithKline has decided to cancel this study.)
Preliminary Assessment of the Effect of PulseHaler™ With Albuterol on Lung Deposition of Aerosol and on Pulmonary Functions in COPD Patients [NCT01187589]		15 participants (Anticipated)	Interventional	2010-12-31	Completed
A Randomized, Double- or Evaluator-blind, Active- and Placebo-controlled, Single Dose, Seven-arm, Crossover Dose-ranging Study of A006 in Adult Asthma Patients [NCT01581177]	Phase 2	23 participants (Actual)	Interventional	2012-04-30	Completed
GOLD Stage I COPD: Is it Really a Disease ? Exercise Tolerance, Muscle Function and Response to Bronchodilation in GOLD Stage I COPD Patients [NCT01360788]		53 participants (Actual)	Observational	2009-02-28	Completed
A Randomized, Double-blind, Single-dose, 2-Period, Crossover Study to Assess the Efficacy of PT027 Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult and Adolescent Subjects With Asthma [NCT04234464]	Phase 3	60 participants (Actual)	Interventional	2020-01-15	Completed
A Double-blind Placebo-controlled Crossover Study to Assess the Effects of Bronchodilation on Dyspnea, Ventilatory Responses, and Exercise Tolerance in Adults With Cystic Fibrosis [NCT03522831]		20 participants (Anticipated)	Interventional	2018-05-01	Active, not recruiting
"A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist Rescue Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma" [NCT02969408]	Phase 3	397 participants (Actual)	Interventional	2017-02-13	Completed
An Open Label, Randomised, Parallel Group Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Relvar/Breo ELLIPTA Therapy, in Asthmatic Subjects With Poor Control [NCT03380429]	Phase 4	437 participants (Actual)	Interventional	2018-01-31	Completed
A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed With an Acute Moderate or Seve [NCT03345407]	Phase 2	943 participants (Actual)	Interventional	2017-11-28	Terminated(stopped due to Unfavourable benefit:risk)
A Randomized, Cumulative Dose, Open-label, 2-period Crossover, Multi-center Study to Assess the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Cumulative Doses of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred t [NCT03371459]	Phase 2	46 participants (Actual)	Interventional	2017-12-29	Completed
Cumulative Dose, 2-Way Crossover Study of the Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler Compared With MDI in Subjects With Asthma [NCT03643874]	Phase 2	13 participants (Actual)	Interventional	2018-06-30	Completed
Enabling Innovative Respiratory Real World Evidence Generation: Sensor and EHR Integration Pilot Study [NCT03357341]		194 participants (Actual)	Observational	2018-07-23	Completed
A Phase III, 52-week, Open-label Study to Evaluate Long-term Safety of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Patients With Asthma [NCT03184987]	Phase 3	111 participants (Actual)	Interventional	2017-06-22	Completed
A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI With the Fixed Dose Dual Combination of FF/VI, Administered Once-daily Via a Dry Powde [NCT02924688]	Phase 3	2,436 participants (Actual)	Interventional	2016-10-13	Completed
The Effects of Salbutamol on Mannitol Induced Cough Responses in Healthy Controls [NCT04565847]	Phase 2	20 participants (Actual)	Interventional	2020-11-30	Completed
Effectiveness of Salbutamol Administration by Nebulizer Versus Metered Dose Inhaler With Spacer in Acute Asthma in Children in Suez Canal University Hospital Emergency Department: A Randomized Control Trial [NCT03816267]	Phase 3	60 participants (Actual)	Interventional	2018-05-15	Completed
A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol With Tiotropium/Olodaterol Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [NCT02799784]	Phase 4	236 participants (Actual)	Interventional	2016-07-14	Completed
The Effects of Inhaled Beta-2-Agonists and Air Pollution on Lung Function and Athletic Capacity [NCT02252302]		20 participants (Anticipated)	Interventional	2015-05-31	Completed
Salbutamol: Tolerance to Bronchoprotection vs. Methacholine: Time Course of Onset [NCT01338311]	Phase 4	15 participants (Actual)	Interventional	2011-03-31	Completed
Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study) [NCT03137303]	Phase 3	402 participants (Actual)	Interventional	2017-07-01	Completed
[NCT01076322]	Phase 3	17 participants (Anticipated)	Interventional	2009-03-31	Completed
[NCT01375361]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2009-04-30	Withdrawn(stopped due to Low enrollment.)
Effect of Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen During Resuscitation of OP Pesticide Poisoned Patients [NCT02160548]	Phase 3	75 participants (Actual)	Interventional	2015-04-30	Completed
Evaluation of Electrical Impedance Tomography for the Diagnosis of Chronic Rejection in Lung Transplants Recipients [NCT02863835]		50 participants (Actual)	Interventional	2016-04-30	Completed
Open Study on the Efficacy and Safety of Combivent® Aerosol (120 mcg Salbutamol Sulfate Plus 20 mcg Ipratropium Bromide) + Spacer, 12 to 24 Puffs, in Adult Patients With Moderate to Severe Asthma Crisis [NCT02182700]	Phase 3	47 participants (Actual)	Interventional	1998-07-31	Terminated
A Randomised, Double-blind, Active-controlled, Within-patient Trial Comparing the Effect of Single Doses of Nebulised Ipratropium 500µg, Salbutamol Sulphate 3mg, Salbutamol 6mg and the Combination Therapy Salbutamol Sulphate 3 mg Plus Ipratropium 500µg on [NCT02182856]	Phase 4	33 participants (Actual)	Interventional	1998-02-28	Completed
Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis [NCT03914638]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2019-04-01	Recruiting
Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes [NCT01203592]	Phase 1	21 participants (Actual)	Interventional	2010-09-30	Completed
Study of Drug Exposure in Systemic Circulation of Primatene Mist (0.25mg) by Oral Inhalation, Versus Epinephrine Injection (0.30mg) by Intramuscular Injection and ProAir (0.18mg) by Oral Inhalation in Healthy Individuals: A Randomized, Safety Evaluator-bl [NCT04207840]	Phase 4	28 participants (Actual)	Interventional	2019-12-09	Completed
A Phase IV, 12-week, Randomised, Double-blind, Triple Dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) With Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) Based on Lung Functi [NCT03478696]	Phase 4	732 participants (Actual)	Interventional	2018-06-25	Completed
Randomized Trial Assessing the Effectiveness of Beclomethasone and Combination Beclomethasone and Salbutamol as Compared With Placebo in Preschool Aged Children With Wheeze [NCT02319564]	Phase 4	0 participants (Actual)	Interventional	2016-04-30	Withdrawn(stopped due to Study population too narrow - unable to recruit any patients.)
A Comparison of Ipratropium Bromide/Salbutamol (40 mcg / 200 mcg, One Inhalation) Delivered by the Respimat ® Inhaler to COMBIVENT Inhalation Aerosol (Two Inhalations), Ipratropium Bromide Respimat ® and Placebo of Each Formulation in a 12-week, Double-bl [NCT02177253]	Phase 3	1,118 participants (Actual)	Interventional	2002-10-31	Completed
Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm [NCT02182713]	Phase 4	30 participants (Actual)	Interventional	1998-05-31	Completed
Lung Anatomic, Physiologic, and Inflammatory Changes With Chronic Exposure to Secondhand Tobacco Smoke [NCT02797275]	Phase 4	107 participants (Actual)	Interventional	2016-06-06	Active, not recruiting
A 2-Period, Crossover Study to Assess the Impact of Nebulizer With Filtered Mouthpiece vs MDI With Spacer on Viral Load in Rooms of Subjects With Mild to Moderate COVID-19 [NCT04681079]		14 participants (Actual)	Observational	2021-05-04	Completed
Efficacy of Intermittent Tiotropium in Early Childhood Wheezing [NCT03199976]	Phase 4	80 participants (Actual)	Interventional	2016-04-20	Completed
A Phase III, Randomized, Active-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Long-Term Safety of Mometasone Furoate/Formoterol Fumarate (MF/F, MK-0887A [SCH418131]), Compared With Mometasone Furoate (MF, MK-0887 [SCH032088]), in Chi [NCT02741271]	Phase 3	181 participants (Actual)	Interventional	2016-05-11	Completed
Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease [NCT02296047]		22 participants (Actual)	Interventional	2014-12-31	Completed
Efficacy of a Loading Dose of IV Salbutamol in Children Admitted to a PICU for Severe Acute Asthma or Severe Acute Wheeze [NCT03493503]	Phase 4	58 participants (Actual)	Interventional	2017-04-05	Completed
A Phase IIb, 24 Week, Randomized, Double-blind, 3 Arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of Two Doses of Umeclidinium Bromide Administered Once-daily Via a Dry Powder Inhaler, Versus Placebo, in Participants With Asthma [NCT03012061]	Phase 2	425 participants (Actual)	Interventional	2017-01-25	Completed
Comparing Rapid Bronchodilatory Effect of Formoterol and Salbutamol in Children Between 5-15 Years With Mild to Moderate Acute Exacerbation of Asthma- A Double Blind Randomized Controlled Trial [NCT00900874]	Phase 4	78 participants (Anticipated)	Interventional	2009-01-31	Recruiting
Randomized, Double-blind, Placebo-controlled, Dose Exploration, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. [NCT05987371]	Phase 2	72 participants (Anticipated)	Interventional	2023-08-23	Recruiting
Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle [NCT04558190]		10 participants (Actual)	Interventional	2020-09-02	Completed
Double-blind, Controlled Trial to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, for 120 Minutes, in Acute Asthmatic Attacks in Young Children [NCT02235428]	Phase 4	3 participants (Actual)	Interventional	1998-09-30	Terminated
Bronchodilator Effects of Nebulized Versus Inhaled Albuterol in Subjects With Lymphangioleiomyomatosis [NCT01799538]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2013-06-10	Recruiting
A Single-Dose Efficacy Comparison of Albuterol Hydrofluoroalkane (HFA) Breath-operated Inhaler (BOI) (Volare Easi-Breathe™) and Albuterol HFA Meter Dose Inhaler (MDI) (Volare™) in Adolescents and Adults With Exercise-Induced Bronchospasm [NCT00085774]	Phase 3	24 participants (Actual)	Interventional	2004-06-30	Completed
In Vivo Efficacy of Salbutamol (Sandoz) Versus Salbutamol Ventolin (GSK) in Children With Asthma [NCT05884970]	Phase 3	80 participants (Anticipated)	Interventional	2023-03-30	Recruiting
Comparison of Single-dose Efficacy of Albuterol-HFA-BOI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability [NCT00054964]	Phase 2	14 participants (Actual)	Interventional	2003-03-31	Completed
A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems [NCT03098680]	Phase 1	18 participants (Actual)	Interventional	2017-04-24	Terminated(stopped due to Unable to recruit in time before end of PhD studentship)
Effectiveness of Routine Nebulization of Mucolytics and Bronchodilators in Mechanically Ventilated Intensive Care Patients' [NCT02159196]		950 participants (Actual)	Interventional	2014-07-31	Completed
Evaluation on the Efficacy of Bronchodilator Nebulization Via High Flow Nasal Cannula [NCT03091504]		42 participants (Actual)	Interventional	2017-09-04	Completed
An Open-Label, Randomized, Cross-Over Study to Evaluate the Dose Response of SYN006 HFA MDI in Asthma Patients [NCT02162784]	Phase 2	39 participants (Actual)	Interventional	2013-02-28	Completed
Efficacy of Nebulized Heparin and Salbutamol in Mechanically Ventilated Patients With Acute Exacerbation Chronic Obstructive Pulmonary Disease: a Randomized Clinical Trial [NCT03333395]	Phase 4	60 participants (Actual)	Interventional	2017-02-01	Completed
Acute Effect of Salbutamol on Heart Rate and Blood Pressure During Exercise in Patients With Moderate or Severe Asthma and Healthy Subjects: Randomized, Double-blind, and Crossover Study [NCT03044938]	Phase 4	15 participants (Actual)	Interventional	2016-08-06	Completed
Salbutamol Reversal of Methacholine Induced Bronchoconstriction: Vibrating Mesh Nebulizer Versus Pressurized Metered Dose Inhaler [NCT05977699]	Phase 4	20 participants (Anticipated)	Interventional	2023-12-15	Not yet recruiting
A Single Dose Two-way Cross-over Study in Healthy Participants to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers Containing Propellants HFA-152a and HFA-134a [NCT05791565]	Phase 1	28 participants (Actual)	Interventional	2023-04-03	Completed
A Double-blind Randomized Controlled Trial of Inhaled Salbutamol vs Placebo for the Treatment of Acute Abdominal Pain From Food-induced IgE-mediated Reactions [NCT05653024]	Phase 3	498 participants (Anticipated)	Interventional	2023-07-01	Recruiting
Modifying Genes in Cystic Fibrosis: The Beta-2 Adrenergic Receptors and Epithelial Na+ Channels [NCT01880723]		32 participants (Actual)	Interventional	2009-05-31	Completed
A Proof of Concept Study to Evaluate the Trough Bronchoprotection Conferred by Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics [NCT00831376]	Phase 4	30 participants (Actual)	Interventional	2009-01-31	Completed
A Randomized Clinical Trial to Assess the Effects of Inhaled Fluticasone on Sputum Neutrophils After Low-dose Inhaled Endotoxin Challenge in Healthy Subjects [NCT00869596]	Phase 1	22 participants (Actual)	Interventional	2009-03-31	Completed
A Randomized, Single-Dose, Double-Blind, Double-Dummy, Four-Period, Four-Sequence, Four-Treatment, Placebo and Active Controlled, Comparative, Multiple-Center, Crossover-Design, Bronchoprovocation Study to Evaluate the Pharmacodynamic Equivalence of Albut [NCT03549897]	Phase 3	100 participants (Anticipated)	Interventional	2018-03-16	Recruiting
Randomized, Parallel-group Trial to Evaluate Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD [NCT04655170]	Phase 4	60 participants (Anticipated)	Interventional	2020-12-09	Recruiting
The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children [NCT02743663]		121 participants (Actual)	Observational	2014-06-30	Completed
A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older Wit [NCT03769090]	Phase 3	3,132 participants (Actual)	Interventional	2018-12-13	Completed
A Randomized, Methodology Study to Investigate the Use of 3He-MRI Lung Ventilation and Proton MRI Perfusion Imaging to Detect Changes in Ventilation Perfusion Relationships in Chronic Obstructive Pulmonary Disease (COPD) Patients; a Proof of Concept Study [NCT02207452]	Phase 1	11 participants (Actual)	Interventional	2010-08-05	Completed
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients [NCT01189396]	Phase 2	27 participants (Actual)	Interventional	2010-07-31	Completed
Phase II Study Randomized, Double- or Evaluator-blind, Active- and Placebo-controlled, Single Dose, Seven-arm, Cross-over and Dose-ranging Study of A006 DPI, Albuterol Inhalation Powder, in Adult Asthma Patients [NCT01174732]	Phase 2	26 participants (Actual)	Interventional	2010-07-31	Completed
Video Assisted Study of Salbutamol Response in Viral Wheezing [NCT06093152]		50 participants (Anticipated)	Observational	2023-10-23	Not yet recruiting
Cardiovascular Consequences of Prolonged Inhaled Short-acting Beta-agonist Use in Healthy Participants [NCT06027606]	Phase 1	90 participants (Anticipated)	Interventional	2023-09-01	Recruiting
Comparison of 3% Normal Saline Nebulization Versus Steroid Nebulization in the Treatment of Bronchiolitis [NCT06139029]	Early Phase 1	60 participants (Actual)	Interventional	2022-11-15	Completed
"COPDGene Ancillary Proposal: Symbicort Intervention in Airway Predominant" [NCT01253473]	Phase 4	46 participants (Actual)	Interventional	2012-04-30	Completed
A Prospective Study on the Use of Hypertonic Saline Inhalation in Acute Bronchiolitis in Children [NCT03880903]	Phase 4	75 participants (Anticipated)	Interventional	2020-07-20	Not yet recruiting
A Phase IV, 12-week, Randomised, Double-blind, Triple Dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) With Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) Based on Lung Functi [NCT03478683]	Phase 4	729 participants (Actual)	Interventional	2018-06-25	Completed
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chro [NCT03474081]	Phase 4	800 participants (Actual)	Interventional	2018-03-29	Completed
A Randomized, Double-blind, Single Dose, Placebo-controlled, 5-Period, 5-Treatment, Crossover, Multi-center, Dose-ranging Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Mild to Moderate Asthma (AN [NCT03364608]	Phase 2	86 participants (Actual)	Interventional	2017-12-15	Completed
A Multi-centre, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Anti-IgE Monoclonal Antibody to Treat Allergic Asthma Patients Not Adequately Controlled Despite Med/High ICS/LABA. [NCT03468790]	Phase 3	393 participants (Actual)	Interventional	2018-05-09	Completed
High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease [NCT03449056]	Phase 3	25 participants (Anticipated)	Interventional	2019-01-11	Recruiting
"CONNected Electronic Inhalers Asthma Control Trial 2 (CONNECT 2), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes i [NCT04677959]	Phase 4	427 participants (Actual)	Interventional	2021-02-16	Completed
"A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist Rescue Agent With an eModule, and Exacerbations in Patients (40 Years of Age or Older) With Chronic Obstructive Pulmonary Diseas [NCT03256695]	Phase 3	405 participants (Actual)	Interventional	2017-09-28	Completed
Albuterol and Immune Cell Composition [NCT03889379]	Early Phase 1	0 participants (Actual)	Interventional	2019-01-20	Withdrawn(stopped due to Team decided not to initiate study.)
A Multi-center, Open-label, Randomized, Controlled Study to Evaluate the Effectiveness of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD [NCT03745261]	Phase 3	240 participants (Anticipated)	Interventional	2018-06-20	Recruiting
A 12-week, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT008 and PT007 Administered QID in Adults and Children 4 Years of Age or Older With Asthma [NCT03847896]	Phase 3	1,001 participants (Actual)	Interventional	2019-03-20	Completed
A Prospective, Open Label, Assessment of [an Albuterol] Hydrofluoroalkane (HFA) Metered Dose Inhaler MDI Integrated Dose Counter [NCT01302587]		306 participants (Actual)	Observational	2011-03-31	Completed
A Randomized, Single-Dose, Double-Blind, Double-Dummy, Four-Period, Four-Sequence, Four-Treatment, Placebo and Active Controlled, Comparative, Multiple-Center, Crossover-Design, Bronchoprovocation Study to Evaluate the Pharmacodynamic Equivalence of Albut [NCT03528577]	Phase 3	128 participants (Actual)	Interventional	2018-09-22	Completed
Retrospective, Real-life Observational Evaluation of the Effectiveness of Mixed Maintenance and Reliever Inhaler Types in Patients in the Management of Asthma in a Representative UK Primary Care Population [NCT01313585]		815,377 participants (Actual)	Observational	1991-01-31	Completed
A Phase 1, Randomized, Open-label, Single-dose, 3-way Cross-over Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately (LOGAN). [NCT03772223]	Phase 1	91 participants (Actual)	Interventional	2019-01-21	Completed
Randomized, Parallel Group, Phase III, Non-inferiority Study Comparing Ipratropium / Levosalbutamol Fixed Dose Combination in pMDI Form and Ipratropium and Salbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD [NCT06040424]	Phase 3	74 participants (Anticipated)	Interventional	2023-09-28	Active, not recruiting
5 Versus 10 Units of Insulin in Hyperkalemia Management: Multi-center, Prospective, Double-blind, Non-inferiority, Randomized Control Trial. [NCT06036823]	Phase 4	336 participants (Anticipated)	Interventional	2023-10-01	Recruiting
Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthm [NCT01312961]	Phase 2	104 participants (Actual)	Interventional	2011-03-31	Completed
A Phase I, Single Center, Placebo-Controlled, Blinded Pilot Study of Ipratropium Bromide in Children Admitted to the Intensive Care Unit With Status Asthmaticus [NCT02872597]	Phase 1	30 participants (Actual)	Interventional	2016-09-05	Completed
A Phase 1, Open-Label Study to Investigate the Effect of Albuterol (Salbutamol) and Fluticasone on the Pharmacokinetics of Inhaled Technosphere® Insulin Inhalation Powder in Healthy Subjects [NCT00674050]	Phase 1	13 participants (Actual)	Interventional	2008-05-31	Completed
A Multi-Center 52-Week Study to Assess the Safety of an Albuterol Dry-powder Inhaler in Subjects With Asthma [NCT01218009]	Phase 3	331 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Change to study required.)
Changes in the Lung Clearance Index as Measured by Multiple-breath Washout, in Pediatric Patients With Asthma After Challenge With Inhaled Steroids and Short-acting Bronchodilator [NCT02678949]		105 participants (Anticipated)	Interventional	2016-03-31	Not yet recruiting
Efficacy of Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation. A Randomized Controlled Trial [NCT02584738]	Phase 4	152 participants (Anticipated)	Interventional	2015-09-30	Recruiting
A Dose Response Study of Levalbuterol and Racemic Albuterol HFA MDI in Pediatric Subjects With Asthma [NCT00685347]	Phase 2	33 participants (Actual)	Interventional	2003-01-31	Completed
A Dose Response and PharmacoDynamic Study of Levalbuterol and Racemic Albuterol HFA MDI in Subjects Twelve Years of Age and Older With Asthma [NCT00685425]	Phase 3	62 participants (Actual)	Interventional	2002-10-31	Completed
Utilizing Advances in Digital Inhaler Technology to Understand Heterogeneous Treatment Responses to Biologics in Severe Asthma [NCT04997304]	Phase 4	101 participants (Actual)	Interventional	2021-07-09	Active, not recruiting
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma [NCT02414854]	Phase 3	1,902 participants (Actual)	Interventional	2015-04-27	Completed
Assessing the Effectiveness of Integrative Treatment That Combines Interior and Exterior Treatment Plans in Pediatric Pneumonia: a Program by PRC National Clinical Research Base of Traditional Chinese Medicine for Major Diseases [NCT02069665]		451 participants (Actual)	Interventional	2011-12-31	Completed
The Effect of Adding Nebulized Epinephrine in Asthma Exacerbation Management in Pediatric Age Group Compared to Standard of Care: Superiority Trial [NCT05667727]	Phase 4	30 participants (Anticipated)	Interventional	2023-10-15	Recruiting
A First in Human, Randomised, Double Blind, Placebo-controlled, Three-part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses (SAD & MAD) of Inhaled ETD002 in Healthy Male and Female Subjects [NCT04488705]	Phase 1	80 participants (Actual)	Interventional	2020-08-13	Completed
Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension [NCT02108743]	Phase 2	0 participants (Actual)	Interventional	2014-06-30	Withdrawn(stopped due to Lack of funding)
A Randomized, Double-blind, Parallel Group, 52-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 in Patients With Poorly Controlled Asthma [NCT02127697]	Phase 3	0 participants (Actual)	Interventional	2015-03-31	Withdrawn
Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate. [NCT02135965]	Early Phase 1	8 participants (Actual)	Interventional	2009-04-30	Completed
A Phase II, Randomised, Double Blind, Placebo Controlled, Seven Way Crossover Study to Assess the Effect of Single Doses of RPL554 Compared to Salbutamol and Placebo Administered by Nebuliser on Lung Function of Patients With Chronic Asthma [NCT02427165]	Phase 2	29 participants (Actual)	Interventional	2015-04-30	Completed
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma [NCT06052267]	Phase 3	2,196 participants (Anticipated)	Interventional	2023-08-30	Recruiting
A Phase 1 Study to Evaluate Safety, Toxicity, and Potential Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma [NCT05035862]	Phase 1	12 participants (Anticipated)	Interventional	2022-03-16	Recruiting
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD [NCT02573870]	Phase 2	63 participants (Actual)	Interventional	2015-12-01	Completed
Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD) [NCT01721291]	Phase 4	65 participants (Actual)	Interventional	2012-10-01	Completed
Phase 3 Study to Evaluate the Chronic-dose Safety and Efficacy of Albuterol-HFA-MDI Relative to Placebo in Pediatric Asthmatics [NCT00577655]	Phase 3	103 participants (Actual)	Interventional	2007-08-31	Completed
Albuterol Integrated Adherence Monitoring in Children With Asthma [NCT04896645]		21 participants (Actual)	Interventional	2021-06-01	Completed
A Phase III, Randomized, Double-blind, Triple-dummy, Placebo Controlled, Multicenter, 5-period, Single-dose Complete Block Crossover Study to Determine the Onset of Action of Indacaterol (150 and 300 μg) in Patients With Moderate to Severe COPD Using Salb [NCT00669617]	Phase 3	89 participants (Actual)	Interventional	2008-04-30	Completed
Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease [NCT05786950]		40 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension [NCT02782052]	Phase 3	0 participants (Actual)	Interventional	2016-07-31	Withdrawn(stopped due to Sponsor's decision)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Adult Subjects With a History of Grass Pollen Induced Rhinoconjunctivitis Wit [NCT00562159]	Phase 3	439 participants (Actual)	Interventional	2007-11-30	Completed
Single-Dose Fasting Bioequivalence Study of Albuterol Sulfate Extended-Release Tablets (8 mg; Mylan) and VoSpire® ER Tablets (8 mg; Pliva) in Healthy Volunteers [NCT00649779]	Phase 1	21 participants (Actual)	Interventional	2005-09-30	Completed
A Randomized, Double-Blind Study to Determine the Efficacy of Levalbuterol Versus Racemic Albuterol in the Treatment of Acute Asthma [NCT00667407]	Phase 3	627 participants (Actual)	Interventional	2000-11-30	Completed
Pharmacoeconomic Outcomes of Levalbuterol and Racemic Albuterol in Inpatients Requiring Nebulization (POLARIS) [NCT00667797]	Phase 4	486 participants (Actual)	Interventional	2003-03-31	Completed
Chronic Obstructive Pulmonary Disease (COPD) Lung Volume and Symptom Scores Following Bronchodilator Therapy Administration by Vibrating Mesh and Standard Jet Nebulisers: A Pilot Comparison Study [NCT02686086]		60 participants (Actual)	Interventional	2016-02-29	Completed
A Randomized, Multicenter, Placebo and Active-Controlled, Single-Dose, 4-Period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA. [NCT00646620]	Phase 3	48 participants (Actual)	Interventional	2003-04-30	Completed
Bronchodilator Test in Mechanical Ventilated Chronic Obstructive Pulmonary Disease Patients, a Randomized Controlled Trial [NCT02218398]		120 participants (Anticipated)	Interventional	2013-05-31	Recruiting
Evaluation of the Effectiveness of the Nebulization Bronchodilators Under High Nasal Flow Humidified Compared to a Usual Method [NCT02812979]		25 participants (Actual)	Interventional	2016-06-30	Completed
To Compare the Bronchoprotective Effects of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Methacholine Bronchoprovocation Challenge Testing in Stable Mild Asthma Patients. [NCT02624505]	Phase 3	110 participants (Actual)	Interventional	2015-12-31	Completed
The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD [NCT02576626]	Phase 4	40 participants (Actual)	Interventional	2015-12-31	Completed
A Randomized, Double-blind, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium 18 mcg Daily to Combivent MDI 2 Actuations Qid in COPD Patients Previously Prescribed Combivent MDI [NCT00359788]	Phase 4	349 participants (Actual)	Interventional	2006-07-31	Completed
COMPIS- Congenital Myopathy Intervention Study. An Open-label, Cross Over, Randomised, Controlled Study Using Oral Salbutamol [NCT05099107]		20 participants (Anticipated)	Interventional	2021-10-25	Enrolling by invitation
A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma [NCT00384189]	Phase 3	1,080 participants (Actual)	Interventional	2006-09-30	Completed
A Hazardous Combination of Cigarette Smoking and Bronchodilation in Chronic Obstructive Pulmonary Disease [NCT00981851]		40 participants (Anticipated)	Interventional	2009-09-30	Completed
A Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatric Subjects With Asthma [NCT00684866]	Phase 2	31 participants (Actual)	Interventional	2003-01-31	Completed
A Randomized, Open-label, Crossover Study to Assess the Safety, Tolerability, and Pharmacodynamics of PUL-042 Inhalation Solution in Healthy Subjects and the Effect of Pretreatment With Cromolyn Sodium or Albuterol Sulfate [NCT02566252]	Phase 1	16 participants (Actual)	Interventional	2015-07-31	Completed
A Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Subjects Twelve Years of Age and Older With Asthma [NCT00685022]	Phase 2	49 participants (Actual)	Interventional	2003-06-30	Completed
Safety and Efficacy of Hypertonic Vrs. Normal Saline as Diluent of Salbutamol to Reduce Respiratory Distress in Outpatients With the Clinical Diagnosis of Bronchiolitis During the RSV Epidemic. [NCT00696540]	Phase 2	74 participants (Anticipated)	Interventional	2008-06-30	Recruiting
A Safety, Efficacy, and Tolerability Study of Daily Dosing With Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to <48 Months With Asthma [NCT00809757]	Phase 3	197 participants (Actual)	Interventional	2008-12-31	Completed
Double Blind, Multinational, Multicentre, Parallel-group, Placebo-controlled Design Trial of the Efficacy and Safety of Nebulised Beclometahsone Dipropionate (400 μg b.i.d.) Plus as Needed Salbutamol Versus as Needed Salbutamol or as Needed Salbutamol/Bec [NCT00497523]	Phase 3	283 participants (Actual)	Interventional	2006-03-31	Completed
Open, Randomized, Two-Way Crossover, Pilot Study to Assess the Effect of Salbutamol in Comparison With Ipratropium Bromide on Central and Peripheral Airway Dimensions in COPD Patients [NCT00911651]	Phase 4	6 participants (Actual)	Interventional	2008-06-30	Completed
The Effect of High Dose Salbutamol on Dynamic and Isometric Muscle Power and Recovery in Well-trained Males [NCT01415596]		20 participants (Actual)	Interventional	2011-08-31	Active, not recruiting
Inhaled Hypertonic Saline to Reduce Hospital Admissions in Infants With Viral Bronchiolitis (HS in ER Study) [NCT00677729]	Phase 2	81 participants (Actual)	Interventional	2008-11-30	Completed
Comparison of Hospital Admission Rates and Plasma(s)-Albuterol Levels in Children Treated With Racemic Albuterol Versus Levalbuterol for Acute Asthma Exacerbations: A Randomized Double-Blind Clinical Trial [NCT00585039]	Phase 4	101 participants (Actual)	Interventional	2005-09-30	Completed
A Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Subjects Twelve Years of Age and Older With Asthma [NCT00684827]	Phase 2	32 participants (Actual)	Interventional	2002-10-31	Completed
A Multicenter Randomized Study Starting With a 4 Week 2 Way Crossover Double Blind Treatment Phase Comparing the Efficacy and Safety of Combivent CFC MDI to Albuterol HFA MDI Followed by a 4 Week Open Label Combivent Respimat Treatment Phase When All Stud [NCT00818454]	Phase 2	226 participants (Actual)	Interventional	2008-12-31	Completed
Effect of Bronchodilators on Respiratory Mechanics in COPD Patients With Poor Reversibility [NCT00783250]	Phase 4	20 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to Problems with data collection)
A Cumulative Dose Safety and Tolerability Crossover Study of Arformoterol Tartrate Inhalation Solution and Levalbuterol Hydrochloride Inhalation Solution in Pediatric Subjects (Aged 2 to 11 Years of Age) With Asthma [NCT00583947]	Phase 2	53 participants (Actual)	Interventional	2008-01-31	Completed
Single-Dose Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets(40 mg; Mylan) and Sular® Extended Release Tablets (40 mg; First Horizon) in Healthy Volunteers [NCT00730197]	Phase 1	48 participants (Actual)	Interventional	2007-02-28	Completed
Role of 11 Weeks of Beta2-adrenergic Signaling and Resistance Training for Cardiac and Skeletal Muscle Hypertrophy in Men [NCT02551276]		42 participants (Actual)	Interventional	2013-11-30	Completed
[NCT02592122]		120 participants (Anticipated)	Interventional	2013-10-31	Recruiting
A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma [NCT01424813]	Phase 3	158 participants (Actual)	Interventional	2012-12-31	Completed
A Randomized, Multicenter, Placebo and Active-controlled, Single-dose, 4-period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA. [NCT00646009]	Phase 3	48 participants (Anticipated)	Interventional	2003-03-31	Completed
Single-Dose Fed Bioequivalence Study of Albuterol Sulfate Extended-Release Tablets (8 mg; Mylan) and VoSpire® ER Tablets (8 mg; Pliva) in Healthy Volunteers [NCT00649987]	Phase 1	21 participants (Actual)	Interventional	2005-09-30	Completed
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SAR443765 in Healthy Adult Participants and of a Single Dose of SAR443765 in Participants With Mild-t [NCT05366764]	Phase 1	36 participants (Actual)	Interventional	2022-06-08	Completed
Dose Escalation Clinical Trial of High-dose Oral Montelukast to Inform Future RCT in Children With Acute Asthma Exacerbations [NCT05819541]	Phase 2	90 participants (Anticipated)	Interventional	2023-11-01	Recruiting
Evaluation of Aerosolized Drugs Deposition Delivered Through a Mechanical Ventilator [NCT02818270]		30 participants (Actual)	Interventional	2016-06-30	Completed
Budesonide Inhalation Suspension for Acute Asthma in Children [NCT00393367]	Phase 4	179 participants (Actual)	Interventional	2006-12-31	Completed
A Phase III, 4-week, Randomized, Double-blind Study to Compare 'Closed' Triple Therapy (FF/UMEC/VI), 'Open' Triple Therapy (FF/VI + UMEC) and Dual Therapy (FF/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [NCT02731846]	Phase 3	0 participants (Actual)	Interventional	2016-06-30	Withdrawn(stopped due to It has been determined on June 10th that the 205165 study will not progress. This decision has been made prior to study start, no patients were screened.)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Ye [NCT02513160]	Phase 3	713 participants (Actual)	Interventional	2015-09-30	Completed
Arg/Arg Genotype and Long Acting Beta Agonists in Asthma. Improved Quality of Care for Patients With Asthma. [NCT00521222]		90 participants (Actual)	Interventional	2007-06-30	Completed
Use of Buventol Easyhaler and Bufomix Easyhaler as Relievers in Methacholine Challenge Testing and Inspiratory Flow Profiles During Induced Bronchoconstriction in Adult Subjects [NCT05084222]	Phase 4	180 participants (Actual)	Interventional	2021-11-11	Completed
Role of Airway Hyperresponsiveness on Performance in Elite Swimmers: Efficiency of a Bronchodilator to Prevent an Exercise-induced Bronchoconstriction [NCT00876135]		57 participants (Actual)	Interventional	2008-12-31	Completed
A Safety, Tolerability and Efficacy Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects Birth to 48 Months Old With Reactive Airways Disease in an Acute Setting [NCT00685126]	Phase 3	117 participants (Actual)	Interventional	2001-02-28	Completed
Diagnostic Yield of Induced Sputum for Rapid Diagnosis of Pulmonary Tuberculosis [NCT00608790]		600 participants (Anticipated)	Interventional	2008-02-29	Recruiting
A Phase II, Randomised, Double Blind, Placebo Controlled, Six Way Crossover Study to Assess the Bronchodilator Effect of RPL554 Administered on Top of Salbutamol and Ipratropium in Patients With COPD. [NCT02542254]	Phase 2	36 participants (Actual)	Interventional	2015-10-31	Completed
Beta2-mimetic and Central Nervous System: Effects of Salbutamol on Cortical Excitability and Cerebral Activation [NCT02925130]		15 participants (Actual)	Interventional	2016-10-31	Completed
Assessment of Ventilation-perfusion Abnormalities in Patients With Smoking-related Airways Disease in Stable Condition and the Effect of Bronchodilator Therapy [NCT00180843]		2 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to lack of resources research fellow left)
"Interventional Study: Hypertonic Saline as Add on Treatment to the Usual Therapy for Preschool Children With Acute Asthmatic Attack Presenting to the ER: A Double Blind Control Study" [NCT01073527]		41 participants (Actual)	Interventional	2009-01-31	Completed
A Proof of Concept Study to Evaluate the Peak Bronchoprotection Conferred by Single and Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics. [NCT00830882]	Phase 4	0 participants (Actual)	Interventional	2009-01-31	Withdrawn(stopped due to Lack of funding)
Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI (PROAIR™ HFA (Albuterol Sulfate) Breath Actuated Inhalation Aerosol) in Pediatric Asthmatics [NCT00308685]	Phase 3	95 participants (Actual)	Interventional	2006-06-10	Completed
Asthma Control Assessment Via ACT and DRC in Asthmatics Treated With Seretide (50/250) Over 12 Weeks [NCT00363480]	Phase 4	221 participants (Actual)	Interventional	2006-05-17	Completed
Assessment of Bronchodilator Responsiveness in Healthy Young Adults Using Forced Oscillations [NCT01067534]		100 participants (Anticipated)	Interventional	2010-02-28	Completed
Patient Acceptability of Ipratropium Bromide/Albuteroll Delivered by the Respimat® Inhaler in Adults With Chronic Obstructive Pulmonary Disease [NCT01019694]	Phase 3	470 participants (Actual)	Interventional	2009-11-30	Completed
Evaluation of 3D Magnetic Resonance Spirometry : Comparison to Spirometry in Healthy Subjects and Patients With Asthma and COPD [NCT05724745]		75 participants (Anticipated)	Interventional	2023-02-28	Not yet recruiting
The Pharmacogenetic Effects of Inhaled Salbutamol on Breathing Mechanics and Cycling Performance [NCT01903785]	Phase 4	94 participants (Actual)	Interventional	2013-05-31	Completed
Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers [NCT04722835]		40 participants (Anticipated)	Observational	2021-03-01	Recruiting
Inhaled Salbutamol in Elective Caesarean Section [NCT01978418]	Phase 4	62 participants (Anticipated)	Interventional	2013-11-30	Recruiting
An Open-label, Randomised, Cross-over, Two Cohort, Single Dose Study in Healthy Volunteers to Evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) for the Delivery of Salbutamol and to Compare the Pharmacokinetic Profile With the MDI and Diskus Presentation [NCT01984086]	Phase 1	60 participants (Actual)	Interventional	2013-10-21	Completed
A Stepwise, Rising Dose Study of Male Subjects With Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI Compared With Placebo Acu-30™ DPI [NCT00565591]	Phase 1	12 participants (Actual)	Interventional	2007-11-30	Completed
Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial [NCT04584034]	Phase 4	0 participants (Actual)	Interventional	2021-09-30	Withdrawn(stopped due to Premature ending of the study due to impossibility of obtaining a suitable placebo-inhaler)
Response to Bronchodilation With Tiotropium Plus Salbutamol Correlates With Radiologic Morphology of the Lung in COPD of the Emphysematous Phenotype [NCT02008162]		60 participants (Anticipated)	Observational	2009-11-30	Recruiting
A Randomised, Open-Label, Four Period, Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate From FLIXOTIDE™ 250 HFA pMDI and of Fluticasone Propionate and Salmeterol From SERETIDE™ 250/25 HFA pMDI When Given With the VENTOLIN Mini-Spa [NCT02045953]	Phase 1	21 participants (Actual)	Interventional	2014-01-29	Completed
A Study to Determine the Reliability of a Top Mount Actuation Indicator When Used With Levalbuterol Tartrate HFA MDI in Adult and Pediatric Subjects With Asthma or Chronic Obstructive Pulmonary Disease [NCT00583986]	Phase 3	150 participants (Actual)	Interventional	2005-09-30	Completed
Cost Effectiveness Analysis of a Randomized Control Trial of q3h vs. q4h Albuterol as Discharge Criteria From the Hospital for Pediatric Asthma Exacerbations [NCT04542005]		0 participants (Actual)	Interventional	2020-12-31	Withdrawn(stopped due to Funding not obtained)
Influence of Salbutamol on Emotional and Cognitive Functions in Healthy Subjects [NCT01957293]	Phase 2	40 participants (Actual)	Interventional	2013-10-31	Completed
Controlled Randomized Double-blind Study Comparing Salbutamol and Placebo Via Aerosol in Chronic Obstructive Respiratory Insufficiency in Exacerbartion Treated With Noninvasive Ventilation [NCT01958814]	Phase 2	43 participants (Actual)	Interventional	2012-02-29	Completed
Non-Invasive Mechanical Ventilation in Elderly Patients Affected by Acute Hypercapnic Respiratory Failure:A Randomized Control Study vs Standard Medical Therapy A Multicentric Randomized Controlled Trial [NCT00600639]	Phase 4	82 participants (Actual)	Interventional	2004-01-31	Terminated
A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With [NCT01323621]	Phase 3	512 participants (Actual)	Interventional	2011-03-18	Completed
Double-blind, Crossover, Placebo-controlled Evaluation of the Effect of Levalbuterol (R-albuterol) on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma [NCT00320034]	Phase 2	15 participants (Anticipated)	Interventional	2006-04-30	Completed
Nebulized Salbutamol Facilitate Management of Hyperkalemia Postreperfusion During Liver Transplantation: a Single-center, Randomized, Positive-controlled Clinical Study [NCT05589441]		100 participants (Anticipated)	Interventional	2022-10-28	Not yet recruiting
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation [NCT03562195]	Phase 3	300 participants (Actual)	Interventional	2018-08-29	Completed
A Phase 1, Open-Label, Controlled Clinical Trial to Evaluate Pharmacokinetics After Administration of Technosphere® Insulin Inhalation Powder Alone and With Salbutamol (Albuterol) and/or After Methacholine Challenge Testing in Subjects With Asthma Versus [NCT00673621]	Phase 1	30 participants (Actual)	Interventional	2008-05-31	Completed
Prospective Trial of Effect of Nebulized Bronchodilators on Heart Rate and Arrhythmias in Critically Ill Adult Patients [NCT01151579]	Phase 4	89 participants (Actual)	Interventional	2008-12-31	Completed
A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Sev [NCT01120691]	Phase 3	2,224 participants (Actual)	Interventional	2010-04-30	Completed
A Study to Investigate the Relative Efficacy of Terbutaline Turbuhaler® 0.4 mg and Salbutamol Pressurized Metered Dose Inhaler (pMDI) 200 μg - a Single Blind, Single Dose, Randomized, Crossover, Phase III Study in Japanese Adult Asthma Patients [NCT01096017]	Phase 3	24 participants (Actual)	Interventional	2010-03-31	Completed
Measurements of Change of Respiratory Admittance Induced by Salbutamol for Pediatric Asthma Diagnosis [NCT02877537]	Phase 4	177 participants (Actual)	Interventional	2008-10-31	Completed
Individual beta2-adrenergic Performance Response to Salbutamol [NCT04615611]		20 participants (Anticipated)	Interventional	2020-11-07	Not yet recruiting
The Effect of β2 Genetic Polymorphisms on the Brochodilatation Effect of Albuterol ex-Vivo [NCT00162422]		150 participants (Anticipated)	Interventional	2003-08-31	Recruiting
A Single Dose, Randomized, Double-blind Crossover Comparison of Combivent CFC MDI and Albuterol HFA MDI in Patients With Moderate to Severe Persistent Asthma and Persistent Symptoms Despite Treatment With Inhaled Corticosteroids [NCT00096616]	Phase 2	113 participants (Actual)	Interventional	2004-11-30	Completed
48-week,Multinational,Randomized,Double-blind,2-parallel Groups,Comparing the Efficacy of Foster for Maintenance and Reliever Versus Fixed-dose Foster for Maintenance Plus Salbutamol as Reliever in Asthmatics >=18 Years of Age [NCT00861926]	Phase 3	2,079 participants (Actual)	Interventional	2009-03-31	Completed
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients [NCT05860244]	Phase 2	36 participants (Anticipated)	Interventional	2023-06-30	Not yet recruiting
[NCT01447069]		30 participants (Anticipated)	Interventional	2011-10-31	Not yet recruiting
Response of Asthmatic Children's Lung Function to Nebulized Magnesium Sulfate After Acetylcholine Provocation Test: a Clinical Trail [NCT01856959]		330 participants (Actual)	Interventional	2011-11-30	Completed
A Clinical Investigation of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease, Whether or Not Receiving Enzyme Replacement Therapy [NCT01859624]	Phase 1	8 participants (Actual)	Interventional	2012-06-30	Completed
The Effect of Inhaled Salbutamol on Sprint Performance During and After Submaximal Endurance Exercise in Non-asthmatic Athletes [NCT04402658]		0 participants (Actual)	Interventional	2022-08-01	Withdrawn(stopped due to Problem with acquiring study medication and lack of resources.)
Characterization of Placebo Responses in Stable Asthma [NCT01143688]		39 participants (Actual)	Interventional	2005-01-31	Completed
A Safety and Tolerability Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects Birth to ≤ 48 Months of Age With Reactive Airways Disease in an Acute Setting [NCT02150499]	Phase 3	18 participants (Actual)	Interventional	2014-07-31	Terminated
A Randomised Double-blind (Sponsor Open), Placebo Controlled, Single Ascending Dose, First Time in Human Study in Participants With Mild to Moderate Asthma to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3511294 [NCT03287310]	Phase 1	50 participants (Actual)	Interventional	2017-10-17	Completed
Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma - Randomized, Controlled Trial. [NCT00487773]	Phase 4	96 participants (Actual)	Interventional	2007-09-30	Completed
Does Inhaled Salbutamol Prevent Lung Edema After Thoracic Surgery? A Randomized Controlled Study [NCT00498251]		30 participants (Actual)	Interventional	2004-09-30	Completed
To Compare the Bronchoprotective Effects of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Methacholine Bronchoprovocation Challenge Testing in Stable Mild Asthma Patients. [NCT06154304]	Phase 3	120 participants (Anticipated)	Interventional	2023-12-11	Not yet recruiting
Multicentre, Multinational, Randomised, Double Blind, Double Dummy, Active Drug Controlled, Parallel Group Study Design Clinical Trial of the Efficacy and Tolerability of Beclomethasone Dipropionate 250 mcg Plus Salbutamol 100 mcg in HFA pMDI Fixed Combin [NCT00528723]	Phase 3	180 participants (Anticipated)	Interventional	2007-11-30	Completed
A Randomized, Parallel Group, Phase III, Non-inferiority Study Comparing Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD [NCT05890638]	Phase 3	74 participants (Anticipated)	Interventional	2023-08-25	Recruiting
A Study to Optimise the Propranolol Block Model for Assessment of the Pharmacological Activity of Bronchodilators in Healthy Volunteers. [NCT00549120]	Phase 1	18 participants (Actual)	Interventional	2007-08-15	Completed
The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial [NCT02914652]	Phase 4	96 participants (Actual)	Interventional	2016-10-15	Completed
A Phase 4, Open-label, Single Arm, 24-week, Study to Evaluate the Safety and Efficacy of Mepolizumab 100 mg SC Administered Every 4 Weeks in Indian Participants Aged ≥18 Years With Severe Eosinophilic asthMa (PRISM) [NCT04276233]	Phase 4	100 participants (Anticipated)	Interventional	2021-06-29	Recruiting
A Randomized, Single-dose, Double-blind, Double-dummy, Placebo and Active Controlled, Crossover Design Study Using Bronchoprovocation to Evaluate the Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol S [NCT04912596]		148 participants (Anticipated)	Interventional	2022-08-15	Recruiting
Comparison of Benzalkonium Chloride Containing Albuterol Versus Preservative Free Albuterol for the Treatment of Status Asthmaticus [NCT02966184]	Phase 4	8 participants (Actual)	Interventional	2018-09-10	Terminated(stopped due to Study Drug Backorder)
A Multi-enter, Randomized, Double-blind, Placebo-controlled, Four-way Incomplete Block Crossover Study to Examine Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Repeat Administration of Three Inhaled Doses (10, 15, and [NCT00358488]	Phase 2	54 participants (Actual)	Interventional	2006-04-30	Completed
Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study [NCT00361452]	Phase 4	30 participants	Interventional	2000-12-31	Terminated
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC [NCT06152653]	Phase 4	20 participants (Anticipated)	Interventional	2023-11-21	Recruiting
An Efficacy, Safety, and Tolerability Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma [NCT00073814]	Phase 3	80 participants (Actual)	Interventional	2002-12-31	Completed
An Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Versus Placebo in Prevention of EIB in Subjects 18 Years of Age and Older With EIB [NCT00268723]	Phase 3	15 participants (Actual)	Interventional	2005-12-31	Completed
Measurement of Exertional Dyspnea in the Primary Care Setting in Patients With COPD, Phase III: Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With COPD [NCT01655199]		40 participants (Anticipated)	Interventional	2012-09-30	Recruiting
The Role of Conformational Diseases on Macrophage Function [NCT01851642]		220 participants (Anticipated)	Observational	2007-08-09	Recruiting
A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 or Albuterol in Subjects With Persistent Asthma [NCT05363670]	Phase 2	30 participants (Anticipated)	Interventional	2022-07-28	Recruiting
A Randomised, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Currently Receiving Mid to High Strength Inhaled Corticosteroids. [NCT01431950]	Phase 3	238 participants (Actual)	Interventional	2011-09-30	Completed
A Double-blind, Randomized, Placebo-controlled, 5-way Crossover, Multicenter, Single-dose, Dose-ranging Study to Compare the Efficacy and Safety of Albuterol Spiromax® and ProAir® HFA in Adult and Adolescent Subjects Ages 12 and Older With Persistent Asth [NCT01058863]	Phase 2	72 participants (Actual)	Interventional	2010-02-28	Completed
Bronchoprotection of Salbutamol in Asthma and COPD [NCT00440245]	Phase 4	28 participants (Actual)	Interventional	2007-02-28	Completed
A Phase II Study to Investigate Mannitol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD [NCT00117182]	Phase 2	140 participants	Interventional	2005-07-31	Completed
A Randomized, Double-Blind, Parallel-group, Multi-Center Study of Albuterol Sulfate HFA Inhalation Aerosol Delivered Cumulatively With a Valved Holding Chamber and an Attached Facemask in Subjects Between Birth to 23 Months of Age With Acute Wheezing Due [NCT00144846]	Phase 3	80 participants (Actual)	Interventional	2004-09-30	Completed
Evaluation of Genetic Factors That May Account for Variability in the Response to Salbutamol Among Patients Suffering From Asthma [NCT00162396]		150 participants (Anticipated)	Interventional	1999-08-31	Recruiting
Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® HFA in Pediatric Patients With Persistent Asthma [NCT01844401]	Phase 1	15 participants (Actual)	Interventional	2013-04-30	Completed
Acute Bronchodilator Responsiveness in Obliterative Bronchiolitis (OB) Following Hematopoietic Stem Cell Transplantation [NCT01112241]	Phase 4	17 participants (Actual)	Interventional	2010-04-30	Completed
Predictive Value of Within-breath Respiratory Input Impedance in the Early Diagnosis of Obliterative Bronchiolitis After Allogeneic Hematopoietic Stem Cell Transplantation [NCT01255449]		26 participants (Actual)	Interventional	2010-12-31	Completed
A RANDOMIZED, DOUBLE BLIND, MULTIPLE DOSING (14 DAYS), PLACEBO-CONTROLLED, INCOMPLETE BLOCK CROSSOVER, MULTI CENTER STUDY TO ASSESS EFFICACY AND SAFETY OF THREE DOSE LEVELS OF AZD7594, GIVEN ONCE DAILY BY INHALATION, IN PATIENTS WITH MILD TO MODERATE ASTH [NCT02479412]	Phase 2	54 participants (Actual)	Interventional	2015-06-25	Completed
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease ( [NCT01331694]		76,130 participants (Actual)	Observational	2009-07-31	Completed
Cumulative Dose Comparison of the Efficacy and Safety of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler) in Adult Patients With Asthma [NCT01056159]	Phase 1	47 participants (Actual)	Interventional	2010-01-31	Completed
Effect of LY2216684 on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Albuterol or Propranolol [NCT01263197]	Phase 1	48 participants (Actual)	Interventional	2010-12-31	Completed
Influence of Mechanical Ventilation Modes on the Efficacy of Nebulized Bronchodilator in the Treatment of Patients With Obstructive Pulmonary Disease [NCT03271905]		10 participants (Anticipated)	Interventional	2017-04-10	Active, not recruiting
[NCT00462540]	Phase 3	100 participants (Anticipated)	Interventional	2007-05-31	Completed
A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Severe Persistent Asthma Uncontrolled on High [NCT01576718]	Phase 2	889 participants (Actual)	Interventional	2012-04-30	Completed
Effect of the Use of Salbutamol on the Mechanical Properties of the Respiratory System of Healthy Individuals, Smokers and COPD Patients [NCT01521572]		200 participants (Anticipated)	Interventional	2011-06-30	Recruiting
A Randomized, Single-dose, Open-label, Two-way Crossover Pivotal Study to Assess the Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation (MDI, eq. to Albuterol 90mcg/Puff) and Proair HFA (Albuterol Sulfate) Inhalation Aerosol [NCT05300087]		60 participants (Actual)	Interventional	2022-02-24	Completed
A Randomized, Single-dose, Open-label, Two-way Crossover Pivotal Study to Assess the Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation (MDI, eq. to Albuterol 90mcg/Puff) and Proair HFA (Albuterol Sulfate) Inhalation Aerosol [NCT04803734]		60 participants (Actual)	Interventional	2021-03-19	Completed
Efficacy and Safety of Increasing Doses of Inhaled Albuterol Administered by Metered Dose Inhalers in Children With Acute Wheezing Episodes [NCT01323010]		119 participants (Actual)	Interventional	2011-09-30	Completed
Randomized Controlled Trial of Epinephrine and Albuterol in Bronchiolitis [NCT00114478]		600 participants	Interventional	2003-11-30	Active, not recruiting
A Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group, 4-Week Study to Evaluate the Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Patients With Asthma in Pediatric Patients With Asthma [NCT00634517]	Phase 3	48 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to IND voluntarily withdrawn, without prejudice)
Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department [NCT00388739]		0 participants (Actual)	Interventional	2006-11-01	Withdrawn(stopped due to Different study was designed)
Clinical Trials of Albuterol and Oxandrolone in FSH Dystrophy [NCT00027391]		160 participants	Interventional	2001-09-30	Completed
Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol [NCT00039988]		40 participants (Actual)	Interventional	2001-11-30	Completed
A Double-Blind, Randomized, Multicenter, Parallel-Group Study of Levalbuterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease [NCT00665600]	Phase 3	257 participants (Actual)	Interventional	2002-02-28	Completed
An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma [NCT00073840]	Phase 3	386 participants (Actual)	Interventional	2002-12-31	Completed
"CONNected Electronic Inhalers Asthma Control Trial 1 (CONNECT 1), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outc [NCT03890666]	Phase 4	333 participants (Actual)	Interventional	2020-10-26	Completed
A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients Presenting to the Emergency Department and to Evaluate Its Side Effect and Safety Profile When Used in This Clinical Situation. [NCT00819637]	Phase 4	2 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to Unable to enroll r/t study design & staffing issues. The trial terminated.)
Personalized Medicine, Biomarker-based Study of Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study [NCT01196377]		16 participants (Actual)	Interventional	2010-09-30	Completed
Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma [NCT00064389]	Phase 3	746 participants (Actual)	Interventional	2003-01-31	Completed
An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma [NCT00073827]	Phase 3	445 participants (Actual)	Interventional	2002-05-31	Completed
Evaluation of β2 Genetic Polymorphisms and the Effect of Albuterol Inhalation on Potassium and Glucose Plasma Concentration [NCT00162487]		150 participants (Anticipated)	Interventional	2002-08-31	Recruiting
Fluticasone Furate/Vilaterol in Exercising Asthmatic Adolescents: a Randomized and Open Label Trial [NCT04750603]	Phase 4	92 participants (Actual)	Interventional	2018-12-01	Completed
Prospective, Randomized, Multicenter Trial of Aerosolized Albuterol Versus Placebo in Acute Lung Injury [NCT00434993]	Phase 2/Phase 3	282 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to Stopped for futility by DSMB)
Comparison of Parasympathetic Activity in Mild, Moderate, and Severe Asthma With Fixed Airway Obstruction [NCT05550402]		60 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Effect of Tiotropium on Airway Remodeling in Patients With Early Stage COPD Accessed by Optical Coherence Tomography [NCT03842839]		100 participants (Anticipated)	Interventional	2018-10-01	Recruiting
A Randomised, Double-blind, Placebo-controlled Trial Assessing the Efficacy of SLITone in House Dust Mite Allergic Patients [NCT00633919]	Phase 2/Phase 3	124 participants (Actual)	Interventional	2006-07-31	Completed
A Prospective, Randomized, Controlled, Single Center Trial of the Use of Heliox in Children Admitted to the Hospital With Status Asthmaticus [NCT00410150]	Phase 2	42 participants (Actual)	Interventional	2006-04-30	Terminated(stopped due to Study was stopped after interim analysis and slow enrollment.)
Effect on Body Composition With Albuterol and Caffeine Versus Placebo in Adolescents: A Pilot Study [NCT02740660]		12 participants (Actual)	Interventional	2016-04-30	Completed
A Single-Dose Study to Assess the Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB) [NCT01791972]	Phase 3	38 participants (Actual)	Interventional	2013-03-31	Completed
Dose-response of Salmeterol Delivered by Advair Diskus in Children: Bioassay by Methacholine Challenge Using Oscillometry as the Endpoint [NCT01907334]	Phase 4	10 participants (Actual)	Interventional	2013-08-31	Completed
Efficacy, Dose-ranging and Safety Evaluation (A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Single Dose, Five-arm, Crossover, and Dose-ranging Study of A006 in Adult Asthma Patients) [NCT02210806]	Phase 2	22 participants (Actual)	Interventional	2014-07-31	Completed
Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers (A Randomized, Double- or Evaluator-blinded, Single-dose, Four-arm, Crossover Pharmacokinetics (PK) Study in Healthy Adults) [NCT02271334]	Phase 2	22 participants (Actual)	Interventional	2014-08-31	Completed
A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Mul [NCT00252863]	Phase 3	1,600 participants	Interventional	2004-12-31	Completed
A Randomized Double Blind Comparison Between Single Doses of Symbicort Turbuhaler (Budesonide/Formoterol Combination), Formoterol, Salbutamol and Placebo in Repeated AMP-challenges in Patients With Mild - to Moderate Asthma. Investigating the Supplementar [NCT00272753]	Phase 4	20 participants	Interventional	2004-04-30	Completed
"Pretreatment With Albuterol vs. Montelukast in Exercise Induced Bronchospasm in Children." [NCT00273689]	Phase 4	13 participants (Actual)	Interventional	2005-12-31	Completed
A Comparison of Combivent® UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg) in a Double-Blind Efficacy and Safety Study in Asthmatic Children With Severe Acute Exacerbation [NCT00273962]	Phase 4	500 participants (Actual)	Interventional	2002-05-31	Completed
Steroid-sparing Management of the Salmeterol/Fluticasone 50/100µg b.i.d. Combination Compared to Fluticasone 200µg b.i.d. in Children and Adolescents With Moderate Asthma [NCT00315744]	Phase 4	285 participants (Actual)	Interventional	2004-11-04	Completed
Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS) [NCT00319488]		238 participants (Actual)	Interventional	2004-02-29	Completed
Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol [NCT00325767]	Phase 4	10 participants	Interventional	2004-05-31	Completed
The Effect of Nebulized Albuterol on Donor Oxygenation [NCT00310401]	Phase 2	506 participants (Actual)	Interventional	2007-04-30	Completed
Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA) [NCT00394329]	Phase 3	288 participants (Actual)	Interventional	2006-11-30	Completed
An Efficacy, Safety, and Tolerability Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma [NCT01656811]	Phase 2	146 participants (Actual)	Interventional	2001-10-31	Completed
The Cost Effectiveness of School-Based Supervised Asthma Therapy [NCT01997463]	Phase 4	442 participants (Actual)	Interventional	2014-08-31	Completed
The Development of Procedures to Optimalize the Intensive Care Units Patients Clinical Condition. Evaluation of Influence of Nebulized Bronchodilatory Drugs on Cardiac Repolarization [NCT01714401]		50 participants (Actual)	Interventional	2012-03-31	Completed
Non-Invasive HaemoDYNAMICs in Primary and Secondary Hypertension: the DYNAMIC-study [NCT01742702]		2,000 participants (Anticipated)	Observational	2006-05-25	Recruiting
A Randomized, Parallel Group Study to Evaluate the Effect of Umeclidinium (UMEC) Added to Inhaled Corticosteroid/ Long-acting Beta-agonist Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease COPD [NCT02257372]	Phase 4	236 participants (Actual)	Interventional	2014-09-30	Completed
A Randomised, Double-blind, Two-way Crossover Study to Investigate the Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma [NCT02502734]	Phase 3	60 participants (Actual)	Interventional	2015-09-07	Completed
A Randomised Open-label Study to Compare the Effectiveness of the Fixed Dose Combination of FF/UMEC/VI (Using the Connected Inhaler System) With the Combination of FP/SAL Plus Tiotropium (Without the Connected Inhaler System) in Participants With Inadequa [NCT03376932]	Phase 3	0 participants (Actual)	Interventional	2019-01-18	Withdrawn(stopped due to withdrawn due to internal reasons)
Ivermectin Will be Used as an Outpatient Treatment Option for COVID-19 Patients. [NCT05045937]		1,000 participants (Anticipated)	Observational [Patient Registry]	2022-05-01	Recruiting
Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison With Levalbuterol in Healthy Adult Volunteers [NCT02802111]		24 participants (Actual)	Interventional	2015-06-30	Completed
Comparative Effectiveness of COPD Assessment and Management Bundle Versus Usual Care in Patients Suspected of Having COPD [NCT01833026]		56 participants (Actual)	Interventional	2013-03-31	Completed
A Multicentre, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Determine the Efficacy and Safety of Nebulized Fluticasone Propionate 1mg Twice Daily Compared With Oral Prednisone Administered for 7 Days to Chinese Pediat [NCT01687296]	Phase 3	261 participants (Actual)	Interventional	2012-11-12	Completed
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With a History of Grass Pollen Induced Rhinoconjunctivi [NCT00550550]	Phase 3	345 participants (Actual)	Interventional	2007-11-30	Completed
Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma [NCT02566902]		118 participants (Actual)	Interventional	2015-10-31	Completed
Multi-center, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Crossover Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg in Stable Mild Asthma Patients [NCT05292976]	Phase 3	0 participants (Actual)	Interventional	2022-04-30	Withdrawn(stopped due to Business reasons)
Effect of Inhaled Albuterol on Pulmonary Hemodynamics in Patients With Group 1 Pulmonary Arterial Hypertension on Oral Pulmonary Vasodilator Therapy: A Proof of Concept Study [NCT03270332]	Phase 2	10 participants (Actual)	Interventional	2017-10-05	Completed
[NCT00005110]		0 participants	Interventional		Suspended
Comparison of Single-Dose Efficacy of Albuterol-HFA-BAI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability [NCT00530062]	Phase 4	49 participants (Actual)	Interventional	2007-07-25	Completed
Examining the Effect of Salbutamol Use in Asthma and/or Exercise Induced Bronchoconstriction Whilst Exercising in Ozone Air Pollution [NCT05087693]	Phase 4	30 participants (Anticipated)	Interventional	2021-11-01	Recruiting
A 24-week Randomised Exploratory Open-Label Study Aiming To Characterise Changes In Airway Inflammation, Symptoms, Lung Function, And Reliever Use In Asthma Patients Using SABA (Salbutamol) Or Anti-Inflammatory Reliever (SYMBICORT®) As Rescue Medication I [NCT03924635]	Phase 4	40 participants (Actual)	Interventional	2019-08-01	Completed
Randomized, Double-Blind, Controlled, Single-Dose, Three-Treatment, Cross-Over Study of The Protective Effects Of Albuterol-HFA In Preventing Exercise-Induced Bronchoconstriction In Adolescent And Adult Asthmatic Patients [NCT00634829]	Phase 3	24 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to IND voluntarily withdrawn, without prejudice)
Randomized Control Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children [NCT02458482]		0 participants (Actual)	Interventional	2015-07-31	Withdrawn(stopped due to The trainee for whom I designed the study did not begin enrollment and has left our institution.)
A Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF) [NCT01457261]	Phase 1	10 participants (Actual)	Interventional	2012-04-30	Completed
The Effect of an Oral Beta-2 Agonist on Respiratory Muscle Strength in SCI [NCT02508311]	Phase 4	5 participants (Actual)	Interventional	2016-06-01	Active, not recruiting
Evaluation of Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis and Its Impact on Exercise Limitation [NCT02523833]		27 participants (Actual)	Interventional	2015-09-01	Completed
A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No [NCT01471340]	Phase 4	11,744 participants (Actual)	Interventional	2012-01-09	Completed
Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease [NCT02405598]	Phase 4	14 participants (Actual)	Interventional	2013-10-31	Completed
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists [NCT05457868]		124,117 participants (Actual)	Observational	2021-02-01	Active, not recruiting
Novel Nano-vesicles of Salbutamol Sulphate in Metered Dose Inhalers: Formulation, Characterization, In Vitro and In Vivo Evaluation [NCT03059017]	Phase 1	20 participants (Actual)	Interventional	2017-02-05	Completed
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype [NCT04901715]	Early Phase 1	30 participants (Anticipated)	Interventional	2021-06-10	Recruiting
Exclusion of Asthmatics From Clinical Trials Due to the 15 Percent Rule [NCT00940927]	Phase 4	81 participants (Actual)	Interventional	1993-07-31	Completed
A 12-week Comparison of the Efficacy and Safety and Steady-State Pharmacokinetics of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma [NCT01747629]	Phase 3	160 participants (Actual)	Interventional	2012-12-31	Completed
A Single-Dose, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Period Crossover, Dose-Ranging Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® HFA in Pediatric Patients With Persistent Asthma [NCT01899144]	Phase 2	61 participants (Actual)	Interventional	2013-07-31	Completed
Continuous Levalbuterol for Treatment of Status Asthmaticus in Children [NCT00124176]	Phase 4	81 participants (Actual)	Interventional	2004-04-30	Completed
A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter [NCT01857323]	Phase 3	317 participants (Actual)	Interventional	2013-05-31	Completed
Randomized, Placebo-Controlled, Parallel, Multi-Center, 12-Week Study to Evaluate the Efficacy and Safety of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Adult and Adolescent Asthmatic Patients [NCT00635505]	Phase 3	300 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to IND voluntarily withdrawn, without prejudice)
InSaKa Trial: Insulin Dextrose Infusion Versus Nebulized Salbutamol Versus Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia: a Randomized Clinical Trial [NCT04012138]	Phase 4	525 participants (Anticipated)	Interventional	2019-12-20	Recruiting
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently P [NCT00388882]	Phase 4	327 participants (Actual)	Interventional	2006-10-04	Completed
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma [NCT01854047]	Phase 2	776 participants (Actual)	Interventional	2013-06-30	Completed
A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial [NCT01313494]	Phase 3	626 participants (Actual)	Interventional	2011-03-31	Completed
Asthma Clinical Research Network (ACRN) [NCT00000577]	Phase 3	0 participants (Actual)	Interventional	1993-09-30	Withdrawn(stopped due to Record is an ACRN grant summary & not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.)
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vilanterol on Exercise Endurance Time in Subjects With COPD [NCT02275052]	Phase 4	198 participants (Actual)	Interventional	2015-01-23	Completed
A Randomised, Multi-centre, Open Label, Cross-over Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of Neumoterol 400 and Symbicort Forte in Adults With Asthma [NCT02233803]	Phase 4	239 participants (Actual)	Interventional	2014-11-14	Completed
A Phase III, 24 Week, Randomized, Double Blind, Double Dummy, Parallel Group Study (With an Extension to 52 Weeks in a Subset of Subjects) Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI Administered Once Da [NCT02345161]	Phase 3	1,811 participants (Actual)	Interventional	2015-01-23	Completed
A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma [NCT02175771]	Phase 3	758 participants (Actual)	Interventional	2014-07-31	Completed
A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects With Chronic Obstructive Pulmonary Disease (COPD) [NCT02299375]	Phase 2	184 participants (Actual)	Interventional	2014-12-09	Completed
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of Once-daily Inhaled Fluticasone Furoate Inhalation Powder for Six Weeks on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma [NCT02483975]	Phase 3	111 participants (Actual)	Interventional	2015-10-09	Completed
Repeat Emergency Department Visits Among Patients With Asthma and COPD [NCT02499887]		6 participants (Actual)	Interventional	2016-01-31	Terminated(stopped due to Exclusion criteria prevented enrollment of adequate # of participants)
Multinational, Double Blind, Randomised, Parallel Group Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate 250 mg Combined With Salbutamol 100 mg in the Treatment of Patients With Mild Persistent Asthma. [NCT00382889]	Phase 3	480 participants	Interventional	2002-08-31	Completed
A 4-Week Randomized Cross-Over Study to Evaluate Daily Lung Function Following the Administration of Albuterol/Salbutamol and Ipratropium in Subjects With Chronic Obstructive Pulmonary Disease [NCT01691482]	Phase 4	56 participants (Actual)	Interventional	2012-07-23	Completed
The Effects of Bronchodilator Therapy On Respiratory and Autonomic Function in Patients With Familial Dysautonomia [NCT01987219]	Phase 3	15 participants (Actual)	Interventional	2013-03-31	Completed
The Effect of NAC on Lung Function and CT Mucus Score [NCT03822637]	Phase 4	30 participants (Anticipated)	Interventional	2019-02-20	Recruiting
A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control and Pari Nebulization for the Treatment of Adults With Moderate Asthma [NCT00385359]	Phase 4	10 participants	Interventional	2006-10-31	Recruiting
SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treat [NCT04159519]	Phase 4	168 participants (Actual)	Interventional	2020-07-27	Completed
Safety and Efficacy of Aerosolized Albuterol in Mechanically Ventilated Infants With Bronchopulmonary Dysplasia (BDP) [NCT02766673]		24 participants (Actual)	Interventional	2016-08-31	Completed
Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial [NCT02885636]	Phase 3	30 participants (Actual)	Interventional	2016-09-30	Completed
Comparison of Doses of Nebulized Magnesium Sulphate as an Adjuvant Treatment With Salbutamol in Children With Status Asthmaticus [NCT04929626]	Phase 1	126 participants (Actual)	Interventional	2022-01-01	Completed
A Randomized, Double-blind, Parallel Group, 26-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 Given Once or Twice Daily, in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease [NCT02371629]	Phase 4	776 participants (Actual)	Interventional	2015-06-24	Completed
Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn [NCT05006235]	Phase 1	135 participants (Actual)	Interventional	2014-02-01	Completed
Study on Dose-response to Bronchodilator Then Bronchodilator Dose-finding Using the Flow Interruption Technique in Children Aged 2.5 TO 6 Years [NCT01470755]	Phase 2	90 participants (Actual)	Interventional	2012-01-31	Completed
A Phase-II, Randomized, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Safety of MK-1029 in Adult Subjects With Persistent Asthma That is Uncontrolled While Receiving Montelukast. [NCT02720081]	Phase 2	142 participants (Actual)	Interventional	2016-05-11	Completed
A Prospective Open Randomized Clinical Trial of Non-invasive Ventilation Versus Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma. [NCT03296579]		100 participants (Anticipated)	Interventional	2018-06-30	Not yet recruiting
A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptom [NCT02141854]	Phase 3	882 participants (Actual)	Interventional	2014-06-30	Completed
Comparison of the Pharmacodynamic Profile of Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Bronchoprovocation in Adult Patients With Stable Mild Asthma [NCT02584257]	Phase 3	217 participants (Actual)	Interventional	2016-04-30	Completed
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler [NCT02040766]	Phase 3	628 participants (Actual)	Interventional	2013-12-31	Completed
A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler [NCT02031640]	Phase 3	1,113 participants (Actual)	Interventional	2013-12-31	Completed
Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes [NCT04184609]	Phase 4	0 participants (Actual)	Interventional	2023-07-01	Withdrawn(stopped due to Funding ran out before participants were enrolled.)
Comparison of a Breath Enhanced High Density Jet Nebulizer With a Standard Jet Nebulizer for the Treatment of Children With a Moderate to Severe Asthma Exacerbation in the Emergency Department [NCT01951378]	Phase 4	40 participants (Actual)	Interventional	2013-09-30	Terminated(stopped due to No data are available for this study as the PI has left the institution.)
Assessment of Salbutamol Effect on Arterial Oxygenation in COPD Patients During One-lung Ventilation [NCT05914285]		90 participants (Anticipated)	Interventional	2023-04-25	Recruiting
ProAir Digihaler in COPD Disease Management: A Real World Study to Assess ProAir Digihaler Inhalation Parameters Thresholds and Their Use to Identify Deterioration in Clinical Practice [NCT04821869]		27 participants (Actual)	Observational	2021-05-10	Completed
A Multicenter, Randomized, Blinded, Double-dummy, Placebo-controlled, 3-period Cross-over Study to Evaluate the Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active [NCT01490125]	Phase 3	247 participants (Actual)	Interventional	2011-10-31	Completed
Lung Function Changes of Mild to Moderate Asthmatic Children Treated by Nebulized MgSO4 [NCT01799109]		90 participants (Actual)	Interventional	2011-11-30	Completed
Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia [NCT02447250]	Phase 4	14 participants (Actual)	Interventional	2013-10-24	Completed
Aerosolized Beta-Agonist Isomers in Asthma [NCT02170532]	Phase 4	10 participants (Actual)	Interventional	2007-07-31	Completed
Nebulized Epinephrine Versus Nebulized Salbutamol in Bronchiolitis Among Children Aged 1month-24months [NCT03814954]		90 participants (Actual)	Interventional	2019-01-01	Completed
Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease [NCT01895998]	Phase 1	5 participants (Actual)	Interventional	2013-08-31	Completed
A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fluticasone Propionate DPI Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Persistent Asthma Uncontrolled on Non-steroidal Therapy [NCT01479621]	Phase 2	909 participants (Actual)	Interventional	2012-01-31	Completed
A Pilot Study to Evaluate the Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Pediatric Patients Following Discharge From the Emergency Department/Outpatient Care Facility [NCT00189436]	Phase 4	61 participants (Actual)	Interventional	2003-03-31	Completed
Use of ProAir Digihaler in Chronic Obstructive Pulmonary Disease (COPD) - Characterization of Inhalation Metrics From a Cohort of Patient At-risk for Acute Exacerbation of COPD (AECOPD) in an Outpatient Setting [NCT05241288]		55 participants (Actual)	Interventional	2022-03-01	Completed
Comparison of Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination Delivered Via pMDI and Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol in Patients With Stable Moderate-Severe-Very Severe Chro [NCT04446637]	Phase 3	0 participants (Actual)	Interventional	2021-09-03	Withdrawn(stopped due to administrative decision)
The Various Effects of Gaseous Albuterol on Serum Lactate [NCT02073747]		28 participants (Actual)	Interventional	2015-04-30	Completed
A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Doses of LAS100977 QD Compared to Placebo and an Active Comparator in Patie [NCT01425801]	Phase 2	62 participants (Actual)	Interventional	2011-08-01	Completed
A Six-Period Crossover, Dose-Ranging Study to Evaluate the Efficacy and Safety of Four Doses of FS Spiromax (Fluticasone Propionate/Salmeterol Xinafoate Inhalation Powder) Administered as Single Doses Compared With Single Doses of Fluticasone Propionate S [NCT01772368]	Phase 2	72 participants (Actual)	Interventional	2013-01-31	Completed
Nebulized In-line Endotracheal Dornase Alfa and Albuterol Administered to Mechanically Ventilated COVID-19 Patients: A Case Series [NCT04387786]		5 participants (Actual)	Observational	2020-03-31	Completed
Emergency Department (ED) Use of Nebulized Budesonide as an Adjunct to Standardized Therapy in Acutely Ill Adults With Refractory Asthma: a Randomized, Double-blinded, Placebo-controlled Trial [NCT00588406]	Phase 3	95 participants (Actual)	Interventional	2007-09-30	Completed
Comparison of Conventional Medicine, TCM Treatment and Combination of Both Conventional Medicine and TCM Treatment for Patients With Chronic Obstructive Pulmonary Disease: A Randomized Comparative Effectiveness Research Trial [NCT01836016]	Phase 3	360 participants (Anticipated)	Interventional	2013-05-31	Not yet recruiting
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma [NCT01698320]	Phase 3	364 participants (Actual)	Interventional	2012-10-31	Completed
[NCT00004685]		90 participants	Interventional	1998-01-31	Completed
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma [NCT02528214]	Phase 3	210 participants (Actual)	Interventional	2015-10-15	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Ye [NCT02040779]	Phase 3	273 participants (Actual)	Interventional	2013-12-26	Completed
Is Levalbuterol an Effective Treatment With Less Cardiac Side Effects Than Albuterol in Hyperkalemia Patients: A Randomized-controlled Clinical Trial Protocol. [NCT05173584]	Phase 4	30 participants (Anticipated)	Interventional	2021-11-04	Recruiting
a Multicentre, Double-blind, Randomized, Placebo-controlled Phase III Trial of the Inhaled β2-adrenergic Receptor Agonist Salbutamol for Transient Tachypnoea of the Newborn (the REFSAL Trial) [NCT05527704]	Phase 3	608 participants (Anticipated)	Interventional	2021-12-31	Recruiting
Effects of Noninvasive Ventilation Compared to Salbutamol in Respiratory Mechanics and Lung Function of Asthmatics After Bronchoprovocation: Randomized Cross-over Trial [NCT03430505]		30 participants (Actual)	Interventional	2017-06-10	Completed
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With [NCT01706328]	Phase 3	828 participants (Actual)	Interventional	2012-10-15	Completed
Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma [NCT03592212]		99 participants (Actual)	Observational	2018-11-25	Active, not recruiting
A Single Center Study to Measure the Bronchodilator Effect of Albuterol Sulfate or Albuterol Sulfate/Ipratropium Bromide Using the Pneuma Respiratory Inhaler and the ProAir HFA Inhaler in Stable COPD Patients [NCT03480997]	Phase 1	46 participants (Actual)	Interventional	2016-12-27	Completed
A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia Artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without [NCT02478398]	Phase 3	1,025 participants (Actual)	Interventional	2015-07-20	Completed
Steroid Therapy in Acute Bronchiolitis A New Old Line of Therapy. [NCT03436225]	Phase 1	80 participants (Anticipated)	Interventional	2019-02-28	Not yet recruiting
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- [NCT02654145]	Phase 4	145 participants (Actual)	Interventional	2016-03-17	Completed
An Open-label, Single-Center, Single-Dose, 3-Way Crossover Study of the Safety and Pharmacokinetics of Albuterol Administered by the Halix(TM) Albuterol Unit Dose Disposable Inhaler [NCT03373409]	Phase 1	12 participants (Actual)	Interventional	2017-11-30	Completed
A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptom [NCT02139644]	Phase 3	787 participants (Actual)	Interventional	2014-06-30	Completed
Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment [NCT02141633]		31 participants (Actual)	Interventional	2013-04-30	Completed
A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol 100/25mcg Versus Fluticasone Furoate 100mcg on Asthma Control in Patients With Uncontrolled Asthma [NCT03363191]	Phase 4	0 participants (Actual)	Interventional	2018-03-07	Withdrawn(stopped due to The study was withdrawn due to an internal decision.)
A Phase IIIB, 24-week Randomised, Double-blind Study to Compare 'Closed' Triple Therapy (FF/UMEC/VI) With 'Open' Triple Therapy (FF/VI + UMEC), in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [NCT02729051]	Phase 3	1,055 participants (Actual)	Interventional	2016-06-29	Completed
A Randomized, Double-blind, Multicenter, 2-period Single-dose Cross-over Study to Assess the Early Bronchodilation of Glycopyrronium Bromide (44 μg o.d.) Compared to Tiotropium (18 µg. o.d.) in Patients With Moderate to Severe COPD (FAST Study) [NCT01922271]	Phase 4	152 participants (Actual)	Interventional	2013-08-31	Completed
A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy [NCT01885936]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2013-06-30	Completed
A 12-week Treatment, Randomized, Blinded, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of NVA237 (50 µg o.d.) Compared to Tiotropium (18 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [NCT01613326]	Phase 3	657 participants (Actual)	Interventional	2012-06-30	Completed
Study DB2116961, A Multicentre, Randomised, Blinded, Parallel Group Study to Compare UMEC/VI (Umeclidinium/Vilanterol) in a Fixed Dose Combination With Indacaterol Plus Tiotropium in Symptomatic Subjects With Moderate to Very Severe COPD [NCT02257385]	Phase 3	967 participants (Actual)	Interventional	2014-10-15	Completed
A Multi-national, Randomized, Double-blind, Placebo-controlled, 3-period Crossover Study With GSK 573719 as Monotherapy in Adult Subjects With Asthma [NCT01641692]	Phase 2	350 participants (Actual)	Interventional	2012-05-31	Completed
A Three-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler (MDPI) Relative to Placebo in Pediatric Asthmatics [NCT02126839]	Phase 3	186 participants (Actual)	Interventional	2014-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00070707 (21) [back to overview]	Change From Baseline in Pulmonary Auscultation/Wheezing Assessment
NCT00070707 (21) [back to overview]	Change From Baseline in AM and PM Chest Tightness Symptom Score
NCT00070707 (21) [back to overview]	Change From Baseline in AM and PM Cough Symptom Score
NCT00070707 (21) [back to overview]	Change From Baseline in AM and PM Difficulty Breathing Symptom Score
NCT00070707 (21) [back to overview]	Change From Baseline in AM and PM Nasal Congestion Symptom Score
NCT00070707 (21) [back to overview]	Change From Baseline in AM and PM Nasal Itching Symptom Score
NCT00070707 (21) [back to overview]	Change From Baseline in AM and PM Nasal Sneezing Symptom Score
NCT00070707 (21) [back to overview]	Change From Baseline in AM and PM Peak Expiratory Flow Rate (PEFR)
NCT00070707 (21) [back to overview]	Change From Baseline in AM and PM Rhinorrhea Symptom Score
NCT00070707 (21) [back to overview]	Change From Baseline in AM and PM Total Nasal Symptom Severity (TNSS)
NCT00070707 (21) [back to overview]	Change From Baseline in AM and PM Wheeze Symptom Score
NCT00070707 (21) [back to overview]	Change From Baseline in Forced Expiratory Flow (FEF) Between 25% and 75% of the Vital Capacity (FEF25%-75%)
NCT00070707 (21) [back to overview]	Change From Baseline in Forced Expiratory Volume in One Second (FEV1)
NCT00070707 (21) [back to overview]	Change From Baseline in Forced Vital Capacity (FVC)
NCT00070707 (21) [back to overview]	Change From Baseline in Morning (AM) and Evening (PM) Total Asthma Symptom Severity (TASS)
NCT00070707 (21) [back to overview]	Change From Baseline in the Weekly Average Number of Puffs of Albuterol/Salbutamol Used
NCT00070707 (21) [back to overview]	Change From Baseline in Weekly Average Interference With Daily Activities
NCT00070707 (21) [back to overview]	Change From Baseline in Weekly Average Interference With Sleep
NCT00070707 (21) [back to overview]	Change From Baseline in Weekly Average Nighttime Awakenings Due to Asthma
NCT00070707 (21) [back to overview]	Therapeutic Response to Asthma Symptoms
NCT00070707 (21) [back to overview]	Therapeutic Response to SAR Nasal Symptoms
NCT00124176 (5) [back to overview]	Duration of Continuous Therapy
NCT00124176 (5) [back to overview]	Change in Pediatric Asthma Severity Score
NCT00124176 (5) [back to overview]	Serum Potassium Levels
NCT00124176 (5) [back to overview]	Serum Albuterol S Isomer Levels
NCT00124176 (5) [back to overview]	Heart Rate
NCT00189436 (3) [back to overview]	Wheezing/Asthma/Bronchospasm Relapse Rate
NCT00189436 (3) [back to overview]	Urinary Cortisol Levels
NCT00189436 (3) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1)
NCT00308685 (2) [back to overview]	Maximum Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Observed up to 2 Hours Following Completion of Dosing (FEV1max%0-2) at Day 22
NCT00308685 (2) [back to overview]	Baseline-Adjusted Area Under the Percent-Predicted FEV1 Versus Time Curve Over 6 Hours (PPFEV1 AUEC0-6) at Day 22
NCT00310401 (4) [back to overview]	Number of Donor Lungs Used for Transplantation
NCT00310401 (4) [back to overview]	Donor Oxygenation
NCT00310401 (4) [back to overview]	Chest X-ray Findings
NCT00310401 (4) [back to overview]	Lung Compliance
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 2
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 3
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 4
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 5
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 6
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 7
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 8
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 9
NCT00359788 (114) [back to overview]	Evening PEFR at Week 1
NCT00359788 (114) [back to overview]	Patient Global Evaluation
NCT00359788 (114) [back to overview]	Evening PEFR at Week 10
NCT00359788 (114) [back to overview]	Evening PEFR at Week 11
NCT00359788 (114) [back to overview]	Evening PEFR at Week 12
NCT00359788 (114) [back to overview]	Evening PEFR at Week 2
NCT00359788 (114) [back to overview]	Evening PEFR at Week 3
NCT00359788 (114) [back to overview]	Evening PEFR at Week 4
NCT00359788 (114) [back to overview]	Evening PEFR at Week 5
NCT00359788 (114) [back to overview]	Evening PEFR at Week 6
NCT00359788 (114) [back to overview]	Evening PEFR at Week 7
NCT00359788 (114) [back to overview]	Evening PEFR at Week 8
NCT00359788 (114) [back to overview]	Evening PEFR at Week 9
NCT00359788 (114) [back to overview]	FEV1 at -10 Minutes at Week 12
NCT00359788 (114) [back to overview]	FEV1 at -10 Minutes at Week 6
NCT00359788 (114) [back to overview]	FEV1 at 1 Hour at Week 12
NCT00359788 (114) [back to overview]	FEV1 at 1 Hour at Week 6
NCT00359788 (114) [back to overview]	FEV1 at 1 Hour on Day 1
NCT00359788 (114) [back to overview]	FEV1 at 15 Minutes at Week 12
NCT00359788 (114) [back to overview]	FEV1 at 3 Hours at Week 6
NCT00359788 (114) [back to overview]	FEV1 at 15 Minutes at Week 6
NCT00359788 (114) [back to overview]	FEV1 at 15 Minutes on Day 1
NCT00359788 (114) [back to overview]	FEV1 at 2 Hours at Week 12
NCT00359788 (114) [back to overview]	FEV1 at 2 Hours at Week 6
NCT00359788 (114) [back to overview]	FEV1 at 2 Hours on Day 1
NCT00359788 (114) [back to overview]	FEV1 at 3 Hours at Week 12
NCT00359788 (114) [back to overview]	FEV1 at 3 Hours on Day 1
NCT00359788 (114) [back to overview]	FEV1 at 30 Minutes at Week 12
NCT00359788 (114) [back to overview]	FEV1 at 30 Minutes at Week 6
NCT00359788 (114) [back to overview]	FEV1 at 30 Minutes on Day 1
NCT00359788 (114) [back to overview]	FEV1 at 4 Hours at Week 12
NCT00359788 (114) [back to overview]	FEV1 at 4 Hours at Week 6
NCT00359788 (114) [back to overview]	FEV1 at 4 Hours on Day 1
NCT00359788 (114) [back to overview]	FEV1 at 6 Hours at Week 12
NCT00359788 (114) [back to overview]	FEV1 at 6 Hours at Week 6
NCT00359788 (114) [back to overview]	FEV1 at 6 Hours on Day 1
NCT00359788 (114) [back to overview]	FVC at -10 Minutes at Week 12
NCT00359788 (114) [back to overview]	FVC at -10 Minutes at Week 6
NCT00359788 (114) [back to overview]	FVC at 1 Hour at Week 12
NCT00359788 (114) [back to overview]	Physician Global Evaluation
NCT00359788 (114) [back to overview]	Physician Global Evaluation
NCT00359788 (114) [back to overview]	Patient Global Evaluation
NCT00359788 (114) [back to overview]	FVC at 3 Hours on Day 1
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 9
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 8
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 7
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 6
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 5
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 4
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 3
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 2
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 12
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 11
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 10
NCT00359788 (114) [back to overview]	Night Time Albuterol Use During Week 1
NCT00359788 (114) [back to overview]	Morning PEFR at Week 9
NCT00359788 (114) [back to overview]	Morning PEFR at Week 8
NCT00359788 (114) [back to overview]	Morning PEFR at Week 7
NCT00359788 (114) [back to overview]	Morning PEFR at Week 6
NCT00359788 (114) [back to overview]	Morning PEFR at Week 5
NCT00359788 (114) [back to overview]	Morning PEFR at Week 4
NCT00359788 (114) [back to overview]	Morning PEFR at Week 3
NCT00359788 (114) [back to overview]	Morning PEFR at Week 2
NCT00359788 (114) [back to overview]	Morning PEFR at Week 12
NCT00359788 (114) [back to overview]	Morning PEFR at Week 11
NCT00359788 (114) [back to overview]	Morning PEFR at Week 10
NCT00359788 (114) [back to overview]	Morning Peak Expiratory Flow Rate (PEFR) at Week 1
NCT00359788 (114) [back to overview]	FVC at 6 Hours on Day 1
NCT00359788 (114) [back to overview]	FVC at 6 Hours at Week 6
NCT00359788 (114) [back to overview]	FVC at 6 Hours at Week 12
NCT00359788 (114) [back to overview]	FVC at 4 Hours on Day 1
NCT00359788 (114) [back to overview]	FVC at 4 Hours at Week 6
NCT00359788 (114) [back to overview]	FVC at 4 Hours at Week 12
NCT00359788 (114) [back to overview]	FVC at 30 Minutes on Day 1
NCT00359788 (114) [back to overview]	FVC at 30 Minutes at Week 6
NCT00359788 (114) [back to overview]	FVC at 30 Minutes at Week 12
NCT00359788 (114) [back to overview]	FVC at 3 Hours at Week 6
NCT00359788 (114) [back to overview]	FVC at 3 Hours at Week 12
NCT00359788 (114) [back to overview]	FVC at 2 Hours on Day 1
NCT00359788 (114) [back to overview]	FVC at 2 Hours at Week 6
NCT00359788 (114) [back to overview]	FVC at 2 Hours at Week 12
NCT00359788 (114) [back to overview]	FVC at 15 Minutes on Day 1
NCT00359788 (114) [back to overview]	FVC at 15 Minutes at Week 6
NCT00359788 (114) [back to overview]	FVC at 15 Minutes at Week 12
NCT00359788 (114) [back to overview]	FVC at 1 Hour on Day 1
NCT00359788 (114) [back to overview]	FVC at 1 Hour at Week 6
NCT00359788 (114) [back to overview]	Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks
NCT00359788 (114) [back to overview]	Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at Week 6
NCT00359788 (114) [back to overview]	Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1
NCT00359788 (114) [back to overview]	Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks
NCT00359788 (114) [back to overview]	Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 6 Weeks
NCT00359788 (114) [back to overview]	Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1
NCT00359788 (114) [back to overview]	Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 12
NCT00359788 (114) [back to overview]	Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 6
NCT00359788 (114) [back to overview]	Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) on Day 1
NCT00359788 (114) [back to overview]	Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 12
NCT00359788 (114) [back to overview]	Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 6
NCT00359788 (114) [back to overview]	Change From Baseline in Peak FVC (Forced Vital Capacity) on Day 1
NCT00359788 (114) [back to overview]	Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 12 Weeks
NCT00359788 (114) [back to overview]	Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 6 Weeks
NCT00359788 (114) [back to overview]	Change From Baseline in Trough FVC (Forced Vital Capacity) at 12 Weeks
NCT00359788 (114) [back to overview]	Change From Baseline in Trough FVC (Forced Vital Capacity) at 6 Weeks
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 1
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 10
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 11
NCT00359788 (114) [back to overview]	Day Time Albuterol Use During Week 12
NCT00363480 (17) [back to overview]	Assessment of Tolerability by Change From Baseline of Pulse Rate
NCT00363480 (17) [back to overview]	Change From Baseline in Mean 24-hour Symptom Score at Week 12
NCT00363480 (17) [back to overview]	Change From Baseline in Mean ACT Score at Visit 6
NCT00363480 (17) [back to overview]	Change From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 12
NCT00363480 (17) [back to overview]	Change From Baseline in Number of Additional Usage of Salbutamol at Week 12
NCT00363480 (17) [back to overview]	Change From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ)
NCT00363480 (17) [back to overview]	Correlation of Change in AQLQ Score and Change in ACT Score
NCT00363480 (17) [back to overview]	Number of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment
NCT00363480 (17) [back to overview]	Number of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements
NCT00363480 (17) [back to overview]	Percent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 12
NCT00363480 (17) [back to overview]	Assessment of Tolerability by Change From Baseline of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT00363480 (17) [back to overview]	Assessment of Tolerability by Number of Participants With at Least One Treatment Emergent Serious and, Non-serious AE
NCT00363480 (17) [back to overview]	Change From Baseline in Forced Expiratory Volume (FEV1) to Week 12
NCT00363480 (17) [back to overview]	Change From Baseline in Percentage of Participants With ACT Score of 20-25 at Week 12
NCT00363480 (17) [back to overview]	Number of Participants With Emergency Visits Due to Asthma
NCT00363480 (17) [back to overview]	Number of Participants With Well Controlled and Totally Controlled Asthma at Week 12
NCT00363480 (17) [back to overview]	Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12
NCT00384189 (13) [back to overview]	Change From Baseline in Lung Function Variable PEF by Spirometry
NCT00384189 (13) [back to overview]	Change From Baseline in Morning Peak Expiratory Flow (PEF)
NCT00384189 (13) [back to overview]	Change From Baseline in Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) Overall
NCT00384189 (13) [back to overview]	Change From Baseline in Pediatric Asthma Quality of Life Questionnaire Standard [PAQLQ(S)] Overall Score
NCT00384189 (13) [back to overview]	Change in Use of Rescue Medications
NCT00384189 (13) [back to overview]	Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication, Morning PEF and PEF Fluctuation
NCT00384189 (13) [back to overview]	Time to First Event of Lack of Efficacy (LOE) by Week 12
NCT00384189 (13) [back to overview]	Change From Baseline in Morning PEF From Diary
NCT00384189 (13) [back to overview]	Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication and Morning PEF
NCT00384189 (13) [back to overview]	Change in Asthma Symptom Total Score
NCT00384189 (13) [back to overview]	Change From Baseline in Diurnal PEF Fluctuations
NCT00384189 (13) [back to overview]	Change From Baseline in Lung Function Variable Forced Expiratory Volume in One Second (FEV1)
NCT00384189 (13) [back to overview]	Change From Baseline in Evening PEF From Diary
NCT00393367 (12) [back to overview]	Number of Participants With Adverse Events (Non-serious).
NCT00393367 (12) [back to overview]	Relapse / Readmission Numbers.
NCT00393367 (12) [back to overview]	Oxygen Saturation.
NCT00393367 (12) [back to overview]	Number of Subjects Remaining in the Severe Asthma Category
NCT00393367 (12) [back to overview]	Number of Subjects Moving From the Severe Asthma to Moderate Asthma Category
NCT00393367 (12) [back to overview]	Number of Subjects Moving From the Severe Asthma to Mild Asthma Category
NCT00393367 (12) [back to overview]	Number of Patients Hospitalized
NCT00393367 (12) [back to overview]	Median Change in Asthma Score 2 Hours After Intervention
NCT00393367 (12) [back to overview]	Mean Change in Asthma Score at 2 Hours
NCT00393367 (12) [back to overview]	Change in Mean Heart Rate
NCT00393367 (12) [back to overview]	Serious Adverse Events
NCT00393367 (12) [back to overview]	Mean Change in Respiratory Rate.
NCT00394329 (10) [back to overview]	Change Between Week 44 and Week 0 in the Pre-bronchodilator Forced Expiratory Volume in One Second (FEV!)
NCT00394329 (10) [back to overview]	Change Between Week 44 and Week 0 in the Morning Peak Expiratory Flow Rate (PEFR)
NCT00394329 (10) [back to overview]	Change Between Week 44 and Week 0 in the Exhaled Nitric Oxide (eNO) Measured in Parts Per Billion
NCT00394329 (10) [back to overview]	Change Between Week 44 and Week 0 in the Evening Peak Expiratory Flow Rate Variability (PEFR)
NCT00394329 (10) [back to overview]	Change Between Week 44 and Week 0 in the Asthma Control Test (ACT)
NCT00394329 (10) [back to overview]	Change Between Week 44 and Week 0 in the Asthma-specific Quality of Life Assessment
NCT00394329 (10) [back to overview]	Change Between Week 44 and Week 0 Peak Expiratory Flow Rate (PEFR) Variability
NCT00394329 (10) [back to overview]	Change Between Week 44 and Week 0 in the Asthma Control Days
NCT00394329 (10) [back to overview]	Change Between Week 44 and Week 0 in Rescue Albuterol Puffs Per Day
NCT00394329 (10) [back to overview]	Participants Experiencing an Asthma Exacerbation That Requires Systemic Corticosteroid Therapy
NCT00410150 (1) [back to overview]	Length of Stay
NCT00434993 (10) [back to overview]	Plasma Levels of IL-6 and IL-8 on Study Day 3
NCT00434993 (10) [back to overview]	Number of ICU-free Days at 28 Days After Randomization
NCT00434993 (10) [back to overview]	Number of Organ Failure-free Days at Day 28 Following Randomization
NCT00434993 (10) [back to overview]	Ventilator Free Days to Day 28 in the Subset of Participants With ARDS
NCT00434993 (10) [back to overview]	Ventilator Free Days to Day 28 in the Subset of Patients With Baseline Shock
NCT00434993 (10) [back to overview]	Mortality Prior to Hospital Discharge With Unassisted Breathing to Day 60
NCT00434993 (10) [back to overview]	Hospital Mortality up to Day 60 in Subjects With Baseline Shock
NCT00434993 (10) [back to overview]	Hospital Mortality to Day 60 in the Subset of Participants With ARDS
NCT00434993 (10) [back to overview]	Mortality Prior to Hospital Discharge With Unassisted Breathing to Day 90
NCT00434993 (10) [back to overview]	Number of Ventilator Free Days (VFD)
NCT00521222 (5) [back to overview]	Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-Bronchodilator
NCT00521222 (5) [back to overview]	Change in Forced Expiratory Volume in 1 Second (FEV1) Post-Bronchodilator
NCT00521222 (5) [back to overview]	Change in Asthma Symptom Score
NCT00521222 (5) [back to overview]	Absolute Change in Morning Peak Flow
NCT00521222 (5) [back to overview]	Change in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted Pre-Bronchodilator
NCT00530062 (9) [back to overview]	Area-Under-the-Effect Curve of Percent Change in Test-Day Baseline Forced Expiratory Volume in 1 Second (FEV1) Versus Time (up to 2 Hours Postdose), %FEV1 AUEC0-2
NCT00530062 (9) [back to overview]	Time to a 15% Increase From Baseline in FEV1 Within 2 Hours Postdose
NCT00530062 (9) [back to overview]	Time to a 12% Increase From Baseline in FEV1 Within 2 Hours Postdose
NCT00530062 (9) [back to overview]	Percentage of Participants With a 15% Increase From Baseline in FEV1 Within 2 Hours Postdose
NCT00530062 (9) [back to overview]	Percentage of Participants With a 12% Increase From Baseline in FEV1 Within 2 Hours Postdose
NCT00530062 (9) [back to overview]	Percent Change From Baseline in FEV1 up to 2 Hours Postdose
NCT00530062 (9) [back to overview]	Time to Maximum Increase in FEV1
NCT00530062 (9) [back to overview]	Area-Under-the-Effect Curve of Change in Test-Day Baseline FEV1 Versus Time (up to 2 Hours Postdose), FEV1 AUEC0-2
NCT00530062 (9) [back to overview]	Percent Change From Baseline in FEV1 Within 30 Minutes Postdose
NCT00550550 (4) [back to overview]	Participant Average Weekly Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) Total Score Over the Entire GPS
NCT00550550 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire GPS
NCT00550550 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Symptom Scores (DSS) Over the Entire GPS
NCT00550550 (4) [back to overview]	Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)
NCT00562159 (4) [back to overview]	Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)
NCT00562159 (4) [back to overview]	Participant Average Weekly Rhinoconjunctivitis Quality-of-Life Questionnaire With Standardized Activities (RQLQ(S)) Total Score Over the Entire GPS
NCT00562159 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Symptom Score (DSS) Over the Entire GPS
NCT00562159 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire GPS
NCT00577655 (17) [back to overview]	Participant Responses: Percentage of Participants With a >=12% Increase in Baseline PEF Within 30 Minutes Post-Dose on Days 1 and 22
NCT00577655 (17) [back to overview]	Participant Responses: Percentage of Participants With a >=15% Increase in Baseline FEV1 Within 30 Minutes Post-Dose on Days 1 and 22
NCT00577655 (17) [back to overview]	Participant Responses: Percentage of Participants With a >=15% Increase in Baseline PEF Within 30 Minutes Post-Dose on Days 1 and 22
NCT00577655 (17) [back to overview]	Baseline Adjusted Area-under-the-Effect Curve for Percent of Predicted Forced Expiratory Volume in One Second (FEV1) Over 6 Hours Post-dose on Day 22 Using Both Day 1 and Day 22 Baselines
NCT00577655 (17) [back to overview]	Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Observed up to Two Hours Post Dose (FEV1max%0-2) on Day 22
NCT00577655 (17) [back to overview]	The Number of Asthma-Related Nocturnal Awakenings Per Week Requiring the Use of Rescue Medication
NCT00577655 (17) [back to overview]	Time To Maximum Forced Expiratory Volume in One Second (FEV1) Over Six Hours Post-Dose On Days 1 and 22
NCT00577655 (17) [back to overview]	Time To Maximum Peak Expiratory Flow (PEF) Over Six Hours Post-Dose On Days 1 and 22
NCT00577655 (17) [back to overview]	Weekly Average Highest (Worst) Daily Asthma Symptom Scores for Weeks 1, 2 and 3
NCT00577655 (17) [back to overview]	Weekly Average Number of Puffs of Rescue Medication Taken Each Day for Study Weeks 1, 2 and 3
NCT00577655 (17) [back to overview]	Weekly Average Peak Expiratory Flow (PEF) Obtained Pre-Dose Each Morning
NCT00577655 (17) [back to overview]	Maximum Percent Change From Baseline in Peak Expiratory Flow (PEF) Observed up to Two Hours Post Dose (PEFmax%0-2) on Day 22
NCT00577655 (17) [back to overview]	Baseline-Adjusted Area-under-the Effect Curve for Peak Expiratory Flow (PEF) Over 6 Hours Post-dose on Day 22 Using Both Day 1 and Day 22 Baselines
NCT00577655 (17) [back to overview]	Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) up to Two Hours Post-Dose (FEV1max%0-2, %) on Study Days 1 and 22 Using Observed Cases
NCT00577655 (17) [back to overview]	Maximum Percent Change From Baseline in Peak Expiratory Flow (PEF) up to Two Hours Post-Dose (PEFmax%0-2) on Study Days 1 and 22 Using Observed Cases
NCT00577655 (17) [back to overview]	Maximum Percent-Predicted FEV1 (Max PPFEV1, %) Observed up to Two Hours Following Completion of Dosing on Study Days 1 and 22 (Observed Case)
NCT00577655 (17) [back to overview]	Participant Responses: Percentage of Participants With a >=12% Increase in Baseline FEV1 Within 30 Minutes Post-Dose on Days 1 and 22
NCT00583947 (15) [back to overview]	Mean Heart Rate
NCT00583947 (15) [back to overview]	Change From Predose in Mean Peak Expiratory Flow Rate (PEFR)
NCT00583947 (15) [back to overview]	Plasma Concentration of (R,R) Formoterol
NCT00583947 (15) [back to overview]	Mean Systolic Blood Pressure
NCT00583947 (15) [back to overview]	Mean Serum Potassium Levels
NCT00583947 (15) [back to overview]	Mean Serum Glucose Values
NCT00583947 (15) [back to overview]	Mean Peak Expiratory Flow Rate (PEFR)
NCT00583947 (15) [back to overview]	Change From Predose in Mean Heart Rate
NCT00583947 (15) [back to overview]	Mean Forced Expiratory Volume in One Second(FEV1)
NCT00583947 (15) [back to overview]	Mean Diastolic Blood Pressure
NCT00583947 (15) [back to overview]	Change From Predose of Mean Forced Expiratory Volume in One Second (FEV1)
NCT00583947 (15) [back to overview]	Change From Predose in Mean Systolic Blood Pressure
NCT00583947 (15) [back to overview]	Change From Predose in Mean Diastolic Blood Pressure
NCT00583947 (15) [back to overview]	Change From Predose in Mean Serum Potassium
NCT00583947 (15) [back to overview]	Change From Predose in Mean Serum Glucose
NCT00585039 (2) [back to overview]	Change in Forced Expiratory Volume in 1 Sec (FEV1) Measured in L/Sec
NCT00585039 (2) [back to overview]	Clinical Asthma Score (CAS)
NCT00588406 (2) [back to overview]	Hospitalization
NCT00588406 (2) [back to overview]	FEV1 Percent Predicted
NCT00633919 (5) [back to overview]	Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2008
NCT00633919 (5) [back to overview]	Global Evaluation of Efficacy by Investigator at the End of the Evaluation Period in Autumn 2008
NCT00633919 (5) [back to overview]	Global Evaluation of Efficacy by Subject and Investigator at the End of the Evaluation Period in Autumn 2007
NCT00633919 (5) [back to overview]	Global Evaluation of Efficacy by Subject at the End of The Evaluation Period in 2008
NCT00633919 (5) [back to overview]	Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2007
NCT00669617 (1) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) at 5 Minutes Post-dose
NCT00809757 (26) [back to overview]	Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoint at Visit 4
NCT00809757 (26) [back to overview]	Rescue Medication Use - Change From Baseline in Mean Number of Doses Used Per Week
NCT00809757 (26) [back to overview]	Rescue Medication Use - Change From Baseline in Mean Number of Days Used Per Week When Used
NCT00809757 (26) [back to overview]	Percent Change From Baseline in the At-Home Mean Daily Peak Expiratory Flow (PEF to Postdose Timepoint at Visit 3 and Visit 4)
NCT00809757 (26) [back to overview]	Percent Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 4
NCT00809757 (26) [back to overview]	Investigator Global Assessment - Question 2
NCT00809757 (26) [back to overview]	Percent Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 2
NCT00809757 (26) [back to overview]	Percent Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 3
NCT00809757 (26) [back to overview]	Change From Baseline to Visit 4 in the Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessments (PACA)
NCT00809757 (26) [back to overview]	Change From Baseline to Visit 4 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Scores as Measured by Pediatric Asthma Questionnaire
NCT00809757 (26) [back to overview]	Change From Baseline to Visit 3 to Visit 4 in the Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessment
NCT00809757 (26) [back to overview]	Change From Baseline to Visit 3 to Visit 4 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Score as Measured by the Pediatric Asthma Questionnaire
NCT00809757 (26) [back to overview]	Change From Baseline to Visit 3 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Scores as Measured by the Pediatric Asthma Questionnaire (PAQ)
NCT00809757 (26) [back to overview]	Change From Baseline to Visit 3 in Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessment
NCT00809757 (26) [back to overview]	Change From Baseline to Visit 2 to Visit 3 in the Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessment
NCT00809757 (26) [back to overview]	Change From Baseline to Visit 2 to Visit 3 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Scores as Measured by the Pediatric Asthma Questionnaire
NCT00809757 (26) [back to overview]	Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoint at Visit 3
NCT00809757 (26) [back to overview]	Change From Baseline in the At-Home Mean Daily Peak Expiratory Flow (PEF to Postdose Timepoint at Visit 3 and Visit 4
NCT00809757 (26) [back to overview]	Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 2
NCT00809757 (26) [back to overview]	Caregiver Global Assessment - Question 3
NCT00809757 (26) [back to overview]	Caregiver Global Assessment - Question 2
NCT00809757 (26) [back to overview]	Caregiver Global Assessment - Question 1
NCT00809757 (26) [back to overview]	Change From Baseline to Visit 3 and Visit 4 in the Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLA) Composite Score
NCT00809757 (26) [back to overview]	Investigator Global Assessment - Question 1
NCT00809757 (26) [back to overview]	Rescue Medication Use - Change From Baseline in Mean Number of Doses Used Per Week During Weeks When Used
NCT00809757 (26) [back to overview]	Rescue Medication Use: Number of Subjects Using Rescue Medication During the Treatment Period
NCT00818454 (10) [back to overview]	Peak FEV1 Response (Crossover Part of the Study)
NCT00818454 (10) [back to overview]	Puffs Open-label Albuterol Used During Night (Crossover Part of the Study)
NCT00818454 (10) [back to overview]	Puffs Open-label Albuterol Used During Day (Crossover Part of the Study)
NCT00818454 (10) [back to overview]	Mini Asthma Quality of Life Questionnaire (Crossover Part of the Study)
NCT00818454 (10) [back to overview]	Asthma Control Questionnaire (Crossover Part of the Study)
NCT00818454 (10) [back to overview]	FEV1 AUC0-6 Response (Parallel Part of the Study)
NCT00818454 (10) [back to overview]	FEV1 AUC0-6 Response (Crossover Part of the Study)
NCT00818454 (10) [back to overview]	Peak FEV1 Response
NCT00818454 (10) [back to overview]	Puffs Study Medication Used During Night (Crossover Part of the Study)
NCT00818454 (10) [back to overview]	Puffs Study Medication Used During Day (Crossover Part of the Study)
NCT00940927 (2) [back to overview]	Effect Maximum (Emax)
NCT00940927 (2) [back to overview]	Effective Dose 50% (ED50)
NCT01019694 (39) [back to overview]	Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24
NCT01019694 (39) [back to overview]	Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12
NCT01019694 (39) [back to overview]	Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 48
NCT01019694 (39) [back to overview]	Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 36
NCT01019694 (39) [back to overview]	Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 3
NCT01019694 (39) [back to overview]	Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 24
NCT01019694 (39) [back to overview]	Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 12
NCT01019694 (39) [back to overview]	Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 0
NCT01019694 (39) [back to overview]	Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 48
NCT01019694 (39) [back to overview]	Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 36
NCT01019694 (39) [back to overview]	Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36
NCT01019694 (39) [back to overview]	Physician's Global Evaluation at Week 12
NCT01019694 (39) [back to overview]	Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Leading to Hospitalization
NCT01019694 (39) [back to overview]	Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
NCT01019694 (39) [back to overview]	Physician's Global Evaluation at Week 48
NCT01019694 (39) [back to overview]	Physician's Global Evaluation at Week 36
NCT01019694 (39) [back to overview]	Physician's Global Evaluation at Week 3
NCT01019694 (39) [back to overview]	Physician's Global Evaluation at Week 24
NCT01019694 (39) [back to overview]	Physician's Global Evaluation at Week 0
NCT01019694 (39) [back to overview]	Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 0
NCT01019694 (39) [back to overview]	Change From Baseline in FEV1 at Day 1
NCT01019694 (39) [back to overview]	Change From Baseline in FEV1 at Week 12
NCT01019694 (39) [back to overview]	Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 0
NCT01019694 (39) [back to overview]	Change From Baseline in FEV1 at Week 24
NCT01019694 (39) [back to overview]	Change From Baseline in FEV1 at Week 48
NCT01019694 (39) [back to overview]	Change From Baseline in FVC at Day 1
NCT01019694 (39) [back to overview]	Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48
NCT01019694 (39) [back to overview]	Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36
NCT01019694 (39) [back to overview]	Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3
NCT01019694 (39) [back to overview]	Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24
NCT01019694 (39) [back to overview]	Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12
NCT01019694 (39) [back to overview]	Change From Baseline in FVC at Week 12
NCT01019694 (39) [back to overview]	Change From Baseline in FVC at Week 24
NCT01019694 (39) [back to overview]	Change From Baseline in FVC at Week 48
NCT01019694 (39) [back to overview]	Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 12
NCT01019694 (39) [back to overview]	Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 24
NCT01019694 (39) [back to overview]	Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 3
NCT01019694 (39) [back to overview]	Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48
NCT01019694 (39) [back to overview]	Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3
NCT01058863 (3) [back to overview]	Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6)
NCT01058863 (3) [back to overview]	Baseline-adjusted Percent-Predicted Forced Expiratory Volume in 1 Second (PPFEV1) Area Under the Curve (AUC 0-6)
NCT01058863 (3) [back to overview]	Participants With Treatment-Emergent Adverse Events
NCT01096017 (12) [back to overview]	FEV1 (Forced Expiratory Volume in 1 Second) at 240 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]	FEV1 (Forced Expiratory Volume in 1 Second) at 30 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]	FEV1 (Forced Expiratory Volume in 1 Second) at 5 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]	FEV1 (Forced Expiratory Volume in 1 Second) at 60 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]	Maximum % Change in FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation
NCT01096017 (12) [back to overview]	Number of Patients With % Change in FEV1 (Forced Expiratory Volume in 1 Second) >15% Within 4 Hours After Drug Inhalation
NCT01096017 (12) [back to overview]	FEV1 (Forced Expiratory Volume in 1 Second) at 180 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]	Time to Peak FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation
NCT01096017 (12) [back to overview]	FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation
NCT01096017 (12) [back to overview]	FEV1 (Forced Expiratory Volume in 1 Second) at 15 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]	FEV1 (Forced Expiratory Volume in 1 Second) at 120 Minutes After Inhalations of Study Drug as Percentage of Pre-dose
NCT01096017 (12) [back to overview]	Time to Change More Than or Equal to 15% (Time to Onset Response) Within 4 Hours After Drug Inhalation
NCT01112241 (10) [back to overview]	Per Cent Change of Functional Residual Capacity (FRC) After Bronchodilators
NCT01112241 (10) [back to overview]	Per Cent Change of Forced Vital Capacity (FVC) After Bronchodilators
NCT01112241 (10) [back to overview]	Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators
NCT01112241 (10) [back to overview]	Absolute Change of Residual Volume (RV) After Bronchodilators
NCT01112241 (10) [back to overview]	Absolute Change of Forced Vital Capacity (FVC) After Bronchodilators
NCT01112241 (10) [back to overview]	Absolute Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators
NCT01112241 (10) [back to overview]	Absolute Change of Functional Residual Capacity (FRC) After Bronchodilators
NCT01112241 (10) [back to overview]	Per Cent Change of Residual Volume (RV) After Bronchodilators
NCT01112241 (10) [back to overview]	Per Cent Change of Partial Forced Expiratory Flow (V'Part) After Bronchodilators
NCT01112241 (10) [back to overview]	Per Cent Change of Instantaneous Maximal Forced Expiratory Flow (V'Max) After Bronchodilators
NCT01120691 (13) [back to overview]	Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Between QVA149, NVA237 and Open Label Tiotropium During the Treatment Period
NCT01120691 (13) [back to overview]	Time to Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.) During the Treatment Period.
NCT01120691 (13) [back to overview]	Cumulative Rates of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations for Multiple COPD Exacerbation at Different Time Points
NCT01120691 (13) [back to overview]	Change in Mean Daily Use (Number of Puffs) of Rescue Therapy Between QVA149, NVA237 and Open Label Tiotropium From Baseling Over the 64 Week Treatment Period
NCT01120691 (13) [back to overview]	Pre-dose Forced Vital Capacity (FVC)After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium
NCT01120691 (13) [back to overview]	Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Requiring the Use of Both Systemic Glucocorticosteroids and Antibiotics
NCT01120691 (13) [back to overview]	St. George's Respiratory Questionnaire (SGRQ) Scores Between QVA149, NVA237 and Open Label Tiotropium Over 12, 26, 38, 52 and 64 Weeks of Treatment
NCT01120691 (13) [back to overview]	Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.)During the Treatment Period
NCT01120691 (13) [back to overview]	Change From Baseline of Percentage of Days Without Rescue Therapy Use Between QVA149,NVA237 and Open Label Tiotropium Over the 64 Week Treatment Period
NCT01120691 (13) [back to overview]	Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and Open-label Tiotropium Treatment Arms During the Treatment Period.
NCT01120691 (13) [back to overview]	Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period.
NCT01120691 (13) [back to overview]	Number of Days With Moderate or Severe Exacerbation That Required Treatment With Systemic Corticosteroids and Antibiotics
NCT01120691 (13) [back to overview]	Pre-dose Forced Expiratory Volume in 1 Second (FEV-1) After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium
NCT01143688 (2) [back to overview]	Asthma Symptoms
NCT01143688 (2) [back to overview]	Change in FEV1
NCT01151579 (3) [back to overview]	Total Number of Participants With Arrhythmias
NCT01151579 (3) [back to overview]	Heart Rate in Beats Per Minute
NCT01151579 (3) [back to overview]	Arrhythmias
NCT01196377 (1) [back to overview]	%FEV1
NCT01218009 (3) [back to overview]	Pulse at Screening and End of Study
NCT01218009 (3) [back to overview]	Blood Pressure at Screening and End of Study
NCT01218009 (3) [back to overview]	Participants With Treatment-Emergent Adverse Events
NCT01255449 (2) [back to overview]	Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
NCT01255449 (2) [back to overview]	Post-HSCT Changes in Lung Tissue Density
NCT01263197 (3) [back to overview]	Maximum, Minimum and Average Changes in Diastolic Blood Pressure
NCT01263197 (3) [back to overview]	Maximum, Minimum and Average Changes in Heart Rate
NCT01263197 (3) [back to overview]	Maximum, Minimum and Average Changes in Systolic Blood Pressure
NCT01312961 (11) [back to overview]	Change From Baseline in Asthma Control Questionnaire (5-question Version [ACQ-5]) to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Forced Expiratory Flow in One Second (FEV1) to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Evening Asthma Symptom Scores to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in 22-item Sinonasal Outcome Test (SNOT-22) Score to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Morning Asthma Symptom Scores to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Number of Inhalations Per Day of Albuterol or Levalbuterol to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Number of Nocturnal Awakenings Per Day to Week 12
NCT01312961 (11) [back to overview]	Percentage of Participants With Composite Asthma Events
NCT01312961 (11) [back to overview]	Percentage of Participants With Asthma Exacerbation
NCT01312961 (11) [back to overview]	Time to First Asthma Exacerbation: Kaplan-Meier Estimates at Week 4, Week 8 and Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Peak Expiratory Flow (PEF) to Week 12
NCT01313494 (24) [back to overview]	Change From Baseline in Pre-bronchodilator Forced Expiratory Flow 25-75%
NCT01313494 (24) [back to overview]	Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
NCT01313494 (24) [back to overview]	Time to Onset of First Moderate or Severe COPD Exacerbation
NCT01313494 (24) [back to overview]	Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)
NCT01313494 (24) [back to overview]	Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC)
NCT01313494 (24) [back to overview]	Change From Baseline in Post-bronchodilator FEV1
NCT01313494 (24) [back to overview]	Percentage of Participants With Moderate or Severe COPD Exacerbations
NCT01313494 (24) [back to overview]	Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)
NCT01313494 (24) [back to overview]	Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity
NCT01313494 (24) [back to overview]	Number of Participants With Adverse Events
NCT01313494 (24) [back to overview]	Change From Baseline in COPD Symptom Scores
NCT01313494 (24) [back to overview]	Transition Dyspnoea Index (TDI) Total Score at Week 24
NCT01313494 (24) [back to overview]	Time to Onset of Second Moderate or Severe COPD Exacerbation
NCT01313494 (24) [back to overview]	Change From Baseline in Post-bronchodilator Forced Expiratory Flow 25-75%
NCT01313494 (24) [back to overview]	Change From Baseline in Pre-bronchodilator Peak Expiratory Flow Rate (PEF)
NCT01313494 (24) [back to overview]	Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds
NCT01313494 (24) [back to overview]	Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity
NCT01313494 (24) [back to overview]	Change From Baseline in Use of Rescue Medication
NCT01313494 (24) [back to overview]	Change From Baseline in Post-bronchodilator Peak Expiratory Flow Rate (PEF)
NCT01313494 (24) [back to overview]	Mean Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year
NCT01313494 (24) [back to overview]	Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)
NCT01313494 (24) [back to overview]	Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)
NCT01313494 (24) [back to overview]	Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)
NCT01313494 (24) [back to overview]	Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds
NCT01323010 (22) [back to overview]	Hospital Admission
NCT01323010 (22) [back to overview]	Lengths of Stay in the Emergency Room
NCT01323010 (22) [back to overview]	Need for Additional Therapies
NCT01323010 (22) [back to overview]	Change in Pulse Oximetry One Hour Post-treatment
NCT01323010 (22) [back to overview]	Admission Rates in Patients With and Without Any Virus Detected
NCT01323010 (22) [back to overview]	Admission Rates in Patients With and Without Rhinovirus Detect
NCT01323010 (22) [back to overview]	Admission Rates in Patients With the Arg16Gly Polymorphisms
NCT01323010 (22) [back to overview]	Albuterol Determination in the Plasma
NCT01323010 (22) [back to overview]	Change in PRAM Score After One Hour
NCT01323010 (22) [back to overview]	Changes in Bicarbonate Serum Levels
NCT01323010 (22) [back to overview]	Changes in Glucose Serum Levels
NCT01323010 (22) [back to overview]	Changes in Heart Rate After One Hour
NCT01323010 (22) [back to overview]	Changes in Heart Rate at Discharge or Hospital Admission
NCT01323010 (22) [back to overview]	Changes in Potassium Serum Levels
NCT01323010 (22) [back to overview]	Changes in PRAM Score at Discharge or Hospital Admission
NCT01323010 (22) [back to overview]	Changes in Pulse Oximetry at Discharge or Hospital Admission.
NCT01323010 (22) [back to overview]	Changes in Respiratory Rate After One Hour
NCT01323010 (22) [back to overview]	Changes in Respiratory Rate at at Discharge or Hospital Admission.
NCT01323010 (22) [back to overview]	Electrocardiogram at Baseline
NCT01323010 (22) [back to overview]	Electrocardiogram at Discharge or Hospital Admission
NCT01323010 (22) [back to overview]	Electrocardiogram One Hour Post-treatment.
NCT01323010 (22) [back to overview]	Forced Expiratory Volume in the First Second
NCT01323621 (2) [back to overview]	Time to Onset on Treatment Day 1
NCT01323621 (2) [back to overview]	Change From Baseline Trough in 24-Hour Weighted Mean FEV1 on Treatment Day 84
NCT01331694 (2) [back to overview]	Average Annual Adjusted Post-Index COPD-Related Costs
NCT01331694 (2) [back to overview]	Time to First Chronic Obstructive Pulmonary Disease (COPD) Event
NCT01424813 (7) [back to overview]	Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 85
NCT01424813 (7) [back to overview]	Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period
NCT01424813 (7) [back to overview]	Participants With Adverse Events
NCT01424813 (7) [back to overview]	Participants With Clinically Significant Vital Sign Assessments
NCT01424813 (7) [back to overview]	Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 1
NCT01424813 (7) [back to overview]	Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 8
NCT01424813 (7) [back to overview]	Physical Examination Findings Shifts From Baseline to Endpoint by Treatment Group
NCT01425801 (16) [back to overview]	Change From Baseline to Trough Forced Expiratory Volume in One Second (FEV1)
NCT01425801 (16) [back to overview]	Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-24h at Day 1
NCT01425801 (16) [back to overview]	Change From Baseline in Normalized Forced Vital Capacity (FVC) Area Under the Curve (AUC)
NCT01425801 (16) [back to overview]	Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)
NCT01425801 (16) [back to overview]	Change From Baseline in Peak Forced Vital Capacity (FVC)
NCT01425801 (16) [back to overview]	Percentage Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint
NCT01425801 (16) [back to overview]	Change From Baseline in Forced Vital Capacity (FVC) at Each Timepoint
NCT01425801 (16) [back to overview]	Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint
NCT01425801 (16) [back to overview]	Absolute Values of Forced Vital Capacity (FVC) at Each Timepoint
NCT01425801 (16) [back to overview]	Absolute Values of Forced Expiratory Volume (FEV1) at Each Timepoint
NCT01425801 (16) [back to overview]	Time to Peak Forced Vital Capacity (FVC)
NCT01425801 (16) [back to overview]	Time to Peak Forced Expiratory Volume in One Second (FEV1)
NCT01425801 (16) [back to overview]	Percentage Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)
NCT01425801 (16) [back to overview]	Peak Forced Vital Capacity (FVC)
NCT01425801 (16) [back to overview]	Peak Forced Expiratory Volume in One Second (FEV1)
NCT01425801 (16) [back to overview]	Change From Baseline to Trough Forced Vital Capacity (FVC)
NCT01431950 (5) [back to overview]	Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period
NCT01431950 (5) [back to overview]	Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods Over the 24-week Treatment Period
NCT01431950 (5) [back to overview]	Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods Over the 24-week Treatment Period
NCT01431950 (5) [back to overview]	Change From Baseline in Daily Morning (AM) PEF Averaged Over the 24-week Treatment Period
NCT01431950 (5) [back to overview]	Change From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 24-week Treatment Period
NCT01471340 (3) [back to overview]	Time-to-First Severe Asthma Exacerbation (SAEX): Number of First SAEX in the MF/F vs MF Arms
NCT01471340 (3) [back to overview]	Number of SAO Components in MF/F Participants vs MF Participants
NCT01471340 (3) [back to overview]	Time-to-First Serious Asthma Outcomes (SAO): Number of First SAO in the MF/F vs MF Arms
NCT01479621 (13) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Fp
NCT01479621 (13) [back to overview]	Kaplan-Meier Estimate of Probability of Remaining in the Study at Week 12
NCT01479621 (13) [back to overview]	Area Under The Curve From Time 0 Until The Last Measurable Concentration (AUC0-t) of Fp
NCT01479621 (13) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data
NCT01479621 (13) [back to overview]	Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT01479621 (13) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
NCT01479621 (13) [back to overview]	Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data
NCT01479621 (13) [back to overview]	Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
NCT01479621 (13) [back to overview]	Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data
NCT01479621 (13) [back to overview]	Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period
NCT01479621 (13) [back to overview]	Change From Baseline in the Percentage of Rescue-Free 24-hour Periods During the 12-Week Treatment Period
NCT01479621 (13) [back to overview]	Oropharyngeal Exam Findings at Each Study Visit
NCT01479621 (13) [back to overview]	Time of Maximum Concentration (Tmax) of Fp
NCT01490125 (6) [back to overview]	Total Total Transient Dyspnea Index (TDI) Score After 6 Weeks of Treatment QVA149 Compared to Tiotropium
NCT01490125 (6) [back to overview]	Total Total Transient Dyspnea Index (TDI) Score After 6 Weeks of Treatment QVA149 Compared to Placebo
NCT01490125 (6) [back to overview]	Standardized Forced Vital Capacity (FVC) Area Under the Curve (AUC) 5min-4 Hrs After First Dose and 6 Weeks of Treatment With QVA149 Compared to Placebo and Tiotropium
NCT01490125 (6) [back to overview]	Change From Baseline in The Capacity of Daily Living During the Morning (CDLM) Score Averaged Over 6 Weeks of Treatment
NCT01490125 (6) [back to overview]	Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Used Over the 6 Weeks of Treatment
NCT01490125 (6) [back to overview]	Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 5min-4h After First Dose and 6 Weeks of Treatment With QVA149 Compared to Placebo and Tiotropium
NCT01576718 (14) [back to overview]	Time Of Maximum Observed Plasma Concentration (Tmax)
NCT01576718 (14) [back to overview]	24-Hour Urinary Cortisol Excretion at Baseline, Week 12 and Endpoint
NCT01576718 (14) [back to overview]	Patients With Positive Swab Test Results for Oral Candidiasis
NCT01576718 (14) [back to overview]	Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT01576718 (14) [back to overview]	The Kaplan-Meier Estimate Of The Probability Of Remaining In The Study At Week 12
NCT01576718 (14) [back to overview]	Area Under The Plasma Concentration-Time Curve From Time Zero To The Time Of The Last Measurable Concentration (AUC0-t)
NCT01576718 (14) [back to overview]	Change From Baseline In The Percentage Of Rescue-Free 24-Hour Periods
NCT01576718 (14) [back to overview]	Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period
NCT01576718 (14) [back to overview]	Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
NCT01576718 (14) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
NCT01576718 (14) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
NCT01576718 (14) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
NCT01576718 (14) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
NCT01576718 (14) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT01613326 (13) [back to overview]	Transition Dyspnea Index (TDI) Focal Score After 4 Weeks and 12 Weeks of Treatment
NCT01613326 (13) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 4
NCT01613326 (13) [back to overview]	Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (5 Min-4 h) Post-dose
NCT01613326 (13) [back to overview]	Peak Forced Expiratory Volume in 1 Second (FEV1) During 5 Min to 4 Hours Post-dose, at Day 1 and Week 12
NCT01613326 (13) [back to overview]	Inspiratory Capacity (IC) at Each Time-point, by Visit
NCT01613326 (13) [back to overview]	Forced Vital Capacity (FVC) at Each Time-point by Visit
NCT01613326 (13) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) at Each Time-point by Visit
NCT01613326 (13) [back to overview]	Event Free Rate at Weeks 4, 8 and 12 After Treatment
NCT01613326 (13) [back to overview]	Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 12 Week Treatment
NCT01613326 (13) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Non-inferiority Analysis)
NCT01613326 (13) [back to overview]	Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Analysis of Superiority)
NCT01613326 (13) [back to overview]	St. George's Respiratory Questionnaire Total Score After 12 Weeks of Treatment
NCT01613326 (13) [back to overview]	Mean Daily, Daytime and Nighttime (Combined) Symptom Scores Over the 12 Week Treatment Period
NCT01641692 (23) [back to overview]	Number of Participants With the Indicated 24 Hour Holter Findings
NCT01641692 (23) [back to overview]	Change From Baseline in Mean Morning (AM) and Evening (PM) Pre-treatment Peak Expiratory Flow (PEF) Over Day 7 to Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline (BL) in the Weighted Mean (WM) 0-24 Hour FEV1 Obtained Post-AM Dose on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in Diastolic Blood Pressure on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in Hematocrit on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in Pulse Rate on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in Systolic Blood Pressure on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Day 7 to Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in Trough FEV1 on Day 15 of Each Treatment Period
NCT01641692 (23) [back to overview]	Number of Participants With Asthma Exacerbations During the Treatment Period
NCT01641692 (23) [back to overview]	Urine pH on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Urine Specific Gravity on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in Albumin, Total Protein, and Hemoglobin on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase (CK), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (ANC - Absolute Neutrophil Count), Platelet, and Leukocytes Count on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, and Creatinine on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Change From Baseline in the Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Segmented Neutrophils in Blood on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Number of Participants With the Indicated Abnormal Electrocardiogram Findings
NCT01641692 (23) [back to overview]	Change in Baseline in Serial FEV1 Over 0-24 Hours After the Morning Dose on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Final Dose-response Model for Trough Forced Expiratory Volume in One Second (FEV1)
NCT01641692 (23) [back to overview]	Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick on Day 14 of Each Treatment Period
NCT01641692 (23) [back to overview]	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
NCT01687296 (8) [back to overview]	Mean Change From Baseline in Clinical Scoring Index at Day 5 and Day 8
NCT01687296 (8) [back to overview]	Mean Global Evaluation for Efficacy by Participant/Parent and Investigator
NCT01687296 (8) [back to overview]	Mean Evening PEF on Diary Card Over the Treatment Assessment Period
NCT01687296 (8) [back to overview]	Mean Morning Peak Expiratory Flow (AM PEF) on Diary Card Over the Treatment Assessment Period in Intent-to-Treat (ITT) Population
NCT01687296 (8) [back to overview]	Mean Morning PEF on Diary Card Over the Treatment Assessment Period in Per Protocol (PP) Population
NCT01687296 (8) [back to overview]	Median Number of Use of Rescue Medications During Day and Night Over the Treatment Assessment Period
NCT01687296 (8) [back to overview]	Clinical Assessment of Lung Function of Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) During the Treatment Period
NCT01687296 (8) [back to overview]	Median Day-time and Night-time Symptom Scores Over the Treatment Assessment Period
NCT01691482 (7) [back to overview]	Variability in Daily Inspiratory Capacity (IC), Estimated by Coefficient of Variation
NCT01691482 (7) [back to overview]	Variability in Daily IC, Estimated by Half Range (i.e., Half the Difference Between Maximum and Minimum)
NCT01691482 (7) [back to overview]	Variability in Daily FEV1, Estimated by Coefficient of Variation
NCT01691482 (7) [back to overview]	The Maximal Bronchodilator Response for the First Administered Agent
NCT01691482 (7) [back to overview]	Percentage of Days for Which Participants Achieved a Threshold Increase From Baseline in FEV1 of 100 mL, 200 mL, and 250 mL
NCT01691482 (7) [back to overview]	Percentage of Days for Which Participants Achieved a >=12% and 200 Milliliter (mL) Increase From Baseline in FEV1
NCT01691482 (7) [back to overview]	Variability in Daily FEV1, Estimated by Half Range (i.e., Half the Difference Between Maximum and Minimum Values)
NCT01698320 (6) [back to overview]	Participants With Adverse Experiences During Weeks 13-52 (Open-Label Period)
NCT01698320 (6) [back to overview]	Participants With Adverse Experiences During Weeks 0-12 (Double-Blind Period)
NCT01698320 (6) [back to overview]	Participants With Abnormal and Clinically Relevant Physical Exam Findings at Weeks 0, 12 and 52
NCT01698320 (6) [back to overview]	Change From Baseline in Pulse Measurements to Week 12 and Week 52
NCT01698320 (6) [back to overview]	Change From Baseline in Blood Pressure Measurements to Week 12 and Week 52
NCT01698320 (6) [back to overview]	Electrocardiogram (ECG) Results At Weeks 0, 12, and 52
NCT01706328 (3) [back to overview]	Change From Baseline in Trough FEV1 on Treatment Day 85
NCT01706328 (3) [back to overview]	Change From Baseline Trough in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) on Treatment Day 84
NCT01706328 (3) [back to overview]	Time to Onset on Treatment Day 1
NCT01721291 (1) [back to overview]	ANALYSIS OF LUNG DEPOSITION - Penetration Index
NCT01747629 (14) [back to overview]	Maximum Observed Plasma Drug Concentration (Cmax) for Albuterol on Days 1 and 8
NCT01747629 (14) [back to overview]	Participants With Adverse Events
NCT01747629 (14) [back to overview]	Participants With Clinically Significant Vital Sign Assessments
NCT01747629 (14) [back to overview]	Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 1
NCT01747629 (14) [back to overview]	Area Under the Concentration-time Curve From Time 0 (Pre-dose) to 24 Hours Post-dose(AUC0-24) for Albuterol on Day 8
NCT01747629 (14) [back to overview]	Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Infinity Post-dose(AUC0-inf) for Albuterol on Day 1
NCT01747629 (14) [back to overview]	Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 8
NCT01747629 (14) [back to overview]	Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) on Day 85
NCT01747629 (14) [back to overview]	Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period
NCT01747629 (14) [back to overview]	Area Under the Concentration-time Curve From Time 0 (Pre-dose) to Last Time of Quantifiable Concentration (AUC0-t) for Albuterol on Days 1 and 8
NCT01747629 (14) [back to overview]	Physical Examination Findings Shifts From Baseline to Endpoint by Treatment Group
NCT01747629 (14) [back to overview]	Terminal Plasma Half-life (t1/2) for Albuterol on Days 1 and 8
NCT01747629 (14) [back to overview]	Time to Observed Peak Plasma Concentration (Tmax) for Albuterol on Days 1 and 8
NCT01747629 (14) [back to overview]	Area Under the Concentration-time Curve From Time 0 (Pre-dose) up to 6 Hours Post-dose (AUC0-6) for Albuterol on Days 1 and 8
NCT01772368 (6) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Salmeterol
NCT01772368 (6) [back to overview]	Change From Baseline at 12 Hours Post-Dose in Forced Expiratory Volume in One Second (FEV1) By Treatment
NCT01772368 (6) [back to overview]	Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT01772368 (6) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) of Salmeterol
NCT01772368 (6) [back to overview]	Time of Maximum Observed Plasma Concentration (Tmax) of Salmeterol
NCT01772368 (6) [back to overview]	Standardized Baseline-Adjusted Area Under the Curve For Forced Expiratory Volume In 1 Second Over 12 Hours Post-dose (FEV1 AUC0-12)
NCT01791972 (3) [back to overview]	Maximum Percentage Fall From Baseline in Forced Expiratory Volume in 1 Second (FEV1) up to 60 Minutes After the Exercise Challenge
NCT01791972 (3) [back to overview]	Participants Whose Maximum Percentage Decrease From the Baseline Forced Expiratory Volume in 1 Second (FEV1) Post-Exercise Challenge Was >20%
NCT01791972 (3) [back to overview]	Percentage of Participants Whose Maximum Percentage Decrease From the Baseline Forced Expiratory Volume in 1 Second (FEV1) Post-Exercise Challenge Was <10%
NCT01833026 (1) [back to overview]	Number of Participants With Accurate Classification of Irreversible Airflow Obstruction
NCT01854047 (23) [back to overview]	Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol at Week 12: ITT Population
NCT01854047 (23) [back to overview]	Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol at Week 12: HEos-ITT Population
NCT01854047 (23) [back to overview]	Change From Baseline in Morning Asthma Symptom Score at Week 12: ITT Population
NCT01854047 (23) [back to overview]	Change From Baseline in Morning Asthma Symptom Score at Week 12: HEos-ITT Population
NCT01854047 (23) [back to overview]	Change From Baseline in FEV1 at Week 12: Subset of ITT Population With Baseline Blood Eosinophil <0.3 G/L
NCT01854047 (23) [back to overview]	Change From Baseline in Evening Asthma Symptom Score at Week 12: HEos-ITT Population
NCT01854047 (23) [back to overview]	Change From Baseline in Evening Asthma Symptom Score at Week 12: ITT Population
NCT01854047 (23) [back to overview]	Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 12: HEos-ITT Population
NCT01854047 (23) [back to overview]	Change From Baseline in AQLQ Global Score at Week 12: ITT Population
NCT01854047 (23) [back to overview]	Change From Baseline in ACQ-5 Score at Week 12: ITT Population
NCT01854047 (23) [back to overview]	Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 12: High Eosinophils -Intent to Treat (HEos-ITT) Population
NCT01854047 (23) [back to overview]	Absolute Change From Baseline in FEV1 at Week 12: ITT Population
NCT01854047 (23) [back to overview]	Percent Change From Baseline in FEV1 at Week 12: ITT Population
NCT01854047 (23) [back to overview]	Percent Change From Baseline in FEV1 at Week 12: HEos-ITT Population
NCT01854047 (23) [back to overview]	Annualized Event Rate of Severe Exacerbation During The Treatment Period: ITT Population
NCT01854047 (23) [back to overview]	Annualized Event Rate of Severe Exacerbation During The Treatment Period: HEos-ITT Population
NCT01854047 (23) [back to overview]	Annualized Event Rate of Loss of Asthma Control (LOAC) During The Treatment Period: HEos-ITT Population
NCT01854047 (23) [back to overview]	Annualized Event Rate of LOAC During The Treatment Period: ITT Population
NCT01854047 (23) [back to overview]	Time to First Severe Exacerbation: Kaplan-Meier Estimates at Week 12 and 24: ITT Population
NCT01854047 (23) [back to overview]	Time to First Severe Exacerbation: Kaplan-Meier Estimates at Week 12 and 24: HEos-ITT Population
NCT01854047 (23) [back to overview]	Time to First LOAC Event: Kaplan-Meier Estimates at Week 12 and Week 24: ITT Population
NCT01854047 (23) [back to overview]	Time to First LOAC Event: Kaplan-Meier Estimates at Week 12 and Week 24: HEos-ITT Population
NCT01854047 (23) [back to overview]	Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12: HEos-ITT Population
NCT01857323 (6) [back to overview]	Absolute Value of Total Discrepancy Size Per Inhaler
NCT01857323 (6) [back to overview]	Dosing Discrepancies Per 200 Dose Cycles: Count Up Unknown Dose Cycle
NCT01857323 (6) [back to overview]	Dosing Discrepancies Per 200 Dose Cycles: Dose Cycle Count Up
NCT01857323 (6) [back to overview]	Dosing Discrepancies Per 200 Dose Cycles: Dose Cycle Not Count
NCT01857323 (6) [back to overview]	Dosing Discrepancies Per 200 Dose Cycles: Count Unknown Dose Cycle
NCT01857323 (6) [back to overview]	Participants With Treatment-Emergent Adverse Events
NCT01880723 (5) [back to overview]	Diffusion Capacity of the Lungs for Nitric Oxide
NCT01880723 (5) [back to overview]	Exhaled Sodium (mmol/L)
NCT01880723 (5) [back to overview]	Net Exhaled Chloride
NCT01880723 (5) [back to overview]	Peripheral Oxygen Saturation
NCT01880723 (5) [back to overview]	Diffusion Capacity of the Lungs for Carbon Monoxide
NCT01885936 (3) [back to overview]	Change in Forced Vital Capacity From Pulmonary Function Tests at 30 Weeks and 52 Weeks.
NCT01885936 (3) [back to overview]	Change in 6 Minute Walk Test
NCT01885936 (3) [back to overview]	Number of Participants With Adverse Events.
NCT01899144 (3) [back to overview]	Baseline-Adjusted Area-Under-The-Percent-Predicted Forced Expiratory Volume In 1 Second (FEV1) Versus Time Curve Over 6 Hours Post-Dose
NCT01899144 (3) [back to overview]	Participants With Treatment-Emergent Adverse Events
NCT01899144 (3) [back to overview]	Baseline-Adjusted Area-Under-The- Forced Expiratory Volume In 1 Second (FEV1) Versus Time Curve Over 6 Hours Post-Dose (FEV1 AUC0-6)
NCT01907334 (1) [back to overview]	Total Airway Resistance Increase
NCT01922271 (7) [back to overview]	Forced Expiratory Volume in One Second (FEV1) 15 Min Post Dose
NCT01922271 (7) [back to overview]	Forced Expiratory Volume in One Second (FEV1) Area Under Curve (AUC) 0-2
NCT01922271 (7) [back to overview]	Total Lung Capacity (TLC)
NCT01922271 (7) [back to overview]	Functional Resistance Capacity (FRCpleth)
NCT01922271 (7) [back to overview]	Residual Volume (RV)
NCT01922271 (7) [back to overview]	Specific Airway Resistance (sRAW)
NCT01922271 (7) [back to overview]	Inspiratory Capacity (IC)
NCT01987219 (4) [back to overview]	Change in Respiratory Function (Airway Resistance at 5 Hz) From Baseline
NCT01987219 (4) [back to overview]	Change in Forced Expiratory Volume (FEV) From Baseline
NCT01987219 (4) [back to overview]	Change in Forced Expiratory Flow Between 25-75% (FEF25-75)
NCT01987219 (4) [back to overview]	Change From Baseline of Forced Vital Capacity
NCT01997463 (1) [back to overview]	The Primary Outcome Will be the Score on the Juniper Asthma Control Questionnaire (ACQ)
NCT02031640 (7) [back to overview]	Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)
NCT02031640 (7) [back to overview]	Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)
NCT02031640 (7) [back to overview]	Standardized Baseline-adjusted Trough Morning Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk) )
NCT02031640 (7) [back to overview]	Number of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period
NCT02031640 (7) [back to overview]	Kaplan-Meier Estimates for Time to Withdrawal From Study Treatment Due to Meeting Stopping Criteria for Worsening Asthma
NCT02031640 (7) [back to overview]	Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)
NCT02031640 (7) [back to overview]	Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)
NCT02040766 (6) [back to overview]	Standardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk))
NCT02040766 (6) [back to overview]	Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period
NCT02040766 (6) [back to overview]	Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period
NCT02040766 (6) [back to overview]	Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12
NCT02040766 (6) [back to overview]	Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12
NCT02040766 (6) [back to overview]	Kaplan-Meier Estimates For Time to Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-week Treatment Period
NCT02040779 (10) [back to overview]	Change From Baseline in Weekly Average of Total Daily Asthma Symptom Score Over the 12-Week Treatment Period
NCT02040779 (10) [back to overview]	Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 12 Weeks (AUEC(0-12wk)) by Actual Treatment Received
NCT02040779 (10) [back to overview]	Participants With Potentially Clinically Relevant Abnormal Vital Sign Results During the Treatment Period
NCT02040779 (10) [back to overview]	Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02040779 (10) [back to overview]	Change From Baseline in Weekly Average of Total Daily Use of Albuterol/Salbutamol Inhalation Aerosol Over Weeks 1-12
NCT02040779 (10) [back to overview]	Participants With Findings During Oropharyngeal Examination During Treatment
NCT02040779 (10) [back to overview]	Kaplan-Meier Estimates of Time to Study Drug Treatment Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period
NCT02040779 (10) [back to overview]	Number of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period
NCT02040779 (10) [back to overview]	Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period
NCT02040779 (10) [back to overview]	Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Rate Over the 12-Week Treatment Period
NCT02073747 (1) [back to overview]	Number of Subjects With a Change From Baseline Serum Lactate Following a One Hour Albuterol Nebulizer Treatment.
NCT02126839 (3) [back to overview]	Summary of Participants With Adverse Events
NCT02126839 (3) [back to overview]	Baseline Adjusted Peak Expiratory Flow (PEF) Area Under The Concentration Time Curve Up From Time Zero up to 6 Hours (AUC0-6) Over 3 Weeks
NCT02126839 (3) [back to overview]	Baseline Adjusted Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) Area Under The Concentration Time Curve Up From Time Zero up to 6 Hours (AUC0-6) Over 3 Weeks
NCT02139644 (9) [back to overview]	Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
NCT02139644 (9) [back to overview]	Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old
NCT02139644 (9) [back to overview]	Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT02139644 (9) [back to overview]	Kaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1
NCT02139644 (9) [back to overview]	Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours Postdose (FEV1 AUEC0-12h) at Week 12
NCT02139644 (9) [back to overview]	Kaplan-Meier Estimate of Probability of Remaining in Study At Week 12
NCT02139644 (9) [back to overview]	Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period
NCT02139644 (9) [back to overview]	Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period
NCT02139644 (9) [back to overview]	Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment
NCT02141633 (2) [back to overview]	Echocardiogram
NCT02141633 (2) [back to overview]	Airway Blood Flow
NCT02141854 (9) [back to overview]	Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment
NCT02141854 (9) [back to overview]	Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period
NCT02141854 (9) [back to overview]	Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT02141854 (9) [back to overview]	Kaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1
NCT02141854 (9) [back to overview]	Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours PostDose (FEV1 AUEC0-12) at Week 12
NCT02141854 (9) [back to overview]	Kaplan-Meier Estimate of Probability of Remaining in Study At Week 12
NCT02141854 (9) [back to overview]	Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period
NCT02141854 (9) [back to overview]	Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
NCT02141854 (9) [back to overview]	Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old
NCT02150499 (3) [back to overview]	The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Serious Adverse Events.
NCT02150499 (3) [back to overview]	The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events Leading to Discontinuation.
NCT02150499 (3) [back to overview]	The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events.
NCT02170532 (2) [back to overview]	Change in Maximum Forced Expiratory Volume at One Second (FEV1)
NCT02170532 (2) [back to overview]	Change in 8 Hour Area-under-the-curve FEV1
NCT02175771 (6) [back to overview]	Participants With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT02175771 (6) [back to overview]	Participants With Potentially Clinically Significant Abnormal Vital Signs During the Treatment Period
NCT02175771 (6) [back to overview]	Analysis of 24-Hour Urine Cortisol Free Over the 26-Week Treatment Period
NCT02175771 (6) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Minute (FEV1) Over the 26-Week Treatment Period
NCT02175771 (6) [back to overview]	Participants With Positive Swab Test Results for Oral Candidiasis
NCT02175771 (6) [back to overview]	Shifts From Baseline to Endpoint in Electrocardiogram (ECG) Findings
NCT02233803 (3) [back to overview]	Change From BL in Asthma Control Test (ACT) at 4 Wks for Each TP
NCT02233803 (3) [back to overview]	Change From Baseline (BL) in Trough Morning Forced Expiratory Volume in One Second (FEV1) at Day (D)29
NCT02233803 (3) [back to overview]	FEV1 Area Under the Curve (AUC) (0-10 h) at D1 of Each TP
NCT02257372 (2) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85
NCT02257372 (2) [back to overview]	Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose on Day 84
NCT02257385 (2) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Treatment Day 85 (Visit 8)
NCT02257385 (2) [back to overview]	Change From Baseline in Weighted Mean (WM) FEV1 Over 0-6 Hour Post-dose at Day 84
NCT02275052 (4) [back to overview]	Change From Baseline in Functional Residual Capacity (FRC) 3 Hours Post-dose at Week 12 of Each Treatment Period
NCT02275052 (4) [back to overview]	Change From Baseline in Exercise Endurance Time (EET) Post-dose at Week 12 of Each Treatment Period
NCT02275052 (4) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period
NCT02275052 (4) [back to overview]	Change From Baseline in Inspiratory Capacity (IC) 3 Hours Post-dose at Week 12 of Each Treatment Period
NCT02299375 (23) [back to overview]	Change From Baseline in Spirometry Parameters in Pre and Post Forced Expiratory Volume in 1 Second (FEV1); Pre and Post Forced Vital Capacity (FVC); Pre and Post Forced Expiratory Volume in 6 Seconds (FEV6).
NCT02299375 (23) [back to overview]	Change From Baseline in St Georges Respiratory Questionnaire (SGRQ) Total, SGRQ Symptoms Score, SGRQ Activity Score and SGRQ Impact Score Over Time
NCT02299375 (23) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points
NCT02299375 (23) [back to overview]	Number of Participants With Electrocardiogram (ECG) Findings
NCT02299375 (23) [back to overview]	Annual Rate of Moderate and Severe Exacerbations of COPD
NCT02299375 (23) [back to overview]	Number of Participants With Abnormal Liver Events During the Treatment Period
NCT02299375 (23) [back to overview]	Number of Participants Having Any Adverse Events (AEs), Serious Adverse Events (SAEs)
NCT02299375 (23) [back to overview]	Time to First Occurrence of Moderate or Severe COPD Exacerbation
NCT02299375 (23) [back to overview]	Change From Baseline in Absolute White Blood Cell (WBC) Count, Total Neutrophil, Total Lymphocyte, Basophil, Eosinophil, Monocyte and Platelet Count at the Indicated Time Point
NCT02299375 (23) [back to overview]	Change From Baseline in Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase and Gamma Glutamyl Transferase at the Indicated Time Points
NCT02299375 (23) [back to overview]	Change From Baseline in Spirometry Parameters in Pre and Post FEV1/FVC, Percent Predicted (PP) FEV1, PP FEV6 and PP FVC
NCT02299375 (23) [back to overview]	Change From Baseline in Chloride, Calcium, Glucose, Potassium, Sodium and Blood Urea Nitrogen at the Indicated Time Points
NCT02299375 (23) [back to overview]	Change From Baseline in Eosinophil Percentage at the Indicated Time Points
NCT02299375 (23) [back to overview]	Change From Baseline in Frequency of Short Acting Beta-agonist or Anti-cholinergic Use
NCT02299375 (23) [back to overview]	Plasma Losmapimod Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to the End of Dosing Interval (AUC[0-tau])
NCT02299375 (23) [back to overview]	Change From Baseline in Hematocrit at the Indicated Time Points
NCT02299375 (23) [back to overview]	Change From Baseline in Hemoglobin, Total Protein, Albumin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points
NCT02299375 (23) [back to overview]	Change From Baseline in Mean Corpuscle Hemoglobin at the Indicated Time Points
NCT02299375 (23) [back to overview]	Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points
NCT02299375 (23) [back to overview]	Change From Baseline in Red Blood Cell Count at the Indicated Time Points
NCT02299375 (23) [back to overview]	Change From Baseline in Total Bilirubin, Direct Bilirubin, Uric Acid and Creatinine at the Indicated Time Point
NCT02299375 (23) [back to overview]	Plasma Losmapimod Maximum Concentration (Cmax) and Lowest Concentration (Ctrough) at Steady State
NCT02299375 (23) [back to overview]	Change From Baseline in Heart Rate (HR) Values at the Indicated Time Points
NCT02345161 (49) [back to overview]	Mean Annual On-treatment Moderate and/or Severe COPD Exacerbations up to Week 24
NCT02345161 (49) [back to overview]	Mean Annual On-treatment Moderate and/or Severe COPD Exacerbations up to Week 52
NCT02345161 (49) [back to overview]	Number of Participants With an On-treatment Penumonia Event in the Extension Part of the Study
NCT02345161 (49) [back to overview]	Number of Participants With an On-treatment Penumonia Event in the Treatment Period
NCT02345161 (49) [back to overview]	Number of Participants With Any Abnormal Holter Electrocardiogram (ECG) Finding at Week 24
NCT02345161 (49) [back to overview]	Number of Participants With at Least One On-treatment Bone Fracture Incident in the Extension Part of the Study
NCT02345161 (49) [back to overview]	Number of Participants With at Least One On-treatment Bone Fracture Incident in the Treatment Period
NCT02345161 (49) [back to overview]	Transitional Dyspnea Index (TDI) Focal Score Expressed as Least Square Mean at Week 24
NCT02345161 (49) [back to overview]	Transitional Dyspnea Index (TDI) Focal Score Expressed as Least Square Mean at Week 52
NCT02345161 (49) [back to overview]	Assessment of Respiratory Symptoms by Change From Baseline in 4-weekly Mean Exacerbations of Chronic Pulmonary Disease Tool (EXACT)-RS Scores up to Week 24
NCT02345161 (49) [back to overview]	Assessment of Respiratory Symptoms by Change From Baseline in 4-weekly Mean EXACT-RS Scores up to Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Hemoglobin at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in QTcF and PR Interval at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Systolic and Diastolic Blood Pressures (BP) at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in Systolic and Diastolic Blood Pressures (BP) at Week 52
NCT02345161 (49) [back to overview]	Number of Participants Reporting an Adverse Event of Special Interest (AESI) of Oropharyngeal Origin in the Treatment Period
NCT02345161 (49) [back to overview]	Number of Participants With Any On-treatment Adverse Event (AE) and Serious Adverse Event (SAE) in the Treatment Period
NCT02345161 (49) [back to overview]	Number of Participants With Any On-treatment AE/SAEs in the Extension Part of the Study
NCT02345161 (49) [back to overview]	Number of Participants With Any On-treatment Cardiovascular (CV) Events (Including Supraventricular Arrhythmia and Non Fatal Myocardial Infarction) in the Treatment Period
NCT02345161 (49) [back to overview]	Number of Participants With Any On-treatment CV Events (Including Supraventricular Arrhythmia and Non Fatal Myocardial Infarction) in the Extension Part of the Study
NCT02345161 (49) [back to overview]	Change From Baseline in Glucose, Calcium, Carbon Dioxide (CO2), Chloride, Phosphate, Potassium, Sodium, and Urea at Week 24
NCT02345161 (49) [back to overview]	Number of Participants Reporting an AESI of Oropharyngeal Origin in the Extension Part of the Study
NCT02345161 (49) [back to overview]	Change From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Aminotransferase (GGT), Alkaline Phosphatase (ALP), and Creatine Kinase at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24
NCT02345161 (49) [back to overview]	Daily Activity Question Percentage of Days Reporting a Score of 2 up to Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in Corrected QT Interval Using Fridericia's Correction (QTcF) and PR Interval at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in Hemoglobin at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in Hematocrit at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Hematocrit at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in Glucose, Calcium, CO2, Chloride, Magnesium, Phosphate, Potassium, Sodium, and Urea at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Erythrocytes at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Erythrocytes at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in Bilirubin, Creatinine, and Urate at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Bilirubin, Creatinine, and Urate at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in Basophils, Eosinophils, Monocytes, Neutrophils, Leukocytes, Lymphocytes, and Platelets at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Basophils, Eosinophils, Monocytes, Neutrophils, Leukocytes, Lymphocytes, and Platelets at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in ALT, AST, GGT, ALP, and Creatine Kinase at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Albumin and Protein at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Albumin and Protein at Week 24
NCT02345161 (49) [back to overview]	Daily Activity Question Percentage of Days Reporting a Score of 2 up to Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Heart Rate at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in Heart Rate at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in Pulse Rate at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in Pulse Rate at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB) at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in QTcB at Week 52
NCT02345161 (49) [back to overview]	Change From Baseline in St George's Respiratory Questionnaire-Chronic Obstructive Pulmonary Disease (COPD; SGRQ) Total Score for COPD Participants at Week 24
NCT02345161 (49) [back to overview]	Change From Baseline in St George's Respiratory Questionnaire-COPD; SGRQ Total Score for COPD Participants at Week 52
NCT02371629 (15) [back to overview]	Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 12
NCT02371629 (15) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
NCT02371629 (15) [back to overview]	Change From Baseline in Area Under The Curve (AUC 0-12 Hour) for Forced Expiratory Volume in One Second (FEV1) Post Dosing at Day 1
NCT02371629 (15) [back to overview]	Percentage of Patients With a Clinically Significant Improvement in St George Respiratory Questionnaire at Week 12 and Week 26
NCT02371629 (15) [back to overview]	Percentage of Patients With a Clinically Important Improvement on Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26
NCT02371629 (15) [back to overview]	Number of Patients With Adverse Events, Serious Adverse Events and Death
NCT02371629 (15) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in the Percentage of Days With no Rescue Medication Use Over the 26 Weeks
NCT02371629 (15) [back to overview]	Change From Baseline in Transitional Dyspnea Index (TDI) Focal Score at Week 12 and Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Total St. George's Respiratory Questionnaire (SGRQ) Score at Week 12 and Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Mean Daily COPD Symptom Score at Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Inspiratory Capacity (IC) at Individual Timepoints at Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Forced Vital Capacity (FVC) at Individual Timepoints at Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Individual Timepoints at Week 26
NCT02371629 (15) [back to overview]	Change From Baseline in Area Under The Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) for Different Time Spans Post Dosing at Week 26
NCT02414854 (39) [back to overview]	Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 24: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Asthma Control Questionnaire 7-item Version (ACQ-7) Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ [S]) Self-Administered Global Score at Week 24: ITT Population
NCT02414854 (39) [back to overview]	Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L
NCT02414854 (39) [back to overview]	Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population
NCT02414854 (39) [back to overview]	Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Weeks 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Morning (AM)/Evening (PM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Number of Puffs of Daily Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, Ages 12+ (RQLQ[S]+12) Score at Weeks 12, 24, 36, and 52: ITT Population With Comorbid Allergic Rhinitis
NCT02414854 (39) [back to overview]	Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Time to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in 22-Item Sino Nasal Outcome Test (SNOT-22) Score at Weeks 12, 24, 36, and 52: ITT Population With Bilateral Nasal Polyposis/Chronic Rhinosinusitis
NCT02414854 (39) [back to overview]	Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline
NCT02414854 (39) [back to overview]	Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L
NCT02414854 (39) [back to overview]	Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L
NCT02414854 (39) [back to overview]	Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population
NCT02414854 (39) [back to overview]	Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population
NCT02414854 (39) [back to overview]	Annualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population
NCT02414854 (39) [back to overview]	Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline
NCT02414854 (39) [back to overview]	Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L
NCT02414854 (39) [back to overview]	Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population
NCT02414854 (39) [back to overview]	Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline
NCT02414854 (39) [back to overview]	Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L
NCT02414854 (39) [back to overview]	Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L
NCT02414854 (39) [back to overview]	Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L
NCT02414854 (39) [back to overview]	Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L
NCT02414854 (39) [back to overview]	Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in ACQ-5 Score at Weeks 2, 4, 8, 12, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Change From Baseline in AQLQ (S) Self- Administered Global Score at Week 24: ITT Population With Baseline Eosinophil >=0.3 Giga/L
NCT02414854 (39) [back to overview]	Change From Baseline in AQLQ (S) Self-Administered Global Score at Weeks 12, 36, and 52: ITT Population
NCT02414854 (39) [back to overview]	Percent Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population
NCT02447250 (8) [back to overview]	Etiology of Preterm Delivery
NCT02447250 (8) [back to overview]	Maternal BMI at Time of Pregnancy and Likelihood of Positive Response to Albuterol
NCT02447250 (8) [back to overview]	Birth Weight of Albuterol Responders vs Non Responders
NCT02447250 (8) [back to overview]	Number of Participants With Positive Response at Different Albuterol Doses
NCT02447250 (8) [back to overview]	Association of Smoke Exposure During Pregnancy and Neonatal Response to Albuterol
NCT02447250 (8) [back to overview]	Gestational Age at Birth
NCT02447250 (8) [back to overview]	Change in Respiratory Resistance
NCT02447250 (8) [back to overview]	Family History of Asthma and Likelihood to Respond to Albuterol
NCT02478398 (7) [back to overview]	Percentage of Participants Reporting Pre-specified Local Application Site Reactions
NCT02478398 (7) [back to overview]	Percentage of Participants Reporting Anaphylaxis and/or Systemic Allergic Reactions
NCT02478398 (7) [back to overview]	Average TCS During the Entire RS
NCT02478398 (7) [back to overview]	Average Rhinoconjunctivitis (RC) DSS During the Peak RS
NCT02478398 (7) [back to overview]	Average Rhinoconjunctivitis (RC) DMS During the Peak RS
NCT02478398 (7) [back to overview]	Total Combined Score (TCS) During the Peak Ragweed Season (RS)
NCT02478398 (7) [back to overview]	Percentage of Participants Treated With Epinephrine
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of Night-time Awakenings
NCT02479412 (26) [back to overview]	Rate and Extent of Absorption of Three Dose Levels of AZD7594 Following Multiple Dose Administration by Assessment of AUC(0-24) of AZD7594
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of the Change From Baseline to Day 8 in Asthma Control Questionnaire-5
NCT02479412 (26) [back to overview]	Number of Participants With Adverse Events
NCT02479412 (26) [back to overview]	Rate and Extent of Absorption of Three Dose Levels of AZD7594 Following Multiple Dose Administration by Assessment of AUC(0-last) of AZD7594
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of the Change From Baseline to Day 15 in Asthma Control Questionnaire-5
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of the Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) on Day 8
NCT02479412 (26) [back to overview]	Rate and Extent of Absorption of Three Dose Levels of AZD7594 Following Multiple Dose Administration by Assessment of Cmax/D of AZD7594
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of the Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) on Day 15
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of the Change From Baseline in Evening Peak Expiratory Flow (ePEF) Before Administration Over the Treatment Period
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of the Change From Baseline in Average Daily Use of Rescue Salbutamol Over the Treatment Period
NCT02479412 (26) [back to overview]	Rate and Extent of Absorption of Three Dose Levels of AZD7594 Following Multiple Dose Administration by Assessment of Cmax,ss of AZD7594
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of Daily Symptom Score
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of Asthma Control Days
NCT02479412 (26) [back to overview]	Rate and Extent of Absorption of Three Dose Levels of AZD7594 Following Multiple Dose Administration by Assessment of Cmin of AZD7594
NCT02479412 (26) [back to overview]	Rate and Extent of Absorption of Three Dose Levels of AZD7594 Following Multiple Dose Administration by Assessment of Cavg,ss of AZD7594
NCT02479412 (26) [back to overview]	Rate and Extent of Absorption of Three Dose Levels of AZD7594 Following Multiple Dose Administration by Assessment of Tmax,ss of AZD7594
NCT02479412 (26) [back to overview]	Rate and Extent of Absorption of Three Dose Levels of AZD7594 Following Multiple Dose Administration by Assessment of AUC(0-24)/D of AZD7594
NCT02479412 (26) [back to overview]	Rate and Extent of Absorption of Three Dose Levels of AZD7594 by Assessment of AUC(0-4) of AZD7594
NCT02479412 (26) [back to overview]	Rate and Extent of Absorption of Three Dose Levels of AZD7594 by Assessment of Cmax of AZD7594
NCT02479412 (26) [back to overview]	Rate and Extent of Absorption of Three Dose Levels of AZD7594 by Assessment of Tmax of AZD7594
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of the Change From Baseline in Trough Forced Vital Capacity (FVC) on Day 8
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of the Change From Baseline in Trough Forced Vital Capacity (FVC) on Day 15
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of the Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) on Day 8
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of the Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) on Day 15
NCT02479412 (26) [back to overview]	Efficacy of AZD7594 by Assessment of the Change From Baseline in Morning Peak Expiratory Flow (mPEF) Before Administration Over the Treatment Period
NCT02483975 (5) [back to overview]	Change From Baseline (Expressed as a Ratio) in 24-hour Urinary Cortisol Excretion at the End of the Six Week Treatment Period (Day 42)
NCT02483975 (5) [back to overview]	Change From Baseline (Expressed as a Ratio) in 0-24 Hour Weighted Mean Serum Cortisol at the End of the Six Week Treatment Period (D 42) in Intention-to-treat (ITT) Population
NCT02483975 (5) [back to overview]	Change From Baseline (Expressed as a Ratio) in 0-24 Hour Weighted Mean Serum Cortisol at the End of the Six Week Treatment Period (Day 42) in SC Population
NCT02483975 (5) [back to overview]	Change From Baseline (Expressed as a Ratio) in 24-hour 6-beta Hydroxycortisol Excretion at the End of the Six Week Treatment Period (Day 42).
NCT02483975 (5) [back to overview]	Change From Baseline (Expressed as a Ratio) in Area Under the Curve (AUC) 0-24 Hour Serum Cortisol at the End of the Six Week Treatment Period (Day 42).
NCT02502734 (2) [back to overview]	Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Event (SAE).
NCT02502734 (2) [back to overview]	Mean Growth Rate in Lower-leg Growth, as Determined by Knemometry.
NCT02513160 (7) [back to overview]	Change From Baseline in Weekly Average of Daily Trough Morning Forced Expiratory Volume in One Minute (FEV1) Rate Over the 6-Week Treatment Period
NCT02513160 (7) [back to overview]	Change From Baseline in Weekly Average of Total Daily Asthma Symptom Score Over the 6-Week Treatment Period
NCT02513160 (7) [back to overview]	Change From Baseline in Weekly Average of Total Daily (24-Hour) Rescue Medication Use Over the 6-Week Treatment Period
NCT02513160 (7) [back to overview]	Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Rate Over the 6-Week Treatment Period
NCT02513160 (7) [back to overview]	Count of Participants Withdrawn From Study Drug Treatment Due to Meeting Stopping Criteria for Worsening Asthma
NCT02513160 (7) [back to overview]	Participants With Treatment-Emergent Adverse Events (TEAE)
NCT02513160 (7) [back to overview]	Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 6 Weeks (AUEC(0-6wk))
NCT02528214 (14) [back to overview]	Percentage of Participants Achieving Maximum Possible Reduction in Oral Corticosteroids Dose Per Protocol at Week 24 While Maintaining Asthma Control
NCT02528214 (14) [back to overview]	Percentage of Participants Who No Longer Required Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
NCT02528214 (14) [back to overview]	Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control
NCT02528214 (14) [back to overview]	Supplementary Presentation of Primary Outcome Measure Data: Median Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
NCT02528214 (14) [back to overview]	Absolute Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
NCT02528214 (14) [back to overview]	Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Score at Weeks 2, 4, 8, 12, 16, 20, and 24
NCT02528214 (14) [back to overview]	Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12 and Week 24
NCT02528214 (14) [back to overview]	Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Week 12 and Week 24
NCT02528214 (14) [back to overview]	Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Weeks 12 and 24
NCT02528214 (14) [back to overview]	Change From Baseline in Sino Nasal Outcome Test-22 (SNOT-22) Global Score at Week 12 and Week 24
NCT02528214 (14) [back to overview]	Annualized Rate of Severe Exacerbation Events During The 24-Week Treatment Period
NCT02528214 (14) [back to overview]	Percentage of Participants Achieving >= 50% Reduction in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
NCT02528214 (14) [back to overview]	Percentage of Participants Achieving a Reduction in Oral Corticosteroids Dose to <5 mg/Day at Week 24 While Maintaining Asthma Control
NCT02528214 (14) [back to overview]	Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Week 12 and Week 24
NCT02566902 (9) [back to overview]	Change in PAS Score (Points on a Scale)
NCT02566902 (9) [back to overview]	Change in PASS Score (Points on a Scale)
NCT02566902 (9) [back to overview]	Change Respiratory Rate (Breaths Per Minute)
NCT02566902 (9) [back to overview]	Emergency Department Length of Stay (Minutes)
NCT02566902 (9) [back to overview]	Percentage of Patients Experiencing Medication Side Effects (%)
NCT02566902 (9) [back to overview]	Percentage of Patients Requiring Inpatient Hospital Admission (% of Subjects)
NCT02566902 (9) [back to overview]	Change in Heart Rate (Beats Per Minute)
NCT02566902 (9) [back to overview]	Total Quantity of Albuterol Given in the Emergency Department (mg)
NCT02566902 (9) [back to overview]	Change in FEV1 (% Predicted)
NCT02573870 (1) [back to overview]	Change From Baseline in 0 to 4 Hours Post-dose Weighted Mean Heart Rate at Day 42, Derived From Electrocardiograms (ECGs)
NCT02584257 (1) [back to overview]	Post-dose PC20 Concentration After Receiving Differing Doses of Test, Reference, or Placebo
NCT02654145 (4) [back to overview]	Mean Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 32
NCT02654145 (4) [back to overview]	Mean Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Score at Week 32
NCT02654145 (4) [back to overview]	Ratio to Baseline in Blood Eosinophil Count at Week 32
NCT02654145 (4) [back to overview]	The Rate of Clinically Significant Asthma Exacerbations Over 32 Weeks' Treatment
NCT02720081 (26) [back to overview]	Change From Baseline in White Blood Cell Count at Week 6
NCT02720081 (26) [back to overview]	Change From Baseline in Systolic Blood Pressure at Week 6
NCT02720081 (26) [back to overview]	Change From Baseline in Systolic Blood Pressure at Week 4
NCT02720081 (26) [back to overview]	Change From Baseline in Systolic Blood Pressure at Week 2
NCT02720081 (26) [back to overview]	Change From Baseline in Respiratory Rate at Week 4
NCT02720081 (26) [back to overview]	Change From Baseline in Respiratory Rate at Week 6
NCT02720081 (26) [back to overview]	Average Change From Baseline in Pre-dose FEV1 at Week 4 and Week 6
NCT02720081 (26) [back to overview]	Baseline Pre-dose Forced Expiratory Volume in One Second (FEV1)
NCT02720081 (26) [back to overview]	Percentage of Days With Worsening Asthma Average Over Weeks 3 to 6
NCT02720081 (26) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an AE
NCT02720081 (26) [back to overview]	Change From Baseline in Hematocrit (%) at Week 6
NCT02720081 (26) [back to overview]	Change From Baseline in Respiratory Rate at Week 2
NCT02720081 (26) [back to overview]	Change From Baseline in Platelet Count at Week 6
NCT02720081 (26) [back to overview]	Change From Baseline in Neutrophil (%) at Week 6
NCT02720081 (26) [back to overview]	Change From Baseline in Heart Rate at Week 6
NCT02720081 (26) [back to overview]	Change From Baseline in Diastolic Blood Pressure at Week 4
NCT02720081 (26) [back to overview]	Change From Baseline in Diastolic Blood Pressure at Week 2
NCT02720081 (26) [back to overview]	Change From Baseline in Heart Rate at Week 4
NCT02720081 (26) [back to overview]	Change From Baseline in Heart Rate at Week 2
NCT02720081 (26) [back to overview]	Change From Baseline in Eosinophil (Percent [%]) at Week 6
NCT02720081 (26) [back to overview]	Change From Baseline in Diastolic Blood Pressure at Week 6
NCT02720081 (26) [back to overview]	Change From Baseline in Bilirubin at Week 6
NCT02720081 (26) [back to overview]	Change From Baseline in Alanine Aminotransferase (ALT) at Week 6
NCT02720081 (26) [back to overview]	Change From Baseline in Alkaline Phosphatase (ALP) at Week 6
NCT02720081 (26) [back to overview]	Change From Baseline in Aspartate Aminotransferase (AST) at Week 6
NCT02720081 (26) [back to overview]	Percentage of Participants Who Experienced an Adverse Event (AE)
NCT02729051 (6) [back to overview]	Change From Baseline in SGRQ Total Score at Week 24
NCT02729051 (6) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24
NCT02729051 (6) [back to overview]	Percentage of Responders Based on the Saint (St) George Respiratory Questionnaire (SGRQ) Total Score at Week 24
NCT02729051 (6) [back to overview]	Percentage of Responders Based on Transitional Dyspnea Index (TDI) Focal Score at Week 24
NCT02729051 (6) [back to overview]	TDI Focal Score at Week 24
NCT02729051 (6) [back to overview]	Time to First Moderate or Severe Exacerbation
NCT02740660 (4) [back to overview]	Number of Participants With Adverse Events
NCT02740660 (4) [back to overview]	Change in Lean Mass With Caffeine/Albuterol
NCT02740660 (4) [back to overview]	Change in Fat Mass With Caffeine/Albuterol
NCT02740660 (4) [back to overview]	Change in Weight With Caffeine/Albuterol
NCT02741271 (13) [back to overview]	Change From Baseline in Morning (AM) Post-Dose % Predicted Forced Expiratory Volume in One Second (FEV1) in the Area Under the Curve (AUC)0-60
NCT02741271 (13) [back to overview]	Change From Baseline in AM Pre-Dose % Predicted FEV1 With MF/F MDI 100/10 mcg BID or MF MDI 100 mcg BID Over the First 12 Weeks of Treatment
NCT02741271 (13) [back to overview]	Change From Baseline AM Post-Dose Percent Predicted FEV1 on Day 1 of Treatment
NCT02741271 (13) [back to overview]	Change From Baseline AM Post-Dose % Predicted FEV1 AUC 0-4 Hours on Day 1 and Week 12 of Treatment
NCT02741271 (13) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Mometsone Furoate
NCT02741271 (13) [back to overview]	Participants Whose SABA Rescue Medication Use Increased Across Weeks 1-12 of the Treatment Period
NCT02741271 (13) [back to overview]	Maximum Plasma Concentration (Cmax) of Mometsone Furoate
NCT02741271 (13) [back to overview]	Mean Change From Baseline in Total Daily Use of Short-Acting Beta-Agonist (SABA) Rescue Medication With MF/F MDI 100/10 mcg BID or MF MDI 100 mcg BID Over the First 12 Weeks of Treatment
NCT02741271 (13) [back to overview]	Count (Percentage) of Participants Experiencing At Least One Adverse Event (AE)
NCT02741271 (13) [back to overview]	Count (Percentage) of Participants Discontinuing From Study Medication Due to An AE
NCT02741271 (13) [back to overview]	Area Under the Plasma Concentration-Time Curve of Mometasone Furoate From Time 0 to Time of Last Measurable Concentration (AUC0-last)
NCT02741271 (13) [back to overview]	Area Under the Plasma Concentration-Time Curve of Mometasone Furoate From Time 0 to 12 Hours (AUC0-12)
NCT02741271 (13) [back to overview]	Participants Using SABA Rescue Medication Across Weeks 1-12 of the Treatment Period
NCT02766673 (2) [back to overview]	Change in Expiratory Flow Between Pre and Post-medication Dosing
NCT02766673 (2) [back to overview]	Percent Change in Heart Rate (Beats/Min) Between Pre and Post-medication Dosing
NCT02799784 (1) [back to overview]	Trough Forced Expiratory Volume in One Second (FEV1) at Week 8
NCT02802111 (2) [back to overview]	Oxygen Consumption
NCT02802111 (2) [back to overview]	Heart Rate
NCT02885636 (14) [back to overview]	Change in Resting Cardiac Output
NCT02885636 (14) [back to overview]	Change in 20 Watt Exercise Pulmonary Vascular Resistance (PVR)
NCT02885636 (14) [back to overview]	Change in Exercise Cardiac Output
NCT02885636 (14) [back to overview]	Change in Exercise Pulmonary Artery Compliance
NCT02885636 (14) [back to overview]	Change in Exercise Pulmonary Artery Pressure
NCT02885636 (14) [back to overview]	Change in Exercise Pulmonary Capillary Wedge Pressure (PCWP)
NCT02885636 (14) [back to overview]	Change in Exercise Pulmonary Elastance
NCT02885636 (14) [back to overview]	Change in Exercise Right Atrial Pressure (RA)
NCT02885636 (14) [back to overview]	Change in Resting Pulmonary Artery Compliance
NCT02885636 (14) [back to overview]	Change in Resting Pulmonary Artery Pressure
NCT02885636 (14) [back to overview]	Change in Resting Pulmonary Capillary Wedge Pressure (PCWP)
NCT02885636 (14) [back to overview]	Change in Resting Pulmonary Elastance
NCT02885636 (14) [back to overview]	Change in Resting Pulmonary Vascular Resistance
NCT02885636 (14) [back to overview]	Change in Resting Right Atrial Pressure (RA)
NCT02924688 (12) [back to overview]	Annualized Rate of Moderate and Severe Asthma Exacerbations
NCT02924688 (12) [back to overview]	Number of Participants With Abnormal Electrocardiogram (ECG) Findings
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Asthma Control Questionnaire-7 (ACQ-7) Total Score at Week 24
NCT02924688 (12) [back to overview]	Number of Participants With Any Serious Adverse Event (SAE) and Common (>=3%) Non-SAE
NCT02924688 (12) [back to overview]	Number of Participants With Abnormal Hematology Values
NCT02924688 (12) [back to overview]	Number of Participants With Abnormal Clinical Chemistry Values
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Clinic FEV1 at 3 Hours Post Study Treatment at Week 24
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Evaluating Respiratory Symptoms (E-RS) Total Score Over Weeks 21 to 24 (Inclusive) of the Treatment Period
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Pulse Rate at Week 24
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Week 24
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 24
NCT02969408 (5) [back to overview]	Number of Albuterol Uses in the 24 Hours Preceding a Severe CAE
NCT02969408 (5) [back to overview]	Clinical Asthma Exacerbation (CAE) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CAE
NCT02969408 (5) [back to overview]	Number of Days Prior to the Peak of a Severe CAE When Albuterol Use Increased
NCT02969408 (5) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT02969408 (5) [back to overview]	Total Number of Inhalations in the Days Preceding the Peak of a Severe CAE
NCT03012061 (6) [back to overview]	Number of Participants With On-treatment Abnormal Electrocardiograms (ECG) Findings
NCT03012061 (6) [back to overview]	Number of Participants With On-treatment Adverse Events (AE), Non-serious Adverse Events (Non-SAE)
NCT03012061 (6) [back to overview]	Mean Change From Baseline in Clinic FEV1 at 3 Hours Post Dose at Week 24
NCT03012061 (6) [back to overview]	Mean Change From Baseline in Clinic Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24
NCT03012061 (6) [back to overview]	Mean Change From Baseline in On-treatment Pulse Rate
NCT03012061 (6) [back to overview]	Mean Change From Baseline in On-treatment Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT03137303 (1) [back to overview]	Total Number of Healthcare Visits
NCT03184987 (20) [back to overview]	Change From Baseline in Hematology Parameter: Eosinophils/Leukocytes
NCT03184987 (20) [back to overview]	Change From Baseline in Chemistry Parameters: Calcium, Glucose, Potassium, Sodium, Urea
NCT03184987 (20) [back to overview]	Number of Participants With Worst Case Post-Baseline Urinalysis Results Relative to Baseline
NCT03184987 (20) [back to overview]	Change From Baseline in Hematology Parameter: Hemoglobin
NCT03184987 (20) [back to overview]	Change From Baseline in Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin
NCT03184987 (20) [back to overview]	Change From Baseline in Chemistry Parameters: Albumin, Protein
NCT03184987 (20) [back to overview]	Change From Baseline in Chemistry Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase
NCT03184987 (20) [back to overview]	Change From Baseline in Hematology Parameter: Hematocrit
NCT03184987 (20) [back to overview]	Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
NCT03184987 (20) [back to overview]	Change From Baseline in Hematology Parameter: Lymphocytes/Leukocytes
NCT03184987 (20) [back to overview]	Change From Baseline in Hematology Parameter: Monocytes/Leukocytes
NCT03184987 (20) [back to overview]	Change From Baseline in Hematology Parameter: Neutrophils/Leukocytes
NCT03184987 (20) [back to overview]	Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
NCT03184987 (20) [back to overview]	Change From Baseline in Hematology Parameter: Platelet Count
NCT03184987 (20) [back to overview]	Change From Baseline in PR Interval and QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)
NCT03184987 (20) [back to overview]	Change From Baseline in Pulse Rate
NCT03184987 (20) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT03184987 (20) [back to overview]	Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
NCT03184987 (20) [back to overview]	Change From Baseline in Hematology Parameter: Basophils/Leukocytes
NCT03184987 (20) [back to overview]	Change From Baseline in Hematology Parameter: Erythrocytes
NCT03256695 (5) [back to overview]	Number of Albuterol Uses in the 24 Hours Preceding a CE-COPD
NCT03256695 (5) [back to overview]	Number of Days Prior to the Symptom Peak of a CE-COPD Event When Albuterol Use Increased
NCT03256695 (5) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT03256695 (5) [back to overview]	Total Number of Albuterol Inhalations in the Days Preceding the Symptom Peak of a CE-COPD Event
NCT03256695 (5) [back to overview]	Clinical Exacerbation of COPD (CE-COPD) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CE-COPD
NCT03270332 (2) [back to overview]	Change in Pulmonary Vascular Resistance (PVR)
NCT03270332 (2) [back to overview]	Change in Mean Pulmonary Artery Pressure (MPAP)
NCT03287310 (131) [back to overview]	Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein
NCT03287310 (131) [back to overview]	Ratio to Baseline in Absolute Blood Eosinophil Count
NCT03287310 (131) [back to overview]	Ratio to Baseline in Absolute Blood Eosinophil Count
NCT03287310 (131) [back to overview]	Ratio to Baseline in Absolute Blood Eosinophil Count
NCT03287310 (131) [back to overview]	Ratio to Baseline in Absolute Blood Eosinophil Count
NCT03287310 (131) [back to overview]	Urine Potential of Hydrogen (pH) Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Urine Potential of Hydrogen (pH) Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Urine Potential of Hydrogen (pH) Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Urine Potential of Hydrogen (pH) Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Urine Potential of Hydrogen (pH) Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Urine Potential of Hydrogen (pH) Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Urine Specific Gravity Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval
NCT03287310 (131) [back to overview]	Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval
NCT03287310 (131) [back to overview]	Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval
NCT03287310 (131) [back to overview]	Urine Specific Gravity Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Urine Specific Gravity Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count
NCT03287310 (131) [back to overview]	Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count
NCT03287310 (131) [back to overview]	Urine Specific Gravity Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Urine Specific Gravity Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Urine Specific Gravity Analysis by Dipstick Method
NCT03287310 (131) [back to overview]	Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count
NCT03287310 (131) [back to overview]	Change From Baseline in Mean Corpuscle Volume (MCV)
NCT03287310 (131) [back to overview]	Change From Baseline in Mean Corpuscle Volume (MCV)
NCT03287310 (131) [back to overview]	Change From Baseline in Mean Corpuscle Volume (MCV)
NCT03287310 (131) [back to overview]	Change From Baseline in Mean Corpuscle Volume (MCV)
NCT03287310 (131) [back to overview]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)
NCT03287310 (131) [back to overview]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)
NCT03287310 (131) [back to overview]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)
NCT03287310 (131) [back to overview]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH)
NCT03287310 (131) [back to overview]	Change From Baseline in Hemoglobin
NCT03287310 (131) [back to overview]	Change From Baseline in Hemoglobin
NCT03287310 (131) [back to overview]	Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein
NCT03287310 (131) [back to overview]	Change From Baseline in Hemoglobin
NCT03287310 (131) [back to overview]	Change From Baseline in Hemoglobin
NCT03287310 (131) [back to overview]	Change From Baseline in Hematocrit
NCT03287310 (131) [back to overview]	Change From Baseline in Hematocrit
NCT03287310 (131) [back to overview]	Change From Baseline in Hematocrit
NCT03287310 (131) [back to overview]	Change From Baseline in Hematocrit
NCT03287310 (131) [back to overview]	Change From Baseline in Heart Rate: Electrocardiogram (ECG)
NCT03287310 (131) [back to overview]	AUC(0-t) of GSK3511294 300 mg
NCT03287310 (131) [back to overview]	CL/F of GSK3511294 30 mg and 100 mg
NCT03287310 (131) [back to overview]	CL/F of GSK3511294 300 mg
NCT03287310 (131) [back to overview]	Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count
NCT03287310 (131) [back to overview]	Cmax of GSK3511294 30 mg and 100 mg
NCT03287310 (131) [back to overview]	Cmax of GSK3511294 300 mg
NCT03287310 (131) [back to overview]	Lambda_z of GSK3511294 30 mg and 100 mg
NCT03287310 (131) [back to overview]	Lambda_z of GSK3511294 300 mg
NCT03287310 (131) [back to overview]	Maximum Observed Concentration (Cmax) of GSK3511294 2 mg and 10 mg
NCT03287310 (131) [back to overview]	Percentage of AUC (0-inf) Obtained by Extrapolation (%AUCex) of GSK3511294 2 mg and 10 mg
NCT03287310 (131) [back to overview]	T1/2 of GSK3511294 30 mg and 100 mg
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP)
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP)
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP)
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin
NCT03287310 (131) [back to overview]	AUC(0-inf) of GSK3511294 300 mg
NCT03287310 (131) [back to overview]	AUC(0-inf) of GSK3511294 30 mg and 100 mg
NCT03287310 (131) [back to overview]	Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK3511294 2 mg and 10 mg
NCT03287310 (131) [back to overview]	Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK3511294 2 mg and 10 mg
NCT03287310 (131) [back to overview]	T1/2 of GSK3511294 300 mg
NCT03287310 (131) [back to overview]	Terminal Phase Elimination Rate Constant (Lambda_z) of GSK3511294 2 mg and 10 mg
NCT03287310 (131) [back to overview]	Terminal Phase Half-life (t1/2) of GSK3511294 2 mg and 10 mg
NCT03287310 (131) [back to overview]	Time of Last Quantifiable Concentration (Tlast) of GSK3511294 2 mg and 10 mg
NCT03287310 (131) [back to overview]	Time of Occurrence of Cmax (Tmax) of GSK3511294 2 mg and 10 mg
NCT03287310 (131) [back to overview]	Titers of Binding ADA to GSK3511294
NCT03287310 (131) [back to overview]	Tlast of GSK3511294 30 mg and 100 mg
NCT03287310 (131) [back to overview]	Tlast of GSK3511294 300 mg
NCT03287310 (131) [back to overview]	Tmax of GSK3511294 30 mg and 100 mg
NCT03287310 (131) [back to overview]	Tmax of GSK3511294 300 mg
NCT03287310 (131) [back to overview]	Vd/F of GSK3511294 30 mg and 100 mg
NCT03287310 (131) [back to overview]	Vd/F of GSK3511294 300 mg
NCT03287310 (131) [back to overview]	Absolute Values of Complement (C)3 and C4
NCT03287310 (131) [back to overview]	Absolute Values of Complement (C)3 and C4
NCT03287310 (131) [back to overview]	Absolute Values of Complement (C)3 and C4
NCT03287310 (131) [back to overview]	Absolute Values of Complement (C)3 and C4
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine
NCT03287310 (131) [back to overview]	Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein
NCT03287310 (131) [back to overview]	Area Under the Concentration-time Curve From Time Zero to Week 4 (AUC[0-Week 4]) of GSK3511294
NCT03287310 (131) [back to overview]	Area Under the Concentration-time Curve From Time Zero to Week 26 (AUC [0-Week 26]) of GSK3511294
NCT03287310 (131) [back to overview]	Area Under the Concentration-time Curve From Time Zero to Week 12 (AUC[0-Week 12]) of GSK3511294
NCT03287310 (131) [back to overview]	Change From Baseline in Heart Rate
NCT03287310 (131) [back to overview]	Change From Baseline in Heart Rate
NCT03287310 (131) [back to overview]	Change From Baseline in Heart Rate
NCT03287310 (131) [back to overview]	Change From Baseline in Heart Rate
NCT03287310 (131) [back to overview]	Change From Baseline in Heart Rate: Electrocardiogram (ECG)
NCT03287310 (131) [back to overview]	Change From Baseline in Heart Rate: Electrocardiogram (ECG)
NCT03287310 (131) [back to overview]	Apparent Volume of Distribution After Subcutaneous Administration (Vd/F) of GSK3511294 2 mg and 10 mg
NCT03287310 (131) [back to overview]	Apparent Clearance Following Subcutaneous Dosing (CL/F) of GSK3511294 2 mg and 10 mg
NCT03287310 (131) [back to overview]	%AUCex of GSK3511294 300 mg
NCT03287310 (131) [back to overview]	%AUCex of GSK3511294 30 mg and 100 mg
NCT03287310 (131) [back to overview]	Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP)
NCT03287310 (131) [back to overview]	Change From Baseline in Heart Rate: Electrocardiogram (ECG)
NCT03287310 (131) [back to overview]	Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein
NCT03287310 (131) [back to overview]	AUC(0-t) of GSK3511294 30 mg and 100 mg
NCT03287310 (131) [back to overview]	Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval
NCT03287310 (131) [back to overview]	Change From Baseline in Red Blood Cell Count (RBC)
NCT03287310 (131) [back to overview]	Change From Baseline in Red Blood Cell Count (RBC)
NCT03287310 (131) [back to overview]	Change From Baseline in Red Blood Cell Count (RBC)
NCT03287310 (131) [back to overview]	Change From Baseline in Red Blood Cell Count (RBC)
NCT03287310 (131) [back to overview]	Change From Baseline in Respiration Rate
NCT03287310 (131) [back to overview]	Change From Baseline in Respiration Rate
NCT03287310 (131) [back to overview]	Change From Baseline in Respiration Rate
NCT03287310 (131) [back to overview]	Change From Baseline in Respiration Rate
NCT03287310 (131) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT03287310 (131) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT03287310 (131) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT03287310 (131) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT03287310 (131) [back to overview]	Change From Baseline in Temperature
NCT03287310 (131) [back to overview]	Change From Baseline in Temperature
NCT03287310 (131) [back to overview]	Change From Baseline in Temperature
NCT03287310 (131) [back to overview]	Change From Baseline in Temperature
NCT03287310 (131) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious AEs (SAE)
NCT03287310 (131) [back to overview]	Number of Participants With Adverse Events of Special Interest (AESI)
NCT03287310 (131) [back to overview]	Number of Participants With Anti-drug Antibody (ADA) Binding to GSK3511294
NCT03287310 (131) [back to overview]	Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein
NCT03287310 (131) [back to overview]	Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein
NCT03345407 (28) [back to overview]	Number of Participants With Time to Next Moderate/Severe Exacerbation Following Index Exacerbation
NCT03345407 (28) [back to overview]	Number of Participants Reporting COPD Exacerbations
NCT03345407 (28) [back to overview]	Maximum Observed Plasma Drug Concentration (Cmax) of Nemiralisib
NCT03345407 (28) [back to overview]	AUC From Time Zero to Time 't' [AUC(0-t)] of Nemiralisib
NCT03345407 (28) [back to overview]	Area Under the Concentration Time Curve (AUC) From Time Zero to 24 Hours [AUC(0-24)] of Nemiralisib
NCT03345407 (28) [back to overview]	Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 84 Measured Post Bronchodilator
NCT03345407 (28) [back to overview]	Plasma Concentration of Nemiralisib
NCT03345407 (28) [back to overview]	Percentage of Responders Using the COPD Assessment Test (CAT) on Treatment Days 28, 56, and 84, and Following EXACT Defined Recovery From the Index Exacerbation
NCT03345407 (28) [back to overview]	Percentage of Responders on the St. George's Respiratory Questionnaire (SGRQ) Total Score as Measured by the SGRQ for COPD Participants (SGRQ-C) at Days 28, 56, and 84
NCT03345407 (28) [back to overview]	Percentage of Rescue-free Days
NCT03345407 (28) [back to overview]	Percentage of Participants Achieving the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Definition of Recovery From the Index Exacerbation
NCT03345407 (28) [back to overview]	Number of Participants With Worst Case Post Baseline Hematology Values
NCT03345407 (28) [back to overview]	Number of Participants With Worst Case Post Baseline Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP) and Pulse Rate
NCT03345407 (28) [back to overview]	Number of Participants With Worst Case Post Baseline Clinical Chemistry Values
NCT03345407 (28) [back to overview]	Number of Participants With Abnormal Electrocardiogram (ECG) Findings
NCT03345407 (28) [back to overview]	Number of Participants Reporting Non-serious Adverse Events (Non-SAEs), SAEs and AE of Special Interest (AESI)
NCT03345407 (28) [back to overview]	Mean Severity of Subsequent Health Care Resource Use (HCRU) Exacerbations Defined by EXACT
NCT03345407 (28) [back to overview]	Mean Number of Occasions of Rescue Medication Use Per Day
NCT03345407 (28) [back to overview]	Change From Hospital Discharge in Clinic Visit Trough FEV1 Measured Pre and Post-bronchodilator
NCT03345407 (28) [back to overview]	Change From Hospital Discharge in Clinic Visit Trough FEV1 Measured Pre and Post-bronchodilator
NCT03345407 (28) [back to overview]	Change From Baseline in SGRQ Total Score at Days 28, 56 and 84
NCT03345407 (28) [back to overview]	Change From Baseline in Clinic Visit Trough FEV1 Measured Pre and Post-bronchodilator
NCT03345407 (28) [back to overview]	Change From Baseline in Clinic Visit Trough FEV1 Measured Pre and Post-bronchodilator
NCT03345407 (28) [back to overview]	Change From Baseline in CAT Total Score
NCT03345407 (28) [back to overview]	Time to Reach Cmax (Tmax) of Nemiralisib
NCT03345407 (28) [back to overview]	Rate of Moderate and Severe Exacerbations Over 12-week Treatment Period
NCT03345407 (28) [back to overview]	Plasma Drug Concentration at Pre-dose (Ctrough) of Nemiralisib
NCT03345407 (28) [back to overview]	Number of Participants With Time to Recovery From Index Exacerbation Using EXACT- PRO Tool
NCT03357341 (20) [back to overview]	Number of Secondary Care Visits for Asthma Conditions or COPD
NCT03357341 (20) [back to overview]	Number of Participants Who Received Short-acting Beta-agonist Therapy
NCT03357341 (20) [back to overview]	Change From Baseline in Asthma Control Test (ACT) Score-asthma Cohort Only
NCT03357341 (20) [back to overview]	Median Rescue Medication Use
NCT03357341 (20) [back to overview]	PROactive Difficulty Domain Score
NCT03357341 (20) [back to overview]	PROactive Amount Domain Score
NCT03357341 (20) [back to overview]	Percentage of Participants With Maintenance Compliance
NCT03357341 (20) [back to overview]	Patient Reported Outcome (PRO) Active Total Score
NCT03357341 (20) [back to overview]	Change From Baseline in COPD Assessment Test (CAT) Score-COPD Cohort Only
NCT03357341 (20) [back to overview]	Number of Primary Care Visits for Asthma Conditions or COPD
NCT03357341 (20) [back to overview]	Number of Participants With New Prescriptions
NCT03357341 (20) [back to overview]	Change From Baseline in Forced Expiratory Volume in One Second (FEV1)
NCT03357341 (20) [back to overview]	Number of All Primary Care Visits
NCT03357341 (20) [back to overview]	Number of All Secondary Care Visits
NCT03357341 (20) [back to overview]	Evaluating Respiratory Symptoms (E-RS) in COPD Total Score-COPD Cohort Only
NCT03357341 (20) [back to overview]	Median Daily Activity Level Based on Vector Magnitude Counts.
NCT03357341 (20) [back to overview]	Median Number of Steps Per Day
NCT03357341 (20) [back to overview]	Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Event Rate-COPD Cohort Only
NCT03357341 (20) [back to overview]	Number of Days in Hospital for Asthma and COPD
NCT03357341 (20) [back to overview]	Number of Participants Who Completed Exit Interview
NCT03364608 (3) [back to overview]	Change From Baseline in FEV1 AUC0-4
NCT03364608 (3) [back to overview]	Change From Baseline in FEV1 AUC0-6
NCT03364608 (3) [back to overview]	Peak Change From Baseline in FEV1
NCT03371459 (2) [back to overview]	Baseline-adjusted FEV1 AUC0-6 After the Last Cumulative Dose
NCT03371459 (2) [back to overview]	Baseline-adjusted FEV1 30 Minutes After Each Cumulative Dose
NCT03380429 (10) [back to overview]	Change From Baseline in Asthma Control Test (ACT) Total Score
NCT03380429 (10) [back to overview]	Number of Doses of Rescue Medication Use Between Month 4 and Month 6 as Determined by the Rescue Medication Sensor
NCT03380429 (10) [back to overview]	Percentage of ELLIPTA Doses Taken (Daily Adherence) Between Month 1 and Month 3 as Determined by the Maintenance Sensor
NCT03380429 (10) [back to overview]	Percentage of ELLIPTA Doses Taken (Daily Adherence) Between Month 1 and Month 6 as Determined by the Maintenance Sensor
NCT03380429 (10) [back to overview]	Percentage of ELLIPTA Doses Taken (Daily Adherence) Between Month 4 and Month 6 as Determined by the Maintenance Sensor
NCT03380429 (10) [back to overview]	Percentage of Participants Attaining Asthma Control (Percentage of Participants With an ACT Total Score >=20) at Month 6
NCT03380429 (10) [back to overview]	Percentage of Participants Who Have Either an ACT Total Score of >=20 and/or an Increase From Baseline >=3 in ACT Total Score at Month 6
NCT03380429 (10) [back to overview]	Percentage of Participants With an Increase From Baseline >=3 in ACT Total Score at Month 6
NCT03380429 (10) [back to overview]	Percentage of Rescue Free Days Between Month 4 and Month 6 as Determined by the Rescue Medication Sensor
NCT03380429 (10) [back to overview]	"Percentage of ELLIPTA Doses Taken (Daily Adherence) Between Month 4 and Month 6 as Determined by the Maintenance Sensor for Arms; (Cohort 1: Data on Maintenance Use Supplied to Participant and HCP andCohort 5: no Data Supplied to Participant or HCP)"
NCT03474081 (6) [back to overview]	Change From Baseline in Pulse Rate
NCT03474081 (6) [back to overview]	Change From Baseline in Trough FEV1 on Day 28
NCT03474081 (6) [back to overview]	Change From Baseline in Trough FEV1 on Day 84
NCT03474081 (6) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) on Day 85
NCT03474081 (6) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT03474081 (6) [back to overview]	Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
NCT03478683 (4) [back to overview]	Weighted Mean Change From Baseline in FEV1 Over 0-24 Hours at Week 12 for ITT Population
NCT03478683 (4) [back to overview]	Weighted Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 0-24 Hours at Week 12 for Modified Per Protocol (mPP) Population
NCT03478683 (4) [back to overview]	Weighted Mean Change From Baseline in FEV1 Over 0-24 Hours on Day 1
NCT03478683 (4) [back to overview]	Change From Baseline in Trough FEV1 on Day 2, Day 28, Day 84 and Day 85
NCT03478696 (4) [back to overview]	Weighted Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 0-24 Hours at Week 12 for Modified Per Protocol (mPP) Population
NCT03478696 (4) [back to overview]	Change From Baseline in Trough FEV1 on Day 2, Day 28, Day 84 and Day 85
NCT03478696 (4) [back to overview]	Weighted Mean Change From Baseline in FEV1 Over 0-24 Hours at Week 12 for ITT Population
NCT03478696 (4) [back to overview]	Weighted Mean Change From Baseline in FEV1 Over 0-24 Hours on Day 1
NCT03528577 (1) [back to overview]	Pharmacodynamic Endpoint Post-dose PC20
NCT03586544 (1) [back to overview]	Maximum % Change in Forced Expiratory Volume in the First Second (FEV1)
NCT03769090 (5) [back to overview]	Total Annualized Dose of Systemic Corticosteroid (SCS)
NCT03769090 (5) [back to overview]	Asthma Quality of Life Questionnaire for Participants Aged 12 Years and Older (AQLQ+12) - Number of Participants Who Were Responders at Week 24
NCT03769090 (5) [back to overview]	Asthma Control Questionnaire-5 (ACQ-5) - Number of Participants Who Were Responders at Week 24
NCT03769090 (5) [back to overview]	Number of Participants With a Severe Asthma Exacerbation Event
NCT03769090 (5) [back to overview]	Annualized Severe Exacerbation Rate
NCT03847896 (6) [back to overview]	Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Concentration Curve From 0 to 6 Hours (AUC0-6 Hours) Over 12 Weeks
NCT03847896 (6) [back to overview]	Time to 15% Increase in FEV1 Over the Pre-treatment Value on Day 1
NCT03847896 (6) [back to overview]	Duration of 15% Increase in FEV1 Over the Pre-treatment Value on Day 1
NCT03847896 (6) [back to overview]	Change From Baseline in Trough FEV1
NCT03847896 (6) [back to overview]	Change From Baseline in Trough FEV1 at Week 1.
NCT03847896 (6) [back to overview]	Number of Participants With a Clinically Meaningful Difference on the Asthma Control Questionnaire 7-item Version (ACQ-7) at Week 12.
NCT03890666 (10) [back to overview]	System Usability Scale (SUS) Overall Score
NCT03890666 (10) [back to overview]	Change From Baseline in Brief Illness Perception Questionnaire (BIPQ) Illness Comprehensibility Subscale Score at Week 12
NCT03890666 (10) [back to overview]	Change From Baseline in Mean Weekly Short-acting Beta2 Agonist (SABA) Usage at Week 12 for the DS Group
NCT03890666 (10) [back to overview]	Change From Baseline in the Number of SABA-free Days at Week 12 for the DS Group
NCT03890666 (10) [back to overview]	Percentage of Participants Achieving Meaningful Asthma Improvement at the End of 12-Week Treatment Period
NCT03890666 (10) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT03890666 (10) [back to overview]	Change From Baseline in BMQ Necessity Subscale Score at Week 12
NCT03890666 (10) [back to overview]	Change From Baseline in BIPQ Emotional Representations Subscale Score at Week 12
NCT03890666 (10) [back to overview]	Change From Baseline in BIPQ Cognitive Subscale Score at Week 12
NCT03890666 (10) [back to overview]	Change From Baseline in Beliefs About Medicines Questionnaire (BMQ) Concern Subscale Score at Week 12
NCT04207840 (6) [back to overview]	t[1/2], Terminal Elimination Half-life of Albuterol or Epinephrine
NCT04207840 (6) [back to overview]	C[Max], Maximum Plasma Concentration of Albuterol or Epinephrine
NCT04207840 (6) [back to overview]	AUC(0-tm)_TOT, Area Under the Curve (AUC) of Total (Exogenous and Endogenous, if Available) Active Product Ingredient (API) From Time 0 to Time (tm)
NCT04207840 (6) [back to overview]	AUC(0-tm)_DE, Area Under the Curve (AUC) of Exogenous Active Product Ingredient (API) From Time 0 to Time (tm)
NCT04207840 (6) [back to overview]	AUC(0-inf), Area Under the Curve (AUC) of Albuterol or Epinephrine From Time 0 to Infinity
NCT04207840 (6) [back to overview]	t[Max], Time at Which Maximum Plasma Concentration of Albuterol or Epinephrine is Observed
NCT04234464 (2) [back to overview]	Maximum Percentage Fall From Post-dose, Pre-exercise Baseline in Forced Expiratory Volume in 1 Second (FEV₁) Observed up to 60 Minutes Post-exercise Challenge
NCT04234464 (2) [back to overview]	Percentage of Subjects With a Maximum Percentage Fall in FEV₁ Post-exercise Challenge of <10%
NCT04606394 (3) [back to overview]	DPI Responder Analysis in Patients With Suboptimal PIF (<60 L/Min)
NCT04606394 (3) [back to overview]	DPI Responder Analysis in Patients With Reduced PIF (<45 L/Min)
NCT04606394 (3) [back to overview]	PIF Measurement Techniques
NCT04677959 (13) [back to overview]	Change From Baseline in the Number of SABA-free Days at Week 24 for the DS Group
NCT04677959 (13) [back to overview]	Number of Decreased Doses of Inhaled Medication
NCT04677959 (13) [back to overview]	Number of Participants Achieving Well-Controlled Asthma or Reaching Clinically Important Improvement in Asthma Control
NCT04677959 (13) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT04677959 (13) [back to overview]	System Usability Scale (SUS) Overall Score for DS Group
NCT04677959 (13) [back to overview]	Change From Baseline in Beliefs About Medicines Questionnaire (BMQ) Concern Subscale Score at Week 24
NCT04677959 (13) [back to overview]	Change From Baseline in Mean Weekly SABA Usage at Week 24 for the DS Group
NCT04677959 (13) [back to overview]	Change From Baseline in Adherence to Maintenance Treatment (FS eMDPI) at Week 24 for the DS Group
NCT04677959 (13) [back to overview]	Change From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score at Week 24
NCT04677959 (13) [back to overview]	Change From Baseline in BIPQ Cognitive Subscale Score at Week 24
NCT04677959 (13) [back to overview]	Change From Baseline in BMQ Necessity Subscale Score at Week 24
NCT04677959 (13) [back to overview]	Change From Baseline in Brief Illness Perception Questionnaire (BIPQ) Illness Comprehensibility Subscale Score at Week 24
NCT04677959 (13) [back to overview]	Change From Baseline in BIPQ Emotional Representations Subscale Score at Week 24
NCT04803734 (7) [back to overview]	Tmax
NCT04803734 (7) [back to overview]	T1/2
NCT04803734 (7) [back to overview]	MRT
NCT04803734 (7) [back to overview]	AUC(0-inf)
NCT04803734 (7) [back to overview]	AUC(0-t)
NCT04803734 (7) [back to overview]	Cmax
NCT04803734 (7) [back to overview]	Kel(λ)
NCT05300087 (7) [back to overview]	Tmax
NCT05300087 (7) [back to overview]	AUC(0-inf)
NCT05300087 (7) [back to overview]	MRT
NCT05300087 (7) [back to overview]	Kel(λ)
NCT05300087 (7) [back to overview]	Cmax
NCT05300087 (7) [back to overview]	AUC(0-t)
NCT05300087 (7) [back to overview]	T1/2

Change From Baseline in Pulmonary Auscultation/Wheezing Assessment

Wheezing was assessed by the investigator or designee based upon pulmonary auscultation (listening with a stethoscope) and reported in the case report form as present or absent. The count of wheezing presence (yes, no) at visits was summarized. (NCT00070707)
Timeframe: Baseline, Day 15 and Day 29

Intervention	Participants (Count of Participants)
	Present at Baseline	Absent at Baseline	Present on Day 15	Absent on Day 15	Present on Day 29	Absent on Day 29
Mometasone	11	101	8	94	10	98
Placebo	9	66	4	68	3	71

Intervention	Score on a scale (Least Squares Mean)
	Baseline (AM)	Change at Week 1 (AM)	Change at Week 2 (AM)	Change at Week 3 (AM)	Change at Week 4 (AM)	Change at Final Week (AM)	Baseline (PM)	Change at Week 1 (PM)	Change at Week 2 (PM)	Change at Week 3 (PM)	Change at Week 4 (PM)	Change at Final Week (PM)
Mometasone	1.6	-0.2	-0.3	-0.5	-0.5	-0.4	1.6	-0.3	-0.4	-0.6	-0.6	-0.6
Placebo	1.6	-0.4	-0.4	-0.7	-0.7	-0.6	1.6	-0.5	-0.5	-0.7	-0.7	-0.6

Intervention	Score on a scale (Least Squares Mean)
	Baseline (AM)	Week 1 (AM)	Week 2 (AM)	Week 3 (AM)	Week 4 (AM)	Final Week (AM)	Baseline (PM)	Week 1 (PM)	Week 2 (PM)	Week 3 (PM)	Week 4 (PM)	Final Week (PM)
Mometasone	8.4	-1.7	-2.3	-3.2	-3.5	-3.1	8.2	-1.8	-2.6	-3.4	-3.6	-3.3
Placebo	7.9	-0.9	-1.3	-1.8	-2.4	-2.2	7.9	-1.5	-1.8	-2.4	-2.8	-2.6

Intervention	Liters/sec (Least Squares Mean)
	Baseline	Change at Day 15	Change at Day 29
Mometasone	2.98	0.12	0.15
Placebo	3.00	0.00	0.03

Intervention	Number of puffs (Least Squares Mean)
	Baseline	Change at Week 1	Change at Week 2	Change at Week 3	Change at Week 4	Change at Final Week
Mometasone	2.4	-0.4	-0.6	-0.8	-0.7	-0.7
Placebo	2.1	-0.5	-0.5	-0.5	-0.6	-0.6

Intervention	Score on a scale (Mean)
	SAR Nasal: Day 15	SAR Nasal: Day 29
Mometasone	3.2	3.0
Placebo	3.4	3.4

Intervention	Hours (Median)
Continuous Levalbuterol (R) Nebulized Solution	18.3
Continuous Racemic (R+S) Albuterol	16

Intervention	units on a scale (Mean)
Continuous Levalbuterol (R) Nebulized Solution	-1.0
Continuous Racemic (R+S) Albuterol	-0.64

Intervention	ng/mL (Mean)
Continuous Levalbuterol (R) Nebulized Solution	5.5
Continuous Racemic (R+S) Albuterol	28.6

Intervention	percentage of predicted FEV1*hour (Mean)
	PPFEV1 AUEC0-6 on Day 22 Using Day 22 Baseline	PPFEV1 AUEC0-6 on Day 22 Using Day 1 Baseline
Albuterol-HFA-BAI	29.473	43.182
Placebo-HFA-BAI	11.672	6.767

Intervention	units on a scale (Mean)
	Enrollment	at organ procurement (about ~40h after enrollment)
Albuterol	4.7	5.0
Saline	4.6	4.4

Intervention	ml/cmH2O (Mean)
	baseline	at organ procurement (mean ~40h after enrollment)
Albuterol	48	52
Saline	50	56

Intervention	millimeters of mercury (mmHg) (Mean)
	SBP, Week 4	SBP, Week 8	SBP, Week 12	DBP, Week 4	DBP, Week 8	DBP, Week 12
SFC 50/250 mcg	0.8	-0.7	0.2	0.2	-0.2	0.6

Intervention	Participants (Number)
	At least 1 day	1 day	2 days	3-4 days	5-9 days
SFC 50/250 mcg	13	10	2	1	0

Intervention	liters/minute (Least Squares Mean)
Ciclesonide 40 µg	20.68
Ciclesonide 80 µg	21.71
Ciclesonide 160 µg	22.25
Placebo	15.13

Intervention	liters/minute (Least Squares Mean)
Ciclesonide 40 µg	15.23
Ciclesonide 80 µg	14.79
Ciclesonide 160 µg	17.37
Placebo	5.40

Intervention	puffs/day (Mean)
Ciclesonide 40 µg	-0.872
Ciclesonide 80 µg	-0.999
Ciclesonide 160 µg	-0.886
Placebo	-0.527

Intervention	percentage of days (Median)
Ciclesonide 40 µg	7.14
Ciclesonide 80 µg	10.53
Ciclesonide 160 µg	6.67
Placebo	0.0

Intervention	Percent (Number)
Ciclesonide 40 µg	72.8
Ciclesonide 80 µg	74.5
Ciclesonide 160 µg	73.2
Placebo	66.9

Intervention	liters/minute (Least Squares Mean)
	Change at Week 1 (n=303,311,310,146)	Change at Week 2 (n=303,311,310,146)	Change at Week 3 (n=304,312,310,146)	Change at Week 4 (n=304,312,310,146)	Change at Week 5	Change at Week 6	Change at Week 7	Change at Week 8	Change at Week 9	Change at Week 10	Change at Week 11	Change at Week 12
Ciclesonide 160 µg	11.54	12.26	13.15	15.60	15.39	14.71	14.14	13.63	13.23	14.59	16.24	17.59
Ciclesonide 40 µg	11.61	9.82	11.36	13.63	14.86	13.91	14.57	14.57	15.26	16.35	16.12	15.93
Ciclesonide 80 µg	9.20	11.95	11.11	13.27	13.33	13.26	15.05	15.92	16.02	16.79	15.97	15.43
Placebo	4.54	4.20	6.74	6.31	9.67	7.64	6.21	7.05	7.88	7.66	6.80	6.41

Intervention	percentage of days (Median)
Ciclesonide 40 µg	8.33
Ciclesonide 80 µg	13.64
Ciclesonide 160 µg	13.04
Placebo	0.0

albuterol

Description

Cross-References

Synonyms (304)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (3)

Protein Targets (29)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (123)

Molecular Functions (62)

Ceullar Components (40)

Bioassays (265)

Research

Studies (9,496)

Market Indicators

Research Demand Index: 86.88

Study Types

Clinical Trials (393)

Trial Overview

Trial Outcomes

Change From Baseline in Pulmonary Auscultation/Wheezing Assessment

Change From Baseline in AM and PM Chest Tightness Symptom Score

Change From Baseline in AM and PM Cough Symptom Score

Change From Baseline in AM and PM Difficulty Breathing Symptom Score

Change From Baseline in AM and PM Nasal Congestion Symptom Score

Change From Baseline in AM and PM Nasal Itching Symptom Score

Change From Baseline in AM and PM Nasal Sneezing Symptom Score

Change From Baseline in AM and PM Peak Expiratory Flow Rate (PEFR)

Change From Baseline in AM and PM Rhinorrhea Symptom Score

Change From Baseline in AM and PM Total Nasal Symptom Severity (TNSS)

Change From Baseline in AM and PM Wheeze Symptom Score

Change From Baseline in Forced Expiratory Flow (FEF) Between 25% and 75% of the Vital Capacity (FEF25%-75%)

Change From Baseline in Forced Expiratory Volume in One Second (FEV1)

Change From Baseline in Forced Vital Capacity (FVC)

Change From Baseline in Morning (AM) and Evening (PM) Total Asthma Symptom Severity (TASS)

Change From Baseline in the Weekly Average Number of Puffs of Albuterol/Salbutamol Used

Change From Baseline in Weekly Average Interference With Daily Activities

Change From Baseline in Weekly Average Interference With Sleep

Change From Baseline in Weekly Average Nighttime Awakenings Due to Asthma

Therapeutic Response to Asthma Symptoms

Therapeutic Response to SAR Nasal Symptoms

Duration of Continuous Therapy

Change in Pediatric Asthma Severity Score

Serum Potassium Levels

Serum Albuterol S Isomer Levels

Heart Rate

Wheezing/Asthma/Bronchospasm Relapse Rate

Urinary Cortisol Levels

Forced Expiratory Volume in 1 Second (FEV1)

Maximum Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Observed up to 2 Hours Following Completion of Dosing (FEV1max%0-2) at Day 22

Baseline-Adjusted Area Under the Percent-Predicted FEV1 Versus Time Curve Over 6 Hours (PPFEV1 AUEC0-6) at Day 22

Number of Donor Lungs Used for Transplantation

Donor Oxygenation

Chest X-ray Findings

Lung Compliance

Day Time Albuterol Use During Week 2

Day Time Albuterol Use During Week 3

Day Time Albuterol Use During Week 4

Day Time Albuterol Use During Week 5

Day Time Albuterol Use During Week 6

Day Time Albuterol Use During Week 7

Day Time Albuterol Use During Week 8

Day Time Albuterol Use During Week 9

Evening PEFR at Week 1

Patient Global Evaluation

Evening PEFR at Week 10

Evening PEFR at Week 11

Intervention	score on a scale (Mean)
	Asthma Total Symptom Score (n=304,312,310,146)	Asthma Daytime Symptom Score (n=304,312,310,146)	Asthma Nighttime Symptom Score
Ciclesonide 160 µg	-0.879	-0.517	-0.350
Ciclesonide 40 µg	-0.916	-0.529	-0.392
Ciclesonide 80 µg	-0.983	-0.553	-0.435
Placebo	-0.572	-0.354	-0.233

Intervention	percent change (Mean)
Ciclesonide 40 µg	-0.841
Ciclesonide 80 µg	-1.209
Ciclesonide 160 µg	-1.192
Placebo	0.214

Intervention	liters (Least Squares Mean)
Ciclesonide 40 µg	0.123
Ciclesonide 80 µg	0.122
Ciclesonide 160 µg	0.139
Placebo	0.039

Intervention	liters/minute (Least Squares Mean)
Ciclesonide 40 µg	10.16
Ciclesonide 80 µg	9.37
Ciclesonide 160 µg	12.71
Placebo	4.02

Intervention	Participants (Number)
	Rhinorrhea	Headache	Diarrhea	Sore throat	Cough	Hyperglycemia
Budesonide Inhalation Suspension (BIS)	6	5	3	4	2	2
Placebo (Normal Saline)	11	9	7	3	3	0

Intervention	Units on a scale (Mean)
Budesonide Inhalation Suspension (BIS)	-2.9
Placebo (Normal Saline)	-3.0

Intervention	participants (Number)
	Return within 5 days with hosptial admission	Increased level of care
Budesonide Inhalation Suspension (BIS)	2	1
Placebo (Saline)	2	0

Intervention	liters (Least Squares Mean)
A: Daily ICS + Rescue ICS	0.104
B: Daily ICS	0.113
C: Rescue ICS	0.097
D: Placebo	0.063

Intervention	liters per minute (Least Squares Mean)
A: Daily ICS + Rescue ICS	17.7
B: Daily ICS	16.3
C: Rescue ICS	16.5
D: Placebo	21.1

Intervention	parts per billion (Least Squares Mean)
Daily ICS + Rescue ICS	-0.08
Daily ICS	0.07
Rescue ICS	0.58
Placebo	0.34